Method of detecting at least one mechanism of resistance to carbapenems by mass spectrometry

ABSTRACT

The present invention pertains to a method of detection, by mass spectrometry, of at least one marker of at least one mechanism of resistance to at least one antimicrobial, resistance of at least one microorganism contained in a sample, characterized in that the antimicrobial is a carbapenem, and said resistance markers are proteins or peptides. Preferably, said proteins or peptides are proteins from said microorganism.

This is a Division of application Ser. No. 14/111,083 filed Oct. 10,2013, which in turn is a national stage of PCT/EP2012/057323, filed Apr.20, 2012, which claims the benefit of U.S. Provisional Application No.61/477,915 filed Apr. 21, 2011. The disclosure of the prior applicationsis hereby incorporated by reference herein in its entirety.

The present invention relates to the field of microbiology. Moreprecisely, the invention relates to the detection of at least onemechanism of resistance to carbapenems of at least one microorganismfrom a sample by using mass spectrometry.

Since Pasteur's discovery of microbes, microorganisms have been studiedby microscopy and biochemical analyses. These conventional methods areoften long and tedious, and analytical alternatives were sought veryearly on. This is why the analysis of bacteria by mass spectrometry wasinitiated from 1975 by J. Anhalt and C. Fenselau [1].

This preliminary work was followed by the study of fatty acids from thewall of the microorganisms using gas chromatography combined with massspectrometry (GC-MS) [2]. This method was popularised under the Englishterm FAME, standing for Fatty Acid Methyl Ester. It currentlyconstitutes a reference method for taxonomic studies. However, its useremains limited to certain specialised laboratories dealing with thetreatment of the sample by saponification, hydrolysis and derivation.

In 1996, the works by M. Claydon et al. [3] as well as by T.Krishnamurthy and P. Ross [4] demonstrated the possibility ofidentifying different bacterial species with a MALDI-TOF massspectrometer (English acronym for Matrix Assisted Laser DesorptionIonization-Time Of Flight). The analysis combines the acquisition of amass spectrum and the interpretation of expert software. It is extremelysimple and can be carried out in a few minutes. However it has only beenmaking it into medical analysis laboratories fairly recently [5]. Itsclinical use is currently limited to the identification of bacteria andyeast species. It is not routinely used to identify resistances toantimicrobials.

Yet the identification of resistances to antimicrobials such asantibiotics is an essential element in ensuring optimal patient care.

Other mass spectrometry methods, particularly in tandem, have beenproposed to meet these needs. By way of example, it is possible to citethe work of C. Fenselau et al. for identifying β-Lactamase with aquadripole-TOF (Q-TOF) [6].

However these research results are not applicable to routine clinicaluse. They were obtained with research instruments requiring highlyqualified personnel. The analysis times, often greater than one hour persample, are incompatible with the workload of a microbiological analysislaboratory.

More recently, S. Hofstadler et al. [7] proposed a method combining amicrobial genome amplification by PCR to a detection of the PCR productsby electrospray-TOF (ESI-TOF). This method is now fully automated [8].However, it requires a PCR amplification with the flaws inherent inmolecular biology, namely extraction yield, cost of the probes, etc.

In this context, the objective of the present invention is to propose amethod of detecting mechanisms of resistance to carbapenems which makesit possible to overcome the disadvantages of the prior art methods,namely providing an inexpensive method, without reagents specific toeach species, particularly compared to molecular biology methods, whichgives a result in a short amount of time, less than one hour, and whichcan be used in routine clinical work, without requiring highly qualifiedpersonnel.

To this end, the invention proposes a new method of detecting, by massspectrometry, at least one mechanism of resistance to at least oneantimicrobial of at least one microorganism from a sample, characterisedin that the antimicrobial is a carbapenem and in that proteins and/orpeptides are detected as markers of said mechanism of resistance to atleast one carbapenem-class antibiotic.

Preferably, the resistance markers are proteins from said at least onemicroorganism. Advantageously, markers of resistance to severaldifferent antimicrobials can be detected simultaneously.

As indicated in application PCT/FR2010/052181, markers of type and/orvirulence of said microorganisms can be detected in the same way by massspectrometry prior to or at the same time as the detection of theresistance mechanism markers.

Markers of resistance to at least one carbapenem-class antimicrobial isunderstood to mean molecules of protein origin which are characteristicof said properties.

Carbapenems are antibiotics belonging to the beta-lactam family andtheir main representatives are imipenem, meropenem, ertapenem anddoripenem. These molecules are broken down by the beta-lactamases 2df,2f and 3a of the classification by Bush and Jacoby ([9], AntimicrobialAgents and Chemotherapy, 2010; 54 (3): 969-976).

Determination of the resistance to at least one antimicrobial isunderstood to mean determining the susceptibility of a microorganism tobeing destroyed by an antimicrobial. The proteins involved in theresistance mechanisms will differ depending on the family and thespecies.

The nomenclature of the beta-lactamases, beta-lactam-resistant bacterialenzymes, is not standardised. They are either classified in fourmolecular classes (A to D) on the basis of their primary structure, orin functional groups on the basis of the target substrates and theirresistance to inhibitors (for an overview, see [9] Bush and Jacoby,supra). For molecular classification, sequencing techniques have mademore precise classification possible: for example, 183 variants of theTEM protein have been described (labelled TEM-i, with i being between 1and 183). For the functional classification, Bush and Jacoby (supra)have proposed new functional subgroups:

-   -   the group 1 enzymes are cephalosporinases belonging to the        molecular class C. CMY and FOX are plasmid-borne enzymes,        belonging to this subgroup.    -   the group 2 enzymes belong to molecular classes A and D. This        group is itself subdivided into subgroups, 2b, 2be, 2br, 2ber,        2d, 2de, 2df, 2f, etc. CTX-M (2be) and TEM (including 2be, 2br)        are enzymes belonging to this subgroup. The subgroup 2b        corresponds to broad-spectrum beta-lactamases which are        inhibited by clavulanic acid, sulfobactam, or tazobactam. The        subgroup 2be corresponds to extended-spectrum beta-lactamases        (ESBL), which are also inhibited by clavulanic acid, sulfobactam        or tazobactam. The subgroup 2br corresponds to beta-lactamases        from the subgroup 2b which are insensitive to inhibition by        clavulanic acid, sulfobactam or tazobactam. The subgroup 2df        includes OXAs having a spectrum extended to carbapenems. Group        2f corresponds to carbapenemase beta-lactamases such as KPC.    -   group 3 encompasses the metallo-beta-lactamases which hydrolyse        carbapenems, such as IMP, VIM, SPM, GIM, SIM, AIM, KHM, DIM or        NDM.

NDM-1 beta-lactamase was described in 2010 (Kumarasamy et al., 2010,Lancet Infect. Dis., 10:597-602). It corresponds to ametallo-beta-lactamase which confers a resistance to all beta-lactamsexcept aztreonam.

KPC beta-lactamases were described from 2001 in the United States (Yigitet al., 2001, Antimicrobio. Agents Chemother., 45:1151-1161) and thenthroughout the world. They correspond to class-A beta-lactamases whichconfer a resistance to cephalosporins and to carbapenems, in particularto imipenem and to meropenem. IMP beta-lactamases were described from1994 in Japan (Osano et al., 1994, Antimicrobio. Agents Chemother.,38:71-78) and then throughout the world. They correspond tometallo-beta-lactamases which confer a resistance to cephalosporins andto carbapenems, but which do not confer resistance to Temocillin and toaztreonam.

VIM beta-lactamases were described from 1999 in Europe (Lauretti et al.,1999, Antimicrobio. Agents Chemother., 43:1584-1590) and then throughoutthe world. They correspond to metallo-beta-lactamases which confer aresistance to cephalosporins and to carbapenems, but which do not conferresistance to aztreonam.

The first GES beta-lactamase was isolated in 1998 in French Guiana(Poirel et al., 2000, Antimicrobio. Agents Chemother., 43:622-632). Thisenzyme (GES-1) conferred an ESBL resistance. The second isolate from abacterium bearing a GES beta-lactamase was achieved in 2000 in SouthAfrica (Poirel et al., 2001, Antimicrobio. Agents Chemother.,45:2598-2603). This enzyme (GES-2) conferred a resistance tocephalosporins and to carbapenems such as imipenem.

IND beta-lactamases were described for the first time in 1999 (Bellaiset al., 1999, FEMS Microbio. Lett., 171:127-132). They correspond tometallo-beta-lactamases which confer a resistance to cephalosporins andto carbapenems.

SME beta-lactamases were described for the first time in 1994 (Naas etal., 1994, Antimicrobio. Agents Chemother., 38:1262-1270). Theycorrespond to class-A beta-lactamases which confer a resistance tocephalosporins and to carbapenems.

OXA beta-lactamases (or oxacillinases) correspond to Class-Dbeta-lactamases. According to their primary sequence, they can conferresistances to cephalosporins or to cephalosporins and to carbapenems(Poirel et al., 2010, Antimicrobio. Agents Chemother., 54:24-38).

The method of the invention can be employed to detect mechanisms ofresistance to carbapenems in bacteria. Thus, for example, as bacteria inwhich it is possible to seek a mechanism of resistance to carbapenemsaccording to the method of the invention, non-exhaustive mention may bemade of: Escherichia coli, Klebsiella pneumoniae, Pseudomonasaeruginosa, Acinetobacter baumannii, Bacillus spp, Stenotrophomonasmaltophilia, Aeromonas spp, Bacteroides fragilis, Pseudomonas otitidisand Enterobacter cloacae, and more generally, the Enterobacteriaceae,which carry the bla_(NDM-1) or bla_(KPC) resistance gene. It shouldfurther be noted that the strains known to be resistant to carbapenemsare also resistant to cephalosporins and to penicillins.

Thus, the method according to the invention also makes it possible todetect a mechanism of resistance to said antibiotics.

The sample on which the method of the invention can be employed is anysample susceptible of containing a target microorganism. The sample canbe of biological origin, either animal, vegetable or human. In this caseit may correspond to a specimen of biological fluid (whole blood, serum,plasma, urine, cerebrospinal fluid, organic secretion, for example), atissue specimen or isolated cells. This specimen can be used such as itis, insofar as the markers of mechanisms of bacterial resistance tobeta-lactams are available in the sample tested, or it can, prior to theanalysis, undergo preparation by enrichment, extraction, concentration,purification, culturing, in accordance with methods known to the personskilled in the art.

The sample can be of industrial origin, or, according to anon-exhaustive list, can be an air specimen, a water specimen, a surfacespecimen, a part or a manufactured product, or a food product. Amongstthe food samples, non-exhaustive mention can be made of a sample of adairy product (yogurts, cheeses), of meat, of fish, of egg, of fruit, ofvegetable, of water, of a beverage (milk, fruit juice, soda, etc.).These food samples can also come from sauces or ready meals. Finally, afood sample can come from an animal feed, such as animal meals.

Upstream of the detection by mass spectrometry, the sample to beanalysed is preferably pretreated to produce peptides from the entiretyof the proteins present in the sample to fragment these proteins intopeptides, for example by digestion with a proteolytic enzyme (protease),or by the action of a chemical reagent. In fact, the cleaving of theprotein can be performed by a physico-chemical treatment, by abiological treatment or by a combination of the two treatments. Amongstthe useable treatments, mention can be made of treatment by hydroxylradicals, in particular with H₂O₂. Treatment by hydroxyl radicalsresults in a cutting of the peptide bonds which takes place randomly onany of the protein's peptide bonds. The hydroxyl radical concentrationdetermines the number of cleavages performed, and therefore the lengthof the peptide fragments obtained. Other chemical treatments can also beused such as, for example, cyanogen bromide (CNBr) treatment whichspecifically splits the peptide bonds at the carboxyl group of themethionyl residues. It is also possible to perform partial acid cleavingat the aspartyl residues by heating a solution of proteins intrifluoroacetic acid to 1000° C.

Treatment of the proteins by enzymatic digestion is neverthelesspreferred over physico-chemical treatment because it preserves more ofthe structure of the protein, and is easier to control. “Enzymaticdigestion” is understood to mean the single or combined action of one ormore enzymes under appropriate reaction conditions. The enzymes carryingout the proteolysis, which are called proteases, cut the proteins atspecific locations. Each protease generally recognises a sequence ofamino acids within which it always makes the same cut. Certain proteasesrecognise a single amino acid or a sequence of two amino acids betweenwhich they perform a cleavage, whereas other proteases only recogniselonger sequences. These proteases can be endoproteases or exoproteases.Amongst the known proteases, mention may be made of the following asdescribed in WO2005/098071:

-   -   specific enzymes such as trypsin which splits the peptide bond        at the carboxyl group of the Arg and Lys residues, endolysin        which cleaves the peptide bond of the —CO group of the lysines,        chymotrypsin which hydrolyses the peptide bond at the carboxylic        group of the aromatic residues (Phe, Tyr and Tip), pepsin which        makes a cut at the NH₂ group of the aromatic residues (Phe, Tyr        and Trp), the protease V8 from the V8 strain of Staphylococcus        aureus which cleaves the peptide bond at the carboxylic group of        the Glu residue;    -   the non-specific enzymes such as thermolysin from the bacteria        Bacillus thermoproteolyticus which hydrolyses the peptide bond        of the NH₂ group of hydrophobic amino acids (Xaa-The, Xaa-Ile,        Xaa-Phe), subtilisin and pronase which are bacterial proteases        which hydrolyse practically all the bonds and can transform the        proteins into oligopeptides under controlled reaction conditions        (enzyme concentration and duration of reaction).

Several proteases may be used simultaneously, if their modes of actionare compatible, or they may be used successively. Within the frameworkof the invention, the digestion of the sample is preferably performed bythe action of a protease enzyme, for example trypsin.

The generation of peptides using a chemical reagent or a protease can beobtained by means of a simple reaction in solution. It can also beperformed with a microwave oven [10], or under pressure [11], or evenwith an ultrasound device [12]. In these three latter cases, theprotocol will be much faster.

Amongst the peptides thus obtained, the peptides specific to the proteinare referred to as proteotypic peptides. It is these which will beassayed by mass spectrometry. According to the invention, the markers ofthe mechanisms of bacterial resistance to carbapenems are proteins fromthe bacterium in which the mechanisms of resistance to cephalosporinsare to be sought. In particular, said proteins are digested intopeptides, preferably by an enzyme, and more preferably by trypsin.

Similarly, the sample containing protein markers characterisingmechanisms of bacterial resistance to carbapenems can also be pretreatedfor the purposes of purification. This purification pretreatment can beemployed before or after the peptide production step as described above.

The sample purification pretreatment is widely known to the personskilled in the art and may in particular employ the techniques ofcentrifugation, filtration, electrophoresis or chromatography. Theseseparating techniques can be used alone or in combination with oneanother to obtain a multidimensional separation. For example,multidimensional chromatography can be used by combining separation byion exchange chromatography with reversed-phase chromatography, asdescribed by T. Fortin et al. [13], or H. Keshishian et al. [14]. Inthese publications, the chromatography medium can be in a column or in acartridge (solid-phase extraction).

The electrophoretic or chromatographic fraction (or the retention timein monodimensional or multidimensional chromatography) of theproteotypic peptides is characteristic of each peptide, and employingthese techniques therefore makes it possible to select the proteotypicpeptide or peptides to be assayed. Such a fractionation of the producedpeptides makes it possible to increase the specificity of the subsequentassay by mass spectrometry.

An alternative to the electrophoresis or chromatography techniques forthe fractionation of the peptides consists in specifically purifying theN-glycopeptides ([15] and patent application WO 2008/066629). However,such a purification only makes it possible to quantify the peptideswhich have undergone an N-glycosylation post-translational modification.Not all proteins are glycosylated though, which therefore limits itsuse.

The mass spectrometry to be employed in the method of the invention iswidely known to the person skilled in the art as a powerful tool foranalysing and detecting different types of molecules. Generally, anytype of molecule able to be ionised can be detected according to itsmolecular mass with the aid of a mass spectrometer. According to thenature of the molecule to be detected, whether of protein or metabolicorigin, certain mass spectrometry technologies can be more suitable.Nevertheless, whatever mass spectrometry method is used for thedetection, this latter includes a step of ionising the target moleculeinto so-called molecular ions, in the present case a step of ionisingthe characterising markers, and a step of separating the molecular ionsobtained according to their mass.

All mass spectrometers therefore comprise:

-   -   an ionising source intended to ionise the markers present in the        sample to be analysed, i.e. to confer a positive or negative        charge upon these markers;    -   a mass analyser intended to separate the ionised markers, or        molecular ions, according to their mass-to-charge ratio (m/z);    -   a detector intended to measure the signal produced either        directly by the molecular ions, or by ions produced from        molecular ions as detailed hereafter.

The ionisation step necessary for employing mass spectrometry can beperformed via any method known to the person skilled in the art. Theionising source makes it possible to transform the molecules to beassayed into a gaseous and ionised state. An ionising source can be usedeither in positive mode to study the positive ions, or in negative modeto study the negative ions. Several types of sources exist and will beused depending on the result sought and the molecules analysed. Inparticular, mention may be made of:

-   -   electron ionisation (EI), chemical ionisation (CI) and        desorption chemical ionisation (DCI)    -   fast atom bombardment (FAB), metastable atom bombardment (MAB)        or ion bombardment (SIMS, LSIMS)        http://fr.wikipedia.org/wiki/Spectrom%C3%A9trie_de_masse_%C3%A0_ionisation_secondaire    -   inductively coupled plasma (ICP)        http://fr.wikipedia.org/wiki/Torche_%C3%A0_plasma_(chimie)    -   atmospheric-pressure chemical ionisation (APCI) and        atmospheric-pressure photoionisation (APPI)        http://fr.wikipedia.org/wiki/Ionisation_chimique_%C3%A0_pression_atmosph%C3%A9rique    -   electronebulisation or electrospray (ESI)        http://fr.wikipedia.org/wiki/Ionisation_par_%C3%A9lectron%C3%A9buliseur_(ESI)    -   matrix-assisted laser desorption/ionisation (MALDI),        surface-activated laser desorption/ionisation (SELDI) or        desorption/ionisation on silicon (DIOS)        http://fr.wikipedia.org/wiki/D%C3%A9sorption-ionisation_laser_assist%C3%A9e_par_matrice    -   ionisation/desorption by interaction with metastable species        (DART)

In particular, ionisation can be employed as follows: the samplecontaining the target molecules is introduced into an ionisation source,where the molecules are ionised in gaseous state and thus transformedinto molecular ions which correspond to the initial molecules. Anelectrospray ionisation (ESI) source makes it possible to ionise amolecule by making it pass from a liquid state into a gaseous state. Themolecular ions obtained therefore correspond to the molecules present inliquid state, with, in positive mode, one, two, or even three or moreadditional protons and therefore carry one, two, or even three or morecharges. For example, when the target molecule is a protein, anionisation of the proteotypic peptides obtained after fractionation ofthe target protein, by means of an electrospray source functioning inpositive mode, leads to polypeptide ions in gaseous state, with one,two, or even three or more additional protons and which therefore carryone, two, or even three or more charges, and makes it possible to movefrom a liquid state to a gaseous state [16]. This type of source isparticularly well suited when the target molecules or proteotypicpeptides obtained are separated beforehand by reversed-phase liquidchromatography. Nevertheless, the ionisation yield of the moleculespresent in the sample may vary depending on the concentration and thenature of the different species present. This phenomenon leads to amatrix effect well known to the person skilled in the art.

A MALDI ionisation source will allow ionisation of the molecules from asolid-state sample.

The mass analyser in which the step of separating the ionised markersaccording to their mass-to-charge ratio (m/z) is performed is any massanalyser known to the person skilled in the art. Mention can be made oflow-resolution analysers, quadripole or quadrupole (Q), 3D ion trap (IT)or linear ion trap (LIT), also called ion trap, and high-resolutionanalysers which make it possible to measure the exact mass of theanalytes and which in particular use the magnetic sector linked to anelectric sector, the time of flight (TOF), Fourier transform ioncyclotron resonance (FT-ICR), orbitrap.

The separation of the molecular ions depending upon their m/z ratio canbe employed just once (single mass spectrometry or MS), or severalsuccessive MS separations can be conducted. When two successive MSseparations are carried out, the analysis is called MS/MS or MS². Whenthree successive MS separations are carried out, the analysis is calledMS/MS/MS or MS³, and more generally, when n successive MS separationsare carried out, the analysis is called MS^(n).

Amongst the techniques which employ several successive separations, SRM(Selected Reaction Monitoring) mode when detecting or assaying a singletarget molecule, or MRM (Multiple Reaction Monitoring) mode whendetecting or assaying several target molecules are particular uses ofMS² separation. Similarly the MRM³ mode is a particular use of MS/MS/MSseparation. This is referred to as targeted mass spectrometry.

In the case of a detection in single MS mode, it is the mass-to-chargeratio of the molecular ions obtained which is correlated to the targetmolecule to be detected.

In the case of detection in MS/MS mode, essentially two steps are added,compared to an MS assay, which are:

-   -   a fragmentation of the molecular ions, then called precursor        ions, to give ions called 1^(st) generation fragment ions, and    -   a separation of the ions called 1^(st) generation fragment ions        according to their mass (m/z)₂, the ratio (m/z)₁ corresponding        to the ratio (m/z) of the precursor ions.

It is therefore the mass-to-charge ratio of the 1^(st) generationfragment ions thus obtained which is correlated to the target moleculeto be detected. First-generation fragment ion is understood to be an ionderived from the precursor ion, following a fragmentation step and ofwhich the mass-to-charge ratio m/z is different from the precursor ion.

The (m/z)₁ and (m/z)₂ pairs are called transitions and arerepresentative of the characteristic ions to be detected.

The choice of the characteristic ions which are detected to becorrelated to the target molecule is made by the person skilled in theart in accordance with the standard methods. Their selection willadvantageously lead to the most sensitive, specific and robust assayspossible, in terms of reproducibility and reliability. In the methodsdeveloped for the selection of proteotypic peptides (m/z)₁, and of thefirst-generation fragment (m/z)₂, the choice is essentially based on theintensity of the response. For more details, it is possible to refer toV. Fusaro et al. [17]. Commercially available software, such as theMIDAS and MRM Pilot software from Applied Biosystems or MRMaid [18] canbe used by the person skilled in the art to allow him to predict all thepossible transition pairs. He can also make use of a database calledPeptideAtlas constructed by F Desiere et al. [19] to compile all of theMRM transitions of peptides described by the scientific community. Thisdatabase PeptideAtlas is freely available on the internet. Fornon-protein molecules, it is also possible to use databases, such as,for example, the one accessible through the Cliquid software from thecompany Applied Biosystems (United States of America).

An alternative approach to selecting the proteotypic peptides (m/z)₁ and(m/z)₂ consists in using MS/MS fragmentation spectra obtained duringother work. This work can be, for example, the phases of biomarkerdiscovery and identification by proteomic analysis. This approach wasproposed by Thermo Scientific during user conferences [18]. It makes itpossible to generate a list of candidate transitions from the peptidesidentified through testing by the SIEVE (Thermo Scientific) software.Certain criteria were detailed by J. Mead et al. [18] for the choice ofthe ions (m/z)₁ and (m/z)₂ and are detailed hereafter:

-   -   peptides with internal cleavage sites, i.e. with internal Lysine        or Arginine, must be avoided, unless the Lysine or Arginine is        followed by Proline,    -   peptides with Aspargine or Glutamine must be avoided because        they may deaminate,    -   peptides with Glutamine or Glutamic Acid at the N-terminal must        be avoided because they may cyclise spontaneously,    -   peptides with Methionine must be avoided because they may be        oxidised,    -   peptides with Cysteine must be avoided because they may be        non-reproducibly modified during a potential step of        denaturation, reduction and blocking of the thiol functions,    -   peptides with Proline may be considered to be favourable because        they generally produce intense fragments in MS/MS with a very        strong single peak. However, a very strong single fragment does        not make it possible to validate the identity of the transition        in a complex mixture. Indeed, only the simultaneous presence of        several characteristic fragments makes it possible to verify        that the precursor ion sought has actually been detected,    -   the peptides having a Proline adjacent to the C-terminal        (Position n-1) or in second position relative to the C-terminal        (position n-2) should be avoided because, in this case, the size        of the first-generation peptide fragment is generally considered        to be too small to be sufficiently specific,    -   the selection of fragments having a mass greater than the        precursor should be given preference in order to promote        specificity. To this end, it is necessary to select a dicharged        precursor ion and select the most intense first-generation ion        fragment having a mass greater than the precursor, i.e. a        monocharged first-generation fragment ion.

The fragmentation of the selected precursor ions is performed in afragmentation cell such as the triple quadripole model [20], ion trapmodel [21], or time-of-flight (TOE) model [22], which also make itpossible to separate ions. The fragmentation or fragmentations will beconventionally performed by collision with an inert gas such as argon ornitrogen, within an electrical field, by photo-excitation orphoto-dissociation using an intense light source, collision withelectrons or radical species, by applying a potential difference, forexample in a time-of-flight tube, or by any other activation mode. Thecharacteristics of the electrical field determine the intensity andnature of the fragmentation. Thus, the electrical field applied in thepresence of an inert gas, for example in a quadripole, determines thecollision energy provided to the ions. This collision energy will beoptimised, by the person skilled in the art, to increase the sensitivityof the transition to be assayed. By way of example, it is possible tovary the collision energy between 5 and 180 eV in q2 in an AB SCIEXQTRAP® 5500 mass spectrometer from the company Applied Biosystems(Foster City, United States of America). Similarly, the duration of thecollision step and the excitation energy within, for example, an iontrap will be optimised by the person skilled in the art to lead to themost sensitive assay. By way of example, it is possible to vary thisduration, called excitation time, between 0.010 et 50 ms and theexcitation energy between 0 and 1 (arbitrary unit) in Q3 in an AB SCIEXQTRAP® 5500 mass spectrometer by the company Applied Biosystems.

Finally, the detection of the selected characteristic ions takes placein the conventional manner, particularly by means of a detector and aprocessing system. The detector collects the ions and produces anelectrical signal whose intensity depends on the amount of ionscollected. The signal obtained is then amplified such that it can beprocessed by computer. A computer data processing assembly makes itpossible to transform the information received by the mass spectrumdetector.

The principle of the SRM mode, or even of the MRM mode, is tospecifically select a precursor ion, fragment it, and then specificallyselect one of its fragment ions. For such applications, triplequadripole or hybrid triple quadripole/ion trap devices are generallyused.

In the case of a triple quadripole device (Q1q2Q3) used in MS² mode,with a view to assaying or detecting a target protein, the firstquadripole (Q1) makes it possible to filter the molecular ionscorresponding to the proteotypic peptides characteristic of the proteinto be assayed and obtained during an earlier digestion step, dependingon their mass-to-charge ratio (m/z). Only the peptides having themass-to-charge ratio of the proteotypic peptide sought, which ratio iscalled (m/z)₁, are transmitted into the second quadripole (q2) and actas precursor ions for the subsequent fragmentation. The analyser q2 canfragment the peptides of mass-to-charge ratio (m/z)₁ intofirst-generation fragment ions. Fragmentation is generally obtainedthrough collision of the precursor peptides with an inert gas, such asnitrogen or argon in q2. The first-generation fragment ions aretransmitted into a third quadripole (Q3) which filters thefirst-generation fragment ions depending on a specific mass-to-chargeratio, called (m/z)₂. Only the first-generation fragment ions having themass-to-charge ratio of a fragment characteristic of the soughtproteotypic peptide (m/z)₂ are transmitted into the detector in order tobe detected, or even quantified.

This mode of operation exhibits a double selectivity, with regard to theselection of the precursor ion on the one hand, and the selection of thefirst-generation fragment ion on the other hand. Mass spectrometry inSRM or MRM mode is therefore advantageous for quantification.

When the mass spectrometry employed in the method according to inventionis tandem mass spectrometry (MS², MS³, MS⁴ or MS⁵), several massanalysers can be linked to one another. For example, a first analyserseparates the ions, a collision cell makes it possible to fragment theions, and a second analyser separates the fragment ions. Certainanalysers, such as the ion traps or the FT-ICR, constitute severalanalysers in one and make it possible to fragment the ions and analysethe fragments directly.

According to preferred embodiments of the invention, the method of theinvention comprises one or more of the following characteristics:

-   -   the mass spectrometry employed for the properties of potential        resistance to at least one antimicrobial is MS/MS spectrometry,        which has the advantage of producing a fragment which is        specific to the molecule to be detected or quantified, and thus        of providing great specificity to the assaying method;    -   the MS/MS spectrometry is MRM which has the advantage of using        an analysis cycle time in the mass spectrometer of several tens        of milliseconds, which makes it possible to detect or quantify,        with a high degree of sensitivity, a large number of different        molecules in a multiplexed manner;    -   where applicable, the determination of the type properties and        of the virulence factor is performed in the same mass        spectrometry apparatus as the determination of the markers of        resistance to at least one antimicrobial, preferably        simultaneously, which has the advantage of reducing the analysis        time and the cost of the instrument, which also facilitates the        processing and the yielding of the results.

In addition to determining the resistance to an antibiotic, it isnecessary to identify the microorganism or microorganisms present in thesample to be tested.

The methods of identifying microorganisms are widely known to the personskilled in the art, as described for example by Murray P. R. et al. inManual of Clinical Microbiology, 2007, 9^(th) edition, and especially inVol. I, Section III, chapters 15 and 16 for bacteria and yeasts, Vol.II, Section VI, chapter 82 for viruses, and Vol. II, Section X, chapter135 for protozoa. As an example of conventional identification methods,mention can be made of the determination of the biological profile, byusing the Vitek 2 (bioMérieux) identification cards, for example, oreven by using molecular biology techniques with identification criteriabased on the study of the presence of certain genes, and on the study oftheir sequence.

Identification can be performed directly from the sample in which theidentification is made, or the microorganisms contained in the samplecan be cultured using methods well known to the person skilled in theart with optimal culture media and culturing conditions tailored to thespecies of microorganisms to be sought, as described by Murray P. R. etal. in Manual of Clinical Microbiology, 2007, 9^(th) edition, Vol. I,Section III, chapter 14, and in particular in Vol. I, Section IV,chapter 21 for bacteria, and Vol. II, Section VI, chapter 81 forviruses, Vol. II, Section VIII, chapter 117 for yeasts, and Vol. II,Section X, chapter 134 for protozoa.

Thus, generally, in the case of an identification using a biochemicalmethod of a bacterium in a specimen, it is first necessary to obtain itin a pure culture, for example after seeding on agar. Molecular biology(PCR) can in certain cases be applied directly to the sample to beanalysed.

Instead of cultivating the microorganisms, they can be concentrated bycapture directly in the sample by means of active surfaces. Such amethod was described by W.-J. Chen et al. [10] who captured differentbacterial species with the aid of magnetic beads with anFe₃O₄/TiO₂-activated surface. Capture by other means is also possible,such as a capture by lectins [23], or by antibodies [24], or byVancomycin [25]. The capture makes it possible to concentrate themicroorganisms and thus to reduce or even eliminate the culture step.This results in a considerable time saving.

The identification may also be performed by mass spectrometry, inaccordance with the techniques described previously, preferably by MS,by MS/MS, or even by MS followed by MS/MS spectrometry, whichconstitutes one embodiment of the invention. In this case too, thesample can be subjected to a culture step beforehand, such as seeding onagar.

The use of an MS identification method is advantageous in that it may becarried out in a few minutes, and in that it requires a massspectrometer with a single analyser, i.e. a less complex instrument thana tandem mass spectrometer used in MS/MS.

The use of a method of identification by MS followed by MS/MSspectrometry is also advantageous. It makes it possible to check theidentity of the ions observed by MS, which increases the specificity ofthe analysis.

The use of an MRM-type MS/MS identification method has the advantage ofbeing more sensitive and simpler than the conventional MS followed byMS/MS approaches. This method requires neither a high-performancesoftware to process the information between the acquisition of the MSspectrum and of the MS/MS spectrum, nor a change in the setting of themachine parameters for linking up MS then MS/MS spectra.

The method of identification by MS may be employed with an electrospraysource on a raw sample, as described by S. Vaidyanathan et al. [26] orby R. Everley et al. [27] after chromatographic separation. Differentm/z ranges thus make it possible to identify the microorganisms. S.Vaidyanathan et al. used a window of between 200 and 2000 Th, and R.Everley et al. used a window of between 620 and 2450 Th. The massspectra may also be deconvoluted to access the mass of the proteinsindependently of their charge state. R. Everley et al. therefore usedmasses of between about 5,000 and 50,000 Da. Alternatively, the methodof identification by MS can also be employed with the aid of aMALDI-TOF, as described by Claydon et al. [3] and T. Krishnamurthy andP. Ross [4]. The analysis combines acquisition of a mass spectrum andinterpretation of expert software. It is extremely simple and can becarried out in a few minutes. This method of identification is currentlybecoming more widespread in medical analysis laboratories [28].

The identification of bacteria by MS followed by MS/MS via theirproteins present in the sample has been applied widely by a number ofteams. By way of example, mention can be made of the recent work ofManes N. et al. [29], who studied the peptidome of Salmonella enterica,or the work of R. Nandakumar et al. [30] or of L. Hernychova et al. [31]who have studied the proteome of bacteria after digestion of theproteins with trypsin. The conventional approach consists in i)acquiring an MS spectrum, ii) successively selecting each precursor ionobserved on the MS spectrum with an intense signal, iii) successivelyfragmenting each precursor ion and acquiring its MS/MS spectrum, iv)interrogating protein databases such as SWISS-PROT or NCBI, throughsoftware such as Mascot (Matrix Science, London, United Kingdom) orSEQUEST (Thermo Scientific, Waltham, United States of America), toidentify the peptide which has a strong probability of matching theMS/MS spectrum observed. This method may lead to the identification of amicroorganism if a protein or a peptide characteristic of the species isidentified.

One of the advantages of the use of mass spectrometry lies in that it isparticularly useful for quantifying molecules, in the present case themarkers of the mechanisms of bacterial resistance to beta-lactams. Tothis end, the current intensity detected is used, which is proportionalto the quantity of target molecule. The current intensity thus measuredmay serve as a quantitative measurement making it possible to determinethe quantity of target molecule present, which is characterised by itsexpression in International System (SI) mol/m³ or kg/m³ units, or bymultiples or sub-multiples of these units, or by the usual derivativesof the SI units, including multiples or sub-multiples thereof. As anon-limiting example, the units such as ng/ml or fmol/l are unitscharacterising a quantitative measurement.

A calibration is nevertheless necessary in order to be able to correlatethe measured area of the peak, which corresponds to the currentintensity induced by the detected ions, to the quantity of targetmolecule to be assayed. For this purpose, the calibrationsconventionally used in mass spectrometry may be employed, within theframework of the invention. MRM assays are conventionally calibratedwith the aid of external standards or, preferably, with the aid ofinternal standards such as described by T. Fortin et al. [13]. If thetarget molecule is a proteotypic peptide which permits the assaying of aprotein of interest, the correlation between the quantitativemeasurement and the quantity of target proteotypic peptide, andsubsequently of protein of interest, is obtained by calibrating themeasured signal relative to a standard signal for which the quantity tobe assayed is known. The calibration may be performed using acalibration curve, for example obtained by successive injections ofstandard proteotypic peptide at different concentrations (externalcalibration), or preferably by internal calibration using a heavypeptide as an internal standard, for example in accordance with theAQUA, QconCAT or PSAQ methods detailed below. “Heavy peptide” isunderstood to mean a peptide corresponding to the proteotypic peptide,but in which one or more atoms of carbon 12 (¹²C) is (are) replaced bycarbon 13 (¹³C), and/or one or more atoms of nitrogen 14 (¹⁴N) is (are)replaced by nitrogen 15 (¹⁵N).

The use of heavy peptides as internal standards (AQUA) was also proposedin US patent application 2004/0229283. The principle is to artificiallysynthesise proteotypic peptides with amino acids containing isotopeswhich are heavier than the usual natural isotopes. Such amino acids areobtained, for example, by replacing some of the atoms of carbon 12 (¹²C)with carbon 13 (¹³C), or by replacing some of the atoms of nitrogen 14(¹⁴N) with nitrogen 15 (¹⁵N). The artificial peptide (AQUA) thussynthesised has strictly the same physicochemical properties as thenatural peptide (with the exception of a higher mass). It is generallyadded, at a given concentration, to the sample, upstream of assaying bymass spectroscopy, for example between the treatment entailing thecleaving of the proteins in the sample of interest and the fractionationof the peptides obtained after the treatment step. Thus, the AQUApeptide is co-purified with the natural peptide to be assayed, duringfractionation of the peptides. The two peptides are therefore injectedsimultaneously into the mass spectrometer, for assaying. They thenundergo the same ionisation yield in the source. The comparison of thepeak areas of the natural and AQUA peptides, whose concentration isknown, makes it possible to calculate the concentration of the naturalpeptide and thus the concentration of the protein to be assayed. Avariation of the AQUA technique was proposed by J.-M. Pratt et al. [32]under the name QconCat. This variant is also described in patentapplication WO 2006/128492. It consists in concatenating various AQUApeptides and producing the artificial polypeptide in the form of a heavyrecombinant protein. The recombinant protein is synthesised with aminoacids comprising heavy isotopes. In this way, it is possible to obtain astandard to calibrate the simultaneous assay of several proteins atlower cost. The QconCAT standard is added from the start, upstream ofthe treatment entailing the cleaving of the proteins and prior to thesteps of protein fractionation, denaturation, reduction and blocking ofthe protein thiol functions, if these are present. The QconCAT standardtherefore undergoes the same treatment cycle entailing the cleaving ofthe proteins as the natural protein, which makes it possible to takeaccount of the yield from the treatment step which entails the cleavingof the proteins. In fact, the treatment, particularly by digestion, ofthe natural protein may not be complete. In this case, the use of anAQUA standard would lead to underestimating the quantity of naturalprotein. For full assaying, it may therefore be important to take intoaccount the yields from treatment which entails the cleaving of theproteins. However, V. Brun et al. [33] have shown that the QconQATstandards sometimes do not exactly reproduce the treatment yieldparticularly by digestion of the natural protein, undoubtedly due to athree-dimensional conformation different from the QconCAT protein.

V. Brun et al. [33] then proposed the use of a method dubbed PSAQ, anddescribed in patent application WO 2008/145763. In this case, theinternal standard is a recombinant protein having the same sequence asthe natural protein but synthesised with heavy amino acids. Thesynthesis is performed ex-vivo with heavy amino acids. This standard hasstrictly the same physicochemical properties as the natural protein(with the exception of a higher mass). It is added from the start,before the protein fractionation step, when the latter is present. It istherefore co-purified with the native protein, during the proteinfractionation step. It exhibits the same treatment yield, particularlyby digestion, as the native protein. The heavy peptide obtained aftercleaving is also co-purified with the natural peptide, if a peptidefractionation step is performed. The two peptides are therefore injectedsimultaneously into the mass spectrometer, to be quantitatively assayed.They then undergo the same ionisation yields in the source. Comparisonof the peak areas of the natural and the reference peptides in the PSAQmethod makes it possible to calculate the concentration of the proteinto be assayed taking into account all of the steps of the assay method.

All of these techniques, namely AQUA, QconCAT or PSAQ or any othercalibration technique, used in the mass spectrometry assays and inparticular in MRM or MS assays, may be employed to carry outcalibration, within the framework of the invention.

Preferably, the mass spectrometry used in the detection method accordingto the invention is MS/MS. More preferably, the mass spectrometry isMRM.

The method of the invention makes it possible to detect resistances tocarbapenems, characterised by the detection of at least one peptide as aresistance marker. Said resistance marker peptide preferably belongs tothe proteins NDM, KPC, GES, IMP, IND, SME, VIM or OXA.

In particular, the detection of a mechanism of resistance to carbapenemsinduced by the expression of an NDM protein is characterised by thedetection of at least one peptide belonging to an NDM protein and itsdifferent sequence variants SEQ ID No. 1 and SEQ ID No. 1078 to SEQ IDNo. 1080.

SEQ ID No. 1: MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLVFRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH SAPDSRAAITHTARMADKLRSEQ ID No. 1078 MELPNIMHPVAKLSTALAAALMLSGCMAGEIRPTIGQQMETGDQRFGDLVFRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH SAPDSRAAITHTARMADKLRSEQ ID No. 1079 MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLVFRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLLVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGLVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH SAPDSRAAITHTARMADKLRSEQ ID No. 1080 MELPNIMHPVAKLSTALAAALMLSGCMPGEIRPTIGQQMETGDQRFGDLVFRQLAPNVWQHTSYLDMPGFGAVASNGLIVRDGGRVLVVDTAWTDDQTAQILNWIKQEINLPVALAVVTHAHQDKMGGMDALHAAGIATYANALSNQLAPQEGMVAAQHSLTFAANGWVEPATAPNFGPLKVFYPGPGHTSDNITVGIDGTDIAFGGCLIKDSKAKSLGNLGDADTEHYAASARAFGAAFPKASMIVMSH SAPDSRAAITHTARMADKLR

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 2 to SEQ ID No. 9 and SEQ ID No. 1083 as defined hereafter:

Peptide SEQ ID No. Amino acid sequence Position of the peptide in theNDM protein(s) SEQ ID AAITHTAR 257-264 for the proteins of SEQ No. 1,1078, No. 2 1079, 1080 SEQ ID AFGAAFPK 235-242 for the proteins of SEQNo. 1, 1078, No. 3 1079, 1080 SEQ ID ASMIVMSHSAPDSR 243-256 for theproteins of SEQ No. 1, 1078, No. 4 1079, 1080 SEQ ID FGDLVFR 46-52 forthe proteins of SEQ No. 1, 1078, No. 5 1079, 1080 SEQ ID MELPNIMHPVAK1-12 for the proteins of SEQ No. 1, 1078, 1079, No. 6 1080 SEQ IDQEINLPVALAVVTHAHQDK 107-125 for the proteins of SEQ No. 1, 1078, No. 71079, 1080 SEQ ID SLGNLGDADTEHYAASAR 217-234 for the proteins of SEQ No.1, 1078, No. 8 1079, 1080 SEQ ID VLVVDTAWTDDQTAQILNWIK 86-106 for theproteins of SEQ No. 1, 1078, No. 9 1080 SEQ ID LSTALAAALMLSGCMAGEIR13-32 for the protein of SEQ No. 1078 No. 1081 SEQ IDLSTALAAALMLSGCMPGEIR 13-32 for the protein of SEQ No. 1, 1079, 1080 No.1082 SEQ ID VLLVDTAWTDDQTAQILNWIK 86-106 for the protein of SEQ No. 1079No. 1083

Preferably, the resistance markers are NDM markers, chosen from thepeptides of sequence SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 5, or SEQ IDNo. 7.

The detection of a mechanism of resistance to carbapenems induced by theexpression of a KPC protein is characterised by the detection of atleast one peptide belonging to a KPC protein and to its differentsequence variants SEQ ID No. 10 to SEQ ID No. 19 and SEQ ID No. 1084 toSEQ ID No. 1093.

SEQ ID No. 10: MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 11:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 12:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 13:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 14:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 15:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAIDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 16:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 17:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGAYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLG SEQ ID No. 18:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 19:MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVLWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1084MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1085MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1086MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1087MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1088MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPSDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1089MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELEMNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1090MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1091MSLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGVYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLGVNGQ SEQ ID No. 1092RLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVPWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGAYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKYSEAVIAAAARLALEGLG SEQ ID No. 1093SLYRRLVLLSCLSWPLAGFSATALTNLVAEPFAKLEQDFGGSIGVYAMDTGSGATVSYRAEERFPLCSSFKGFLAAAVLARSQQQAGLLDTPIRYGKNALVRWSPISEKYLTTGMTVAELSAAAVQYSDNAAANLLLKELGGPAGLTAFMRSIGDTTFRLDRWELELNSAIPGDARDTSSPRAVTESLQKLTLGSALAAPQRQQFVDWLKGNTTGNHRIRAAVPADWAVGDKTGTCGGYGTANDYAVVWPTGRAPIVLAVYTRAPNKDDKHSEAVIAAAARLALEGLGVNGQ

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 20 to SEQ ID No. 33 and SEQ ID No. 1094 to SEQ ID No. 1097 asdefined hereafter:

Peptide SEQ ID No. Amino acid sequence Position of the peptide in theKPC protein(s) SEQ AAVPADWAVGDK 221-232 for the protein of SEQ No. 1093;222-233 for the ID No. proteins of sequence SEQ ID No. 10, 11, 12, 13,14, 15, 16, 20 17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,1091, 1092 SEQ APIVLAVYTR 254-263 for the protein of SEQ No. 1093;255-264 for the ID No. proteins of sequence SEQ ID No. 10, 11, 12, 13,14, 15, 16, 21 17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090,1091, 1092 SEQ AVTESLQK 183-190 for the protein of SEQ No. 1093; 184-191for the ID No. proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15,16, 22 17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092SEQ ELGGPAGLTAFMR 139-151 for the protein of SEQ No. 1093; 140-152 forthe ID No. proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16,23 17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092 SEQFPLCSSFK 64-71 for the protein of SEQ No. 1093; 65-72 for the ID No.proteins of sequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16, 24 17, 18,19, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092 SEQ GFLAAAVLAR72-81 for the protein of SEQ No. 1093; 73-82 for the ID No. proteins ofsequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16, 25 17, 18, 19, 1084,1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092 SEQ GNTTGNHR 211-218 forthe protein of SEQ No. 1093; 212-219 for the ID No. proteins of sequenceSEQ ID No. 10, 11, 12, 13, 14, 15, 16, 26 17, 18, 19, 1084, 1085, 1086,1087, 1088, 1089, 1090, 1091, 1092 SEQ LALEGLGVNGQ 282-292 for theprotein of SEQ No. 1093; 283-293 for the ID No. proteins of sequence SEQID No. 10, 11, 12, 13, 14, 15, 16, 27 18, 19, 1084, 1085, 1086, 1087,1088, 1089, 1090, 1091 SEQ LTLGSALAAPQR 191-202 for the protein of SEQNo. 1093; 192-203 for the ID No. proteins of sequence SEQ ID No. 10, 11,12, 13, 14, 15, 16, 28 17, 18, 19, 1084, 1085, 1086, 1087, 1088, 1089,1090, 1091, 1092 SEQ NALVPWSPISEK 94-105 for the protein of SEQ No.1092; 99-110 for the ID No. proteins of sequence SEQ ID No. 10, 11, 14,15, 16, 17, 29 1084, 1085, 1086, 1087, 1088, 1089 SEQ QQFVDWLK 203-210for the protein of SEQ No. 1093; 204-211 for the ID No. proteins ofsequence SEQ ID No. 10, 11, 12, 13, 14, 15, 16, 30 17, 18, 19, 1084,1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092 SEQ SIGDTTFR 152-159 forthe protein of SEQ No. 1093; 153-160 for the ID No. proteins of sequenceSEQ ID No. 10, 11, 12, 13, 14, 15, 16, 31 17, 18, 19, 1084, 1085, 1086,1087, 1088, 1089, 1090, 1091, 1092 SEQ SQQQAGLLDTPIR 82-94 for theprotein of SEQ No. 1093; 83-95 for the ID No. proteins of sequence SEQID No. 10, 11, 12, 13, 14, 15, 16, 32 17, 18, 19, 1084, 1085, 1086,1087, 1088, 1089, 1090, 1091, 1092 SEQ WELELNSAIPGDAR 163-176 for theprotein of SEQ No. 1093; 164-177 for the ID No. proteins of sequence SEQID No. 10, 11, 12, 13, 14, 15, 16, 33 17, 18, 19, 1084, 1085, 1086,1087, 1090, 1091, 1092 SEQ NALVR 98-102 for the proteins of SEQ No.1093; 99-103 for the ID No. proteins of sequence SEQ ID No. 12, 13, 18,1090, 1091 1094 SEQ TGTCGAYGTANDYAVVWPTGR 229-249 for the protein of SEQNo. 1092; 234-254 for the ID No. protein of sequence SEQ ID No. 17 1095SEQ WELELNSAIPSDAR 164-177 for the protein of SEQ No. 1088 ID No. 1096SEQ WELEMNSAIPGDAR 164-177 for the protein of SEQ No. 1089 ID No. 1097

Preferably, the resistance markers are KPC markers, chosen from thepeptides of sequence SEQ ID No. 20, SEQ ID No. 21, SEQ ID No. 23, SEQ IDNo. 25, SEQ ID No. 28, SEQ ID No. 29, SEQ ID No. 31, or SEQ ID No. 32.

The detection of a mechanism of resistance to carbapenems and/or tocephalosporins induced by the expression of a GES protein ischaracterised by the detection of at least one peptide belonging to aGES protein and to its different sequence variants SEQ ID No. 34 to SEQID No. 50.

SEQ ID No. 34: MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 35:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 36:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQLAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 37:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMNDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 38:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 39:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 40:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGSRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 41:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 42:MRFIHALLLAGTAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLCDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 43:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMNDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 44:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKESEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 45:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 46:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAEIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 47:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGARNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 48:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 49:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRTAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVKWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMSDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGTCANGGRNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK SEQ ID No. 50:MRFIHALLLAGIAHSAYASEKLTFKTDLEKLEREKAAQIGVAIVDPQGEIVAGHRMAQRFAMCSTFKFPLAALVFERIDSGTERGDRKLSYGPDMIVEWSPATERFLASGHMTVLEAAQAAVQLSDNGATNLLLREIGGPAAMTQYFRKIGDSVSRLDRKEPEMGDNTPGDLRDTTTPIAMARTVAKVLYGGALTSTSTHTIERWLIGNQTGDATLRAGFPKDWVVGEKTGACANGARNDIGFFKAQERDYAVAVYTTAPKLSAVERDELVASVGQVITQLILSTDK

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 51 to SEQ ID No. 79 as defined hereafter:

Peptide SEQ ID Clinical No. Amino acid sequence Position of the peptidein the GES protein(s) interest SEQ ID AAEIGVAIVDPQGEIVAGHR 36-55 for theprotein of SEQ No. 46 carba No. 51 SEQ ID AAQIGVAIVDPQGEIVAGHR 36-55 forthe proteins of SEQ No. 34, 35, 36, 37, 38, ESBL No. 52 39, 40, 41, 42,43, 44, 45, 47, 48, 49, 50 SEQ ID AGFPK 218-222 for the proteins of SEQNo. 34, 35, 36, 37, ESBL No. 53 38, 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50 SEQ ID DTTTPIAMAR 174-183 for the proteins of SEQ No. 34, 35,36, 37, ESBL No. 54 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50SEQ ID DWVVGEK 223-229 for the proteins of SEQ No. 34, 35, 36, 37, ESBLNo. 55 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ IDDYAVAVYTTAPK 250-261 for the proteins of SEQ No. 34, 35, 36, 37, ESBLNo. 56 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ IDEIGGPAAMTQYFR 136-148 for the proteins of SEQ No. 34, 35, 36, 37, ESBLNo. 57 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ IDEPEMGDNTPGDLR 161-173 for the proteins of SEQ No. 34, 35, 36, 40, ESBLNo. 58 41, 42, 47, 48, 50 SEQ ID EPEMNDNTPGDLR 161-173 for the proteinsof SEQ No. 37, 43 carba No. 59 SEQ ID EPEMSDNTPGDLR 161-173 for theproteins of SEQ No. 38, 39, 45, 46, carba No. 60 49 SEQ ID ESEMSDNTPGDLR161-173 for the protein of SEQ No. 44 carba No. 61 SEQ ID FAMCSTFK 60-67for the proteins of SEQ No. 34, 35, 36, 37, 38, ESBL No. 62 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ ID FIHALLLAGTAHSAYASEK 3-21 forthe proteins of SEQ No. 34, 35, 36, 37, 38, ESBL No. 63 39, 40, 41, 43,44, 45, 46, 47, 48, 49, 50 SEQ ID FIHALLLAGTAHSAYASEK 3-21 for theprotein of SEQ No. 42 carba No. 64 SEQ ID FPLAALVFER 68-77 for theproteins of SEQ No. 34, 35, 36, 37, 38, ESBL No. 65 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50 SEQ ID IDSGTER 78-84 for the proteins of SEQNo. 34, 35, 36, 37, 38, ESBL No. 66 39, 40, 41, 42, 43, 44, 45, 46, 47,48, 49, 50 SEQ ID IGDSVSR 150-156 for the proteins of SEQ No. 34, 35,36, 37, ESBL No. 67 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50SEQ ID LSAVER 262-267 for the proteins of SEQ No. 34, 35, 36, 37, ESBLNo. 68 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ IDLSYGPDMIVEWSPATER 89-105 for the proteins of SEQ No. 34, 36, 37, 38,ESBL No. 69 40, 41, 42, 44, 45, 46, 50 SEQ ID LSYGPDMIVK 89-98 for theproteins of SEQ No. 35, 39, 43, 47, 48, carba No. 70 49 SEQ ID NDIGFEK239-245 for the proteins of SEQ No. 34, 35, 36, 37, ESBL No. 71 38, 39,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ ID TDLEK 26-30 for theproteins of SEQ No. 34, 35, 36, 37, 38, ESBL No. 72 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50 SEQ ID TGACANGAR 230-238 for the protein ofSEQ No. 50 carba No. 73 SEQ ID TGTCANGAR 230-238 for the proteins of SEQNo. 41, 45, 47 carba No. 74 SEQ ID TGTCANGGR 230-238 for the proteins ofSEQ No. 34, 35, 36, 37, ESBL No. 75 38, 39, 42, 43, 44, 46, 48, 49 SEQID TGTCANGSR 230-238 for the protein of SEQ No. 40 carba No. 76 SEQ IDVLYGGALTSTSTHTIER 188-204 for the proteins of SEQ No. 34, 35, 36, 37,ESBL No. 77 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ IDWLIGNQTGDATLR 205-217 for the proteins of SEQ No. 34, 35, 36, 37, ESBLNo. 78 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 SEQ ID WSPATER99-105 for the proteins of SEQ No. 34, 35, 36, 37, carba No. 79 38, 39,40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50

In the clinical interest column, the ESBL and carba entries correspondto the GES beta-lactamase activities which the corresponding peptidemakes it possible to detect. Therefore, the detection of a carba peptidewill indicate the presence of a carbapenemase beta-lactamase capable ofhydrolysing carbapenems.

If no peptide referred to as carba is detected, the detection of apeptide referred to as ESBL will indicate the presence of abeta-lactamase with an extended spectrum (ESBL) capable of hydrolysingpenicillins, first-generation cephalosporins such as cephaloridine andcefalotin, and at least one antibiotic from the oxyimino-beta-lactamclass such as cefotaxime, ceftazidime or monobactams such as aztreonam.

The detection of a mechanism of resistance to carbapenems induced by aGES protein is thus characterised by the detection of at least oneresistance-marking carba peptide chosen from the sequences SEQ ID No.51, 59, 60, 61, 64, 70, 73, 74, 76, 79.

The detection of a mechanism of resistance to carbapenems induced by theexpression of an IMP protein is characterised by the detection of atleast one peptide belonging to an IMP protein and to its differentsequence variants SEQ ID No. 80 to SEQ ID No. 105.

SEQ ID No. 80: MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGVVGVVPKHGLVVLVNAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKLWPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 81:MKKLSVFFMFLFCSIAASGEALPDLKIEKLDEGVYVHTSFEEVNGWGWPKHGLVVLVNTDAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDSTGGIEWLNSOSIPTYASELTNELLKKDGKVQAKNSFSGASYVVLVKKKIEIFYPGPGHTPDNVVVWLPEHRVLFGGCFVKPYGLGNLGDANLEAWPKSAKLLVSKYGKAKLVVPSHSEVGDASLLKRTLEQAVKGLNESKKLSKPSN SEQ ID No. 82:MSKLSVFFIFLFCSIATAAEPLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVDAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFGGVNYVVLVKNKIEVFYPGPGHTPDNLVVWLPERKILFGGCFIKPYGLGNLGDANLEAWPKSAKLLISKYGKAKLVVPSHSEAGDASLLKLTLEQAVKGLNESKKPSKLSN SEQ ID No. 83:MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVVSKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYWLVKNKIEVFYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAKILMSKYGKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESKKPSQPSN SEQ ID No. 84:MSKLFVFFMFLFCSITAAAESLPDLKIEKLDEGVYVHTSFEEVNGWGWPKHGLVVLVNTEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGASYVVLVKKKIEVFYPGPGHTPDNVVVWLPENRVLFGGCFVKPYGLGNLGDANVEAWPKSAKLLMSKYGKAKLVVPSHSEVGDASLLKRTLEQAVKGLNESKKPSKPSN SEQ ID No. 85:MSKLFVFFMFLFCSITAAGESLPDLKIEKLDEGVYVHTSFEEVNGWGVIPKHGLVVLVNTDAYLIDTPFTAKDTENLVNWFVERGYRIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKYSFSGVSYVVLVKKKIEVFYPGPGHAPDNVVVWLPENRVLFGGCFVKPYGLGNLGDANLEAWPKSAKLLMSKYSKAKLWPSHSDIGDSSLLKLTVVEQTVKGFNESKKSTTAH SEQ ID No. 86:MKKLFVLCVFFFCNIAVAEESLPDLKIEKLEEGVYVHTSFEEVKGWSVVTKHGLVVLVKNDAYLIDTPITAKDTEKLVNWFVERGYKIKGSISTHFHGDSTAGIEVVLNSQSIPTYASELTNELLKKDNKVQAKHSFNGVSYSLIKNKIEVFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGYLGDANLEAINPKSAKILMSKYGKAKLVVSSHSDIGDVSLLKRTVVEQAVKGLNESKKSSQPSD SEQ ID No. 87:MNKLSVFFMFMFCSITAAGESLPDLKIEKLDEGVYVHTSFEEVNGVVGVVPKHGLVVLVNTEAYLIDTPFTAKDTEKLVTINFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGGSYINLVNNKIEVFYPGPGHTPDNVVVVVLPENRVLFGGCFVKPYGLGNLGDANLEAWPKSAKILMSKYGKAKLVVSSHSETGNASLLKLTWEQAVKGLKESKKPSLPSN SEQ ID No. 88:MKKLFVLCVFFLCNIAAADDSLPDLKIEKLEKGVYVHTSFEEVKGWGVVTKHGLVVLVKNDAYLIDTPITAKDTEKLVNINFIEHGYRIKGSISTHFHGDSTAGIEWLNSQSISTYASELTNELLKKDNKVQATNSFSGVSYSLIKNKIEVFYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAKILMSKYGKAKLVVSSHSEIGNASLLQRTVVEQAVKGLNESKKPLQPSS SEQ ID No. 89:MKKLFVLCVFLFCSITAAGESLPDLKIEKLEEGVYVHTSFEEVNGWGVVSKHGLVILVNTDAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNDLLKQNGKVQAKNSFSGVSYVVLVKNKIEVFYPGPGHTQDNVVVINLPEKKILFGGCFVKPYGLGNLDDANVVAWPHSAEILMSRYGNAKLVVPSHSDIGDASLLKLTWEQAVKGLKESKKPSEPSN SEQ ID No. 90:MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFKEVNGWGVVPKHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKIEVFYPGPGHTPDNVWVVLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 91:MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVVSKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKIEVFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAKILMSKYVKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESKKPSQPSN SEQ ID No. 92:MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGWSKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYWLVKNKIEVFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAWPKSAKILMSKYGKAKLVVSSHSEIGDASLLKRTWEQAVKGLNESRKPSQPSN SEQ ID No. 93:MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFlKPYGLGNLSDANIEAWPKSAKLLKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 94:MSKLSVFFIFLFCSIATAAEPLPDLKIEKLDEGVYVHTSFEEVNGWGVFPKHGLVVLVDAEAYLIDTPFTAKDTEKLVIVVFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFGGVNYWLVKNKIEVFYPGPGHTPDNLVVVVLPERKILFGGCFIKPYGLGNLGDANLEAWPKSAKLLISKYGKAKLVVPSHSEAGDASLLKLTLEQAVKGLNESKKPSKLSN SEQ ID No. 95:MKKLFVLCVFVFCSITVAGETLPNLRVEKLEEGVYVHTSYEEVKGWGVVTKHGLVVLIGADAYLIDTPFTAKDTEKLVNWFVERGYKIKGTVSSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFDGVSYVVLAKDKIEVFYPGPGHTQDNVVVWLPEKEILFGGCFVKPHGLGNLGDANLEAWPESAKILMEKYGKAKLVVSGHSETGDATHLKRTWEQAVKGLKESKKTLQPSN SEQ ID No. 96:MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNAEAYLIDTPFTAKDTEKLVTWFVERGYKIKGSISSHFHSDSTGGIGWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIEVFYPGPGHTPDNVVVWLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 97:MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVVPKHGLVVLVNAEAYLIDTPFTAKDTEKLVIWFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYWLVKNKIEVFYPGPGHTPDNVVVVVLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPGHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 98:MSKLSVFFIFLFCSIATAAESLPDLKIEKLDEGVYVHTSFEEVNGWGVFPKHGLVVLVNAEAYLIDTPFTAKDTEKLVTVVFVERGYKIKGSISSHFHSDSTGGIEWLNSRSIPTYASELTNELLKKDGKVQATNSFSGVNYVVLVKNKIEVFYPGPGHTPDNVVINVLPERKILFGGCFIKPYGLGNLGDANIEAWPKSAKLLKSKYGKAKLVVPSHSEVGDASLLKLTLEQAVKGLNESKKPSKPSN SEQ ID No. 99:MKKLFVLCIFLFCSITAAGASLPDLKIEKLEEGVYVHTSFEEVNGWGVVSKHGLVVLVNTDAYLIDTPFTAKDTEKLVNWFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASVLTNELLKKDGKVQAKNSFSGVSYWLVKNKIEVFYPGPGHTQDNVVVWLPKNKILFGGCFVKPYGLGNLDDANVEAWPHSAEKLISKYGNAKLVVPSHSDIGDASLLKLIVVEQAVKGLNESKKSNTVH SEQ ID No. 100:MKKLFVLCVCFLCSITAAGAALPDLKIEKLEEGVYVHTSFEEVNGWGVFSKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDSTGGIEINLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKIEVFYPGPGHTQDNVVVVVLPEKKILFGGCFVKPDGLGNLGDANLEAVVPKSAKILMSKYVKAKLVVSSHSEIGDASLLKRTVVEQAVKGLNESKKPSQPS N SEQ ID No. 101:MKKLFVLCIFLFCSITAAGASLPDLKIEKLEEGVYVHTSFEEVNGVVGVASKHGLVVLVNTDAYLIDTPFTAKDTEKLVNVVFVERGYKIKGSISSHFHSDSTGGIEWLNSQSIPTYASVLTNELLKKDGKVQAKNSFSGVSYVVLVKNKIEVFYPGPGHTQDNVVVVVLPKNKILFGGCFVKPYGLGNLDDANVEAINPHSAEKLISKYGNAKLVVPSHSDIGDASLLKLTVVEQAVKGLNESKKSNTV H SEQ ID No. 102:MKKLFVLCVCFLCSITAAGARLPDLKIEKLEEGVYVHTSFEEVNGVVGVVSKHGLVVLVNTDAYLIDTPFTATDTEKLVNWFVERGYKIKGTISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKDGKVQAKNSFSGVSYVVLVKNKIEVFYPGPGHTQDNVVVWLPEKKILFGGCFVKPDGLGNLGDANLEAVVPKSAKILMSKYVKAKLVVSSHSEIGDASLLKRTVVEQAVKGLNESKKPSQPSN SEQ ID No. 103:MKKLFVLCIFLFLSITASGEVLPDLKIEKLEEGVYLHTSFEEVSGINGVVTKHGLVVLVNNDAYLIDTPFTNKDTEKLVAWFVGRGFTIKGSVSSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKNGKVQATNSFSGVSYWLVKNKIEIFYPGPGHTQDNVVVVVLPENKILFGGCFVKPDGLGNLDDANLKAWPKSAKILMSKYGKAKLWSGHSEIGNASLLKLTWEQAVKGLKESKKPLLPSN SEQ ID No. 104:MKKLFVLCVCFFCSITAAGAALPDLKIEKLEEGVFVHTSFEEVNGWGVVTKHGLWLVNTDAYLIDTPFTATDTEKLVNWFVERGYEIKGTISSHFHSDSTGGIEWLNSQSIPTYASELTNELLKKSGKVQAKYSFSEVSYVVLVKNKIEVFYPGPGHTQDNLVVVVLPESKILFGGCFIKPHGLGNLGDANLEAWPKSAKILMSKYGKAKLVVSSHSEKGDASLMKRTWEQALKGLKESKKTSSPSN SEQ ID No. 105:MKKLFVLCIFLFCSITAAGESLPDLKIEKLEDGVYVHTSFEEVNGWGVVTKHGLVFLVNTDAYLIDTPFAAKDTEKLVNWFVERGYKIKGSISSHFHSDSSGGIEWLNSQSIPTYASELTNELLKKNGKVQAKNSFSGVSYWLLKNKIEIFYPGPGHTQDNVVVWLPEKKILFGGCFVKPYGLGNLDDANVEAWPHSAEILMSRYGNAKLVVPSHSDVGDASLLKLTANEQAVKGLKESKKPSQPSN

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 106, SEQ ID No. 108 to SEQ ID No. 130, SEQ ID No. 133 to SEQID No. 173, SEQ ID No. 175 to SEQ ID No. 180, as defined hereafter:

Peptide SEQ ID Position of the peptide in the IMP No. Amino acidsequence protein(s) SEQ ID DTENLVNWFVER 73-84 for the protein of SEQ No.85 No. 106 SEQ ID EILFGGCFVK 170-179 for the protein of SEQ No. 95 No.107 SEQ ID EVNGWGVVPK 42-51 for the proteins of SEQ No. 80, 81, No. 10882, 84, 87, 90, 93, 96, 97 SEQ ID GDASLMK 219-225 for the protein of SEQNo. 104 No. 109 SEQ ID GFNESK 234-239 for the protein of SEQ No. 85 No.110 SEQ ID GFTIK 85-89 for the protein of SEQ No. 103 No. 111 SEQ IDGLNESK 234-239 for the proteins of SEQ No. 80, 81, No. 112 82, 83, 84,86, 88, 90, 91, 93, 94, 96, 97, 98, 99, 100, 101, 102 SEQ ID GLNESR234-239 for the protein of SEQ No. 92 No. 113 SEQ IDGSISSHFHSDSTGGIEWLNSR 90-110 for the proteins of SEQ No. 80, 90, No. 11493, 97, 98 SEQ ID GSISSHFHSDSTGGIGWLNSR 90-110 for the protein of SEQNo. 96 No. 115 SEQ ID GVYVHTSFEEVK 33-44 for the proteins of SEQ No. 86,88 No. 116 SEQ ID GWGVVTK 45-51 for the proteins of SEQ No. 88, 95, No.117 103, 104, 105 SEQ ID GWSVVTK 45-51 for the protein of SEQ No. 86 No.118 SEQ ID GYEIK 85-89 for the protein of SEQ No. 104 No. 119 SEQ IDHGLVFLVNTDAYLIDTPFAAK 52-72 for the protein of SEQ No. 105 No. 120 SEQID HGLVILVNTDAYLIDTPFTAK 52-72 for the protein of SEQ No. 89 No. 121 SEQID HGLVVLIGADAYLIDTPFTAK 52-72 for the protein of SEQ No. 95 No. 122 SEQID HGLVVLVDAEAYLIDTPFTAK 52-72 for the proteins of SEQ No. 82, 94 No.123 SEQ ID HGLVVLVK 52-59 for the proteins of SEQ No. 86, 88 No. 124 SEQID HGLVVLVNAEAYLIDTPFTAK 52-72 for the proteins of SEQ No. 80, 90, No.125 93, 96, 97, 98 SEQ ID HGLVVLVNNDAYLIDTPFTNK 52-72 for the protein ofSEQ No. 103 No. 126 SEQ ID HGLVVLVNTDAYLIDTPFTAK 52-72 for the proteinsof SEQ No. 81, 85, No. 127 99, 101 SEQ ID HGLVVLVNTEAYLIDTPFTAK 52-72for the proteins of SEQ No. 84, 87 No. 128 SEQ ID HSFNGVSYSLIK 134-145for the protein of SEQ No. 86 No. 129 SEQ ID IEVFYPGPGHTQDNVVVWLPK148-168 for the proteins of SEQ No. 99, 101 No. 130 SEQ ID ILFGGCFIK171-179 for the proteins of SEQ No. 80, 82, No. 131 90, 93, 94, 96, 97,98, 104 SEQ ID ILFGGCFVK 171-179 for the proteins of SEQ No. 83, 86, No.132 88, 89, 91, 92, 95, 99, 100, 101, 102, 103, 105 SEQ ID ILMEK 200-204for the protein of SEQ No. 95 No. 133 SEQ ID ILMSK 200-204 for theproteins of SEQ No. 83, 86, No. 134 87, 88, 91, 92, 100, 102, 103, 104SEQ ID LDEGVYVHTSFK 30-41 for the protein of SEQ No. 90 No. 135 SEQ IDLEEGVYVHTSFEEVK 30-44 for the protein of SEQ No. 86 No. 136 SEQ IDLEEGVYVHTSYEEVK 30-44 for the protein of SEQ No. 95 No. 137 SEQ IDLFVLCVCFLCSITAAGAR 4-21 for the protein of SEQ No. 102 No. 138 SEQ IDLLISK 200-204 for the proteins of SEQ No. 82, 94 No. 139 SEQ ID LLMSK200-204 for the proteins of SEQ No. 84, 85 No. 140 SEQ ID LLVSK 200-204for the protein of SEQ No. 81 No. 141 SEQ ID LPDLK 22-26 for theproteins of SEQ No. 80, 81, No. 142 82, 83, 84, 85, 86, 87, 88, 89, 90,91, 92, 93, 94, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105 SEQ IDLTLEQAVK 226-233 for the proteins of SEQ No. 80, 82, No. 143 90, 93, 94,96, 97, 98 SEQ ID LTWEQAVK 226-233 for the proteins of SEQ No. 87, 89,No. 144 99, 101, 103, 105 SEQ ID LTWEQTVK 226-233 for the protein of SEQNo. 85 No. 145 SEQ ID LVAWFVGR 77-84 for the protein of SEQ No. 103 No.146 SEQ ID LVNWFIEHGYR 77-87 for the protein of SEQ No. 88 No. 147 SEQID LVNWFVER 77-84 for the proteins of SEQ No. 83, 85, No. 148 86, 91,92, 95, 99, 100, 101, 102, 104, 105 SEQ ID LVTWFVER 77-84 for theproteins of SEQ No. 80, 81, No. 149 82, 84, 87, 89, 90, 93, 94, 96, 97,98 SEQ ID LVVPGHSEVGDASLLK 210-225 for the proteins of SEQ No. 93, 96,No. 150 97 SEQ ID LVVPSHSDIGDASLLK 210-225 for the proteins of SEQ No.89, 99, No. 151 101 SEQ ID LVVPSHSDIGDSSLLK 210-225 for the protein ofSEQ No. 85 No. 152 SEQ ID LVVPSHSDVGDASLLK 210-225 for the protein ofSEQ No. 105 No. 153 SEQ ID LVVPSHSEAGDASLLK 210-225 for the proteins ofSEQ No. 82, 94 No. 154 SEQ ID LVVPSHSEVGDASLLK 210-225 for the proteinsof SEQ No. 80, 81, No. 155 84, 90, 98 SEQ ID LVVSGHSEIGNASLLK 210-225for the protein of SEQ No. 103 No. 156 SEQ ID LVVSGHSETGDATHLK 210-225for the protein of SEQ No. 95 No. 157 SEQ ID LVVSSHSDIGDVSLLK 210-225for the protein of SEQ No. 86 No. 158 SEQ ID LVVSSHSEIGDASLLK 210-225for the proteins of SEQ No. 83, 91, No. 159 92, 100, 102 SEQ IDLVVSSHSEIGNASLLQR 210-226 for the protein of SEQ No. 88 No. 160 SEQ IDLVVSSHSEK 210-218 for the protein of SEQ No. 104 No. 161 SEQ IDLVVSSHSETGNASLLK 210-225 for the protein of SEQ No. 87 No. 162 SEQ IDNDAYLIDTPITAK 60-72 for the proteins of SEQ No. 86, 88 No. 163 SEQ IDNSFDGVSYWLAK 134-145 for the protein of SEQ No. 95 No. 164 SEQ IDNSFGGVNYWLVK 134-145 for the proteins of SEQ No. 82, 94 No. 165 SEQ IDNSFSGASYWLVK 134-145 for the proteins of SEQ No. 81, 84 No. 166 SEQ IDNSFSGGSYWLVNNK 134-147 for the protein of SEQ No. 87 No. 167 SEQ IDNSFSGVSYWLLK 134-145 for the protein of SEQ No. 105 No. 168 SEQ IDNSFSGVSYWLVK 134-145 for the proteins of SEQ No. 83, 89, No. 169 91, 92,99, 100, 101, 102, 103 SEQ ID SIPTYASELTNELLK 111-125 for the proteinsof SEQ No. 80, 81, No. 170 82, 83, 84, 85, 86, 87, 90, 91, 92, 93, 94,95, 96, 97, 98, 100, 102, 103, 104, 105 SEQ ID TLEQAVK 227-233 for theproteins of SEQ No. 80, 81, No. 171 82, 84, 90, 93, 94, 96, 97, 98 SEQID TWEQALK 227-233 for the protein of SEQ No. 104 No. 172 SEQ ID TWEQAVK227-233 for the proteins of SEQ No. 83, 86, No. 173 87, 88, 89, 91, 92,95, 99, 100, 101, 102, 103, 105 SEQ ID VLFGGCFVK 171-179 for theproteins of SEQ No. 81, 84, No. 174 85, 87 SEQ ID VQATNSFSGVNYWLVK130-145 for the proteins of SEQ No. 80, 90, No. 175 93, 96, 97, 98 SEQID VQATNSFSGVSYSLIK 130-145 for the protein of SEQ No. 88 No. 176 SEQ IDVQATNSFSGVSYWLVK 130-145 for the protein of SEQ No. 103 No. 177 SEQ IDYGNAK 205-209 for the proteins of SEQ No. 89, 99, No. 178 101, 105 SEQID YSFSEVSYWLVK 134-145 for the protein of SEQ No. 104 No. 179 SEQ IDYSFSGVSYWLVK 134-145 for the protein of SEQ No. 85 No. 180

The detection of a mechanism of resistance to carbapenems induced by theexpression of the IND protein is characterised by the detection of atleast one peptide belonging to the IND protein and to its differentsequence variants SEQ ID No. 181 to SEQ ID No. 187.

SEQ ID No. 181: MKKSIRFFIVSILLSPFASAQVKDFVIEPPIKNNLHIYKTFGVFGGKEYSANSMYLVTKKGVVLFDVPWEKIQYQSLMDTIKKRHNLPVVAVFATHSHDDRAGDLSFFNNKGIKTYATAKTNEFLKKDGKATSTEIIKTGKPYRIGGEEFVVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSNSATDLGYIKEANVEQWPKTINKLKAKYSKATLIIPGHDEWKGGGHVEHTLELLNKK SEQ ID No. 182:MKKSIQLLMMSMFLSPLINAQVKDFVIEPPVKPNLYLYKSFGVFGGKEYSANAVYLTTKKGVVLFDVPWQKEQYQTLMDTIQKRHHLPVIAVFATHSHDDRAGDLSFYNQKGIKTYATAKTNELLKKDGKATSTEIIKTGKPYKIGGEEFMVDFLGEGHTVDNVVVWFPKYKVLDGGCLVKSRTATDLGYTGEANVKQWPETMRKLKTKYAQATLVIPGHDEWKGGGHVQHTLDLLDKNKKPE SEQ ID No. 183:MKKSIQLLMMSMFLSPLINAQVKDFVIEPPVKPNLYLYKSFGVFGGKEYSANAVYLTTKKGWLFDVPWQKEQYQTLMDTIQKRHHLPVIAVFATHSHDDRAGDLSFYNQKGIKTYATAKTNELLKKDGKATSTEIIKTGKPYKIGGEEFMVDFLGEGHTVDNVVVWFPKYKVLDGGCLVKSRTATDLGYTGEANVKQWPETMRKLKTKYAQATLVIPGHEEWKGGGHVQHTLDLLDKNKKPE SEQ ID No. 184:MKKRIQFFMVSMMLSSLFSAQVKDFVIEPPIKKNLHIYKTFGVFGGKEYSANSVYLVTQKGVVLFDVPWEKVQYQSLMDTIQKRHNLPVIAVFATHSHDDRAGDLSFFNNKGIKTYATSKTNEFLKKDGKATSTEIIKTGKPYRIGGEEFVVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSKAATDLGYIKEANVEQWPKTINKLKSKYSKASLVIPGHDEWKGGGHVKHTLELLNKK SEQ ID No. 185:MRKNVRIFTVLSLFLINFFNAQARDFVIEQPFGKQLYLYKTFGVFDGKEYSTNALYLVTKKGVVLFDVPWQKTQYQSLMDTIKKRHNLPVIAVFATHSHSDRAGDLSFYNKKGIPTYATAKTNELLKKEGKATSSKLTKIGKKYKIGGEEFTVDFLGEGHTADNVVVWFPKYNVLDGGCLVKSSAAVDLGYTGEANVEQWPATMKKLQAKYPSTAKVIPGHDEWKGNDHVKHTLELLDQQKQ SEQ ID No. 186:MKKRIQFFMVSMMLAPMFNAQVKDFVIEPPIKNNLHIYKTFGVFGGKEYSANSVYLVTKKGVVLFDVPWEKAQYQSLMDTIKKRHNLPVIAVFATHSHDDRAGDLSFFNNKGIKTYATSKTNEFLKKDGKATSTEIIKTGKPYRIGGEEFTVDFLGEGHTADNVVVVVFPKYNVLDGGCLVKSNSATDLGYIKEANVEQWPITIDKLKAKYSKATLIIPGHDDWKGGGHVEHTLELLNKK SEQ ID No. 187:MKRRIQFFMVSMMLTPLFSAQVKDFVIEPPIKKNLYIYKTFGVFGGKEYSANSVYLVTKTGVVLFDVPWEKAQYQSLMDTIKKRHNLPVVAVFATHSHDDRAGDLSFFNNKGIKTYATPKTNQFLKRDGKATSTELIKPGKPYRFGGEEFVVDFLGEGHTADNVVVWFPKYKVLDGGCLVKSNSATDLGYIKEANLEQWPKTMHKLKTKYSEAVLIIPGHDEWKGGGHVEHTLELLDKK

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 188 to SEQ ID No. 197, SEQ ID No. 200, SEQ ID No. 201, SEQ IDNo. 203 to SEQ ID No. 262, as defined hereafter:

Peptide SEQ ID No. Amino acid sequence Position of the peptide in theIND protein(s) SEQ ID AATDLGYIK 184-192 for the protein of SEQ No. 184No. 188 SEQ ID AGDLSFFNNK 102-111 for the proteins of SEQ No. 181, 184,186, No. 189 187 SEQ ID AGDLSFYNK 103-111 for the protein of SEQ No. 185No. 190 SEQ ID AGDLSFYNQK 102-111 for the proteins of SEQ No. 182, 183No. 191 SEQ ID AQYQSLMDTIK 72-82 for the proteins of SEQ No. 186, 187No. 192 SEQ ID ASLVIPGHDEWK 213-224 for the protein of SEQ No. 184 No.193 SEQ ID ATLIIPGHDDWK 213-224 for the protein of SEQ No. 186 No. 194SEQ ID ATLIIPGHDEWK 213-224 for the protein of SEQ No. 181 No. 195 SEQID ATSSK 132-136 for the protein of SEQ No. 185 No. 196 SEQ ID ATSTEIIK131-138 for the proteins of SEQ No. 181, 182, 183, No. 197 184, 186 SEQID ATSTELIK 131-138 for the protein of SEQ No. 187 No. 198 SEQ IDATSTELIKPGK 131-141 for the protein of SEQ No. 187 No. 199 SEQ IDATSTELIKPGKPYR 131-144 for the protein of SEQ No. 187 No. 200 SEQ IDDFVIEPPIK 24-32 for the proteins of SEQ No. 181, 184, 186, 187 No. 201SEQ ID DFVIEPPVK 24-32 for the proteins of SEQ No. 182, 183 No. 202 SEQID DFVIEPPVKPNLYLYK 24-39 for the proteins of SEQ No. 182, 183 No. 203SEQ ID DFVIEQPFGK 25-34 for the protein of SEQ No. 185 No. 204 SEQ IDEANLEQWPK 193-201 for the protein of SEQ No. 187 No. 205 SEQ IDEANVEQWPITIDK 193-205 for the protein of SEQ No. 186 No. 206 SEQ IDEANVEQWPK 193-201 for the proteins of SEQ No. 181, 184 No. 207 SEQ IDEQYQTLMDTIQK 72-83 for the proteins of SEQ No. 182, 183 No. 208 SEQ IDEYSANAVYLTTK 48-59 for the proteins of SEQ No. 182, 183 No. 209 SEQ IDEYSANSMYLVTK 48-59 for the protein of SEQ No. 181 No. 210 SEQ IDEYSANSVYLVTK 48-59 for the proteins of SEQ No. 186, 187 No. 211 SEQ IDEYSANSVYLVTQK 48-60 for the protein of SEQ No. 184 No. 212 SEQ IDEYSTNALYLVTK 49-60 for the protein of SEQ No. 185 No. 213 SEQ IDFFIVSILLSPFASAQVK 7-23 for the protein of SEQ No. 181 No. 214 SEQ IDGGGHVEHTLELLDK 225-238 for the protein of SEQ No. 187 No. 215 SEQ IDGGGHVEHTLELLNK 225-238 for the proteins of SEQ No. 181, 186 No. 216 SEQID GGGHVK 225-230 for the protein of SEQ No. 184 No. 217 SEQ IDGGGHVQHTLDLLDK 225-238 for the proteins of SEQ No. 182, 183 No. 218 SEQID GIPTYATAK 113-121 for the protein of SEQ No. 185 No. 219 SEQ IDGNDHVK 226-231 for the protein of SEQ No. 185 No. 220 SEQ ID GVVLFDVPWEK61-71 for the proteins of SEQ No. 181, 184, 186, 187 No. 221 SEQ IDGVVLFDVPWQK 62-72 for the protein of SEQ No. 185; 61-71 for the No. 222protein of sequence SEQ ID No. 182; 61-71 for the protein of sequenceSEQ ID No. 183 SEQ ID HHLPVIAVFATHSHDDR 85-101 for the proteins of SEQNo. 182, 183 No. 223 SEQ ID HNLPVIAVFATHSHDDR 85-101 for the proteins ofSEQ No. 184, 186 No. 224 SEQ ID HNLPVIAVFATHSHSDR 86-102 for the proteinof SEQ No. 185 No. 225 SEQ ID HNLPVVAVFATHSHDDR 85-101 for the proteinsof SEQ No. 181, 187 No. 226 SEQ ID HTLELLDQQK 232-241 for the protein ofSEQ No. 185 No. 227 SEQ ID HTLELLNK 231-238 for the proteins of SEQ No.181, 184, 186 No. 228 SEQ ID IFTVLSLFLINFFNAQAR 7-24 for the protein ofSEQ No. 185 No. 229 SEQ ID IQFFMVSMMLAPMFNAQVK 5-23 for the protein ofSEQ No. 186 No. 230 SEQ ID IQFFMVSMMLSSLFSAQVK 5-23 for the protein ofSEQ No. 184 No. 231 SEQ ID IQFFMVSMMLTPLFSAQVK 5-23 for the protein ofSEQ No. 187 No. 232 SEQ ID IQYQSLMDTIK 72-82 for the protein of SEQ No.181 No. 233 SEQ ID NLHIYK 34-39 for the proteins of SEQ No. 181, 184,186 No. 234 SEQ ID NLYIYK 34-39 for the protein of SEQ No. 187 No. 235SEQ ID NNLHIYK 33-39 for the proteins of SEQ No. 181, 186 No. 236 SEQ IDQLYLYK 35-40 for the protein of SEQ No. 185 No. 237 SEQ ID QWPETMR198-204 for the proteins of SEQ No. 182, 183 No. 238 SEQ ID SFGVFGGK40-47 for the proteins of SEQ No. 182, 183 No. 239 SEQ IDSIQLLMMSMFLSPLINAQVK 4-23 for the proteins of SEQ No. 182, 183 No. 240SEQ ID SNSATDLGYIK 182-192 for the proteins of SEQ No. 181, 186, 187 No.241 SEQ ID TATDLGYTGEANVK 184-197 for the proteins of SEQ No. 182, 183No. 242 SEQ ID TFGVFDGK 41-48 for the protein of SEQ No. 185 No. 243 SEQID TFGVFGGK 40-47 for the proteins of SEQ No. 181, 184, 186, 187 No. 244SEQ ID TGKPYK 139-144 for the proteins of SEQ No. 182, 183 No. 245 SEQID TGKPYR 139-144 for the proteins of SEQ No. 181, 184, 186 No. 246 SEQID TGVVLFDVPWEK 60-71 for the protein of SEQ No. 187 No. 247 SEQ IDTNEFLK 121-126 for the proteins of SEQ No. 181, 184, 186 No. 248 SEQ IDTNELLK 122-127 for the protein of SEQ No. 185; 121-126 for No. 249 theproteins of sequence SEQ ID No. 182, 183 SEQ ID TNQFLK 121-126 for theprotein of SEQ No. 187 No. 250 SEQ ID TQYQSLMDTIK 73-83 for the proteinof SEQ No. 185 No. 251 SEQ ID TYATAK 116-121 for the protein of SEQ No.185; 115-120 for No. 252 the proteins of sequence SEQ ID No. 181, 182,183 SEQ ID TYATPK 115-120 for the protein of SEQ No. 187 No. 253 SEQ IDTYATSK 115-120 for the proteins of SEQ No. 184, 186 No. 254 SEQ IDVIPGHDEWK 217-225 for the protein of SEQ No. 185; 216-224 for No. 255the protein of sequence SEQ ID No. 182; 216-224 for the protein ofsequence SEQ ID No. 184 SEQ ID VLDGGCLVK 173-181 for the proteins of SEQNo. 181, 182, 183, No. 256 184, 186, 187; 174-182 for the protein ofsequence SEQ ID No. 185 SEQ ID VQYQSLMDTIQK 72-83 for the protein of SEQNo. 184 No. 257 SEQ ID YAQATLVIPGHDEWK 210-224 for the protein of SEQNo. 182 No. 258 SEQ ID YAQATLVIPGHEEWK 210-224 for the protein of SEQNo. 183 No. 259 SEQ ID YNVLDGGCLVK 171-181 for the proteins of SEQ No.181, 184, 186; No. 260 172-182 for the protein of sequence SEQ ID No.185 SEQ ID YPSTAK 211-216 for the protein of SEQ No. 185 No. 261 SEQ IDYSEAVLIIPGHDEWK 210-224 for the protein of SEQ No. 187 No. 262

The detection of a mechanism of resistance to carbapenems induced by theexpression of the SME protein is characterised by the detection of atleast one peptide belonging to the SME protein and to its differentsequence variants SEQ ID No. 263 to SEQ ID No. 265.

SEQ ID No. 263: MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGVFAIDIGSGNIFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKYESRDLEYHSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPEGMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALGNVLNAKEKAIYQNWLKGNITGDARIRASVPADVVVVGDKTGSCGAYGTANDYAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID SEQ ID No. 264:MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGVFAIDTGSGNTFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKYESRDLEYYSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPEGMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALGNVLNAKVKAIYQNWLKGNTTGDARIRASVPADWVVGDKTGSCGAYGTANDYAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID SEQ ID No. 265:MSNKVNFKTASFLFSVCLALSAFNAHANKSDAAAKQIKKLEEDFDGRIGVFAIDTGSGNTFGYRSDERFPLCSSFKGFLAAAVLERVQQKKLDINQKVKYESRDLEYHSPITTKYKGSGMTLGDMASAALQYSDNGATNIIMERFLGGPEGMTKFMRSIGDNEFRLDRWELELNTAIPGDKRDTSTPKAVANSLNKLALGNVLNAKVKAIYQNWLKGNTTGDARIRASVPADVINVGDKTGSCGAIGTANDYAVIWPKNRAPLIVSIYTTRKSKDDKHSDKTIAEASRIAIQAID

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 266 to SEQ ID No. 287 as defined hereafter:

Peptide SEQ ID Position of the peptide in the SME No. Amino acidsequence protein(s) SEQ ID AIYQNWLK 209-216 for the proteins of SEQ No.263, No. 266 264, 265 SEQ ID APLIVSIYTTR 260-270 for the proteins of SEQNo. 263, No. 267 264, 265 SEQ ID ASVPADWVVGDK 227-238 for the proteinsof SEQ No. 263, No. 268 264, 265 SEQ ID AVANSLNK 189-196 for theproteins of SEQ No. 263, No. 269 264, 265 SEQ ID DLEYHSPITTK 104-114 forthe proteins of SEQ No. 263, No. 270 265 SEQ ID DLEYYSPITTK 104-114 forthe protein of SEQ No. 264 No. 271 SEQ ID DTSTPK 183-188 for theproteins of SEQ No. 263, No. 272 264, 265 SEQ ID FLGGPEGMTK 145-154 forthe proteins of SEQ No. 263, No. 273 264, 265 SEQ ID GFLAAAVLER 77-86for the proteins of SEQ No. 263, No. 274 264, 265 SEQ ID GNTTGDAR217-224 for the proteins of SEQ No. 263, No. 275 264, 265 SEQ IDIGVFAIDTGSGNTFGYR 48-64 for the proteins of SEQ No. 263, No. 276 264,265 SEQ ID LALGNVLNAK 197-206 for the proteins of SEQ No. 263, No. 277264, 265 SEQ ID LDINQK 92-97 for the proteins of SEQ No. 263, No. 278264, 265 SEQ ID LEEDFDGR 40-47 for the proteins of SEQ No. 263, No. 279264, 265 SEQ ID SDAAAK 30-35 for the proteins of SEQ No. 263, No. 280264, 265 SEQ ID SIGDNEFR 158-165 for the proteins of SEQ No. 263, No.281 264, 265 SEQ ID TASFLFSVCLALSAFNAHANK 9-29 for the proteins of SEQNo. 263, 264, No. 282 265 SEQ ID TGSCGAIGTANDYAVIWPK 239-257 for theprotein of SEQ No. 265 No. 283 SEQ ID TGSCGAYGTANDYAVIWPK 239-257 forthe proteins of SEQ No. 263, No. 284 264 SEQ ID TIAEASR 281-287 for theproteins of SEQ No. 263, No. 285 264, 265 SEQ ID WELELNTAIPGDK 169-181for the proteins of SEQ No. 263, No. 286 264, 265 SEQ ID FPLCSSFK 69-76for the proteins of SEQ No. 263, No. 287 264, 265

The detection of a mechanism of resistance to carbapenems induced by theexpression of a VIM protein is characterised by the detection of atleast one peptide belonging to a VIM protein and to its differentsequence variants SEQ ID No. 288 to SEQ ID No. 313.

SEQ ID No. 288: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL KHTTNVVKAHTNRSVVE SEQID No. 289: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVVVSHIATKSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL KHTTNVVKAHTNRSVVE SEQID No. 290: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVHELSRTSAGNVADADLAEWPTSVERIQKHYPEAEWIPGHGLPGGLDLLQ HTANVVKAHKNRSVAE SEQID No. 291: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRKAGVATYASPSTRRLAEAEGNE1PTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVLALSRTSAGNVADADLAEWPTSVERIOKHYPEAEWIPGHGLPGGLDLLQH TANVVTAHKNRSVAE SEQID No. 292: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATRSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 293: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSARRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA1YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 294: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQ1ADGVVVSHIATQSFDGAVYPSNGL1VRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSIRRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLL KHTTNVVKAHTNRSVVE SEQID No. 296: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIER1QQHYPEAQYVIPGHGLPGGLDLL KHTTNWKAHTNRSVVE SEQID No. 296: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSH1ATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGSEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 297: MLKVISSLLVYMTASVMAVASPLAHSGEPSSEYPTVNElPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVHELSRTSAGNVADADLAEWPTSVERIOKHYPEAEVVIPGHGLPGGLDLL QHTANVVKAHKNRSVAE SEQID No. 298: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIADGV1NSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLWYVPSANVLYGGCAVHELSSTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 299: MLKVISSLLFYMTASLMAVASPLAHSGESRGEYPTVSEIPVGEVRLYQIDDGVVVSHIATHTFDGVVYPSNGLIVRDGDELWDTAWGTKNTVALLAEIEKQIGLPVTRSVSTHFHDDRVGGVDALRAAGVATYASPSTRRLAEAEGNEVPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVLELSRTSAGNVADADLAEWPGSVERIQQHYPEAEVVIPGHGLPGGLDLLQH TANVVKAHTNRSVAE SEQID No. 300: MFKLLSKLLVYLTASMMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQ1GLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCA1YELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 301: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLL1DTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLFGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 302: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWLHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQ1GLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 303: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSSTSAGNVADADLAEWPTS1ERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 304: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQ1ADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSAKVLYGGCAVHELSRTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLLQ HTANVVKAHKNRSVAE SEQID No. 305: MFKLLSKLLVYLTAS1MAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSLTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNWKAHTNRSWE SEQ IDNo. 306: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRKAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVLALSRTSAGNVADADLAEWPTSVERIQKHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 307: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIADGVWSHISTQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNElPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVHELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLLQ HTANVVKAHKNRSVAE SEQID No. 308: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNElPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVLELSRTSAGNVADADLAEWPTSVER1QKHYPEAEVVIPGHGLPGGLDLL QHTANVVKAHKNRSVAE SEQID No. 309: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVNEIPVGEVRLYQIADGVWSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEVEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLK HTTNVVKAHTNRSVVE SEQID No. 310: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQ1ADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVHELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLL QHTANVVKAHKNRSVAE SEQID No. 311: MFQIRSFLVGISAFVMAVLGSAAYSAQPGGEYPTVDDIPVGEVRLYKIGDGVVVSHIATQKLGDTVYSSNGLIVRDADELLLIDTAWGAKNTVALLAEIEKQIGLPVTRSISTHFHDDRVGGVDVLRAAGVATYTSPLTRQLAEAAGNEVPAHSLKALSSSGDVVRFGPVEVFYPGAAHSGDNLVVYVPAVRVLFGGCAVHEASRESAGNVADANLAEWPATIKRIQQRYPEAEVVIPGHGLPGGLELLQ HTTNWKTHKVRPVAE SEQID No. 312: MFKLLSKLLVYLTASIMAIASPLAFSVDSSGEYPTVSEIPVGEVRLYQIADGVWSHIATRSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLANEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSASVLYGGCAIYELSRTSAGNVADADLAEWPTSIERIQQHYPEAQFVIPGHGLPGGLDLLKHTTN VVKAHTNRSVVE SEQ IDNo. 313: MLKVISSLLVYMTASVMAVASPLAHSGEPSGEYPTVNEIPVGEVRLYQIADGVVVSHIATQSFDGAVYPSNGLIVRDGDELLLIDTAWGAKNTAALLAEIEKQIGLPVTRAVSTHFHDDRVGGVDVLRAAGVATYASPSTRRLAEAEGNEIPTHSLEGLSSSGDAVRFGPVELFYPGAAHSTDNLVVYVPSANVLYGGCAVLELSSTSAGNVADADLAEWPTSVERIQKHYPEAEVVIPGHGLPGGLDLL QHTANVVKAHKNRSVAE

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 314 to SEQ ID No. 346 as defined hereafter:

Peptide SEQ ID No. Amino acid sequence Position of the peptide in theVIM protein(s) SEQ ID AAGVATYASPSAR 128-140 for the protein of SEQ No.293 No. 314 SEQ ID AAGVATYASPSIR 128-140 for the protein of SEQ No. 294No. 315 SEQ ID AAGVATYASPSTR 128-140 for the proteins of SEQ No. 288,289, No. 316 290, 292, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304,305, 307, 308, 309, 310, 312, 313 SEQ ID AAGVATYTSPLTR 127-139 for theprotein of SEQ No. 311 No. 317 SEQ ID AGVATYASPSTR 129-140 for theproteins of SEQ No. 288, 289, No. 318 290, 291, 292, 295, 296, 297, 298,299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 312, 313 SEQID AHTNR 254-258 for the protein of SEQ No. 312; 258-262 No. 319 for theproteins of sequence SEQ ID No. 288, 289, 292, 293, 294, 295, 296, 298,299, 300, 301, 302, 303, 305, 306, 309 SEQ ID ALSSSGDVVR 156-165 for theprotein of SEQ No. 311 No. 320 SEQ ID AVSTHFHDDR 110-119 for theproteins of SEQ No. 288, 289, No. 321 290, 291, 292, 293, 294, 295, 296,297, 298, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 312,313 SEQ ID DADELLLIDTAWGAK 75-89 for the protein of SEQ No. 311 No. 322SEQ ID DGDELLLIDTAWGAK 76-90 for the proteins of SEQ No. 288, 289, 290,No. 323 291, 292, 293, 294, 295, 296, 297, 298, 300, 301, 302, 303, 304,305, 306, 307, 308, 309, 310, 312, 313 SEQ ID DGDELLLIDTAWGTK 76-90 forthe protein of SEQ No. 299 No. 324 SEQ ID ESAGNVADANLAEWPATIK 205-223for the protein of SEQ No. 311 No. 325 SEQ ID GEYPTVSEIPVGEVR 31-45 forthe proteins of SEQ No. 288, 289, 292, No. 326 293, 294, 295, 296, 299,300, 301, 302, 303, 305, 312 SEQ ID HTTNVVK 247-253 for the protein ofSEQ No. 312; 251-257 No. 327 for the proteins of sequence SEQ ID No.288, 289, 292, 293, 294, 295, 296, 298, 300, 301, 302, 303, 305, 306,309; 250-256 for the protein of sequence SEQ ID No. 311 SEQ IDIGDGVWSHIATQK 48-60 for the protein of SEQ No. 311 No. 328 SEQ IDLANEIPTHSLEGLSSSGDAVR 142-162 for the protein of SEQ No. 312 No. 329 SEQID LGDTVYSSNGLIVR 61-74 for the protein of SEQ No. 311 No. 330 SEQ IDLYQIADGVWSHIATK 46-60 for the protein of SEQ No. 289 No. 331 SEQ IDLYQIADGVWSHIATR 46-60 for the proteins of SEQ No. 292, 312 No. 332 SEQID NTAALLAEIEK 91-101 for the proteins of SEQ No. 288, 289, No. 333 290,291, 292, 293, 294, 295, 296, 297, 298, 300, 301, 302, 303, 304, 305,306, 307, 308, 309, 310, 312, 313 SEQ ID NTVALLAEIEK 90-100 for theprotein of SEQ No. 311; 91-101 No. 334 for the protein of sequence SEQID No. 299 SEQ ID QIGLPVTR 102-109 for the proteins of SEQ No. 288, 289,No. 335 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302,303, 304, 305, 306, 307, 308, 309, 310, 312, 313; 101-108 for theprotein of sequence SEQ ID No. 311 SEQ ID QLAEAAGNEVPAHSLK 140-155 forthe protein of SEQ No. 311 No. 336 SEQ ID SFDGAVYPSNGLIVR 61-75 for theproteins of SEQ No. 288, 289, 290, No. 337 291, 292, 293, 294, 295, 296,297, 298, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 312,313 SEQ ID SISTHFHDDR 109-118 for the protein of SEQ No. 311 No. 338 SEQID SVSTHFHDDR 110-119 for the protein of SEQ No. 299 No. 339 SEQ IDTSAGNVADADLAEWPGSVER 206-225 for the protein of SEQ No. 299 No. 340 SEQID TSAGNVADADLAEWPTSIER 202-221 for the protein of SEQ No. 312; 206-225No. 341 for the protein of sequence SEQ ID No. 288, 289, 292, 293, 294,295, 296, 298, 300, 301, 302, 303, 305, 309 SEQ ID TSAGNVADADLAEWPTSVER206-225 for the proteins of SEQ No. 290, 291, No. 342 297, 304, 306,307, 308, 310, 313 SEQ ID VGGVDALR 120-127 for the protein of SEQ No.299 No. 343 SEQ ID VGGVDVLR 120-127 for the proteins of SEQ No. 288,289, No. 344 290, 291, 292, 293, 294, 295, 296, 297, 298, 300, 301, 302,303, 304, 305, 306, 307, 308, 309, 310, 312, 313; 119-126 for theprotein of sequence SEQ ID No. 311 SEQ ID VLFGGCAVHEASR 192-204 for theprotein of SEQ No. 311 No. 345 SEQ ID VLYGGCAVHELSR 193-205 for theproteins of SEQ No. 290, 297, No. 346 304

The detection of a mechanism of resistance to carbapenems and/or tocephalosporins induced by the expression of an OXA protein ischaracterised by the detection of at least one peptide belonging to anOXA protein and to its different sequence variants SEQ ID No. 347 to SEQID No. 508.

SEQ ID No. 347:MSRLLLSGLLATGLLCAVPASAASGCFLYADGNGQTLSSEGDCSSQLPPASTFKIPLALMGYDSGFLVNEEHPALPYKPSYDGWLPAWRETTTPRRWETYSVVWFSQQITEWLGMERFQQYVDRFDYGNRDLSGNPGKHDGLTQAWLSSSLAISPEEQARFLGKMVSGKLPVSAQTLQYTANILKVSEVEGWQIHGKTGMGYPKKLDGSLNRDQQIGWFVGWASKPGKQLIFVHTVVQKPGKQFASIKAKEEVLAALPAQLKKL SEQ ID No. 348:IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 349:MKKILLLHMLVFVSATLPISSVASDEVETLKCTIIADAITGNTLYETGECARRVSPCSSFKLPLAIMGFDSGILQSPKSPTWELKPEYNPSPRDRTYKQVYPALWQSDSVVWFSQQLTSRLGVDRFTEYVKKFEYGNQDVSGDSGKHNGLTQSWLMSSLTISPKEQIQFLLRFVAHKLPVSEAAYDMAYATIPQYQAAEGWAVHGKSGSGWLRDNNGKINESRPQGWFVGWAEKNGRQVVFARLEIGKEKSDIPGGSKAREDILVELPVLMGNK SEQ ID No. 350:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIWADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNAGPSTSNGDYWIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 351:MQRSLSMSGKRHFIFAVSFVISTVCLTFSPANAAQKLSCTLVIDEASGDLLHREGSCDKAFAPMSTFKLPLAIMGYDADILLDATTPRWDYKPEFNGYKSQQKPTDPTIWLKDSIVWYSQELTRRLGESRFSDYVQRFDYGNKDVSGDPGKHNGLTHAWLASSLKISPEEQVRFLRRFLRGELPVSEDALEMTKAVVPHFEAGDWDVQGKTGTGSLSDAKGGKAPIGWFIGWATRDDRRVVFARLTVGARKGEQPAGPAARDEFLNTLPALSENF SEQ ID No. 352:MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 353:IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQITREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 354:IACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 355:MIIRFLALLFSAVVLVSLGHAQEKTHESSNWGKYFSDFNAKGTIVVVDERTNGNSTSVYNESRAQQRYSPASTFKIPHTLFALDAGAVRDEFHVFRWDGAKRSFAGHNQDQNLRSAMRNSTVWVYQLFAKEIGENKARSYLEKLNYGNADPSTKSGDYWIDGNLAISANEQISILKKLYRNELPFRVEHQRLVKDLMIVEAKRDWILRAKTGWDGQMGWWVGWVEWPTGPVFFALNIDTPNRMEDLHKREAIARAILQSVNALPPN SEQ ID No. 356:MAIRIFAILFSTFVFGTFAHAQEGMRERSDWRKFFSEFQAKGTIVVADERQTDRVILVFDQVRSEKRYSPASTFKIPHTLFALDAGAARDEFQVFRWDGIKRSFAAHNQDQDLRSAMRNSTVWIYELFAKEIGEDKARRYLKQIDYGNADPSTSNGDYWIDGNLAIAAQEQIAFLRKLYHNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRIGWWVGWVEWPTGPVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 357:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 358:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVSKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 359:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFGLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 360:MKNTIHINFAIFLIIANIIYSSASASTDISTVASPLFEGTEGCFLLYDASTNAEIAQFNKAKCATQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKTPKGMEIWNSNHTPKTWMQFSVVWVSQEITQKIGLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQIQFLRKIINHNLPVKNSAIENTIENMYLQDLDNSTKLYGKTGAGFTANRTLQNGWFEGFIISKSGHKYVFVSALTGNLGSNLTSSIKAKKNAITILNTLNL SEQ ID No. 361:ANIIYSSASASTDISTVASPLFEGTEGCFLLYDVSTNAEIAQFNKAKCATQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKTPKGMEIWNSNHTPKTWMQFSVVWVSQEITQKIGLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQIQFLRKIINHNLPVKNSAIENTIENMYLQDLENSTKLYGKTGAGFTANRTLQNGWFEGFIISKSGHKYVFVSALTGNLGSNLTSSIKAKKNAITIL SEQ ID No. 362:IFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNAYPSTSNGDYWIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAIL SEQ ID No. 363:MIIRFLALLFSAVVLVSLGHAQDKTHESSNWGKYFSDFNAKGTIVVVDERTNGNSTSVYNESRAQQRYSPASTFKIPHTLFALDAGAVRDEFHVFRWDGAKRSFAGHNQDQNLRSAMRNSTVWVYQLFAKEIGENKARSYLEKLNYGNADPSTKSGDYWIDGNLAISANEQISILKKLYRNELPFRVEHQRLVKDLMIVEAKRDWILRAKTGWDGQMGWWVGWVEWPTGPVFFALNIDTPNRMEDLHKREAIARAILQSVNALPPN SEQ ID No. 364:MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVEKMLLIKEVNGSKIYAKSGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKLLENLGII SEQ ID No. 365:MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMTGSIRNEITYKSLENLGII SEQ ID No. 366:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKADINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALKMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 367:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYCIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAIL SEQ ID No. 368:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 369:MAIRFLTILLSTFFLTSFVHAQEHVLERSDWKKFFSDLRAEGAIVISDERQAEHALLVFGQERAAKRYSPASTFKLPHTLFALDADAVRDEFQVFRWDGVKRSFAGHNQDQDLRSAMRNSAVWVYELFAKEIGKDKARHYLKQIDYGNADPSTIKGDYWIDGNLEISAHEQISFLRKLYRNQLPFQVEHQRLVKDLMITEAGRNWILRAKTGWEGRFGWWVGWVEWPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN SEQ ID No. 370:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSIAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 371:MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII SEQ ID No. 372:MAIRFLTILLSTFFLTSFVHAQEHVLERSDWKKFFSDLRAEGAIVISDERQAEHALLVFGQERAAKRYSPASTFKLPHTLFALDADAVRDEFQVFRWDGVKRSFAGHNQDQDLRSAMRNSAVVWYELFAKEIGEDKARRYLKQIDYGNADPSTIKGDYWIDGNLEISAHEQISFLRKLYRNQLPFQVEHQRLVKDLMITEAGRNWILRAKTGWEGRFGWWVGWVEWPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN SEQ ID No. 373:MAIRFFTILLSTFFLTSFVYAQEHVVIRSDWKKFFSDLQAEGAIVIADERQAKHTLSVFDQERAAKRYSPASTFKIPHTLFALDADAVRDEFQVFRWDGVNRSFAGHNQDQDLRSAMRNSTVWVYELFAKDIGEDKARRYLKQIDYGNVDPSTIKGDYWIDGNLKISAHEQILFLRKLYRNQLPFKVEHQRLVKDLMITEAGRSWILRAKTGWEGRFGWWVGWIEWPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN SEQ ID No. 374:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVERIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 375:MAIQIFAILFSTFVLATFAHAQDGTLERSDWGKFFSDFQAKGTIVVADERQADHAILVFDQARSMKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVKRSFAGHNKDQDLRSAMRNSTVWVYELFAKEIGDGKARRYLKQIGYGNADPSTSHGDYWIEGSLAISAQEQIAFLRKLYQNDLPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGSMGWWVGWVEWPTGPVFFALNIDTPNRMDDLFKREAIARAILLSIEALPPNPAVHSDAAR SEQ ID No. 376:MKNTIHINFAIFLIIANIIYSSASASTDISTVASQLFEGTEGCFLLYDASTNAEIAQFNKAKCAAQMAPDSTFKIALSLMAFDAEIIDQKTIFKWDKIPKGMEIWNSNHTPKTWMQFSVVWVSQEITQKIGLNKIKNYLKDFDYGNQDFSGDKERNNGLTEAWLESSLKISPEEQIQFLRKIINHNLPVRNSAIENTIDNMYLQDLENSTKLYGKTGAGFTANRTLQNGWFEGFIISKSGHKYVFVSALTGSLGSNLTSSIKAKKNAITILNTLNL SEQ ID No. 377:MLLFMFSIISFGNENQFMKEIFERKGLNGTFVVYDLKNDKIDYYNLDRANERFYPASSFKIFNTLIGLENGIVKNVDEMFYYYDGSKVFLDSWAKDSNLRYAIKVSQVPAYKKLARELGKERMQEGLNKLNYGNKEIGSEIDKFWLEGPLKISAMEQVKLLNLLSQSKLPFKLENQEQVKDITILEKKDDFILHGKTGWATDNIWPIGWFVGWIETSDNIYSFAINLDISDSKFLPKREEIVREYFKNINVIK SEQ ID No. 378:MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGFTNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLITAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATEQISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSTRIEPKIGWWVGWVELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP SEQ ID No. 379:MLSRYSKTLAFAVVACTLAISTATAHAELWRNDLKRVFDDAGVSGTFVLMDITADRTYVVDPARAARSIHPASTFKIPNSLIAFDTGAVRDDQEVLPYGGKPQPYEQWEHDMALPEAIRLSAVPIYQEVARRVGFERMQAYVDAFDYGNRQLGSAIDQFWLRGPLEISAFEEARFTSRMALKQLPVKPRTWDMVQRMLLIEQQGDAALYAKTGVATEYQPEIGWWAGWVERAGHVYAFALNIDMPREGDMAKRIPLGKQLMRALEVWPAP SEQ ID No. 380:MRPLLFSALLLLSGHTQASEWNDSQAVDKLFGAAGVKGTFVLYDVQRQRYVGHDRERAETRFVPASTYKVANSLIGLSTGAVRSADEVLPYGGKPQRFKAWEHDMSLRDAIKASNVPVYQELARRIGLERMRANVSRLGYGNAEIGQVVDNFWLVGPLKISAMEQTRFLLRLAQGELPFPAPVQSTVRAMTLLESGPGWELHGKTGWCFDCTPELGWWVGWVKRNERLYGFALNIDMPGGEADIGKRVELGKASLKALGILP SEQ ID No. 381:MNKGLHRKRLSKRLLLPMLLCLLAQQTQAVAAEQTKVSDVCSEVTAEGWQEVRRWDKLFESAGVKGSLLLWDQKRSLGLSNNLSRAAEGFIPASTFKLPSSLIALETGAVRDETSRFSWDGKVREIAVWNRDQSFRTAMKYSVVPVYQQLAREIGPKVMAAMVRQLEYGNQDIGGQADSFWLDGQLRITAFQQVDFLRQLHDNKLPVSERSQRIVKQMMLTEASTDYIIRAKTGYGVRRTPAIGWWVGWLELDDNTVYFAVNLDLASASQLPLRQQLV KQVLKQEQLLP SEQID No. 382: MNTIISRRWRAGLWRRLVGAVVLPATLAATPAAYAADVPKAALGRITERADWGKLFAAEGVKGTIVVLDARTQTYQAYDAARAEKRMSPASTYKIFNSLLALDSGALDNERAIIPWDGKPRRIKNWNAAMDLRTAFRVSCLPCYQVVSHKIGRRYAQAKLNEVGYGNRTIGGAPDAYWVDDSLQISAREQVDFVQRLARGTLPFSARSQDIVRQMSIVEATPDYVLHGKTGWFVDKKPDIGWWVGWIERDGNITSVAINIDMLSEADAPKRARIVKAVLKDLK LI SEQ ID No.383: MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQIFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGAEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 384:MRVLALSAVLVVASIVGMPAMANEWQEKPSWNTHFSEHKAQGVIVLWNENKQQGFTNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIAAWNRDHDLITAMKYSVVPVYQEFARQIGQARMSKMLHAFDYGNEDISGNLDSFWLDGGIRISATEQVAFLRKLYHNKLHVSERSQRIVKQAMLTEANSDYIIRAKTGYSTRIEPQIGWWVGWVELDDNVWFFAMNMDMPTADGLGLRQAITKEVLKQEKIIP SEQ ID No. 385:MKKITLFLLFLNLVFGQDKILNNWFKEYNTSGTFVFYDGKTWASNDFSRAMETFSPASTFKIFNALIALDSGVIKTKKEIFYHYRGEKVFLSSWAQDMNLSSAIKYSNVLAFKEVARRIGIKTMQEYLNKLHYGNAKISKIDTFWLDNSLKISAKEQAILLFRLSQNSLPFSQEAMNSVKEMIYLKNMENLELFGKTGFNDGQKIAWIVGFVYLKDENKYKAFALNLDIDKFEDLYKREKILEKYLDELVKKVKNDG SEQ ID No. 386:MSKKNFILIFIFVILISCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAEQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKLMAKSFLESWAKDSNLRYAIKNSQVPAYKELARRIGIKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQVKLLTKLAQNELQYPIEIQKAISDITITRANLHITLHGKTGLADSKNMTTEPIGWFVGWLEENDNIYVFALNIDNINSDDLAKRINIVKESLKALNLLK SEQ ID No. 387:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALKMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 388:MNIQALLLITSAIFISACSPYIVTANPNYSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRIGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGISSSVRKEITYRGLEQLGIL SEQ ID No. 389:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKGEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 390:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 391:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 392:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQEVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 393:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 394:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQHEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 395:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKTTTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 396:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTAVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGTPSSVRKEITYKSLEQLGIL SEQ ID No. 397:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLPRRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 398:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEKLGIL SEQ ID No. 399:MNIKTLLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASIEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSLKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 400:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAISVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLAGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 401:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASALPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPGQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 402:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGSVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 403:MNIKTLLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASIEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSLKAQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 404:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 405:MNIKTLLLITSAIFISACSHYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFTYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 406:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 407:MNIKALLLITSTIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALISLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 408:MNIQALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPHGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 409:MNIKALFLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 410:MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISADAVFVTYDGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFFKAWDKDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQMGTEVDQFWLKGPLTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVDPQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL SEQ ID No. 411:MNIKALLLITSTIFISACSPYIVTANPNHSTSKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEIFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSLKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 412:MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIRQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEMNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 413:MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISGDAVFVTYDGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFFKAWDKDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQIGTEVDQFWLKGPLTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVDPQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL SEQ ID No. 414:MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMDVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII SEQ ID No. 415:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIESSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 416:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 417:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 418:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 419:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 420:MNIKALLLITSAIFISACSPYIVTTNPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNTDIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 421:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIQVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 422:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTLGDAMKASALPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 423:MNIKTLLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEMNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 424:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGEKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFPLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 425:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGGDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 426:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 427:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 428:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKTTTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWWGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 429:MSKKNFILIFIFVILISCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAEQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNSQVPAYKELARRIGLKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQVKLLTKLAQNELPYPIEIQKAVSDITILEQTYNYTLHGKTGLADSKNMTTEPIGWFVGWLEENDNIYVFALNIDNINSDDLAKRINIVKESLKALNLLK SEQ ID No. 430:MSKKNFILIFIFVILTSCKNTEKISNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAEQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNSQVPAYKELARRIGLKKMKENIEKLDFGNKSIGDSVDTFWLEGPLEISAMEQIKLLTKLAQNELPYPIEIQKAVSDITILEQTYNYTLHGKTGLADSKNMTTEPIGWFVGWLEENDNIYVFALNIDNINSDDLAKRINIVKESLKALNLLK SEQ ID No. 431:LLITSAIFISACSPYIVSANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSL SEQ ID No. 432:LLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTEWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSL SEQ ID No. 433:MTVRRLSCALGAALSLSALGGGPVQAAVLCTVVADAADGRILFQQGTQQACAERYTPASTFKLAIALMGADAGILQGPHEPVWNYQPAYPDWGGDAWRQPTDPARWIKYSVVWYSQLTAKALGQDRFQRYTSAFGYGNADVSGEPGKHNGTDGAWIISSLRISPLEQLAFLRKLVNRQLPVKAAAYELAENLFEAGQADGWRLYGKTGTGSPGSNGVYTAANAYGWFVGWARKDGRQLVYARLLQDERATRPNAGLRARDELVRDWPAMAGAWRP SEQ ID No. 434:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNVLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQEVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 435:MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 436:MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 437:MNIKALLLITSAIFISACSPYIVTTNPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNTDIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 438:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNQQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 439:MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEMTYKSLEQLGIL SEQ ID No. 440:MNKYFTCYVVASLFFSGCTVQHNLINETQSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTTWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVERIDFGNAEIGQQVDNFWLIGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEENNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 441:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 442:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFLLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 443:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGDADPSTSNGDYWIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 444:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDKKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKASTTEVFKWNGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVKSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 445:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKHVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 446:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKHVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 447:MKKFILPILSISTLLSVSACSSIQTKFEDTFHTSNQQHEKAIKSYFDEAQTQGVIIIKKGKNISTYGNNLTRAHTEYVPASTFKMLNALIGLENHKATTTEIFKWDGKKRSYPMWEKDMTLGDAMALSAVPVYQELARRTGLDLMQKEVKRVGFGNMNIGTQVDNFWLVGPLKITPIQEVNFADDFANNRLPFKLETQEEVKKMLLIKEFNGSKIYAKSGWGMDVTPQVGWLTGWVEKSNGEKVAFSLNIEMKQGMPGSIRNEITYKSLENLGII SEQ ID No. 448:MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQEVQDEVQSILFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 449:MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTSQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII SEQ ID No. 450:MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGFTNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLITAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATEQISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSARIEPKIGWWVGWVELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP SEQ ID No. 451:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 452:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAVPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVNLQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 453:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEKLGIL SEQ ID No. 454:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIRNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 455:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDSKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 456:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDGVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 457:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDSKKRLFPEWEKDMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKIITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 458:MKLLKILSLVCLSISIGACAEHSMSRAKTSTIPQVNNSIIDQNVQALFNEISADAVFVTYDGQNIKKYGTHLDRAKTAYIPASTFKIANALIGLENHKATSTEIFKWDGKPRFLKAWDKDFTLGEAMQASTVPVYQELARRIGPSLMQSELQRIGYGNMQIGTEVDQFWLKGPLTITPIQEVKFVYDLAQGQLPFKPEVQQQVKEMLYVERRGENRLYAKSGWGMAVDPQVGWYVGFVEKADGQVVAFALNMQMKAGDDIALRKQLSLDVLDKLGVFHYL SEQ ID No. 459:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDVKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 460:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGALVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 461:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELMMKSLKQLNII SEQ ID No. 462:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLAGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 463:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDERNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 464:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEKSNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 465:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASTRNELLMKSLKQLNII SEQ ID No. 466:MKKFILPIFSISILLSLSACSSIQTKFEDTFHISNQKHEKAIKSYFDEAQTQGVIIIKEGKNISSYGNNLVRAHTEYVPASTFKMLNALIGLENHKATTNEIFKWDGKKRSYPMWEKDMTLGEAMALSAVPVYQDLARRIGLNLMQKEVKRVGFGNMNIGTQVDNFWLIGPLKITPIQEVNFADDLANNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMDVSPQVGWLTGWVEKSNGEKVSFSLNIEMKQGMSGSIRNEITYKSLENLGII SEQ ID No. 467:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIAVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 468:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAIKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 469:MKILIFLPLLSCLGLTACSLPVSSLPSQSISTQAIASLFDQAQSSGVLVIQRDQQVQVYGNDLNRANTEYVPASTFKMLNALIGLQHGKATTNEIFKWDGKKRSFTAWEKDMTLGQAMQASAVPVYQELARRIGLELMQQEVQRIQFGNQQIGQQVDNFWLVGPLKVTPKQEVQFVSALAREQLAFDPQVQQQVKAMLFLQERKAYRLYVKSGWGMDVEPQVGWLTGWVETPQAEIVAFSLNMQMQNGIDPAIRLEILQQALAELGLYPKAEG SEQ ID No. 470:MHKHMSKLFIAFLAFLLSVPAAAEDQTLAELFAQQGIDGTIVISSLHNGKTFIHNDPRAKQRFSTASTFKILNTLISLEEKAISGKDDVLKWDGHIYDFPDWNRDQTLESAFKVSCVWCYQALARQVGAEKYRNYLRKSVYGELREPFEETTFWLDGSLQISAIEQVNFLKKVHLRTLPFSASSYETLRQIMLIEQTPAFTLRAKTGWATRVKPQVGWYVGHVETPTDVWFFATNIEVRDEKDLPLRQKLTRKALQAKGIIE SEQ ID No. 471:MKTFAAYVITACLSSTALASSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGTDKFWLEDQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 472:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAILVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGLDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 473:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIQVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 474:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAMPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 475:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 476:MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGFTNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIATWNRDHNLITAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATEQISFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYDTKIGWWVGWVELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP SEQ ID No. 477:MSKKNFILIFIFVILISCKNTEKTSNETTLIDNIFTNSNAEGTLVIYNLNDDKYIIHNKERAEQRFYPASTFKIYNSLIGLNEKAVKDVDEVFYKYNGEKVFLESWAKDSNLRYAIKNSQVPAYKELARRIGLEKMKENIEKLDFGNKNIGDSVDTFWLEGPLEISAMEQVKLLTKLAQNELPYPIEIQKAVSDITILEQTDNYTLHGKTGLADSENMTTEPIGWLVGWLEENNNIYVFALNIDNINSDDLAKRINIVKESLKALNLLK SEQ ID No. 478:MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 479:MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPSSQKVQDEVQSMLFIEEKNGNKMYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 480:MNIKALFLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEIAYKSLEQLGIL SEQ ID No. 481:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDCWIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 482:MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWVVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 483:MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEYHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 484:MAIRFLTILLSTFFLTSFVHAQEHVVVRSDWKKFFSDLQAEGAIVIADERQAEHALLVFGQERAAKRYSPASTFKLPHTLFALDAGAVRDEFQVFRWDGVKRSFAGHNQDQDLRSAMRNSAVWVYELFAKEIGEDNARRYLKQIDYGNADPSTIKGNYWIDGNLEISAHEQISFLRKLYRNQLPFQVEHQRLVKYLMITEAGRNWILRAKTGWEGRFGWWIGWVEWPTGPVFFALNIDTPNRTDDLFKREAIARAILRSIDALPPN SEQ ID No. 485:MRVLALSAVFLVASIIGMPAVAKEWQENKSWNAHFTEHKSQGVVVLWNENKQQGFTNNLKRANQAFLPASTFKIPNSLIALDLGVVKDEHQVFKWDGQTRDIAAWNRDHDLITAMKYSVVPVYQEFARQIGEARMSKMLHAFDYGNEDISGNVDSFWLDGGIRISATQQIAFLRKLYHNKLHVSERSQRIVKQAMLTEANGDYIIRAKTGYSTRIEPKIGWWVGWVELDDNVWFFAMNMDMPTSDGLGLRQAITKEVLKQEKIIP SEQ ID No. 486:MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKSQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 487:MNIKALLLITSAIFISACSPYIVTANPNHSASKSDVKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAISVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 488:MAIRIFAILFSIFSLATFAHAQEGTLERSDWRKFFSEFQAKGTIVVADERQADRAMLVFDPVRSKKRYSPASTFKIPHTLFALDAGAVRDEFQIFRWDGVNRGFAGHNQDQDLRSAMRNSTVWVYELFAKEIGDDKARRYLKKIDYGNADPSTSNGDYWIEGSLAISAQEQIAFLRKLYRNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGSVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 489:MKTIAAYLVLVFYASTALSESISENLAWNKEFSSESVHGVFVLCKSSSNSCTTNNAARASTAYIPASTFKIPNALIGLETGAIKDERQVFKWDGKPRAMKQWEKDLKLRGAIQVSAVPVFQQIAREVGEIRMQKYLNLFSYGNANIGGGIDKFWLEGQLRISAFNQVKFLESLYLNNLPASKANQLIVKEAIVTEATPEYIVHSKTGYSGVGTESSPGVAWWVGWVEKGTEVYFFAFNMDIDNESKLPSRKSISTKIMASEGIIIGG SEQ ID No. 490:MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKLACATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQIFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGAEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 491:MAIRIFAILFSTFVFGTFAHAQEGMRERSDWRKFFSEFQAKGTIVVADERQTDRVILVFDQVRSEKRYSPASTFKIPHTLFALDAGAARDEFQVFRWDGIKRSFAAHNQDQDLRSAMRNSTVWIYELFAKEIGEDKARRYLKQIDYGNADPSTSNGDYWIDGNLAIAAQEQIAFLRKLYHNELPFRVEHQRLVKDLMIVEAGRNWILRAKTGWEGRMGWWVGWVEWPTGPVFFALNIDTPNRMDDLFKREAIVRAILRSIEALPPNPAVNSDAAR SEQ ID No. 492:MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGSQNISGGIDKFWLEDQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 493MNKYFTCYVVASLFLSGCTVQHNLINETPSQIVQGHNQVIHQYFDEKNTSGVLVIQTDKKINLYGNALSRANTEYVPASTFKMLNALIGLENQKTDINEIFKWKGEKRSFTAWEKDMTLGEAMKLSAVPVYQELARRIGLDLMQKEVKRIGFGNAEIGQQVDNFWLVGPLKVTPIQEVEFVSQLAHTQLPFSEKVQANVKNMLLLEESNGYKIFGKTGWAMDIKPQVGWLTGWVEQPDGKIVAFALNMEMRSEMPASIRNELLMKSLKQLNII SEQ ID No. 494MKKLSVLLWLTLFYCGTIWAQSTCFLVQENQTVLKHEGKDCNKRFAPESTFKIALSLMGFDSGILKDTLNPEWPYKKEYELYLNVWKYPHNPRTWIRDSCVWYSQVLTQQLGMTRFKNYVDAFHYGNQDISGDKGQNNGLTHSWLSSSLAISPSEQIQFLQKIVNKKLSVNPKAFTMTKDILYIQELAGGWKLYGKTGNGRQLTKDKSQKLSLQHGWFIGWIEKDGRVITFTKHIADSKKHVTFASFRAKNETLNQLFYLINELEK SEQ ID No. 495MNIKTLLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEVHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSPKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 496MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIAISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQVAHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGKMLNRKLPVSPTAVDMTERIVESTTLADGTWHGKTGVSYPLLADGTRDWARGSGWFVGWIVRGNQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR SEQ ID No. 497MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIAISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYPVVWYSQQVAHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGKMLNRKLPVSPTAVDMTERIVESTTLADGTVVHGKTGVSYPLLADGTRDWARGSGWFVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR SEQ ID No. 498MRGKHTVILGAALSALFAGAAGAQMLECTLVADAASGQELYRKGACDKAFAPMSTFKVPLAVMGYDAGILVDAHNPRWDYKPEFNGYKFQQKTTDPTIWEKDSIVWYSQQLTRKMGQKRFAAYVAGFGYGNGDISGEPGKSNGLTHSWLGSSLKISPEGQVRFVRDLLSAKLPASKDAQQMTVSILPHFAAGDWAVQGKTGTGSFIDARGAKAPLGWFIGWATHEERRVVFARMTAGGKKGEQPAGPAARDAFLKALPDLAKRF SEQ ID No. 499MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIAISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQVAHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGKMLDRKLPVSPTAVDMTERIVESTTLADGTVVHGKTGVSYPLLADGTRDWARGSGWFVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR SEQ ID No. 500MKFRHALSSAFVLLGCIAASAHAKTICTAIADAGTGKLLVQDGDCGRRASPASTFKIAISLMGYDAGFLRNEHDPVLPYRDSYIAWGGEAWKQPTDPTRWLKYSVVWYSQQVAHHLGAQRFAQYAKAFGYGNADVSGDPGQNNGLDRAWIGSSLQISPLEQLEFLGKMLNRKLPVSPTAVDMTERIVESTTILADGTVVHGKTGVSYPLLADGTRDWARGSGWFVGWIVRGKQTLVFARLTQDERKQPVSAGIRTREAFLRDLPRLLAAR SEQ ID No. 501MKTFAAYVIIACLSSTALAGSITENTSWNKEFSAEAVNGVFVLCKSSSKSCATNDLARASKEYLPVSTFKIPSAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLTLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLYLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKETEVYFFAFNMDIDNESKLPLRKSIPTKIMESEGIIGG SEQ ID No. 502MNIKALLLITSAIFISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGKKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 503MNIKALLLITSAIFISACSPYIVSANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKNMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVNPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 504MKTFAAYVITACLSSTALASSITENTFWNKEFSAEAVNGVFVLCKSSSKSCATNNLARASKEYLPASTFKIPNAIIGLETGVIKNEHQVFKWDGKPRAMKQWERDLSLRGAIQVSAVPVFQQIAREVGEVRMQKYLKKFSYGNQNISGGIDKFWLEGQLRISAVNQVEFLESLFLNKLSASKENQLIVKEALVTEAAPEYLVHSKTGFSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNENKLPLRKSIPTKIMASEGIIGG SEQ ID No. 505MKTIAAYLVLVFFAGTALSESISENLAWNKEFSSESVHGVFVLCKSSSNSCTTNNATRASTAYIPASTFKIPNALIGLETGAIKDARQVFKWDGKPRAMKQWEKDLTLRGAIQVSAVPVFQQIARDIGKKRMQKYLNLFSYGNANIGGGIDKFWLEGQLRISAVNQVKFLESLYLNNLPASKANQLIVKEAIVTEATPEYIVHSKTGYSGVGTESNPGVAWWVGWVEKGTEVYFFAFNMDIDNESKLPSRKSIPTKIMASEGIIIGG SEQ ID No. 506MKKFILPIFSISILVSLSACSSIKTKSEDNFHISSQQHEKAIKSYFDEAQTQGVIIIKEGKNLSTYGNALARANKEYVPASTFKMLIALIGLENHKATTNEIFKWDGKKRTYPMWEKDMTLGEAMALSAVPVYQELARRTGLELMQKEVKRVNFGNTNIGTQVDNFWLVGPLKITPVQEVNFADDLAHNRLPFKLETQEEVKKMLLIKEVNGSKIYAKSGWGMGVTPQVGWLTGWVEQANGKKIPFSLNLEMKEGMSGSIRNEITYKSLENLGII SEQ ID No. 507MNIKALLLITSAIFISACSPYIVTANPNHSASKSDDKAEKIKNLFNEAHTTGVLVIHQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWNGQKRLFPEWEKDMTLGDAMKASAIPVYQDLARRIGLELMSNEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL SEQ ID No. 508MNIKALLLITSAISISACSPYIVTANPNHSASKSDEKAEKIKNLFNEAHTTGVLVIQQGQTQQSYGNDLARASTEYVPASTFKMLNALIGLEHHKATTTEVFKWDGQKRLFPEWEKDMTLGDAIKASAIPVYQDLARRIGLELMSKEVKRVGYGNADIGTQVDNFWLVGPLKITPQQEAQFAYKLANKTLPFSQKVQDEVQSMLFIEEKNGNKIYAKSGWGWDVDPQVGWLTGWVVQPQGNIVAFSLNLEMKKGIPSSVRKEITYKSLEQLGIL

said peptides being chosen, preferably, from the peptides of sequenceSEQ ID No. 509 to SEQ ID No. 523, SEQ ID No. 525 to SEQ ID No. 572, SEQID No. 574 to SEQ ID No. 604, SEQ ID No. 606 to SEQ ID No. 618, SEQ IDNo. 620 to SEQ ID No. 696, SEQ ID No. 698 to SEQ ID No. 1077 and SEQ IDNo. 1098 to SEQ ID No. 1109, as defined hereafter:

Peptide Position of the peptide in the OXA Clinical SEQ ID No. Aminoacid sequence protein(s) interest SEQ ID AAAYELAENLFEAGQADGWR 183-202for the protein of SEQ No. 433 2d No. 509 SEQ ID AAEGFIPASTFK 86-97 forthe protein of SEQ No. 381 2df No. 510 SEQ ID AALGR 41-45 for theprotein of SEQ No. 382 2df No. 511 SEQ ID ADGQVVAFALNMQMK 241-255 forthe proteins of SEQ No. 410, 2df No. 512 413, 458 SEQ ID ADINEIFK 95-102for the protein of SEQ No. 366 2df No. 513 SEQ ID ADWGK 50-54 for theprotein of SEQ No. 382 2df No. 514 SEQ ID AEGAIVISDER 40-50 for theproteins of SEQ No. 369, 372 OXA No. 515 SEQ ID AFALNLDIDK 222-231 forthe protein of SEQ No. 385 2d No. 516 SEQ ID AFAPMSTFK 49-57 for theprotein of SEQ No. 498; 60-68 OXA No. 517 for the protein of sequenceSEQ ID No. 351 SEQ ID AFGYGNADVSGDPGQNNGLDR 127-147 for the proteins ofSEQ No. 496, 2d No. 518 497, 499, 500 SEQ ID AFTMTK 174-179 for theprotein of SEQ No. 494 2d No. 519 SEQ ID AGDDIALR 256-263 for theproteins of SEQ No. 410, 2df No. 520 413, 458 SEQ ID AGHVYAFALNIDMPR233-247 for the protein of SEQ No. 379 2df No. 521 SEQ ID AGLWR 11-15for the protein of SEQ No. 382 2df No. 522 SEQ ID AHTEYVPASTFK 73-84 forthe proteins of SEQ No. 447, 466 2df No. 523 SEQ ID AIIPWDGK 112-119 forthe protein of SEQ No. 382 2df No. 524 SEQ ID AIIPWDGKPR 112-121 for theprotein of SEQ No. 382 2df No. 525 SEQ ID AISDITITR 190-198 for theprotein of SEQ No. 386 2d No. 526 SEQ ID AISGK 82-86 for the protein ofSEQ No. 470 2df No. 527 SEQ ID ALGQDR 121-126 for the protein of SEQ No.433 2d No. 528 SEQ ID ALPDLAK 256-262 for the protein of SEQ No. 498 2dNo. 529 SEQ ID ALQAK 254-258 for the protein of SEQ No. 470 2df No. 530SEQ ID AMETFSPASTFK 50-61 for the protein of SEQ No. 385 2d No. 531 SEQID AMLFLQER 196-203 for the protein of SEQ No. 469 2df No. 532 SEQ IDAMLVFDPVR 55-63 for the proteins of SEQ No. 350, 367, OXA No. 533 370,415, 443, 481, 488; 44-52 for the protein of sequence SEQ ID No. 362 SEQID AMTLLESGPGWELHGK 189-204 for the protein of SEQ No. 380 2d No. 534SEQ ID ANLHITLHGK 199-208 for the protein of SEQ No. 386 2d No. 535 SEQID ANQLIVK 183-189 for the proteins of SEQ No. 489, 505 OXA No. 536 SEQID ANTEYVPASTFK 71-82 for the proteins of SEQ No. 366, 374, 2df No. 537387, 440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493; 66-77 forthe protein of sequence SEQ ID No. 469 SEQ ID ANVSR 133-137 for theprotein of SEQ No. 380 2d No. 538 SEQ ID APIGWFIGWATR 224-235 for theprotein of SEQ No. 351 2de No. 539 SEQ ID APLGWFIGWATHEER 213-227 forthe protein of SEQ No. 498 2d No. 540 SEQ ID AQDEVQSMLFIEEK 196-209 forthe protein of SEQ No. 403 2df No. 541 SEQ ID AQGVIVLWNENK 40-51 for theprotein of SEQ No. 384 2df No. 542 SEQ ID ASAIAVYQDLAR 126-137 for theprotein of SEQ No. 467 2df No. 543 SEQ ID ASAILVYQDLAR 126-137 for theproteins of SEQ No. 417, 2df No. 544 426, 457, 472 SEQ ID ASAIPVYQDLAR126-137 for the proteins of SEQ No. 388, 2df No. 545 389, 390, 391, 392,393, 394, 395, 396, 398, 399, 402, 403, 404, 405, 406, 407, 408, 409,411, 412, 416, 418, 419, 420, 423, 424, 425, 427, 428, 434, 436, 437,439, 444, 445, 446, 448, 453, 454, 455, 456, 468, 475, 478, 479, 480,482, 483, 495, 502, 503, 507, 508; 120-131 for the proteins of sequenceSEQ ID No. 431, 432 SEQ ID ASAIPVYQDLPR 126-137 for the protein of SEQNo. 397 2df No. 546 SEQ ID ASAIQVYQDLAR 126-137 for the proteins of SEQNo. 421, 473 2df No. 547 SEQ ID ASAISVYQDLAR 126-137 for the proteins ofSEQ No. 400, 487 2df No. 548 SEQ ID ASALPVYQDLAR 126-137 for theproteins of SEQ No. 401, 422 2df No. 549 SEQ ID ASAMPVYQDLAR 126-137 forthe protein of SEQ No. 474 2df No. 550 SEQ ID ASAVPVYQDLAR 126-137 forthe proteins of SEQ No. 438, 2df No. 551 451, 452 SEQ ID ASIEYVPASTFK72-83 for the proteins of SEQ No. 399, 403 2df No. 552 SEQ IDASNVPVYQELAR 113-124 for the protein of SEQ No. 380 2d No. 553 SEQ IDASPASTFK 49-56 for the proteins of SEQ No. 496, 497, 2d No. 554 499, 500SEQ ID ASTAYIPASTFK 59-70 for the proteins of SEQ No. 489, 505 OXA No.555 SEQ ID ASTEYVPASTFK 72-83 for the proteins of SEQ No. 388, 389, 2dfNo. 556 390, 391, 392, 393, 394, 395, 396, 397, 398, 400, 401, 402, 404,405, 406, 407, 408, 409, 411, 412, 416, 417, 418, 419, 420, 421, 422,423, 424, 425, 426, 427, 428, 434, 436, 437, 438, 439, 444, 445, 446,448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472, 473, 474, 475,478, 479, 480, 482, 483, 487, 495, 502, 503, 507, 508; 66-77 for theproteins of sequence SEQ ID No. 431, 432 SEQ ID ASTTEVFK 96-103 for theprotein of SEQ No. 444 2df No. 557 SEQ ID ATSTEIFK 99-106 for theproteins of SEQ No. 410, 413, 2df No. 558 458 SEQ ID ATTNEIFK 97-104 forthe proteins of SEQ No. 364, 365, 2df No. 559 371, 414, 449, 466, 506;90-97 for the protein of sequence SEQ ID No. 469 SEQ ID ATTTAVFK 96-103for the protein of SEQ No. 396 2df No. 560 SEQ ID ATTTEIFK 97-104 forthe protein of SEQ No. 447; 96-103 No. 561 for the proteins of sequenceSEQ ID No. 2df 399, 403, 411 SEQ ID ATTTEVFK 96-103 for the proteins ofSEQ No. 388, 389, 2df No. 562 390, 391, 392, 393, 394, 397, 398, 400,401, 402, 404, 405, 406, 407, 408, 409, 412, 416, 417, 418, 419, 420,421, 422, 423, 424, 425, 426, 427, 434, 436, 437, 438, 439, 445, 446,448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472, 473, 474, 475,478, 479, 480, 482, 483, 487, 495, 502, 503, 507, 508; 90-97 for theproteins of sequence SEQ ID No. 431, 432 SEQ ID AVSDITILEQTDNYTLHGK191-209 for the protein of SEQ No. 477 OXA No. 563 SEQ IDAVSDITILEQTYNYTLHGK 191-209 for the proteins of SEQ No. 429, 430 2d No.564 SEQ ID AVVPHFEAGDWDVQGK 195-210 for the protein of SEQ No. 351 2deNo. 565 SEQ ID AWEHDMSLR 100-108 for the protein of SEQ No. 380 2d No.566 SEQ ID AWIGSSLQISPLEQLEFLGK 148-167 for the proteins of SEQ No. 496,2d No. 567 497, 499, 500 SEQ ID CAAQMAPDSTFK 63-74 for the protein ofSEQ No. 376 2d No. 568 SEQ ID CATQMAPDSTFK 48-59 for the protein of SEQNo. 361; 63-74 2d No. 569 for the protein of sequence SEQ ID No. 360 SEQID CTIIADAITGNTLYETGECAR 32-52 for the protein of SEQ No. 349 2d No. 570SEQ ID DAFLK 251-255 for the protein of SEQ No. 498 2d No. 571 SEQ IDDDFILHGK 189-196 for the protein of SEQ No. 377 2d No. 572 SEQ IDDDQEVLPYGGK 92-102 for the protein of SEQ No. 379 2df No. 573 SEQ IDDDVLK 87-91 for the protein of SEQ No. 470 2df No. 574 SEQ ID DEFHVFR90-96 for the proteins of SEQ No. 355, 363 2d No. 575 SEQ ID DEFQIFR90-96 for the proteins of SEQ No. 350, 367, OXA No. 576 370, 375, 415,443, 481, 488; 79-85 for the protein of sequence SEQ ID No. 362 SEQ IDDEFQVFR 90-96 for the proteins of SEQ No. 356, 369, 2d No. 577 372, 373,484, 491 SEQ ID DELVR 260-264 for the protein of SEQ No. 433 2d No. 578SEQ ID DETSR 112-116 for the protein of SEQ No. 381 2df No. 579 SEQ IDDFDYGNQDFSGDK 141-153 for the proteins of SEQ No. 360, 2d No. 580 376;126-138 for the protein of sequence SEQ ID No. 361 SEQ IDDFTLGEAMQASTVPVYQELAR 120-140 for the proteins of SEQ No. 410, 2df No.581 413, 458 SEQ ID DGNITSVAINIDMLSEADAPK 250-270 for the protein of SEQNo. 382 2df No. 582 SEQ ID DHDLITAMK 108-116 for the proteins of SEQ No.384, 485 2df No. 583 SEQ ID DIAAWNR 101-107 for the proteins of SEQ No.384, 485 2df No. 584 SEQ ID DIGEDK 131-136 for the protein of SEQ No.373 2d No. 585 SEQ ID DILYIQELAGGWK 180-192 for the protein of SEQ No.494 2de No. 586 SEQ ID DITILEK 181-187 for the protein of SEQ No. 377 2dNo. 587 SEQ ID DLLSAK 166-171 for the protein of SEQ No. 498 2d No. 588SEQ ID DLMITEAGR 195-203 for the proteins of SEQ No. 369, 2d No. 589372, 373 SEQ ID DLMIVEAGR 195-203 for the proteins of SEQ No. 350, OXANo. 590 356, 367, 370, 375, 415, 443, 481, 488, 491; 184-192 for theprotein of sequence SEQ ID No. 362 SEQ ID DLMIVEAK 195-202 for theproteins of SEQ No. 355, 363 2d No. 591 SEQ ID DLPLR 243-247 for theprotein of SEQ No. 470 2df No. 592 SEQ ID DLSGNPGK 131-138 for theprotein of SEQ No. 347 2d No. 593 SEQ ID DLSLR 105-109 for the proteinsof SEQ No. 357, OXA No. 594 358, 359, 368, 383, 442, 471, 504; 106-110for the protein of sequence SEQ ID No. 490 SEQ ID DLTLR 105-109 for theproteins of SEQ No. 352, OXA No. 595 435, 492, 501, 505; 96-100 for theproteins of sequence SEQ ID No. 348, 353, 354 SEQ ID DMTLGDAIK 117-125for the proteins of SEQ No. 468, 508 2df No. 596 SEQ IDDMTLGDAMALSAVPVYQELAR 118-138 for the protein of SEQ No. 447 2df No. 597SEQ ID DMTLGDAMK 117-125 for the proteins of SEQ No. 389, 2df No. 598390, 391, 394, 395, 398, 399, 400, 401, 403, 404, 407, 408, 409, 411,412, 417, 418, 420, 421, 423, 425, 426, 427, 428, 436, 437, 438, 439,444, 451, 452, 453, 454, 455, 456, 457, 467, 472, 473, 474, 478, 479,480, 482, 483, 487, 495, 502, 507 SEQ ID DMTLGEAMALSAVPVYQDLAR 118-138for the protein of SEQ No. 466 2df No. 599 SEQ ID DMTLGEAMALSAVPVYQELAR118-138 for the proteins of SEQ No. 364, 2df No. 600 365, 371, 414, 449,506 SEQ ID DMTLGEAMK 116-124 for the proteins of SEQ No. 366, 2df No.601 374, 387, 440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQID DMTLGQAMQASAVPVYQELAR 111-131 for the protein of SEQ No. 469 2df No.602 SEQ ID DNNGK 214-218 for the protein of SEQ No. 349 2d No. 603 SEQID DQDLR 110-114 for the proteins of SEQ No. 350, 2d No. 604 356, 367,369, 370, 372, 373, 375, 415, 443, 481, 484, 488, 491; 99-103 for theprotein of sequence SEQ ID No. 362 SEQ ID DQQIGWFVGWASK 213-225 for theprotein of SEQ No. 347 2d No. 605 SEQ ID DQQIGWFVGWASKPGK 213-228 forthe protein of SEQ No. 347 2d No. 606 SEQ ID DQQVQVYGNDLNR 53-65 for theprotein of SEQ No. 469 2df No. 607 SEQ ID DQSFR 132-136 for the proteinof SEQ No. 381 2df No. 608 SEQ ID DQTLESAFK 105-113 for the protein ofSEQ No. 470 2df No. 609 SEQ ID DSCVWYSQVLTQQLGMTR 98-115 for the proteinof SEQ No. 494 2de No. 610 SEQ ID DSIVWYSQELTR 113-124 for the proteinof SEQ No. 351 2de No. 611 SEQ ID DSIVWYSQQLTR 102-113 for the proteinof SEQ No. 498 2d No. 612 SEQ ID DSNLR 109-113 for the proteins of SEQNo. 429, 2d No. 613 430, 477; 96-100 for the proteins of sequence SEQ IDNo. 377, 386 SEQ ID DSYIAWGGEAWK 81-92 for the proteins of SEQ No. 496,497, 2d No. 614 499, 500 SEQ ID DTLNPEWPYK 67-76 for the protein of SEQNo. 494 2de No. 615 SEQ ID DVDEVFYK 88-95 for the proteins of SEQ No.386, 429, 2d No. 616 430, 477 SEQ ID DVSGDPGK 144-151 for the protein ofSEQ No. 351 2de No. 617 SEQ ID DWILR 204-208 for the proteins of SEQ No.355, 363 2d No. 618 SEQ ID DWPAMAGAWR 265-274 for the protein of SEQ No.433 2d No. 619 SEQ ID EAFLR 256-260 for the proteins of SEQ No. 496, 2dNo. 620 497, 499, 500 SEQ ID EAIAR 250-254 for the proteins of SEQ No.355, 2d No. 621 363, 369, 372, 373, 375, 484 SEQ ID EAIVR 250-254 forthe proteins of SEQ No. 350, OXA No. 622 356, 367, 370, 415, 443, 481,488, 491; 239-243 for the protein of sequence SEQ ID No. 362 SEQ IDEAIVTEATPEYIVHSK 190-205 for the proteins of SEQ No. 489, 505 OXA No.623 SEQ ID EALVTEAAPEYLVHSK 190-205 for the proteins of SEQ No. 352, OXANo. 624 357, 358, 359, 368, 383, 435, 442, 471, 492, 501, 504; 181-196for the proteins of sequence SEQ ID No. 348, 353, 354 SEQ IDEALVTEAPEYLVHSK 191-205 for the protein of SEQ No. 490 2d No. 625 SEQ IDEEIVR 240-244 for the protein of SEQ No. 377 2d No. 626 SEQ IDEEVLAALPAQLK 251-262 for the protein of SEQ No. 347 2d No. 627 SEQ IDEFNGSK 209-214 for the protein of SEQ No. 447 2df No. 628 SEQ IDEFSAEAVNGVFVLCK 31-45 for the proteins of SEQ No. 352, 357, OXA No. 629358, 359, 368, 383, 435, 442, 471, 490, 492, 501, 504; 22-36 for theproteins of sequence SEQ ID No. 348, 353, 354 SEQ ID EFSSESVHGVFVLCK31-45 for the proteins of SEQ No. 489, 505 OXA No. 630 SEQ ID EGDMAK248-253 for the protein of SEQ No. 379 2df No. 631 SEQ ID EGMSGSIR254-261 for the proteins of SEQ No. 364, 2df No. 632 371, 414, 449, 506SEQ ID EGMTGSIR 254-261 for the protein of SEQ No. 365 2df No. 633 SEQID EGSCDK 54-59 for the protein of SEQ No. 351 2de No. 634 SEQ IDEIAVWNR 125-131 for the protein of SEQ No. 381 2df No. 635 SEQ ID EIAYK262-266 for the protein of SEQ No. 480 2df No. 636 SEQ ID EIFER 20-24for the protein of SEQ No. 377 2d No. 637 SEQ ID EIFYHYR 79-85 for theprotein of SEQ No. 385 2d No. 638 SEQ ID EIGDDK 131-136 for the proteinsof SEQ No. 350, OXA No. 639 367, 370, 415, 443, 481, 488; 120-125 forthe protein of sequence SEQ ID No. 362 SEQ ID EIGDGK 131-136 for theprotein of SEQ No. 375 2d No. 640 SEQ ID EIGEDK 131-136 for the proteinsof SEQ No. 356, 2d No. 641 372, 491 SEQ ID EIGEDNAR 131-138 for theprotein of SEQ No. 484 OXA No. 642 SEQ ID EIGENK 131-136 for theproteins of SEQ No. 355, 363 2d No. 643 SEQ ID EIGPK 153-157 for theprotein of SEQ No. 381 2df No. 644 SEQ ID EIGSEIDK 136-143 for theprotein of SEQ No. 377 2d No. 645 SEQ ID EITYK 262-266 for the proteinsof SEQ No. 389, 2df No. 646 390, 391, 392, 393, 394, 395, 396, 397, 398,399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 411, 412, 416,417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 434, 436,437, 438, 444, 445, 446, 448, 451, 452, 453, 454, 455, 456, 457, 467,468, 472, 473, 474, 475, 478, 479, 482, 483, 487, 495, 502, 503, 507,508; 263-267 for the proteins of sequence SEQ ID No. 364, 365, 371, 414,447, 449, 466, 506; 256-260 for the proteins of sequence SEQ ID No. 431,432 SEQ ID EITYR 262-266 for the protein of SEQ No. 388 2df No. 647 SEQID EMIYLK 181-186 for the protein of SEQ No. 385 2d No. 648 SEQ IDEMLYVER 205-211 for the proteins of SEQ No. 410, 2df No. 649 413, 458SEQ ID EMTYK 262-266 for the protein of SEQ No. 439 2df No. 650 SEQ IDENIEK 138-142 for the proteins of SEQ No. 429, 2d No. 651 430, 477;137-141 for the protein of sequence SEQ ID No. 386 SEQ ID ENQLIVK183-189 for the proteins of SEQ No. 352, OXA No. 652 357, 358, 359, 368,383, 435, 442, 471, 492, 501, 504; 174-180 for the proteins of sequenceSEQ ID No. 348, 353, 354; 184-190 for the protein of sequence SEQ ID No.490 SEQ ID EQAILLFR 156-163 for the protein of SEQ No. 385 2d No. 653SEQ ID EQIQFLLR 165-172 for the protein of SEQ No. 349 2d No. 654 SEQ IDEQLAFDPQVQQQVK 182-195 for the protein of SEQ No. 469 2df No. 655 SEQ IDEQVDFVQR 189-196 for the protein of SEQ No. 382 2df No. 656 SEQ IDETEVYFFAFNMDIDNESK 229-246 for the proteins of SEQ No. 352, OXA No. 657435, 492, 501; 220-237 for the proteins of sequence SEQ ID No. 348, 353,354 SEQ ID ETTTPR 90-95 for the protein of SEQ No. 347 2d No. 658 SEQ IDEVGEIR 126-131 for the protein of SEQ No. 489 2d No. 659 SEQ ID EVGEVR126-131 for the proteins of SEQ No. 352, OXA No. 660 357, 358, 359, 368,383, 435, 442, 471, 492, 501, 504; 117-122 for the proteins of sequenceSEQ ID No. 348, 353, 354; 127-132 for the protein of sequence SEQ ID No.490 SEQ ID EVNGSK 209-214 for the proteins of SEQ No. 364, 2df No. 661365, 371, 414, 449, 466, 506 SEQ ID EWQENK 24-29 for the proteins of SEQNo. 378, 450, 2df No. 662 476, 485 SEQ ID EYELYLNVWK 78-87 for theprotein of SEQ No. 494 2de No. 663 SEQ ID EYLPASTFK 62-70 for theproteins of SEQ No. 352, 357, OXA No. 664 358, 359, 368, 383, 435, 442,471, 492, 504; 53-61 for the proteins of sequence SEQ ID No. 348, 353,354; 63-71 for the protein of sequence SEQ ID No. 490 SEQ ID EYLPVSTFK62-70 for the protein of SEQ No. 501 2de No. 665 SEQ ID EYNTSGTFVFYDGK27-40 for the protein of SEQ No. 385 2d No. 666 SEQ ID EYVPASTFX 75-83for the proteins of SEQ No. 388, 389, 2df No. 667 390, 391, 392, 393,394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407,408, 409, 411, 412, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425,426, 427, 428, 434, 436, 437, 438, 439, 444, 445, 446, 448, 451, 452,453, 454, 455, 456, 457, 467, 468, 472, 473, 474, 475, 478, 479, 480,482, 483, 487, 495, 502, 503, 507, 508; 69-77 for the proteins ofsequence SEQ ID No. 431, 432, 469; 74-82 for the proteins of sequenceSEQ ID No. 366, 374, 387, 440, 441, 459, 460, 461, 462, 463, 464, 465,486, 493; 76-84 for the proteins of sequence SEQ ID No. 364, 365, 371,414, 447, 449, 466, 506 SEQ ID FAAYVAGFGYGNGDISGEPGK 120-140 for theprotein of SEQ No. 498 2d No. 668 SEQ ID FAPESTFK 45-52 for the proteinof SEQ No. 494 2de No. 669 SEQ ID FAQYAK 121-126 for the proteins of SEQNo. 496, 2d No. 670 497, 499, 500 SEQ ID FDYGNK 138-143 for the proteinof SEQ No. 351 2de No. 671 SEQ ID FDYGNR 146-151 for the protein of SEQNo. 379; 125-130 No. 672 for the protein of sequence SEQ ID No. 2d 347SEQ ID FEDLYK 232-237 for the protein of SEQ No. 385 2d No. 673 SEQ IDFEDTFHISNQK 27-37 for the protein of SEQ No. 466 2df No. 674 SEQ IDFEDTFHTSNQQHEK 27-40 for the protein of SEQ No. 447 2df No. 675 SEQ IDFEYGNQDVSGDSGK 133-146 for the protein of SEQ No. 349 2d No. 676 SEQ IDFFSDFQAK 34-41 for the protein of SEQ No. 375 2d No. 677 SEQ IDFFSDLQAEGAIVIADER 34-50 for the proteins of SEQ No. 373, 484 2d No. 678SEQ ID FFSDLR 34-39 for the proteins of SEQ No. 369, 372 OXA No. 679 SEQID FFSEFQAK 34-41 for the proteins of SEQ No. 350, 356, OXA No. 680 367,370, 415, 443, 481, 488, 491; 23-30 for the protein of sequence SEQ IDNo. 362 SEQ ID FGLEGQLR 153-160 for the protein of SEQ No. 359 2de No.681 SEQ ID FILPIFSISILVSLSACSSIK 4-24 for the proteins of SEQ No. 364,365, 2df No. 682 371, 414, 449, 506 SEQ ID FLALLFSAVVVSLGHAQDK 5-24 forthe protein of SEQ No. 363 2d No. 683 SEQ ID FLALLFSAVVLVSLGHAQEK 5-24for the protein of SEQ No. 355 2d No. 684 SEQ ID FLESLYLNNLPASK 169-182for the proteins of SEQ No. 489, 505 OXA No. 685 SEQ ID FLLEGQLR 153-160for the protein of SEQ No. 442 2de No. 686 SEQ ID FQQYVDR 118-124 forthe protein of SEQ No. 347 2d No. 687 SEQ ID FSDYVQR 131-137 for theprotein of SEQ No. 351 2de No. 688 SEQ ID FSTASTFK 63-70 for the proteinof SEQ No. 470 2df No. 689 SEQ ID FSWDGK 117-122 for the protein of SEQNo. 381 2df No. 690 SEQ ID FSYGNQNISGGIDK 139-152 for the proteins ofSEQ No. 352, OXA No. 691 357, 358, 359, 368, 383, 435, 442, 501, 504;130-143 for the proteins of sequence SEQ ID No. 348, 353, 354; 140-153for the protein of sequence SEQ ID No. 490 SEQ ID FSYGNQNISGGTDK 139-152for the protein of SEQ No. 471 2de No. 692 SEQ ID FSYGSQNISGGIDK 139-152for the protein of SEQ No. 492 2de No. 693 SEQ ID FTEYVK 126-131 for theprotein of SEQ No. 349 2d No. 694 SEQ ID FVAHK 173-177 for the proteinof SEQ No. 349 2d No. 695 SEQ ID FVPASTYK 62-69 for the protein of SEQNo. 380 2d No. 696 SEQ ID FVYDLAQGQLPFK 184-196 for the proteins of SEQNo. 410, 2df No. 697 413, 458 SEQ ID FVYDLAQGQLPFKPEVQQQVK 184-204 forthe proteins of SEQ No. 410, 2df No. 698 413, 458 SEQ ID FWLEDQLR153-160 for the proteins of SEQ No. 358, 2de No. 699 435, 471, 492;144-151 for the proteins of sequence SEQ ID No. 348, 353 SEQ ID FWLEGPLK144-151 for the protein of SEQ No. 377 2d No. 700 SEQ ID FWLEGQLR153-160 for the proteins of SEQ No. 352, OXA No. 701 357, 368, 383, 489,501, 504, 505; 144-151 for the protein of sequence SEQ ID No. 354;154-161 for the protein of sequence SEQ ID No. 490 SEQ ID FYPASSFK 53-60for the protein of SEQ No. 377 2d No. 702 SEQ ID FYPASTFK 66-73 for theproteins of SEQ No. 386, 429, 2d No. 703 430, 477 SEQ ID GACDK 44-48 forthe protein of SEQ No. 498 2d No. 704 SEQ ID GAEVYFFAFNMDIDNENK 229-246for the proteins of SEQ No. 383, 490 2d No. 705 SEQ ID GAIQVSAVPVFQQIAR110-125 for the proteins of SEQ No. 352, OXA No. 706 357, 358, 359, 368,383, 435, 442, 471, 489, 492, 501, 504, 505; 101-116 for the proteins ofsequence SEQ ID No. 348, 354; 111-126 for the protein of sequence SEQ IDNo. 490 SEQ ID GAIQVSAVPVFQQITR 101-116 for the protein of SEQ No. 3532de No. 707 SEQ ID GDYWIDGNLEISAREQISFER 156-176 for the proteins of SEQNo. 369, 372 OXA No. 708 SEQ ID GDYWIDGNLK 156-165 for the protein ofSEQ No. 373 2d No. 709 SEQ ID GELPVSEDALEMTK 181-194 for the protein ofSEQ No. 351 2de No. 710 SEQ ID GEQPAGPAAR 241-250 for the protein of SEQNo. 498; 252-261 OXA No. 711 for the protein of sequence SEQ ID No. 351SEQ ID GFAGHNQDQDLR 103-114 for the proteins of SEQ No. 350, OXA No. 712367, 370, 415, 443, 481, 488; 92-103 for the protein of sequence SEQ IDNo. 362 SEQ ID GIPSSVR 254-260 for the proteins of SEQ No. 389, 2df No.713 390, 391, 392, 393, 394, 395, 397, 398, 399, 400, 401, 402, 403,404, 405, 406, 407, 408, 409, 411, 412, 416, 417, 418, 419, 420, 421,422, 423, 424, 425, 426, 427, 428, 434, 436, 437, 438, 439, 444, 445,446, 448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472, 473, 474,475, 478, 479, 480, 482, 483, 487, 495, 502, 503, 507, 508; 248-254 forthe proteins of sequence SEQ ID No. 431, 432 SEQ ID GISSSVR 254-260 forthe protein of SEQ No. 388 2df No. 714 SEQ ID GLNGTFVVYDLK 26-37 for theprotein of SEQ No. 377 2d No. 715 SEQ ID GMEIWNSNHTPK 101-112 for theproteins of SEQ No. 360, 2d No. 716 376; 86-97 for the protein ofsequence SEQ ID No. 361 SEQ ID GNQTLVFAR 230-238 for the protein of SEQNo. 496 2d No. 717 SEQ ID GNYWIDGNLEISAHEQISFLR 156-176 for the proteinof SEQ No. 484 OXA No. 718 SEQ ID GPLEISAFEEAR 164-175 for the proteinof SEQ No. 379 2df No. 719 SEQ ID GPLTITPIQEVK 172-183 for the proteinsof SEQ No. 410, 2df No. 720 413, 458 SEQ ID GSGWFVGWIVR 219-229 for theproteins of SEQ No. 496, 2d No. 721 497, 499, 500 SEQ ID GSLLEWDQK 66-74for the protein of SEQ No. 381 2df No. 722 SEQ ID GTEVYFFAFNMDIDNENK229-246 for the proteins of SEQ No. 357, OXA No. 723 358, 359, 368, 442,471, 504 SEQ ID GTEVYFFAFNMDIDNESK 229-246 for the proteins of SEQ No.489, 505 OXA No. 724 SEQ ID GTFVEYDVQR 38-47 for the protein of SEQ No.380 2d No. 725 SEQ ID GTIVVADER 42-50 for the proteins of SEQ No. 350,356, OXA No. 726 367, 370, 375, 415, 443, 481, 488, 491; 31-39 for theprotein of sequence SEQ ID No. 362 SEQ ID GTIVVLDAR 63-71 for theprotein of SEQ No. 382 2df No. 727 SEQ ID GTIVVVDER 42-50 for theproteins of SEQ No. 355, 363 2d No. 728 SEQ ID GTLPFSAR 200-207 for theprotein of SEQ No. 382 2df No. 729 SEQ ID GTPSSVR 254-260 for theprotein of SEQ No. 396 2df No. 730 SEQ ID HALSSAFVLLGCIAASAHAK 5-24 forthe proteins of SEQ No. 496, 497, 2d No. 731 499, 500 SEQ ID HIADSK234-239 for the protein of SEQ No. 494 2de No. 732 SEQ ID HNGLTHAWLASSLK152-165 for the protein of SEQ No. 351 2de No. 733 SEQ IDHNGLTQSWLMSSLTISPK 147-164 for the protein of SEQ No. 349 2d No. 734 SEQID HNGTDGAWIISSLR 148-161 for the protein of SEQ No. 433 2d No. 735 SEQID HTLSVFDQER 54-63 for the protein of SEQ No. 373 2d No. 736 SEQ IDHVTFASFR 241-248 for the protein of SEQ No. 494 2de No. 737 SEQ IDIAISLMGYDAGFLR 57-70 for the proteins of SEQ No. 496, 497, 2d No. 738499, 500 SEQ ID IALSLMAFDAEIIDQK 75-90 for the proteins of SEQ No. 360,376; 2d No. 739 60-75 for the protein of sequence SEQ ID No. 361 SEQ IDIALSLMGFDSGILK 53-66 for the protein of SEQ No. 494 2de No. 740 SEQ IDIANALIGLENHK 87-98 for the proteins of SEQ No. 410, 413, 2df No. 741 458SEQ ID IAWIVGEVYLK 205-215 for the protein of SEQ No. 385 2d No. 742 SEQID IDTFWLDNSLK 141-151 for the protein of SEQ No. 385 2d No. 743 SEQ IDIDYYNLDR 41-48 for the protein of SEQ No. 377 2d No. 744 SEQ IDIFNALIALDSGVIK 62-75 for the protein of SEQ No. 385 2d No. 745 SEQ IDIFNSLLALDSGALDNER 95-111 for the protein of SEQ No. 382 2df No. 746 SEQID IFNTLIGLENGIVK 61-74 for the protein of SEQ No. 377 2d No. 747 SEQ IDIGLDLMQK 138-145 for the proteins of SEQ No. 366, 2df No. 748 374, 387,440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQ ID IGLEK131-135 for the protein of SEQ No. 477 OXA No. 749 SEQ ID IGLELMQQEVQR133-144 for the protein of SEQ No. 469 2df No. 750 SEQ ID IGLELMSK139-146 for the proteins of SEQ No. 389, 2df No. 751 390, 391, 393, 395,398, 399, 400, 401, 402, 403, 404, 408, 409, 411, 412, 417, 419, 420,421, 422, 423, 424, 425, 426, 427, 428, 436, 437, 438, 439, 451, 452,453, 454, 455, 456, 457, 467, 468, 472, 473, 474, 478, 479, 480, 482,483, 487, 495, 502, 508 SEQ ID IGLELMSNEVK 139-149 for the proteins ofSEQ No. 388, 2df No. 752 392, 394, 396, 397, 405, 406, 407, 416, 418,434, 444, 445, 446, 448, 475, 503, 507; 133-143 for the proteins ofsequence SEQ ID No. 431, 432 SEQ ID IGLER 126-130 for the protein of SEQNo. 380 2d No. 753 SEQ ID IGLNK 130-134 for the proteins of SEQ No. 360,2d No. 754 376; 115-119 for the protein of sequence SEQ ID No. 361 SEQID IGLNLMQK 140-147 for the protein of SEQ No. 466 2df No. 755 SEQ IDIGPSLMQSELQR 142-153 for the proteins of SEQ No. 410, 2df No. 756 413,458 SEQ ID IGYGNMQIGTEVDQFWLK 154-171 for the proteins of SEQ No. 413,458 2df No. 757 SEQ ID IGYGNMQMGTEVDQFWLK 154-171 for the protein of SEQNo. 410 2df No. 758 SEQ ID IINHNLPVK 167-175 for the protein of SEQ No.361; 182-190 2d No. 759 for the protein of sequence SEQ ID No. 360 SEQID IINHNLPVR 182-190 for the protein of SEQ No. 376 2d No. 760 SEQ IDILFQQGTQQACAER 41-54 for the protein of SEQ No. 433 2d No. 761 SEQ IDILNNWFK 20-26 for the protein of SEQ No. 385 2d No. 762 SEQ IDILNTLISLEEK 71-81 for the protein of SEQ No. 470 2df No. 763 SEQ IDILSLVCLSISIGACAEHSMSR 6-26 for the proteins of SEQ No. 410, 413, 2df No.764 458 SEQ ID INESR 219-223 for the protein of SEQ No. 349 2d No. 765SEQ ID INIVK 255-259 for the proteins of SEQ No. 429, 2d No. 766 430,477; 254-258 for the protein of sequence SEQ ID No. 386 SEQ IDINLYGNALSR 61-70 for the proteins of SEQ No. 366, 374, 2df No. 767 387,440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQ ID IPFSLNLEMK244-253 for the proteins of SEQ No. 364, 2df No. 768 365, 371, 414, 449,506 SEQ ID IPHTLFALDADAVR 76-89 for the protein of SEQ No. 373 2d No.769 SEQ ID IPHTLFALDAGAAR 76-89 for the proteins of SEQ No. 356, 491 2dNo. 770 SEQ ID IPHTLFALDAGAVR 76-89 for the proteins of SEQ No. 350,355, OXA No. 771 363, 367, 370, 375, 415, 443, 481, 488; 65-78 for theprotein of sequence SEQ ID No. 362 SEQ ID IPLGK 255-259 for the proteinof SEQ No. 379 2df No. 772 SEQ ID IPNAIIGLETGVIK 71-84 for the proteinsof SEQ No. 352, 358, OXA No. 773 359, 368, 383, 442, 471, 492, 504;62-75 for the proteins of sequence SEQ ID No. 348, 353; 72-85 for theprotein of sequence SEQ ID No. 490 SEQ ID IPNALIGLETGAIK 71-84 for theproteins of SEQ No. 489, 505 OXA No. 774 SEQ ID IPNSLIAFDTGAVR 78-91 forthe protein of SEQ No. 379 2df No. 775 SEQ ID IPSAIIGLETGVIK 71-84 forthe proteins of SEQ No. 357, 435, No. 776 501; 62-75 for the protein ofsequence SEQ 2de ID No. 354 SEQ ID ISAFNQVK 161-168 for the protein ofSEQ No. 489 2d No. 777 SEQ ID ISAHEQILFLR 166-176 for the protein of SEQNo. 373 2d No. 778 SEQ ID ISAMEQTR 160-167 for the protein of SEQ No.380 2d No. 779 SEQ ID ISAMEQVK 165-172 for the proteins of SEQ No. 429,2d No. 780 477; 152-159 for the protein of sequence SEQ ID No. 377;164-171 for the protein of sequence SEQ ID No. 386 SEQ ID ISATEQVAFLR164-174 for the protein of SEQ No. 384 2df No. 781 SEQ ID ISATQQIAFLR164-174 for the protein of SEQ No. 485 2df No. 782 SEQ IDISAVNQVEFLESLFLNK 161-177 for the proteins of SEQ No. 357, OXA No. 783358, 359, 368, 383, 442, 471, 504; 162-178 for the protein of sequenceSEQ ID No. 490 SEQ ID ISAVNQVEFLESLYLNK 161-177 for the proteins of SEQNo. 352, OXA No. 784 435, 492, 501; 152-168 for the proteins of sequenceSEQ ID No. 348, 353, 354 SEQ ID ISAVNQVK 161-168 for the protein of SEQNo. 505 2de No. 785 SEQ ID ISPEEQIQFLR 170-180 for the proteins of SEQNo. 360, 2d No. 786 376; 155-165 for the protein of sequence SEQ ID No.361 SEQ ID ISPEEQVR 166-173 for the protein of SEQ No. 351 2de No. 787SEQ ID ISPEGQVR 155-162 for the protein of SEQ No. 498 2d No. 788 SEQ IDISPLEQLAFLR 162-172 for the protein of SEQ No. 433 2d No. 789 SEQ IDITAFQQVDFLR 188-198 for the protein of SEQ No. 381 2df No. 790 SEQ IDITLFLLFLNLVFGQDK 4-19 for the protein of SEQ No. 385 2d No. 791 SEQ IDITPIQEVNFADDFANNR 174-190 for the protein of SEQ No. 447 2df No. 792 SEQID ITPIQEVNFADDLANNR 174-190 for the protein of SEQ No. 466 2df No. 793SEQ ID ITPQQEAQFAYK 173-184 for the proteins of SEQ No. 388, 2df No. 794389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402,403, 404, 406, 407, 408, 409, 411, 412, 416, 417, 418, 419, 420, 421,422, 423, 424, 425, 426, 427, 428, 434, 436, 437, 438, 439, 444, 445,446, 448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472, 473, 474,475, 478, 479, 480, 482, 483, 487, 495, 502, 503, 507, 508; 167-178 forthe proteins of sequence SEQ ID No. 431, 432 SEQ ID ITPQQEAQFTYK 173-184for the protein of SEQ No. 405 2df No. 795 SEQ ID ITPVQEVNFADDLAHNR174-190 for the proteins of SEQ No. 364, 2df No. 796 365, 371, 414, 449,506 SEQ ID IVAFALK 241-247 for the proteins of SEQ No. 366, 387 2df No.797 SEQ ID IVAFALNMEMR 241-251 for the proteins of SEQ No. 440, 2df No.798 459, 460, 461, 462, 463, 464, 465, 486, 493; 242-252 for theproteins of sequence SEQ ID No. 374, 441 SEQ ID IVESTTLADGTVVHGK 186-201for the proteins of SEQ No. 496, 2d No. 799 497, 499, 500 SEQ IDIYNSLIGLNEK 74-84 for the proteins of SEQ No. 386, 429, 2d No. 800 430,477 SEQ ID KPDIGWWVGWIER 237-249 for the protein of SEQ No. 382 2df No.801 SEQ ID LACATNNLAR 50-59 for the protein of SEQ No. 490 2d No. 802SEQ ID LAQGELPFPAPVQSTVR 172-188 for the protein of SEQ No. 380 2d No.803 SEQ ID LAQNELPYPIEIQK 177-190 for the proteins of SEQ No. 429, 2dNo. 804 430, 477 SEQ ID LAQNELQYPIEIQK 176-189 for the protein of SEQNo. 386 2d No. 805 SEQ ID LDFGNK 143-148 for the proteins of SEQ No.429, 2d No. 806 430, 477; 142-147 for the protein of sequence SEQ ID No.386 SEQ ID LDGSLNR 206-212 for the protein of SEQ No. 347 2d No. 807 SEQID LEIGK 244-248 for the protein of SEQ No. 349 2d No. 808 SEQ IDLEILQQALAELGLYPK 255-270 for the protein of SEQ No. 469 2df No. 809 SEQID LENQEQVK 173-180 for the protein of SEQ No. 377 2d No. 810 SEQ IDLETQEEVEK 195-203 for the protein of SEQ No. 364 2df No. 811 SEQ IDLETQEEVK 195-202 for the proteins of SEQ No. 365, 2df No. 812 371, 414,447, 449, 466, 506 SEQ ID LFAAEGVK 55-62 for the protein of SEQ No. 3822df No. 813 SEQ ID LFESAGVK 58-65 for the protein of SEQ No. 381 2df No.814 SEQ ID LFGAAGVK 30-37 for the protein of SEQ No. 380 2d No. 815 SEQID LFPEWEK 110-116 for the proteins of SEQ No. 388, 2df No. 816 389,390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403,404, 405, 406, 407, 408, 409, 411, 412, 416, 417, 418, 419, 420, 421,422, 423, 424, 425, 426, 427, 428, 434, 436, 437, 438, 439, 444, 445,446, 448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472, 473, 474,475, 478, 479, 480, 482, 483, 487, 495, 502, 503, 507, 508; 104-110 forthe proteins of sequence SEQ ID No. 431, 432 SEQ ID LGESR 126-130 forthe protein of SEQ No. 351 2de No. 817 SEQ ID LGVDR 121-125 for theprotein of SEQ No. 349 2d No. 818 SEQ ID LHVSER 181-186 for the proteinsof SEQ No. 378, 2df No. 819 384, 450, 476, 485 SEQ ID LHYGNAK 131-137for the protein of SEQ No. 385 2d No. 820 SEQ ID LLNLLSQSK 160-168 forthe protein of SEQ No. 377 2d No. 821 SEQ ID LLQDER 243-248 for theprotein of SEQ No. 433 2d No. 822 SEQ ID LLVQDGDCGR 38-47 for theproteins of SEQ No. 496, 497, 2d No. 823 499, 500 SEQ ID LNEVGYGNR160-168 for the protein of SEQ No. 382 2df No. 824 SEQ ID LNYGNADPSTK144-154 for the proteins of SEQ No. 355, 363 2d No. 825 SEQ ID LNYGNK130-135 for the protein of SEQ No. 377 2d No. 826 SEQ ID LPASK 178-182for the proteins of SEQ No. 489, 2d No. 827 505; 172-176 for the proteinof sequence SEQ ID No. 498 SEQ ID LPHTLFALDADAVR 76-89 for the proteinsof SEQ No. 369, 372 OXA No. 828 SEQ ID LPHTLFALDAGAVR 76-89 for theprotein of SEQ No. 484 OXA No. 829 SEQ ID LPLAIMGFDSGILQSPK 62-78 forthe protein of SEQ No. 349 2d No. 830 SEQ ID LPLAIMGYDADILLDATTPR 69-88for the protein of SEQ No. 351 2de No. 831 SEQ ID LPSSLIALETGAVR 98-111for the protein of SEQ No. 381 2df No. 832 SEQ ID LPVSAQTLQYTANILK170-185 for the protein of SEQ No. 347 2d No. 833 SEQ ID LPVSER 205-210for the protein of SEQ No. 381 2df No. 834 SEQ ID LPVSPTAVDMTER 173-185for the proteins of SEQ No. 496, 2d No. 835 497, 499, 500 SEQ ID LSASK178-182 for the proteins of SEQ No. 352, OXA No. 836 357, 358, 359, 368,383, 435, 442, 471, 492, 501, 504; 169-173 for the proteins of sequenceSEQ ID No. 348, 353, 354; 179-183 for the protein of sequence SEQ ID No.490 SEQ ID LSAVPIYQEVAR 121-132 for the protein of SEQ No. 379 2df No.837 SEQ ID LSAVPVYQELAR 127-138 for the proteins of SEQ No. 364, 2df No.838 365, 371, 414, 447, 449, 506; 125-136 for the proteins of sequenceSEQ ID No. 366, 374, 387, 440, 441, 459, 460, 461, 462, 463, 464, 465,486, 493 SEQ ID LSCTLVIDEASGDLLHR 37-53 for the protein of SEQ No. 3512de No. 839 SEQ ID LSLQHGWFIGWIEK 211-224 for the protein of SEQ No. 4942de No. 840 SEQ ID LSQNSLPFSQEAMNSVK 164-180 for the protein of SEQ No.385 2d No. 841 SEQ ID LSVNPK 168-173 for the protein of SEQ No. 494 2deNo. 842 SEQ ID LTQDER 239-244 for the proteins of SEQ No. 496, No. 843497, 499, 500 2d SEQ ID LTVGAR 245-250 for the protein of SEQ No. 3512de No. 844 SEQ ID LYGFALNIDMPGGEADIGK 228-246 for the protein of SEQNo. 380 2d No. 845 SEQ ID LYHNELPFR 178-186 for the proteins of SEQ No.356, 491 2d No. 846 SEQ ID LYHNK 176-180 for the proteins of SEQ No.378, 2df No. 847 384, 450, 476, 485 SEQ ID LYQNDLPFR 178-186 for theprotein of SEQ No. 375 2d No. 848 SEQ ID MDDLFK 243-248 for the proteinsof SEQ No. 350, OXA No. 849 356, 367, 370, 375, 415, 443, 481, 488, 491;232-237 for the protein of sequence SEQ ID No. 362 SEQ ID MEDLHK 243-248for the proteins of SEQ No. 355, 363 2d No. 850 SEQ ID MLIALIGLENHK85-96 for the protein of SEQ No. 506 2df No. 851 SEQ ID MLLIEQQGDAALYAK198-212 for the protein of SEQ No. 379 2df No. 852 SEQ ID MLLIK 204-208for the proteins of SEQ No. 364, 2df No. 853 365, 371, 414, 447, 449,466, 506 SEQ ID MLNTALIGLEHHK 84-95 for the proteins of SEQ No. 388,389, 2df No. 854 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400,401, 402, 403, 404, 405, 406, 408, 409, 411, 412, 416, 417, 418, 419,420, 421, 422, 423, 424, 425, 426, 427, 428, 434, 436, 437, 438, 439,444, 445, 446, 448, 451, 452, 453, 454, 455, 456, 457, 467, 468, 472,473, 474, 475, 478, 479, 480, 482, 487, 495, 502, 503, 507, 508; 78-89for the proteins of sequence SEQ ID No. 431, 432 SEQ ID MLNALIGLENHK85-96 for the proteins of SEQ No. 364, 365, 2df No. 855 371, 414, 447,449, 466 SEQ ID MLNALIGLENQK 83-94 for the proteins of SEQ No. 366, 374,2df No. 856 387, 440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493SEQ ID MLNALIGLEYHK 84-95 for the protein of SEQ No. 483 2df No. 857 SEQID MLNALIGLQHGK 78-89 for the protein of SEQ No. 469 2df No. 858 SEQ IDMLNALISLEHHK 84-95 for the protein of SEQ No. 407 2df No. 859 SEQ IDMQAYVDAFDYGNR 139-151 for the protein of SEQ No. 379 2df No. 860 SEQ IDMQEGLNK 123-129 for the protein of SEQ No. 377 2d No. 861 SEQ IDMSPASTYK 87-94 for the protein of SEQ No. 382 2df No. 862 SEQ ID MTAGGK234-239 for the protein of SEQ No. 498 2d No. 863 SEQ ID MVSGK 165-169for the protein of SEQ No. 347 2d No. 864 SEQ ID NEHDPVLPYR 71-80 forthe proteins of SEQ No. 496, 497, 2d No. 865 499, 500 SEQ ID NEHQIFK86-92 for the protein of SEQ No. 490; 85-91 2d No. 866 for the proteinof sequence SEQ ID No. 383 SEQ ID NEHQVFK 85-91 for the proteins of SEQNo. 352, 357, OXA No. 867 358, 359, 368, 435, 442, 471, 492, 501, 504;76-82 for the proteins of sequence SEQ ID No. 348, 353, 354 SEQ IDNEITYK 262-267 for the proteins of SEQ No. 364, 2df No. 868 365, 371,414, 447, 449, 466, 506 SEQ ID NELLMK 260-265 for the proteins of SEQNo. 366, 2df No. 869 387, 440, 459, 460, 462, 463, 464, 465, 486, 493;261-266 for the proteins of sequence SEQ ID No. 374, 441 SEQ ID NELMMK260-265 for the protein of SEQ No. 461 2df No. 870 SEQ ID NELPFR 181-186for the proteins of SEQ No. 350, OXA No. 871 355, 356, 363, 367, 370,415, 443, 481, 488, 491; 170-175 for the protein of sequence SEQ ID No.362 SEQ ID NFILIFIFVILISCK 5-19 for the proteins of SEQ No. 386, 429, 2dNo. 872 477 SEQ ID NFILIFIFVILTSCK 5-19 for the protein of SEQ No. 4302d No. 873 SEQ ID NISSYGNNLVR 62-72 for the protein of SEQ No. 466 2dfNo. 874 SEQ ID NISTYGNNLTR 62-72 for the protein of SEQ No. 447 2df No.875 SEQ ID NLFNEVHTTGVLVIR 43-57 for the protein of SEQ No. 412 2df No.876 SEQ ID NLSTYGNALAR 62-72 for the proteins of SEQ No. 364, 365, 2dfNo. 877 371, 414, 449, 506 SEQ ID NMENLELFGK 187-196 for the protein ofSEQ No. 385 2d No. 878 SEQ ID NMLLLEENNGYK 201-212 for the protein ofSEQ No. 440 2df No. 879 SEQ ID NMLLLEESNGYK 201-212 for the proteins ofSEQ No. 366, 2df No. 880 374, 387, 441, 459, 460, 461, 462, 463, 465,486, 493 SEQ ID NMLLLEK 201-207 for the protein of SEQ No. 464 2df No.881 SEQ ID NMTLGDAMK 117-125 for the proteins of SEQ No. 388, 2df No.882 392, 393, 396, 397, 402, 405, 406, 416, 419, 422, 424, 434, 445,446, 448, 475, 503; 111-119 for the proteins of sequence SEQ ID No. 431,432 SEQ ID NNGLTEAWLESSLK 156-169 for the proteins of SEQ No. 360, 2dNo. 883 376; 141-154 for the protein of sequence SEQ ID No. 361 SEQ IDNQLPFK 181-186 for the protein of SEQ No. 373 2d No. 884 SEQ IDNQLPFQVEHQR 181-191 for the proteins of SEQ No. 369, OXA No. 885 372,484 SEQ ID NSAIENTIDNMYLQDLENSTK 191-211 for the protein of SEQ No. 3762d No. 886 SEQ ID NSAIENTIENMYLQDLDNSTK 191-211 for the protein of SEQNo. 360 2d No. 887 SEQ ID NSAIENTIENMYLQDLENSTK 176-196 for the proteinof SEQ No. 361 2d No. 888 SEQ ID NSAVWVYELFAK 119-130 for the proteinsof SEQ No. 369, OXA No. 889 372, 484 SEQ ID NSQVPAYK 118-125 for theproteins of SEQ No. 429, 2d No. 890 430, 477; 117-124 for the protein ofsequence SEQ ID No. 386 SEQ ID NSTVWIYELFAK 119-130 for the proteins ofSEQ No. 356, 491 2d No. 891 SEQ ID NSTVWVYELFAK 119-130 for the proteinsof SEQ No. 350, OXA No. 892 367, 370, 373, 375, 415, 443, 481, 488;108-119 for the protein of sequence SEQ ID No. 362 SEQ ID NSTVWVYQLFAK119-130 for the proteins of SEQ No. 355, 363 2d No. 893 SEQ IDNTSGALVIQTDK 48-59 for the protein of SEQ No. 460 2df No. 894 SEQ IDNTSGVLVIQTDK 48-59 for the proteins of SEQ No. 366, 374, 2df No. 895387, 440, 441, 459, 461, 462, 463, 464, 465, 486, 493 SEQ IDNVDEMFYYYDGSK 75-87 for the protein of SEQ No. 377 2d No. 896 SEQ IDNWILR 204-208 for the proteins of SEQ No. 350, OXA No. 897 356, 367,369, 370, 372, 375, 415, 443, 481, 484, 488, 491; 193-197 for theprotein of sequence SEQ ID No. 362 SEQ ID NWNAAMDLR 125-133 for theprotein of SEQ No. 382 2df No. 898 SEQ ID NYVDAFHYGNQDISGDK 118-134 forthe protein of SEQ No. 494 2de No. 899 SEQ ID QADHAILVFDQAR 51-63 forthe protein of SEQ No. 375 2d No. 900 SEQ ID QAEHALLVFGQER 51-63 for theproteins of SEQ No. 369, 372, OXA No. 901 484 SEQ ID QAITK 251-255 forthe proteins of SEQ No. 378, 2df No. 902 384, 450, 485; 247-251 for theprotein of sequence SEQ ID No. 476 SEQ ID QAMLTEANSDYIIR 193-206 for theprotein of SEQ No. 384 2df No. 903 SEQ ID QEVQFVSALAR 171-181 for theprotein of SEQ No. 469 2df No. 904 SEQ ID QFASIK 243-248 for the proteinof SEQ No. 347 2d No. 905 SEQ ID QGMPGSIR 254-261 for the protein of SEQNo. 447 2df No. 906 SEQ ID QGMSGSIR 254-261 for the protein of SEQ No.466 2df No. 907 SEQ ID QGQTQQSYGNDLAR 58-71 for the proteins of SEQ No.388, 389, 2df No. 908 390, 391, 392, 393, 394, 395, 396, 397, 398, 399,400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 411, 412, 416, 417,418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 436, 437, 438,439, 444, 445, 446, 448, 451, 452, 453, 454, 455, 456, 457, 467, 468,472, 473, 474, 475, 478, 479, 480, 482, 483, 487, 495, 502, 503, 507,508; 52-65 for the proteins of sequence SEQ ID No. 431, 432 SEQ IDQIDYGNADPSTIK 143-155 for the proteins of SEQ No. 369, OXA No. 909 372,484 SEQ ID QIDYGNVDPSTIK 143-155 for the protein of SEQ No. 373 2d No.910 SEQ ID QIGEAR 129-134 for the proteins of SEQ No. 378, 2df No. 911450, 476, 485 SEQ ID QIGQAR 129-134 for the protein of SEQ No. 384 2dfNo. 912 SEQ ID QIMLIEQTPAFTLR 190-203 for the protein of SEQ No. 470 2dfNo. 913 SEQ ID QLGSAIDQFWLR 152-163 for the protein of SEQ No. 379 2dfNo. 914 SEQ ID QLHDNK 199-204 for the protein of SEQ No. 381 2df No. 915SEQ ID QLIFVHTVVQK 229-239 for the protein of SEQ No. 347 2d No. 916 SEQID QLIFVHTVVQKPGK 229-242 for the protein of SEQ No. 347 2d No. 917 SEQID QLPVK 178-182 for the protein of SEQ No. 433; 184-188 OXA No. 918 forthe protein of sequence SEQ ID No. 379 SEQ ID QLPVKPR 184-190 for theprotein of SEQ No. 379 2df No. 919 SEQ ID QLSLDVLDK 265-273 for theproteins of SEQ No. 410, 2df No. 920 413, 458 SEQ ID QLVYAR 237-242 forthe protein of SEQ No. 433 2d No. 921 SEQ ID QMMLTEASTDYIIR 217-230 forthe protein of SEQ No. 381 2df No. 922 SEQ ID QMSIVEATPDYVLHGK 214-229for the protein of SEQ No. 382 2df No. 923 SEQ ID QPTDPAR 99-105 for theprotein of SEQ No. 433 2d No. 924 SEQ ID QPTDPTR 93-99 for the proteinsof SEQ No. 496, 497, 2d No. 925 499, 500 SEQ ID QPVSAGIR 246-253 for theproteins of SEQ No. 496, 2d No. 926 497, 499, 500 SEQ ID QQLVK 275-279for the protein of SEQ No. 381 2df No. 927 SEQ ID QTLVFAR 232-238 forthe proteins of SEQ No. 496, 2d No. 928 497, 499, 500 SEQ ID QVGAEK126-131 for the protein of SEQ No. 470 2df No. 929 SEQ ID QVVFAR 238-243for the protein of SEQ No. 349 2d No. 930 SEQ ID SADEVLPYGGK 84-94 forthe protein of SEQ No. 380 2d No. 931 SEQ ID SADEVLPYGGKPQR 84-97 forthe protein of SEQ No. 380 2d No. 932 SEQ ID SCATNDLAR 50-58 for theproteins of SEQ No. 352, 435, OXA No. 933 492, 501; 41-49 for theproteins of sequence SEQ ID No. 348, 353, 354 SEQ ID SCATNNLAR 50-58 forthe proteins of SEQ No. 357, 358, OXA No. 934 359, 368, 383, 442, 471,504 SEQ ID SDIPGGSK 251-258 for the protein of SEQ No. 349 2d No. 935SEQ ID SDWGK 29-33 for the protein of SEQ No. 375 2d No. 936 SEQ IDSEDNFHISSQQHEK 27-40 for the proteins of SEQ No. 364, 365, 2df No. 937371, 414, 449, 506 SEQ ID SEMPASIR 252-259 for the proteins of SEQ No.366, 2df No. 938 387, 440, 459, 460, 461, 462, 463, 464, 486, 493;253-260 for the proteins of sequence SEQ ID No. 374, 441 SEQ ID SEMPASTR252-259 for the protein of SEQ No. 465 2df No. 939 SEQ ID SFAAHNQDQDLR103-114 for the proteins of SEQ No. 356, 491 2d No. 940 SEQ ID SFAGHNK103-109 for the protein of SEQ No. 375 2d No. 941 SEQ ID SFAGHNQDQDLR103-114 for the proteins of SEQ No. 369, 2d No. 942 372, 373, 484 SEQ IDSFAGHNQDQNLR 103-114 for the proteins of SEQ No. 355, 363 2d No. 943 SEQID SFLESWAK 100-107 for the protein of SEQ No. 386 2d No. 944 SEQ IDSFTAWEK 109-115 for the proteins of SEQ No. 366, 2df No. 945 374, 387,441, 459, 460, 461, 462, 463, 464, 465, 486, 493; 104-110 for theprotein of sequence SEQ ID No. 469 SEQ ID SFTTWEK 109-115 for theprotein of SEQ No. 440 2df No. 946 SEQ ID SGSGWLR 207-213 for theprotein of SEQ No. 349 2d No. 947 SEQ ID SGWGMAVDPQVGWYVGFVEK 221-240for the proteins of SEQ No. 410, 2df No. 948 413, 458 SEQ IDSGWGMDVSPQVGWLTGWVEK 219-238 for the protein of SEQ No. 466 2df No. 949SEQ ID SGWGMDVTPQVGWLTGWVEK 219-238 for the protein of SEQ No. 447 2dfNo. 950 SEQ ID SIHPASTFK 69-77 for the protein of SEQ No. 379 2df No.951 SEQ ID SIPTK 252-256 for the proteins of SEQ No. 352, OXA No. 952357, 358, 359, 368, 383, 435, 442, 471, 490, 492, 501, 504, 505; 243-247for the proteins of sequence SEQ ID No. 348, 353, 354 SEQ ID SISTK252-256 for the protein of SEQ No. 489 2d No. 953 SEQ ID SLGLSNNLSR76-85 for the protein of SEQ No. 381 2df No. 959 SEQ ID SLSMSGK 4-10 forthe protein of SEQ No. 351 2de No. 955 SEQ ID SMLFIEEK 202-209 for theproteins of SEQ No. 388, 2df No. 956 389, 390, 391, 392, 393, 394, 395,396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409,411, 416, 417, 418, 419, 420, 421, 422, 424, 425, 426, 427, 428, 434,436, 437, 438, 439, 444, 445, 446, 451, 452, 453, 454, 455, 456, 457,467, 468, 472, 473, 474, 475, 478, 479, 480, 482, 483, 487, 495, 502,503, 507, 508; 196-203 for the proteins of sequence SEQ ID No. 431, 432SEQ ID SNGEK 239-243 for the proteins of SEQ No. 447, 466 2df No. 957SEQ ID SNGLTHSWLGSSLK 141-154 for the protein of SEQ No. 498 2d No. 958SEQ ID SNGYK 208-212 for the proteins of SEQ No. 366, 2df No. 959 374,387, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQ ID SPTWELK79-85 for the protein of SEQ No. 349 2d No. 960 SEQ ID SPTWELKPEYNPSPR79-93 for the protein of SEQ No. 349 2d No. 961 SEQ ID SQDIVR 208-213for the protein of SEQ No. 382 2df No. 962 SEQ ID SQQKPTDPTIWLK 100-112for the protein of SEQ No. 351 2de No. 963 SEQ ID SQVGWLTGWVEQPDGK225-240 for the protein of SEQ No. 486 2df No. 969 SEQ ID SSSNSCTTNNAAR46-58 for the protein of SEQ No. 489 2d No. 965 SEQ ID SSSNSCTTNNATR46-58 for the protein of SEQ No. 505 2de No. 966 SEQ ID SVYGELR 139-145for the protein of SEQ No. 470 2df No. 967 SEQ ID SWILR 204-208 for theprotein of SEQ No. 373 2d No. 968 SEQ ID SYFDEAQTQGVIIIK 44-58 for theproteins of SEQ No. 364, 365, 2df No. 969 371, 414, 447, 449, 466, 506SEQ ID SYLEK 139-143 for the proteins of SEQ No. 355, 363 2d No. 970 SEQID SYPMWEK 111-117 for the proteins of SEQ No. 447, 466 2df No. 971 SEQID TAYIPASTFK 61-70 for the proteins of SEQ No. 489, 505; 2df No. 97277-86 for the proteins of sequence SEQ ID No. 410, 413, 458 SEQ IDTDDLFK 243-248 for the proteins of SEQ No. 369, 2d No. 973 372, 373, 484SEQ ID TDINEIFK 95-102 for the proteins of SEQ No. 374, 387, 2df No. 974440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQ ID TFIHNDPR51-58 for the protein of SEQ No. 470 2df No. 975 SEQ ID TGAGFTANR216-224 for the proteins of SEQ No. 360, 2d No. 976 376; 201-209 for theprotein of sequence SEQ ID No. 361 SEQ ID TGFNDGQK 197-204 for theprotein of SEQ No. 385 2d No. 977 SEQ ID TGLADSK 210-216 for theproteins of SEQ No. 429, 2d No. 978 430; 209-215 for the protein ofsequence SEQ ID No. 386 SEQ ID TGLDLMQK 140-147 for the protein of SEQNo. 447 2df No. 979 SEQ ID TGLELMQK 140-147 for the proteins of SEQ No.364, 2df No. 980 365, 371, 414, 449, 506 SEQ ID TGMGYPK 198-204 for theprotein of SEQ No. 347 2d No. 981 SEQ ID TGNGR 197-201 for the proteinof SEQ No. 494 2de No. 982 SEQ ID TGTGSFIDAR 200-209 for the protein ofSEQ No. 498 2d No. 983 SEQ ID TGTGSLSDAK 211-220 for the protein of SEQNo. 351 2de No. 984 SEQ ID TGVATEYQPEIGWWAGWVER 213-232 for the proteinof SEQ No. 379 2df No. 985 SEQ ID TGVSYPLLADGTR 202-214 for the proteinsof SEQ No. 496, 2d No. 986 497, 499, 500 SEQ ID TGWAAMDIK 217-225 forthe proteins of SEQ No. 374, 441 2df No. 987 SEQ ID TGWAMDIK 217-224 forthe proteins of SEQ No. 366, 2df No. 988 387, 440, 460, 461, 462, 463,464, 465, 486, 493 SEQ ID TGWAMDVK 217-224 for the protein of SEQ No.459 2df No. 989 SEQ ID TGWATR 206-211 for the protein of SEQ No. 470 2dfNo. 990 SEQ ID TGWCFDCTPELGWWVGWVK 205-223 for the protein of SEQ No.380 2d No. 991 SEQ ID TGWEGR 211-216 for the proteins of SEQ No. 350,OXA No. 992 356, 367, 369, 370, 372, 373, 415, 443, 481, 484, 488, 491;200-205 for the protein of sequence SEQ ID No. 362 SEQ ID TGWFVDK230-236 for the protein of SEQ No. 382 2df No. 993 SEQ ID TGYDTK 209-214for the protein of SEQ No. 476 2df No. 994 SEQ ID TGYGVR 233-238 for theprotein of SEQ No. 381 2df No. 995 SEQ ID TGYSAR 209-214 for the proteinof SEQ No. 450 2df No. 996 SEQ ID TGYSTR 209-214 for the proteins of SEQNo. 378, 2df No. 997 384, 485 SEQ ID THESSNWGK 25-33 for the proteins ofSEQ No. 355, 363 2d No. 998 SEQ ID TICTAIADAGTGK 25-37 for the proteinsof SEQ No. 496, 497, 2d No. 999 499, 500 SEQ ID TIGGAPDAYWVDDSLQISAR169-188 for the protein of SEQ No. 382 2df No. 1000 SEQ ID TLPFSASSYETLR177-189 for the protein of SEQ No. 470 2df No. 1001 SEQ ID TLPFSLK189-195 for the proteins of SEQ No. 399, 2df No. 1002 403, 411 SEQ IDTLPFSPK 189-195 for the proteins of SEQ No. 389, 2df No. 1003 395, 412,423, 428, 439, 445, 467, 482, 483, 495 SEQ ID TLPFSQEVQDEVQSILFIEEK189-209 for the protein of SEQ No. 448 2df No. 1004 SEQ IDTLPFSQEVQDEVQSMLFIEEK 189-209 for the proteins of SEQ No. 392, 434 2dfNo. 1005 SEQ ID TLPFSQK 189-195 for the proteins of SEQ No. 388, 2df No.1006 390, 391, 393, 394, 396, 397, 398, 400, 401, 402, 404, 405, 406,407, 408, 409, 416, 417, 418, 419, 420, 421, 422, 424, 425, 426, 427,436, 437, 438, 444, 446, 451, 452, 453, 454, 455, 456, 457, 468, 472,473, 474, 475, 478, 480, 487, 502, 503, 507, 508; 183-189 for theproteins of sequence SEQ ID No. 431, 432 SEQ ID TLPSSQK 189-195 for theprotein of SEQ No. 479 2df No. 1007 SEQ ID TLQNGWFEGFIISK 225-238 forthe proteins of SEQ No. 360, 2d No. 1008 376; 210-223 for the protein ofsequence SEQ ID No. 361 SEQ ID TMQEYLNK 123-130 for the protein of SEQNo. 385 2d No. 1009 SEQ ID TNGNSTSVYNESR 51-63 for the proteins of SEQNo. 355, 363 2d No. 1010 SEQ ID TQTYQAYDAAR 72-82 for the protein of SEQNo. 382 2df No. 1011 SEQ ID TTDPTIWEK 93-101 for the protein of SEQ No.498 2d No. 1012 SEQ ID TTTTEVFK 96-103 for the proteins of SEQ No. 395,428 2df No. 1013 SEQ ID TWASNDFSR 41-49 for the protein of SEQ No. 3852d No. 1014 SEQ ID TWDMVQR 191-197 for the protein of SEQ No. 379 2dfNo. 1015 SEQ ID TWMQFSVVWVSQEITQK 113-129 for the proteins of SEQ No.360, 2d No. 1016 376; 98-114 for the protein of sequence SEQ ID No. 361SEQ ID TYPMWEK 111-117 for the proteins of SEQ No. 364, 2df No. 1017365, 371, 414, 449, 506 SEQ ID TYVVDPAR 58-65 for the protein of SEQ No.379 2df No. 1018 SEQ ID VAFSLNIEMK 244-253 for the protein of SEQ No.447 2df No. 1019 SEQ ID VANSLIGLSTGAVR 70-83 for the protein of SEQ No.380 2d No. 1020 SEQ ID VEHQR 187-191 for the proteins of SEQ No. 350,OXA No. 1021 355, 356, 363, 367, 369, 370, 372, 373, 375, 415, 443, 481,484, 488, 491; 176-180 for the protein of sequence SEQ ID No. 362 SEQ IDVELGK 248-252 for the protein of SEQ No. 380 2d No. 1022 SEQ IDVEDDAGVSGTFVLMDITADR 38-57 for the protein of SEQ No. 379 2df No. 1023SEQ ID VFLDSWAK 88-95 for the protein of SEQ No. 377 2d No. 1024 SEQ IDVFLESWAK 101-108 for the proteins of SEQ No. 429, 2d No. 1025 430, 477SEQ ID VFLSSWAQDMNLSSAIK 89-105 for the protein of SEQ No. 385 2d No.1026 SEQ ID VGFER 134-138 for the protein of SEQ No. 379 2df No. 1027SEQ ID VILVFDQVR 55-63 for the proteins of SEQ No. 356, 491 2d No. 1028SEQ ID VITFTK 228-233 for the protein of SEQ No. 494 2de No. 1029 SEQ IDVMAAMVR 158-164 for the protein of SEQ No. 381 2df No. 1030 SEQ IDVPLAVMGYDAGILVDAHNPR 58-77 for the protein of SEQ No. 498 2d No. 1031SEQ ID VQANVK 195-200 for the proteins of SEQ No. 366, 2df No. 1032 374,387, 440, 441, 459, 460, 461, 462, 463, 464, 465, 486, 493 SEQ ID VQDEVK196-201 for the protein of SEQ No. 444 2df No. 1033 SEQ IDVQDEVQSMLFIEEK 196-209 for the proteins of SEQ No. 388, 2df No. 1034389, 390, 391, 392, 393, 395, 396, 397, 398, 399, 400, 401, 402, 404,405, 406, 407, 408, 409, 411, 416, 417, 418, 419, 420, 421, 422, 424,425, 426, 427, 428, 434, 436, 437, 438, 439, 445, 446, 451, 452, 453,454, 455, 457, 467, 468, 472, 473, 474, 475, 478, 479, 480, 482, 483,487, 495, 502, 503, 507, 508; 190-203 for the proteins of sequence SEQID No. 431, 432 SEQ ID VQDEVQSMLFIEEMNGNK 196-213 for the proteins ofSEQ No. 412, 423 2df No. 1035 SEQ ID VQDGVQSMLFIEEK 196-209 for theprotein of SEQ No. 456 2df No. 1036 SEQ ID VQHEVQSMLFIEEK 196-209 forthe protein of SEQ No. 394 2df No. 1037 SEQ ID VSCLPCYQVVSHK 138-150 forthe protein of SEQ No. 382 2df No. 1038 SEQ ID VSCVWCYQALAR 114-125 forthe protein of SEQ No. 470 2df No. 1039 SEQ ID VSDVCSEVTAEGWQEVR 37-53for the protein of SEQ No. 381 2df No. 1040 SEQ ID VSEVEGWQIHGK 186-197for the protein of SEQ No. 347 2d No. 1041 SEQ ID VSFSLNIEMK 244-253 forthe protein of SEQ No. 466 2df No. 1042 SEQ ID VSPCSSFK 54-61 for theprotein of SEQ No. 349 2d No. 1043 SEQ ID VSQVPAYK 105-112 for theprotein of SEQ No. 377 2d No. 1044 SEQ ID VVFAR 229-233 for the proteinof SEQ No. 498; 239-243 OXA No. 1045 for the proteins of sequence SEQ IDNo. 349.351 SEQ ID WDGAK 97-101 for the proteins of SEQ No. 355, 363 2dNo. 1046 SEQ ID WDGEK 104-108 for the proteins of SEQ No. 393, 2df No.1047 402, 419, 422, 424 SEQ ID WDGHIYDFPDWNR 92-104 for the protein ofSEQ No. 470 2df No. 1048 SEQ ID WDGIK 97-101 for the proteins of SEQ No.356, 491 2d No. 1049 SEQ ID WDGKPR 92-97 for the proteins of SEQ No.352, 357, OXA No. 1050 358, 359, 368, 383, 435, 442, 471, 489, 492, 501,504, 505; 83-88 for the proteins of sequence SEQ ID No. 348, 353, 354;107-112 for the proteins of sequence SEQ ID No. 410, 413, 458; 93-98 forthe protein of sequence SEQ ID No. 490; 116-121 for the protein ofsequence SEQ ID No. 382; SEQ ID WDGQK 104-108 for the proteins of SEQNo. 388, 2df No. 1051 389, 392, 395, 396, 397, 399, 403, 405, 406, 407,411, 412, 423, 428, 434, 439, 445, 446, 448, 467, 468, 482, 483, 495,503, 508; 98-102 for the proteins of sequence SEQ ID No. 431, 432 SEQ IDWDGQTR 95-100 for the proteins of SEQ No. 378, 384, 2df No. 1052 450,476, 485 SEQ ID WDGVK 97-101 for the proteins of SEQ No. 369, 372, 2dNo. 1053 375, 484 SEQ ID WDGVNR 97-102 for the proteins of SEQ No. 350,367, OXA No. 1054 370, 373, 415, 443, 481, 488; 86-91 for the protein ofsequence SEQ ID No. 362 SEQ ID WDYKPEFNGYK 78-88 for the protein of SEQNo. 498; 89-99 OXA No. 1055 for the protein of sequence SEQ ID No. 351SEQ ID WETYSVVWFSQQITEWLGMER 97-117 for the protein of SEQ No. 347 2dNo. 1056 SEQ ID WNGQK 104-108 for the proteins of SEQ No. 394, 2df No.1057 418, 444, 507 SEQ ID YAQAK 155-159 for the protein of SEQ No. 3822df No. 1058 SEQ ID YFSDFNAK 34-41 for the proteins of SEQ No. 355, 3632d No. 1059 SEQ ID YGTHLDR 68-74 for the proteins of SEQ No. 410, 413,2df No. 1060 458 SEQ ID YIIHNK 54-59 for the proteins of SEQ No. 386,429, 2d No. 1061 430, 477 SEQ ID YLDELVK 245-251 for the protein of SEQNo. 385 2d No. 1062 SEQ ID YLMITEAGR 195-203 for the protein of SEQ No.484 OXA No. 1063 SEQ ID YLNLFSYGNANIGGGIDK 135-152 for the proteins ofSEQ No. 489, 505 OXA No. 1064 SEQ ID YNGEK 96-100 for the proteins ofSEQ No. 429, 430, 2d No. 1065 477 SEQ ID YPHNPR 88-93 for the protein ofSEQ No. 494 2de No. 1066 SEQ ID YPVVWYSQQVAHHLGAQR 103-120 for theprotein of SEQ No. 497 2d No. 1067 SEQ ID YSNVLAFK 106-113 for theprotein of SEQ No. 385 2d No. 1068 SEQ ID YSPASTFK 68-75 for theproteins of SEQ No. 350, 355, OXA No. 1069 356, 363, 367, 369, 370, 372,373, 375, 415, 443, 481, 484, 488, 491; 57-64 for the protein ofsequence SEQ ID No. 362 SEQ ID YSVVPVYQQLAR 141-152 for the protein ofSEQ No. 381 2df No. 1070 SEQ ID YSVVWYSQLTAK 109-120 for the protein ofSEQ No. 433 2d No. 1071 SEQ ID YSVVWYSQQVAHHLGAQR 103-120 for theproteins of SEQ No. 496, 2d No. 1072 499, 500 SEQ ID YTPASTFK 55-62 forthe protein of SEQ No. 433 2d No. 1073 SEQ ID YTSAFGYGNADVSGEPGK 130-147for the protein of SEQ No. 433 2d No. 1074 SEQ ID YVFVSALTGNLGSNLTSSIK228-247 for the protein of SEQ No. 361; 243-262 2d No. 1075 for theprotein of sequence SEQ ID No. 360 SEQ ID YVFVSALTGSLGSNLTSSIK 243-262for the protein of SEQ No. 376 2d No. 1076 SEQ ID YVGHDR 50-55 for theprotein of SEQ No. 380 2d No. 1077 SEQ ID ANQAFLPASTFK 62-73 for theproteins of SEQ No. 378, 384, 2df No. 1098 450, 476, 485 SEQ ID DEHQVFK88-94 for the proteins of SEQ No. 378, 384, 2df No. 1099 450, 476, 485SEQ ID DHNLITAMK 108-116 for the proteins of SEQ No. 378, 2df No. 1100450, 476 SEQ ID DIATWNR 101-107 for the proteins of SEQ No. 378, 2df No.1101 450, 476 SEQ ID IPNSLIALDLGVVK 74-87 for the proteins of SEQ No.378, 384, 2df No. 1102 450, 476, 485 SEQ ID ISATEQISFLR 164-174 for theproteins of SEQ No. 378, 2df No. 1103 450, 476 SEQ ID QAMLTEANGDYIIR193-206 for the proteins of SEQ No. 378, 2df No. 1104 450, 476, 485 SEQID QQGFTNNLK 52-60 for the proteins of SEQ No. 378, 384, 2df No. 1105450, 476, 485 SEQ ID SQGVVVLWNENK 40-51 for the proteins of SEQ No. 378,450, 2df No. 1106 476, 485 SEQ ID SWNAHFTEHK 30-39 for the proteins ofSEQ No. 378, 450, 2df No. 1107 476, 485 SEQ ID VLALSAVFLVASIIGMPAVAK3-23 for the proteins of SEQ No. 378, 450, 2df No. 1108 476, 485 SEQ IDYSVVPVYQEFAR 117-128 for the proteins of SEQ No. 378, 2df No. 1109 384,450, 476, 485

In the clinical interest column, the entries 2d, 2de, 2df correspond tothe functional subgroups of OXA beta-lactamases which the correspondingpeptide makes it possible to detect. Therefore, the detection of a 2dfpeptide will indicate the presence of a carbapenemase beta-lactamasecapable of hydrolysing carbapenems.

The entry 2de will indicate the presence of a beta-lactamase with anextended spectrum (ESBL) capable of hydrolysing penicillins,first-generation cephalosporins such as cephaloridine and cefalotin, andat least one antibiotic from the oxyimino-beta-lactam class such ascefotaxime, ceftazidime or monobactams such as aztreonam.

The entry OXA indicates a common peptide between at least two of thesubgroups 2d, 2de and 2df. The corresponding peptide indicates thepresence of an OXA beta-lactamase and the presence of a mechanism ofresistance at least to penicillins and to first-generationcephalosporins.

The detection of a mechanism of resistance to carbapenems induced by anOXA protein is characterised by the detection of at least oneresistance-marking carba peptide chosen from the sequences SEQ ID No.510, 511, 512, 513, 514, 520, 521, 522, 523, 525, 527, 530, 532, 537,541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 556, 557,558, 559, 560, 561, 562, 574, 579, 581, 582, 583, 584, 592, 596, 597,598, 599, 600, 601, 602, 607, 608, 609, 628, 631, 632, 633, 635, 636,644, 646, 647, 649, 650, 655, 656, 661, 662, 667, 674, 675, 682, 689,690, 698, 713, 714, 719, 720, 722, 727, 729, 730, 741, 746, 748, 750,751, 752, 755, 756, 757, 758, 763, 764, 767, 768, 772, 775, 781, 782,790, 792, 793, 794, 795, 796, 797, 798, 801, 809, 811, 812, 813, 814,816, 819, 824, 832, 834, 837, 838, 847, 851, 852, 853, 854, 855, 856,857, 858, 859, 860, 862, 868, 869, 870, 874, 875, 876, 877, 879, 880,881, 882, 894, 895, 898, 902, 903, 904, 906, 907, 908, 911, 912, 913,914, 915, 919, 920, 922, 923, 927, 929, 937, 938, 939, 945, 946, 948,949, 950, 951, 954, 956, 957, 959, 962, 964, 967, 969, 971, 972, 974,975, 979, 980, 985, 988, 990, 993, 994, 995, 996, 997, 1000, 1001, 1002,1003, 1004, 1005, 1006, 1007, 1011, 1013, 1015, 1017, 1018, 1019, 1023,1027, 1030, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1042,1047, 1048, 1051, 1052, 1057, 1058, 1060, 1070, 1098, 1099, 1100, 1101,1102, 1103, 1104, 1105, 1106, 1107, 1108, 1109

Certain peptide sequences can be common to several resistancemechanisms. Therefore, the following sequences are identical:

SEQ ID No. 24 and SEQ ID No. 287

In all cases, the sequences above indicate the expression of a mechanismof resistance to penicillins, to cephalosporins, including those of thethird generation such as cefotaxime/ceftazidime, to monobactams and tocarbapenems.

The method of the invention and its advantages will become apparent fromthe rest of the present description which presents several non-limitingexamples of implementation of said method.

EXAMPLE 1: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY BIOCHEMICALPROFILE

1. Culturing of the Sample on a Culture Medium

The optimum culture media and the optimum culture conditions aredifferent according to the species of microorganism. By default, thesample is seeded on different media:

-   -   sheep blood Columbia agar (bioMérieux ref. 43041) for 18 to 24 h        at 35° C., in an aerobic or anaerobic atmosphere;    -   TSA agar (bioMérieux ref. 43011) for 18 to 24 h at 37° C.

2. Identification of the Microorganisms

The identification is performed as follows:

-   -   1. Selection of isolated colonies    -   2. While maintaining the aseptic conditions, transfer of 3.0 mL        of aqueous sterile saline solution (0.45-0.50% NaCl, pH 4.5 to        7.0) into a transparent plastic (polystyrene) test tube    -   3. With the aid of a stirrer or a sterile swab, transfer of a        sufficient number of identical colonies into the saline solution        tube prepared in step 2, and adjustment of the bacterial        suspension between 0.50 and 0.63 McFarland with a calibrated        DENSICHEK from VITEK®    -   4. Positioning of the bacterial suspension tube and of a VITEK®        identification card on a VITEK® cartridge    -   5. Loading of the cartridge into the VITEK® instrument    -   6. The filling, sealing, incubation and reading operations are        automatic    -   7. Acquisition of a biochemical profile    -   8. Identification with the VITEK® system performed by comparing        to the biochemical profiles of known strains

EXAMPLE 2: PREPARATION OF A PRIMARY URINE SAMPLE BY MICROORGANISMENRICHMENT

The following protocol is performed in 16 steps (steps 5 to 12 areoptional and could be omitted if the enriched sample is subsequentlytreated according to examples 4 and onwards):

-   -   1. Centrifuging of 5 mL of contaminated urine, at 2000 g for 30        seconds    -   2. Recovery of the supernatant    -   3. Centrifuging at 15000 g for 5 minutes    -   4. Elimination of the supernatant    -   5. Washing of the pellet with 3 mL of distilled water by        resuspension    -   6. Centrifuging at 15000 g for 5 minutes    -   7. Elimination of the supernatant    -   8. Place the pellet in the presence of solvent (8 acetone        volumes for 1 methanol volume) for 1/10 dilution    -   9. Leave for 1 hour at −20° C.    -   10. Centrifuging at 15000 g for 5 minutes    -   11. Elimination of the supernatant    -   12. Place the pellet in the presence of solvent (8 acetone        volumes for 1 methanol volume) for 1/10 dilution    -   13. Leave for 1 hour at −20° C.    -   14. Centrifuging at 15000 g for 5 minutes    -   15. Elimination of the supernatant    -   16. The pellet constitutes the microorganism-enriched sample

EXAMPLE 3: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY MALDI-TOF

The identification is performed as follows:

-   -   1. Transfer, with the aid of a 1 μl oese, of a portion of        microorganism colony obtained according to Example 1, or of an        enriched sample according to Example 2, and uniform deposition        on a plate for MALDI-TOF mass spectrometry    -   2. Covering the deposit with 1 μl of matrix. The matrix used is        a saturated solution of HCCA (alpha-cyano-4-hydroxycinnamic        acid) in organic solvent (50% acetonitrile and 2.5%        trifluoroacetic acid)    -   3. Drying at ambient temperature    -   4. Introducing the plate into the mass spectrometer    -   5. Acquiring a mass spectrum    -   6. Comparing the obtained spectrum with the spectra contained in        a knowledge base    -   7. Identification of the microorganism by comparing the obtained        peaks with those in the knowledge base

EXAMPLE 4: IDENTIFICATION OF MICROORGANISMS FROM A SAMPLE BY ESI-TOF

The identification is performed as follows:

-   -   1. Sampling of a microorganism colony, obtained according to        Example 1, or of an enriched sample according to Example 2, and        suspension in 100 μl of demineralised water.    -   2. Centrifuging at 3000 g for 5 minutes.    -   3. Elimination of the supernatant.    -   4. Resuspension in 100 μl of demineralised water.    -   5. Centrifuging at 3000 g for 5 minutes.    -   6. Elimination of the supernatant.    -   7. Resuspension in 100 μl of an acetonitrile, demineralised        water and formic acid mixture (50/50/0.1%).    -   8. Filtration with a filter with a porosity of 0.45 μm.    -   9. Injection into a mass spectrometer in single MS mode.    -   10. Acquisition of a mass spectrum.    -   11. Comparing the obtained spectrum with the spectra contained        in a knowledge base.    -   12. Identification of the microorganism by referring to        reference spectra.

EXAMPLE 5: OBTAINING DIGESTED PROTEINS FROM MICROORGANISMS

The following protocol is conventionally performed in 17 steps:

-   -   1. Sampling of a microorganism colony, obtained according to        Example 1, or of an enriched sample according to Example 2, and        suspension in 10 to 100 μl of a 6M guanidine hydrochloride        solution, 50 mM Tris-HCl, pH=8.0.    -   2. Addition of dithiothreitol (DTT) to achieve an end        concentration of 5 mM.    -   3. Reduction for 20 minutes at 95° C. in a water bath.    -   4. Cooling the tubes to ambient temperature.    -   5. Addition of iodoacetamide to obtain an end concentration of        12.5 mM.    -   6. Alkylation for 40 minutes at ambient temperature and in the        dark.    -   7. Dilution by a factor of 6 with a 50 mM NH₄HCO₃ solution,        pH=8.0 to obtain an end guanidine hydrochloride concentration of        1M.    -   8. Addition of 1 μg of trypsin.    -   9. Digestion at 37° C. for between 6 hours and one night.    -   10. Addition of formic acid down to a pH below 4 to stop the        reaction.    -   11. The sample volume is made up to 1 mL with water/0.5% (v/v)        formic acid    -   12. Balancing of the Waters Oasis HLB columns with 1 ml of        methanol and then 1 ml of H₂O/0.1% (v/v) formic acid    -   13. Deposition of the sample which runs off by gravity    -   14. Washing with 1 ml of H₂O/0.1% (v/v) formic acid    -   15. Elution with 1 ml of a mixture of 80% methanol and 20%        water/0.1% (v/v) formic acid    -   16. The eluate is evaporated with a SpeedVac® SPD2010 evaporator        (Thermo Electron Corporation, Waltham, Mass., United States of        America) over 2 hours, in order to obtain a volume of around 100        μl.    -   17. The eluate is then taken up in a water/0.5% (v/v) formic        acid solution in a quantity sufficient for (QSF) 250 μl

EXAMPLE 6: IDENTIFICATION OF A RESISTANCE TO NDM-1 BETA-LACTAMS

Samples Sam1 to Sam9 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 1.

TABLE 1 Names Species Sam1 K. pneumoniae Sam2 C. freundii Sam3 A.baumannii Sam4 A. caviae Sam5 C. braakii Sam6 E. cloacae Sam7 P.rettgeri Sam8 E. coli Sam9 K. pneumoniae

Samples Sam1 to Sam9 correspond to a species able to comprise an NDM-1resistance mechanism (Enterobacteriaceae, Pseudomonas species,Acinetobacter species . . . ). The following method is then performed tosearch for such a mechanism.

Each sample is treated according to Example 5, then a volume of 50 μl ofdigested proteins is injected and analysed according to the followingconditions:

-   -   Dionex Ultimate 3000 chromatographic channel from the Dionex        Corporation (Sunnyvale, United States of America).    -   Waters BEH130 C18 Column, 2.1 mm inner diameter, 100 mm length,        3.5 μm particle size (Waters, Saint-Quentin En Yvelines,        France).    -   Solvent A: H₂O+0.1% formic acid.    -   Solvent B: ACN+0.1% formic acid.

HPLC gradient defined in Table 2 hereafter:

TABLE 2 Time (min) Flow (μl) Solvent A (%) Solvent B (%) 0 300 98 2 3300 98 2 34 300 54.6 45.4 35 300 0 100 55 300 0 100 55.1 300 98 2 74 30098 2

-   -   The eluate coming from the chromatographic column is directly        injected into the ionising source of the QTRAP® 5500 mass        spectrometer from Applied Biosystems (Foster City, United States        of America).    -   The peptides coming from the digestion of the microorganism        proteins are analysed by the mass spectrometer in MRM mode. Only        the peptides indicated in TABLE 3 are detected. To this end, the        fragment(s) indicated in TABLE 3 is/are detected.

TABLE 3 Charge state Retention (m/z) (m/z) Collision Transition of thetime filtered filtered in energy number Peptide precursor Fragment ion(minutes) in Q1 Q3 (eV) 1 AAITHTAR 2 y4 5.61 420.74 484.26 24monocharged 2 AAITHTAR 2 y5 5.61 420.74 585.31 24 monocharged 3 AAITHTAR2 y6 5.61 420.74 698.39 24 monocharged 4 AFGAAFPK 2 y6 16.03 404.72590.33 23 monocharged 5 AFGAAFPK 2 y7 16.03 404.72 737.4 23 monocharged6 AFGAAFPK 2 y7 dicharged 16.03 404.72 369.2 23 7 ASMIVMSHSAPDSR 2 y713.65 744.85 769.36 38 monocharged 8 ASMIVMSHSAPDSR 2 y8 13.65 744.85856.39 38 monocharged 9 ASMIVMSHSAPDSR 2 y9 13.65 744.85 987.43 38monocharged 10 FGDLVFR 2 y4 19.14 427.23 534.34 24 monocharged 11FGDLVFR 2 y5 19.14 427.23 649.37 24 monocharged 12 FGDLVFR 2 y6 19.14427.23 706.39 24 monocharged 13 MELPNIMHPVAK 2 y10 dicharged 19.09690.36 560.32 35 14 MELPNIMHPVAK 2 y9 19.09 690.36 1006.55 35monocharged 15 MELPNIMHPVAK 2 y9 dicharged 19.09 690.36 503.78 35 16QEINLPVALAVVTHAHQDK 3 y14 dicharged 21.34 695.05 743.41 39 17QEINLPVALAVVTHAHQDK 3 y7 21.34 695.05 836.4 39 monocharged 18QEINLPVALAWTHAHQDK 3 y8 21.34 695.05 935.47 39 monocharged 19SLGNLGDADTEHYAASAR 2 y14 dicharged 14.64 924.43 738.84 46 20SLGNLGDADTEHYAASAR 2 y16 dicharged 14.64 924.43 824.37 46 21SLGNLGDADTEHYAASAR 2 y7 14.64 924.43 775.38 46 monocharged 22VLVVDTAWTDDQTAQILNWIK 3 y5 27.16 810.43 673.4 45 monocharged 23VLVVDTAWTDDQTAQILNWIK 3 y6 27.16 810.43 786.49 45 monocharged 24VLVVDTAWTDDQTAQILNWIK 3 y7 27.16 810.43 914.55 45 monocharged

The precursor peptide charge state, its retention time, the fragment iontype and the transitions, i.e. the (m/z)₁ ratio in Q1 and (m/z)₂ ratioin Q3 are indicated in TABLE 3. The collision energy used to fragmentthe precursor ion is also indicated in TABLE 3.

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: yes    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 50.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 40.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Declustering potential (DP): 80.00 V    -   Entry potential before Q0 (EP): 10.00 V    -   Collision cell exit potential (CXP): 35 V    -   Total cycle time: 1.2 sec    -   Detection window: 90 sec

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. All the transitions having an areagreater than or equal to 2500 (arbitrary unit) are considered to bepositive and have been labelled “1” in TABLE 4. All the transitionshaving an area less than 2500 are considered to be negative and havebeen labelled 0 in TABLE 4. When no signal peak was observed, thetransition has been labelled as negative.

TABLE 4 Tran- sition number Sam1 Sam2 Sam3 Sam4 Sam5 Sam6 Sam7 Sam8 Sam91 1 1 1 1 1 1 0 1 1 2 1 1 1 1 1 1 1 1 1 3 1 1 0 1 1 1 0 1 1 4 1 1 1 1 11 1 1 1 5 1 1 1 1 1 1 1 1 1 6 1 1 0 1 1 1 1 1 1 7 0 0 0 0 0 0 0 0 0 8 00 0 0 0 0 0 0 0 9 0 0 0 0 0 0 0 0 0 10 1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 11 1 1 12 1 1 1 1 1 1 1 1 1 13 0 0 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 150 0 0 0 0 0 0 0 0 16 1 1 0 1 1 0 0 0 1 17 1 1 0 1 1 1 1 0 1 18 1 1 0 1 10 1 0 1 19 0 0 0 0 0 0 0 0 0 20 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 022 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0

The number of positive transitions is then added up and set out in TABLE5:

TABLE 5 Number of positive Names Species transitions Sam1 K. pneumoniae12 Sam2 C. freundii 12 Sam3 A. baumannii 7 Sam4 A. caviae 12 Sam5 C.braakii 12 Sam6 E. cloacae 10 Sam7 P. rettgeri 9 Sam8 E. coli 9 Sam9 K.pneumoniae 12

Samples Sam1 to Sam9 comprise more than 6 positive transitions, theytherefore contain bacteria which express the NDM-1 protein. The bacteriaof Sam1 to Sam9 are therefore resistant to penicillins, tocephalosporins and to carbapenems.

EXAMPLE 7: IDENTIFICATION OF A RESISTANCE TO KPC BETA-LACTAMS

Samples Sam62 to Sam73 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 6.

TABLE 6 Names Species Sam62 K. pneumoniae Sam63 K. pneumoniae Sam64 K.pneumoniae Sam65 K. pneumoniae Sam66 K. pneumoniae Sam67 K. pneumoniaeSam68 K. pneumoniae Sam69 K. pneumoniae Sam70 K. pneumoniae Sam71 K.pneumoniae Sam72 K. pneumoniae Sam73 K. pneumoniae

Samples Sam62 to Sam73 correspond to a species able to comprise a KPCresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 7 instead of thepeptides from TABLE 3.

TABLE 7 Charge Transition Methionine state of the Clinical numberPeptide oxidation precursor Fragment ion interest 1 AAVPADWAVGDK no 2 y9dicharged 2f 2 AAVPADWAVGDK no 2 y10 dicharged 2f 3 AAVPADWAVGDK no 2 y9monocharged 2f 4 APIVLAVYTR no 2 y7 monocharged 2f 5 APIVLAVYTR no 2 y5monocharged 2f 6 APIVLAVYTR no 2 y6 monocharged 2f 7 AVTESLQK no 2 y5monocharged 2f 8 AVTESLQK no 2 y6 monocharged 2f 9 AVTESLQK no 2 y4monocharged 2f 10 ELGGPAGLTAFMR yes 2 y7 monocharged 2f 11 ELGGPAGLTAFMRyes 2 y5 monocharged 2f 12 ELGGPAGLTAFMR yes 2 y9 dicharged 2f 13ELGGPAGLTAFMR no 2 y7 monocharged 2f 14 ELGGPAGLTAFMR no 2 y5monocharged 2f 15 ELGGPAGLTAFMR no 2 y9 dicharged 2f 16 FPLCSSFK no 2 y6monocharged 2f 17 FPLCSSFK no 2 y7 monocharged 2f 18 FPLCSSFK no 2 y5monocharged 2f 19 GFLAAAVLAR no 2 y6 monocharged 2f 20 GFLAAAVLAR no 2y7 monocharged 2f 21 GFLAAAVLAR no 2 y5 monocharged 2f 22 GNTTGNHR no 2y5 monocharged 2f 23 GNTTGNHR no 2 y6 monocharged 2f 24 GNTTGNHR no 2 y4monocharged 2f 25 LALEGLGVNGQ no 3 y8 monocharged 2f 26 LALEGLGVNGQ no 3y7 monocharged 2f 27 LALEGLGVNGQ no 3 y6 monocharged 2f 28 LTLGSALAAPQRno 3 y9 monocharged 2f 29 LTLGSALAAPQR no 3 y5 monocharged 2f 30LTLGSALAAPQR no 3 y6 monocharged 2f 31 NALVPWSPISEK no 2 y8 monocharged2f 32 NALVPWSPISEK no 2 y8 dicharged 2f 33 NALVPWSPISEK no 2 y5monocharged 2f 34 QQFVDWLK no 2 y5 monocharged 2f 35 QQFVDWLK no 2 y6monocharged 2f 36 QQFVDWLK no 2 y4 monocharged 2f 37 SIGDTTFR no 2 y5monocharged 2f 38 SIGDTTFR no 2 y6 monocharged 2f 39 SIGDTTFR no 2 y4monocharged 2f 40 SQQQAGLLDTPIR no 2 y8 monocharged 2f 41 SQQQAGLLDTPIRno 2 y9 monocharged 2f 42 SQQQAGLLDTPIR no 2 y10 monocharged 2f 43WELELNSAIPGDAR no 2 y5 monocharged 2f 44 WELELNSAIPGDAR no 2 y8monocharged 2f 45 WELELNSAIPGDAR no 2 y9 monocharged 2f

The transitions mentioned in TABLE 7 are detected by using theparameters set out in TABLE 8.

Retention (m/z) (m/z) Collision Transition time filtered filtered inenergy Positivity number (minutes) in Q1 Q3 (eV) threshold 1 16.29600.31 479.73 31 2000 2 16.29 600.31 529.27 31 2000 3 16.29 600.31958.46 31 2000 4 19.07 551.83 821.49 29 13000 5 19.07 551.83 609.33 2913000 6 19.07 551.83 722.42 29 13000 7 10.38 438.25 604.33 24 2000 810.38 438.25 705.38 24 2000 9 10.38 438.25 475.29 24 2000 10 18.55668.34 811.41 34 2000 11 18.55 668.34 641.31 34 2000 12 18.55 668.34490.26 34 2000 13 21.72 660.34 795.42 34 2000 14 21.72 660.34 625.31 342000 15 21.72 660.34 482.26 34 2000 16 17.56 493.24 741.36 27 2000 1717.56 493.24 838.41 27 2000 18 17.56 493.24 628.28 27 2000 19 20.67494.8 600.38 27 14000 20 20.67 494.8 671.42 27 14000 21 20.67 494.8529.35 27 14000 22 1.19 428.7 584.29 24 2000 23 1.19 428.7 685.34 242000 24 1.19 428.7 483.24 24 2000 25 18.89 535.8 773.38 42 2000 26 18.89535.8 644.34 42 2000 27 18.89 535.8 587.31 42 2000 28 17.37 599.35870.48 42 2000 29 17.37 599.35 542.3 42 2000 30 17.37 599.35 655.39 422000 31 20 670.86 943.49 35 2000 32 20 670.86 472.25 35 2000 33 20670.86 573.32 35 2000 34 20.48 532.28 660.37 28 2000 35 20.48 532.28807.44 28 2000 36 20.48 532.28 561.3 28 2000 37 13.42 448.73 639.31 252000 38 13.42 448.73 696.33 25 2000 39 13.42 448.73 524.28 25 2000 4017.6 713.89 884.52 36 2000 41 17.6 713.89 955.56 36 2000 42 17.6 713.891083.62 36 2000 43 21.1 785.9 515.26 40 2000 44 21.1 785.9 786.41 402000 45 21.1 785.9 900.45 40 2000

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the 3transitions of the same peptide are greater than or equal to thepositivity threshold described in TABLE 8, the detection of the peptideis considered to be positive and is labelled “1” in TABLE 9. When atleast one transition comprises an area less than the positivitythreshold described in TABLE 8, the corresponding peptide is considerednon-detected and is labelled “0” in TABLE 9.

TABLE 9 Transition number Sam62 Sam63 Sam64 Sam65 Sam66 Sam67 Sam68Sam69 Sam70 Sam71 Sam72 Sam73 1 0 0 0 0 0 0 1 1 1 1 1 1 2 0 0 0 0 0 0 11 1 1 1 1 3 0 0 0 0 0 0 1 1 1 1 1 1 4 0 0 0 0 0 0 1 1 1 1 1 1 5 0 0 0 00 0 1 1 1 1 1 1 6 0 0 0 0 0 0 1 1 1 1 1 1 7 0 0 0 0 0 0 0 0 0 0 0 0 8 00 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 00 11 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 0 0 0 11 1 1 1 1 14 0 0 0 0 0 0 1 1 1 1 1 1 15 0 0 0 0 0 0 1 1 1 1 1 1 16 0 0 00 0 0 0 0 0 0 0 0 17 0 0 0 0 0 0 0 0 0 0 0 0 18 0 0 0 0 0 0 0 0 0 0 0 019 0 0 0 0 0 0 1 1 1 1 1 1 20 0 0 0 0 0 0 1 1 1 1 1 1 21 0 0 0 0 0 0 1 11 1 1 1 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 00 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0 0 0 0 270 0 0 0 0 0 0 0 0 0 0 0 28 0 0 0 0 0 0 1 1 1 1 1 1 29 0 0 0 0 0 0 1 1 11 1 1 30 0 0 0 0 0 0 1 1 1 1 1 1 31 0 0 0 0 0 0 1 1 1 1 1 1 32 0 0 0 0 00 1 1 1 1 1 1 33 0 0 0 0 0 0 1 1 1 1 1 1 34 0 0 0 0 0 0 0 0 0 0 0 0 35 00 0 0 0 0 0 0 0 0 0 0 36 0 0 0 0 0 0 0 0 0 0 0 0 37 0 0 0 0 0 0 1 1 1 11 1 38 0 0 0 0 0 0 1 1 1 1 1 1 39 0 0 0 0 0 0 0 0 0 0 0 0 40 0 0 0 0 0 01 1 1 1 1 1 41 0 0 0 0 0 0 1 1 1 1 1 1 42 0 0 0 0 0 0 1 1 1 1 1 1 43 0 00 0 0 0 0 0 0 0 0 0 44 0 0 0 0 0 0 0 0 0 0 0 0 45 0 0 0 0 0 0 0 0 0 0 00 Sum of the 0 0 0 0 0 0 23 23 23 23 23 23 transitions

Samples Sam68 to Sam73 comprise at least one transition which ischaracteristic of KPCs. The bacteria present in samples Sam68 to Sam73therefore express a beta-lactamase which confers on them a resistance topenicillins, to cephalosporins, including third-generationcephalosporins such as cefotaxime/ceftazidime, to monobactams and tocarbapenems.

Samples Sam62 to Sam67 comprise no transition which is characteristic ofKPCs. The bacteria present in samples Sam62 to Sam67 therefore do notexpress KPC beta-lactamase and may be sensitive to carbapenemantibiotics.

EXAMPLE 8: IDENTIFICATION OF A RESISTANCE TO NDM-1 OR KPC BETA-LACTAMS

The samples corresponding to a species able to comprise an NDM-1 or KPCresistance mechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 10 instead of thepeptides from TABLE 3.

TABLE 10 Transition First-generation Charge state of Clinical Proteinsnumber Peptide fragment ion the precursor interest NDM-1 1 AAITHTAR y4monocharged 2 3a NDM-1 2 AAITHTAR y5 monocharged 2 3a NDM-1 3 AAITHTARy6 monocharged 2 3a NDM-1 4 AFGAAFPK y6 monocharged 2 3a NDM-1 5AFGAAFPK y7 monocharged 2 3a NDM-1 6 AFGAAFPK y7 dicharged 2 3a NDM-1 7FGDLVFR y4 monocharged 2 3a NDM-1 8 FGDLVFR y5 monocharged 2 3a NDM-1 9FGDLVFR y6 monocharged 2 3a NDM-1 10 QEINLPVALAVVTHAHQDK y14 dicharged 33a NDM-1 11 QEINLPVALAVVTHAHQDK y7 monocharged 3 3a NDM-1 12QEINLPVALAVVTHAHQDK y8 monocharged 3 3a KPC 13 AAVPADWAVGDK y9 dicharged2 2f KPC 14 AAVPADWAVGDK y10 dicharged 2 2f KPC 15 AAVPADWAVGDK y9monocharged 2 2f KPC 16 APIVLAVYTR y7 monocharged 2 2f KPC 17 APIVLAVYTRy5 monocharged 2 2f KPC 18 APIVLAVYTR y6 monocharged 2 2f KPC 19ELGGPAGLTAFMR y7 monocharged 2 2f KPC 20 ELGGPAGLTAFMR y5 monocharged 22f KPC 21 ELGGPAGLTAFMR y9 dicharged 2 2f KPC 22 GFLAAAVLAR y6monocharged 2 2f KPC 23 GFLAAAVLAR y7 monocharged 2 2f KPC 24 GFLAAAVLARy5 monocharged 2 2f KPC 25 LTLGSALAAPQR y9 monocharged 3 2f KPC 26LTLGSALAAPQR y5 monocharged 3 2f KPC 27 LTLGSALAAPQR y6 monocharged 3 2fKPC 28 NALVPWSPISEK y8 monocharged 2 2f KPC 29 NALVPWSPISEK y8 dicharged2 2f KPC 30 NALVPWSPISEK y5 monocharged 2 2f KPC 31 SQQQAGLLDTPIR y8monocharged 2 2f KPC 32 SQQQAGLLDTPIR y9 monocharged 2 2f KPC 33SQQQAGLLDTPIR y10 monocharged 2 2f

The entry 2f indicates the presence of a carbapenemase beta-lactamasefrom subgroup 2f according to the Bush and Jacoby classification[Antimicrob Agents Chemother. 2010 March; 54(3):969-76. Epub 2009 Dec.7. Updated functional classification of beta-lactamases], capable ofhydrolysing carbapenems.

The entry 3a indicates the presence of a metallo-beta-lactamase fromsubgroup 3a according to the Bush and Jacoby classification [9], supra,capable of hydrolysing penicillins, cephalosporins and carbapenems.

The transitions mentioned in TABLE 10 are detected by using theparameters set out in TABLE 11.

TABLE 11 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy Positivity number (minutes) Q1 Q3 (eV) threshold 15.61 420.74 484.26 24 2500 2 5.61 420.74 585.31 24 2500 3 5.61 420.74698.39 24 2500 4 16.03 404.72 590.33 23 2500 5 16.03 404.72 737.4 232500 6 16.03 404.72 369.2 23 2500 7 19.14 427.23 534.34 24 2500 8 19.14427.23 649.37 24 2500 9 19.14 427.23 706.39 24 2500 10 21.34 695.05743.41 39 2500 11 21.34 695.05 836.4 39 2500 12 21.34 695.05 935.47 392500 13 16.29 600.31 479.73 31 2000 14 16.29 600.31 529.27 31 2000 1516.29 600.31 958.46 31 2000 16 19.07 551.83 821.49 29 13000 17 19.07551.83 609.33 29 13000 18 19.07 551.83 722.42 29 13000 19 21.72 660.34795.42 34 2000 20 21.72 660.34 625.31 34 2000 21 21.72 660.34 482.26 342000 22 20.67 494.8 600.38 27 14000 23 20.67 494.8 671.42 27 14000 2420.67 494.8 529.35 27 14000 25 17.37 599.35 870.48 42 2000 26 17.37599.35 542.3 42 2000 27 17.37 599.35 655.39 42 2000 28 20 670.86 943.4935 2000 29 20 670.86 472.25 35 2000 30 20 670.86 573.32 35 2000 31 17.6713.89 884.52 36 2000 32 17.6 713.89 955.56 36 2000 33 17.6 713.891083.62 36 2000

When the areas of at least two transitions of the same peptide aregreater than or equal to the positivity threshold described in TABLE 11,the detection of the peptide is considered to be positive. When morethan two transitions of the same peptide comprise an area less than thepositivity threshold described in TABLE 11, the corresponding peptide isconsidered non-detected.

A sample contains bacteria which express the NDM-1 protein, when atleast one peptide corresponding to the NDM-1 resistance mechanism isdetected. These bacteria are resistant to penicillins, to cephalosporinsand to carbapenems.

A sample contains bacteria which express the KPC protein, when at leastone peptide corresponding to the KPC resistance mechanism is detected.These bacteria are resistant to penicillins, to cephalosporins,including third-generation cephalosporins such ascefotaxime/ceftazidime, to monobactams and to carbapenems.

EXAMPLE 9: IDENTIFICATION OF A RESISTANCE TO IND BETA-LACTAMS

Samples Sam84 to Sam88 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 12.

TABLE 12 Names Species Sam84 C. indologenes Sam85 C. indologenes Sam86C. indologenes Sam87 C. indologenes Sam88 C. indologenes

Samples Sam84 to Sam88 correspond to a species able to comprise an INDresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 13 instead of the peptides from TABLE3.

TABLE 13 Collision Retention (m/z) (m/z) Declustering Collision cellexit Transition time filtered filtered potential energy potentialPositivity number Peptide (minutes) in Q1 in Q3 (eV) (eV) (eV) threshold1 AATDLGYIK 14.66 476.26 593.37 65.8 26 15 2000 2 AATDLGYIK 14.66 476.26708.39 65.8 26 15 2000 3 AATDLGYIK 14.66 476.26 809.44 65.8 26 15 2000 4AGDLSFFNNK 18.08 556.77 522.27 71.7 29.5 15 2000 5 AGDLSFFNNK 18.08556.77 669.34 71.7 29.5 15 2000 6 AGDLSFFNNK 18.08 556.77 756.37 71.729.5 15 2000 7 AGDLSFYNK 14.82 507.75 424.22 68.1 27.3 15 2000 8AGDLSFYNK 14.84 507.75 571.29 68.1 27.3 15 2000 9 AGDLSFYNK 14.84 507.75658.32 68.1 27.3 15 2000 10 AGDLSFYNQK 14.91 571.78 552.28 72.8 30.2 152000 11 AGDLSFYNQK 14.93 571.78 699.35 72.8 30.2 15 2000 12 AGDLSFYNQK14.93 571.78 786.38 72.8 30.2 15 2000 13 AQYQSLMDTIK 18.01 649.331098.55 78.5 33.6 15 2000 14 AQYQSLMDTIK 18.01 649.33 607.31 78.5 33.615 2000 15 AQYQSLMDTIK 18.01 649.33 807.43 78.5 33.6 15 2000 16ASLVIPGHDEWK 16.84 676.35 434.70 80.4 34.8 15 2000 17 ASLVIPGHDEWK 16.8676.35 868.40 80.4 34.8 15 2000 18 ASLVIPGHDEWK 16.82 676.35 981.48 80.434.8 15 2000 19 ATLIIPGHDDWK 17.47 683.36 427.69 80.9 35.1 15 2000 20ATLIIPGHDDWK 17.47 683.36 854.38 80.9 35.1 15 2000 21 ATLIIPGHDDWK 17.47683.36 967.46 80.9 35.1 15 2000 22 ATLIIPGHDEWK 17.54 690.37 1094.5681.4 35.4 10 2000 23 ATLIIPGHDEWK 17.54 690.37 868.40 81.4 35.4 10 200024 ATLIIPGHDEWK 17.54 690.37 981.48 81.4 35.4 10 2000 25 ATSTELIKPGK11.63 572.83 301.19 72.9 30.2 15 2000 26 ATSTELIKPGK 11.67 572.83 486.7972.9 30.2 15 2000 27 ATSTELIKPGK 11.67 572.83 655.45 72.9 30.2 15 200028 DFVIEPPIK 19.93 529.30 454.30 69.7 28.3 15 2000 29 DFVIEPPIK 19.93529.30 696.43 69.7 28.3 15 2000 30 DFVIEPPIK 19.93 529.30 795.50 69.728.3 15 2000 31 DFVIEPPVKPNLYLYK 22.03 645.69 730.91 78.2 36.3 15 200032 DFVIEPPVKPNLYLYK 22.03 645.69 787.45 78.2 36.3 15 2000 33DFVIEPPVKPNLYLYK 22.08 645.69 836.99 78.2 36.3 15 2000 34 DFVIEQPFGK19.77 590.31 448.26 74.2 31 15 2000 35 DFVIEQPFGK 19.75 590.31 705.3674.2 31 15 2000 36 DFVIEQPFGK 19.75 590.31 818.44 74.2 31 15 2000 37EANLEQWPK 15.53 557.78 430.25 71.8 29.5 15 2000 38 EANLEQWPK 15.55557.78 558.30 71.8 29.5 15 2000 39 EANLEQWPK 15.55 557.78 687.35 71.829.5 15 2000 40 EANVEQWPITIDK 19.5 514.93 343.71 68.7 29.7 10 2000 41EANVEQWPITIDK 19.5 514.93 686.41 68.7 29.7 10 2000 42 EANVEQWPITIDK19.48 514.93 872.49 68.7 29.7 10 2000 43 EANVEQWPK 13.84 550.77 430.2571.3 29.2 15 2000 44 EANVEQWPK 13.86 550.77 558.30 71.3 29.2 15 2000 45EANVEQWPK 13.86 550.77 687.35 71.3 29.2 15 2000 46 EQYQTLMDTIQK 17.9749.37 735.37 85.7 38 10 2000 47 EQYQTLMDTIQK 17.9 749.37 848.46 85.7 3810 2000 48 EQYQTLMDTIQK 17.9 749.37 949.50 85.7 38 10 2000 49EYSANAVYLTTK 15.26 680.34 1067.57 80.7 34.9 10 2000 50 EYSANAVYLTTK15.28 680.34 625.36 80.7 34.9 10 2000 51 EYSANAVYLTTK 15.26 680.34795.46 80.7 34.9 10 2000 52 EYSANSMYLVTK 16.5 703.34 1113.56 82.4 35.910 2000 53 EYSANSMYLVTK 16.5 703.34 841.45 82.4 35.9 10 2000 54EYSANSMYLVTK 16.5 703.34 955.49 82.4 35.9 10 2000 55 EYSANSVYLVTK 16.19687.35 1081.59 81.2 35.2 10 2000 56 EYSANSVYLVTK 16.14 687.35 623.3881.2 35.2 10 2000 57 EYSANSVYLVTK 16.12 687.35 923.52 81.2 35.2 10 200058 EYSANSVYLVTQK 16.19 501.26 376.22 67.7 29.1 10 2000 59 EYSANSVYLVTQK16.19 501.26 475.29 67.7 29.1 10 2000 60 EYSANSVYLVTQK 16.21 501.26751.44 67.7 29.1 10 2000 61 EYSTNALYLVTK 18.83 701.37 1109.62 82.2 35.910 2000 62 EYSTNALYLVTK 18.83 701.37 460.31 82.2 35.9 10 2000 63EYSTNALYLVTK 18.81 701.37 623.38 82.2 35.9 10 2000 64 GGGHVEHTLELLDK15.6 502.26 730.44 67.7 29.1 10 2000 65 GGGHVEHTLELLDK 15.6 502.26831.48 67.7 29.1 10 2000 66 GGGHVEHTLELLDK 15.6 502.26 968.54 67.7 29.110 2000 67 GGGHVEHTLELLNK 15 501.94 616.37 67.7 29.1 10 2000 68GGGHVEHTLELLNK 15 501.94 729.45 67.7 29.1 10 2000 69 GGGHVEHTLELLNK 15501.94 830.50 67.7 29.1 10 2000 70 GGGHVQHTLDLLDK 15.35 745.39 1082.5885.5 37.8 10 2000 71 GGGHVQHTLDLLDK 15.35 745.39 1181.65 85.5 37.8 102000 72 GGGHVQHTLDLLDK 15.35 745.39 488.31 85.5 37.8 10 2000 73GIPTYATAK 12.63 461.26 376.20 64.7 25.3 15 2000 74 GIPTYATAK 12.63461.26 654.35 64.7 25.3 15 2000 75 GIPTYATAK 12.63 461.26 751.40 64.725.3 15 2000 76 GNDHVK 1.3 335.17 383.24 55.6 19.7 15 2000 77 GNDHVK 1.3335.17 498.27 55.6 19.7 15 2000 78 GNDHVK 1.3 335.17 612.31 55.6 19.7 152000 79 GVVLFDVPWEK 23.79 644.86 559.29 78.1 33.4 15 2000 80 GVVLFDVPWEK23.82 644.86 658.36 78.1 33.4 15 2000 81 GVVLFDVPWEK 23.82 644.86 920.4578.1 33.4 15 2000 82 GVVLFDVPWQK 23.32 644.36 558.30 78.1 33.4 15 200083 GVVLFDVPWQK 23.32 644.36 772.40 78.1 33.4 15 2000 84 GVVLFDVPWQK23.32 644.36 919.47 78.1 33.4 15 2000 85 HNLPVIAVFATHSHSDR 17.94 634.33768.90 77.4 35.7 15 2000 86 HNLPVIAVFATHSHSDR 17.95 634.33 825.44 77.435.7 15 2000 87 HNLPVIAVFATHSHSDR 17.93 634.33 882.46 77.4 35.7 15 200088 HNLPVVAVFATHSHDDR 17.17 638.99 775.89 77.7 35.9 15 2000 89HNLPVVAVFATHSHDDR 17.17 638.99 832.43 77.7 35.9 15 2000 90HNLPVVAVFATHSHDDR 17.17 638.99 889.45 77.7 35.9 15 2000 91 HTLELLDQQK15.02 612.83 403.23 75.8 32 15 2000 92 HTLELLDQQK 15.02 612.83 518.2675.8 32 15 2000 93 HTLELLDQQK 15.02 612.83 986.55 75.8 32 15 2000 94HTLELLNK 14.44 484.28 616.37 66.4 26.3 15 2000 95 HTLELLNK 14.44 484.28729.45 66.4 26.3 15 2000 96 HTLELLNK 14.44 484.28 830.50 66.4 26.3 152000 97 IQYQSLMDTIK 19.41 670.34 1098.55 80 34.5 15 2000 98 IQYQSLMDTIK19.38 670.34 607.31 80 34.5 15 2000 99 IQYQSLMDTIK 19.41 670.34 807.4380 34.5 15 2000 100 NLHIYK 11.54 394.23 337.21 59.9 22.3 15 2000 101NLHIYK 11.54 394.23 423.26 59.9 22.3 15 2000 102 NLHIYK 11.54 394.23560.32 59.9 22.3 15 2000 103 NLYIYK 14.93 407.23 423.26 60.8 22.9 152000 104 NLYIYK 14.91 407.23 586.32 60.8 22.9 15 2000 105 NLYIYK 14.93407.23 699.41 60.8 22.9 15 2000 106 NNLHIYK 11.29 451.25 423.26 64 24.915 2000 107 NNLHIYK 11.29 451.25 560.32 64 24.9 15 2000 108 NNLHIYK11.27 451.25 673.40 64 24.9 15 2000 109 QLYLYK 15.22 414.24 423.26 61.323.2 15 2000 110 QLYLYK 15.2 414.24 586.32 61.3 23.2 15 2000 111 QLYLYK15.22 414.24 699.41 61.3 23.2 15 2000 112 QWPETMR 14.84 474.22 317.1665.7 25.9 15 2000 113 QWPETMR 14.75 474.22 407.21 65.7 25.9 15 2000 114QWPETMR 14.73 474.22 633.30 65.7 25.9 15 2000 115 SFGVFGGK 16.69 399.71356.20 60.3 22.6 15 2000 116 SFGVFGGK 16.69 399.71 408.22 60.3 22.6 152000 117 SFGVFGGK 16.69 399.71 564.31 60.3 22.6 15 2000 118SIQLLMMSMFLSPLINAQVK 32.4 755.41 441.77 86.2 41.8 15 2000 119SIQLLMMSMFLSPLINAQVK 32.4 755.41 882.54 86.2 41.8 15 2000 120SIQLLMMSMFLSPLINAQVK 32.4 755.41 969.57 86.2 41.8 15 2000 121SNSATDLGYIK 14.71 584.80 593.37 73.7 30.7 15 2000 122 SNSATDLGYIK 14.71584.80 809.44 73.7 30.7 15 2000 123 SNSATDLGYIK 14.71 584.80 967.51 73.730.7 15 2000 124 TATDLGYTGEANVK 13.61 720.35 718.37 83.6 36.7 10 2000125 TATDLGYTGEANVK 13.61 720.35 881.44 83.6 36.7 10 2000 126TATDLGYTGEANVK 13.61 720.35 938.46 83.6 36.7 10 2000 127 TFGVFDGK 16.56435.72 466.23 62.9 24.2 15 2000 128 TFGVFDGK 16.58 435.72 622.32 62.924.2 15 2000 129 TFGVFDGK 16.58 435.72 769.39 62.9 24.2 15 2000 130TFGVFGGK 16.78 406.72 408.22 60.8 22.9 15 2000 131 TFGVFGGK 16.76 406.72564.31 60.8 22.9 15 2000 132 TFGVFGGK 16.78 406.72 711.38 60.8 22.9 152000 133 TGKPYK 1.41 347.20 407.23 56.4 20.3 15 2000 134 TGKPYK 1.41347.20 535.32 56.4 20.3 15 2000 135 TGKPYK 1.41 347.20 592.35 56.4 20.315 2000 136 TGKPYR 1.41 361.20 435.24 57.4 20.9 15 2000 137 TGKPYR 1.41361.20 563.33 57.4 20.9 15 2000 138 TGKPYR 1.41 361.20 620.35 57.4 20.915 2000 139 TGVVLFDVPWEK 24.03 695.37 1033.54 81.8 35.6 10 2000 140TGVVLFDVPWEK 23.97 695.37 559.29 81.8 35.6 10 2000 141 TGVVLFDVPWEK23.97 695.37 920.45 81.8 35.6 10 2000 142 TNEFLK 12.85 376.20 407.2758.5 21.6 15 2000 143 TNEFLK 12.88 376.20 536.31 58.5 21.6 15 2000 144TNEFLK 12.85 376.20 650.35 58.5 21.6 15 2000 145 TNELLK 11.69 359.21373.28 57.3 20.8 15 2000 146 TNELLK 11.72 359.21 502.32 57.3 20.8 152000 147 TNELLK 11.69 359.21 616.37 57.3 20.8 15 2000 148 TNQFLK 12.3375.71 407.27 58.5 21.5 15 2000 149 TNQFLK 12.27 375.71 535.32 58.5 21.515 2000 150 TNQFLK 12.27 375.71 649.37 58.5 21.5 15 2000 151 TQYQSLMDTIK18.12 664.33 1098.55 79.5 34.2 15 2000 152 TQYQSLMDTIK 18.1 664.33607.31 79.5 34.2 15 2000 153 TQYQSLMDTIK 18.12 664.33 807.43 79.5 34.215 2000 154 TYATAK 1.9 327.68 319.20 55 19.4 15 2000 155 TYATAK 1.85327.68 390.24 55 19.4 15 2000 156 TYATAK 1.9 327.68 553.30 55 19.4 152000 157 TYATPK 7.79 340.68 345.21 56 20 15 2000 158 TYATPK 7.77 340.68416.25 56 20 15 2000 159 TYATPK 7.79 340.68 579.31 56 20 15 2000 160TYATSK 1.45 335.67 335.19 55.6 19.8 15 2000 161 TYATSK 1.45 335.67406.23 55.6 19.8 15 2000 162 TYATSK 1.47 335.67 569.29 55.6 19.8 15 2000163 VIPGHDEWK 12.43 540.78 434.70 70.5 28.8 15 2000 164 VIPGHDEWK 12.45540.78 771.34 70.5 28.8 15 2000 165 VIPGHDEWK 12.43 540.78 868.40 70.528.8 15 2000 166 VLDGGCLVK 14.44 480.76 633.34 66.2 26.2 15 2000 167VLDGGCLVK 14.44 480.76 748.37 66.2 26.2 15 2000 168 VLDGGCLVK 14.46480.76 861.45 66.2 26.2 15 2000 169 VQYQSLMDTIQK 18.24 727.37 1063.5584.1 37 10 2000 170 VQYQSLMDTIQK 18.24 727.37 1226.61 84.1 37 10 2000171 VQYQSLMDTIQK 18.24 727.37 935.49 84.1 37 10 2000 172 YAQATLVIPGHDEWK18.03 576.63 577.26 73.2 32.8 10 2000 173 YAQATLVIPGHDEWK 18.03 576.63747.39 73.2 32.8 10 2000 174 YAQATLVIPGHDEWK 18.05 576.63 868.40 73.232.8 10 2000 175 YAQATLVIPGHEEWK 17.99 581.30 690.37 73.5 33.1 10 2000176 YAQATLVIPGHEEWK 17.95 581.30 754.40 73.5 33.1 10 2000 177YAQATLVIPGHEEWK 17.97 581.30 882.41 73.5 33.1 10 2000 178 YNVLDGGCLVK17.86 619.32 633.34 76.3 32.2 15 2000 179 YNVLDGGCLVK 17.86 619.32748.37 76.3 32.2 15 2000 180 YNVLDGGCLVK 17.86 619.32 861.45 76.3 32.215 2000 181 YPSTAK 4.3 333.68 319.20 55.4 19.7 15 2000 182 YPSTAK 4.44333.68 406.23 55.4 19.7 15 2000 183 YPSTAK 4.28 333.68 503.28 55.4 19.715 2000 184 YSEAVLIIPGHDEWK 19.76 586.30 753.90 73.9 33.3 15 2000 185YSEAVLIIPGHDEWK 19.72 586.30 797.42 73.9 33.3 15 2000 186YSEAVLIIPGHDEWK 19.72 586.30 868.40 73.9 33.3 15 2000

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: no    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 40.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Entry potential before Q0 (EP): 10.00 V

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE13, the detection of the transition is considered to be positive and islabelled “1” in TABLE 14. When a transition has an area less than thepositivity threshold described in TABLE 13, the transition is considerednon-detected and is labelled “0” in TABLE 14.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 14 Transition number Sam84 Sam85 Sam86 Sam87 Sam88 1 0 1 1 1 1 2 00 1 1 0 3 0 0 0 1 0 4 0 0 0 0 0 5 0 0 0 0 0 6 0 0 0 0 0 7 0 0 0 0 0 8 00 0 1 0 9 0 0 0 0 0 10 0 1 1 0 1 11 0 0 0 0 0 12 0 0 1 0 0 13 0 0 0 0 014 0 0 0 0 0 15 0 0 0 0 0 16 0 0 0 1 0 17 0 0 0 1 0 18 0 1 0 1 1 19 0 00 0 0 20 0 0 0 0 0 21 1 1 1 1 0 22 0 0 0 0 0 23 0 0 0 0 0 24 0 0 0 0 025 1 1 1 1 1 26 1 1 0 1 1 27 1 1 0 1 1 28 0 1 0 1 1 29 0 1 0 1 1 30 0 10 1 1 31 0 0 0 0 0 32 0 0 0 0 0 33 0 0 0 0 0 34 0 0 0 0 0 35 0 0 0 0 036 0 0 0 0 0 37 0 0 0 0 0 38 0 0 0 0 0 39 0 0 0 0 0 40 0 0 0 0 0 41 0 00 0 0 42 0 0 0 0 0 43 0 0 0 0 0 44 0 0 0 0 0 45 0 0 0 0 0 46 0 0 0 0 047 0 0 0 0 0 48 0 0 0 0 0 49 0 0 0 0 0 50 0 0 0 0 0 51 0 0 0 0 0 52 0 00 1 0 53 0 0 0 1 0 54 0 0 0 1 0 55 0 0 0 0 0 56 0 0 0 0 0 57 0 0 0 0 058 0 0 0 0 0 59 0 0 0 0 0 60 0 0 0 0 0 61 0 0 0 0 0 62 0 0 0 0 0 63 0 00 0 0 64 0 0 0 0 0 65 0 0 0 0 0 66 0 0 0 0 0 67 0 0 0 0 0 68 0 0 0 0 069 0 0 0 0 0 70 0 0 0 0 0 71 0 0 0 0 0 72 0 0 0 0 0 73 0 0 0 0 0 74 1 00 0 0 75 0 0 0 0 0 76 0 0 0 0 0 77 0 0 0 0 0 78 1 0 0 0 0 79 0 0 0 0 080 0 0 0 0 0 81 0 0 0 0 0 82 1 0 0 1 0 83 0 0 0 0 0 84 0 0 0 0 0 85 0 00 0 0 86 0 0 0 0 0 87 0 0 0 0 0 88 0 0 0 0 0 89 0 0 0 0 0 90 0 0 0 0 091 0 0 0 0 0 92 0 0 0 0 0 93 0 0 0 0 0 94 0 0 0 0 0 95 0 0 0 0 0 96 0 00 0 0 97 0 0 0 0 0 98 0 0 0 0 0 99 0 0 0 0 0 100 0 0 0 0 0 101 0 0 0 0 0102 0 0 0 0 0 103 0 0 0 0 0 104 0 0 0 0 0 105 0 0 0 0 0 106 0 0 0 0 0107 0 0 0 0 0 108 0 0 0 0 0 109 0 0 0 0 0 110 0 0 0 0 0 111 0 0 0 0 0112 0 0 0 0 0 113 0 0 0 0 0 114 0 0 0 0 0 115 0 0 0 0 0 116 0 0 0 0 0117 0 0 0 0 0 118 0 0 0 0 0 119 0 0 0 0 0 120 0 0 0 0 0 121 0 0 0 0 0122 0 0 0 0 0 123 0 0 0 0 0 124 0 0 0 0 0 125 0 0 0 0 0 126 0 0 0 0 0127 0 0 0 0 0 128 0 0 0 0 0 129 0 0 0 0 0 130 0 0 0 0 0 131 0 0 0 0 0132 0 0 0 0 0 133 0 1 0 0 1 134 0 1 0 0 1 135 0 1 0 0 1 136 1 0 0 0 0137 1 0 0 1 0 138 1 0 0 0 1 139 0 0 0 0 0 140 0 0 0 0 0 141 0 0 0 0 0142 0 0 0 0 0 143 0 0 0 0 0 144 0 0 0 0 0 145 1 0 0 0 0 146 1 0 0 1 0147 1 0 0 0 0 148 0 0 0 0 0 149 0 0 0 0 0 150 0 0 0 0 0 151 0 0 0 0 0152 0 0 0 0 0 153 0 0 0 0 0 154 0 0 0 0 0 155 0 0 0 0 0 156 0 0 0 0 0157 0 0 0 0 0 158 0 0 0 0 0 159 0 0 0 0 0 160 0 0 0 0 0 161 0 0 0 0 0162 0 0 0 0 0 163 0 0 0 0 0 164 0 0 0 0 0 165 0 0 0 0 0 166 0 0 0 0 0167 0 0 0 0 0 168 0 0 0 0 0 169 0 0 0 0 0 170 0 0 0 0 0 171 0 0 0 0 0172 0 0 0 0 0 173 0 0 0 0 0 174 0 0 0 0 0 175 0 1 0 1 1 176 0 1 0 1 1177 1 1 0 1 1 178 0 0 0 0 0 179 0 0 0 0 0 180 0 0 0 0 0 181 0 0 0 0 0182 0 0 0 0 0 183 0 0 0 0 0 184 0 0 0 0 0 185 0 0 0 0 0 186 0 0 0 0 0187 0 0 0 1 0 188 0 0 0 1 0 189 0 1 0 1 0 190 0 0 0 0 0 191 0 0 0 0 0192 0 0 0 0 0 193 0 0 0 0 0 194 0 0 0 0 0 195 0 0 0 0 0

Samples Sam84 to Sam88 comprise at least one peptide which ischaracteristic of INDs. The bacteria present in samples Sam84 to Sam88therefore express a beta-lactamase which confers on them a resistance topenicillins, to cephalosporins and to carbapenems.

EXAMPLE 10: IDENTIFICATION OF A RESISTANCE TO GES BETA-LACTAMS

Samples Sam89 and Sam90 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 15.

TABLE 15 Names Species Sam89 E. coli Sam90 P. aeruginosa

Samples Sam89 and Sam90 correspond to a species able to comprise a GESresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 16 instead of the peptides from TABLE3.

TABLE 16 Decluste Retention (m/z) (m/z) ring Collision Transition timefiltered filtered potential energy number Peptide (minutes) in Q1 in Q3(eV) (eV) 1 AAEIGVAIVDPQGEIVAGHR 19.11 668.03 695.88 79.8 37.4 2AAEIGVAIVDPQGEIVAGHR 19.13 668.03 731.39 79.8 37.4 3AAEIGVAIVDPQGEIVAGHR 19.11 668.03 809.44 79.8 37.4 4AAQIGVAIVDPQGEIVAGHR 18.76 667.70 695.88 79.8 37.4 5AAQIGVAIVDPQGEIVAGHR 18.76 667.70 731.39 79.8 37.4 6AAQIGVAIVDPQGEIVAGHR 18.76 667.70 809.44 79.8 37.4 7 DTTTPIAMAR 14.23538.77 658.37 70.4 28.7 8 DTTTPIAMAR 14.23 538.77 759.42 70.4 28.7 9DTTTPIAMAR 14.23 538.77 860.47 70.4 28.7 10 DWVVGEK 14.41 416.71 432.2561.5 23.3 11 DWVVGEK 14.43 416.71 531.31 61.5 23.3 12 DWVVGEK 14.45416.71 717.39 61.5 23.3 13 DYAVAVYTTAPK 15.83 649.84 680.36 78.5 33.6 14DYAVAVYTTAPK 15.83 649.84 779.43 78.5 33.6 15 DYAVAVYTTAPK 15.85 649.84850.47 78.5 33.6 16 EIGGPAAMTQYFR 20.03 720.85 1198.57 83.7 36.7 17EIGGPAAMTQYFR 20.03 720.85 845.40 83.7 36.7 18 EIGGPAAMTQYFR 20.03720.85 916.44 83.7 36.7 19 EPEMGDNTPGDLR 13.53 715.81 557.30 83.3 36.520 EPEMGDNTPGDLR 13.53 715.81 772.40 83.3 36.5 21 EPEMGDNTPGDLR 13.53715.81 944.44 83.3 36.5 22 ESEMSDNTPGDLR 12.72 725.81 557.30 84 36.9 23ESEMSDNTPGDLR 12.7 725.81 887.42 84 36.9 24 ESEMSDNTPGDLR 12.71 725.81974.45 84 36.9 25 FAMCSTFK 16.14 496.22 642.29 67.3 26.8 26 FAMCSTFK16.12 496.22 773.33 67.3 26.8 27 FAMCSTFK 16.12 496.22 844.37 67.3 26.828 FIHALLLAGIAHSAYASEK 20.93 671.37 1204.60 80.1 37.6 29FIHALLLAGIAHSAYASEK 20.92 671.37 807.95 80.1 37.6 30 FIHALLLAGIAHSAYASEK20.93 671.37 876.48 80.1 37.6 31 FIHALLLAGTAHSAYASEK 18.21 667.36 766.4179.8 37.4 32 FIHALLLAGTAHSAYASEK 18.21 667.36 801.93 79.8 37.4 33FIHALLLAGTAHSAYASEK 18.21 667.36 870.46 79.8 37.4 34 FPLAALVFER 24.46581.84 734.42 73.5 30.6 35 FPLAALVFER 24.46 581.84 805.46 73.5 30.6 36FPLAALVFER 24.44 581.84 918.54 73.5 30.6 37 IDSGTER 1.66 389.19 462.2359.5 22.1 38 IDSGTER 1.84 389.19 549.26 59.5 22.1 39 IDSGTER 1.75 389.19664.29 59.5 22.1 40 IGDSVSR 8.48 367.20 448.25 57.9 21.2 41 IGDSVSR 8.46367.20 563.28 57.9 21.2 42 IGDSVSR 8.44 367.20 620.30 57.9 21.2 43LSAVER 9.1 337.70 403.23 55.7 19.9 44 LSAVER 9.08 337.70 474.27 55.719.9 45 LSAVER 9.1 337.70 561.30 55.7 19.9 46 LSYGPDMIVEWSPATER 22.31650.98 573.30 78.6 36.5 47 LSYGPDMIVEWSPATER 22.29 650.98 660.33 78.636.5 48 LSYGPDMIVEWSPATER 22.26 650.98 846.41 78.6 36.5 49 LSYGPDMIVK17.71 561.80 1009.50 72.1 29.7 50 LSYGPDMIVK 17.69 561.80 759.41 72.129.7 51 LSYGPDMIVK 17.69 561.80 922.47 72.1 29.7 52 NDIGFFK 17.71 420.72498.27 61.8 23.5 53 NDIGFFK 17.69 420.72 611.36 61.8 23.5 54 NDIGFFK17.74 420.72 726.38 61.8 23.5 55 TDLEK 3.66 303.16 389.24 53.2 18.3 56TDLEK 3.73 303.16 459.21 53.2 18.3 57 TDLEK 3.6 303.16 504.27 53.2 18.358 TGACANGAR 1.48 439.20 648.29 63.1 24.3 59 TGACANGAR 1.48 439.20719.33 63.1 24.3 60 TGACANGAR 1.48 439.20 776.35 63.1 24.3 61 TGTCANGAR1.48 454.21 648.29 64.2 25 62 TGTCANGAR 1.48 454.21 749.34 64.2 25 63TGTCANGAR 1.48 454.21 806.36 64.2 25 64 TGTCANGGR 1.48 447.20 474.2463.7 24.7 65 TGTCANGGR 1.48 447.20 634.27 63.7 24.7 66 TGTCANGGR 1.48447.20 735.32 63.7 24.7 67 VLYGGALTSTSTHTIER 15.87 602.65 1245.64 75.134.1 68 VLYGGALTSTSTHTIER 15.85 602.65 715.87 75.1 34.1 69VLYGGALTSTSTHTIER 15.87 602.65 797.40 75.1 34.1 70 WLIGNQTGDATLR 18.93722.88 1032.51 83.8 36.8 71 WLIGNQTGDATLR 19.02 722.88 1145.59 83.8 36.872 WLIGNQTGDATLR 18.96 722.88 733.38 83.8 36.8 73 WSPATER 11.37 423.71476.25 62 23.6 74 WSPATER 11.37 423.71 573.30 62 23.6 75 WSPATER 11.34423.71 660.33 62 23.6

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: yes    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 40.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Entry potential before Q0 (EP): 10.00 V    -   Collision cell exit potential (CXP): 15.00 V

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE16, the detection of the transition is considered to be positive and islabelled “1” in TABLE 17. When a transition has an area less than thepositivity threshold described in TABLE 16, the transition is considerednon-detected and is labelled “0” in TABLE 17.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 17 Transition number Sam89 Sam90 1 0 0 2 0 0 3 0 0 4 0 0 5 1 1 6 00 7 1 1 8 1 1 9 1 1 10 1 1 11 1 1 12 1 1 13 0 0 14 0 0 15 0 0 16 0 0 170 0 18 0 0 19 0 0 20 0 0 21 0 0 22 0 0 23 0 0 24 0 0 25 0 0 26 0 0 27 00 28 0 0 29 0 0 30 0 0 31 0 0 32 0 0 33 0 0 34 0 0 35 0 0 36 0 0 37 1 138 1 1 39 1 1 40 1 1 41 1 1 42 1 1 43 1 1 44 1 1 45 1 1 46 1 1 47 1 1 481 1 49 0 0 50 0 0 51 0 0 52 1 1 53 1 1 54 1 1 55 0 0 56 0 0 57 0 0 58 00 59 0 0 60 0 0 61 0 0 62 0 0 63 0 0 64 1 0 65 0 1 66 1 1 67 1 1 68 1 169 1 1 70 1 1 71 1 1 72 1 1 73 0 0 74 0 0 75 0 0

Samples Sam89 and Sam90 comprise at least one peptide which ischaracteristic of the carbapenemase phenotype. The bacteria present insamples Sam89 to Sam90 therefore express a beta-lactamase which conferson them a resistance to penicillins, to cephalosporins and tocarbapenems.

EXAMPLE 11: IDENTIFICATION OF A RESISTANCE TO SME BETA-LACTAMS

Samples Sam91 to Sam95 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 18.

TABLE 18 Names Species Sam91 S. marcescens Sam92 S. marcescens Sam93 S.marcescens Sam94 S. marcescens Sam95 S. marcescens

Samples Sam91 to Sam95 correspond to a species able to comprise an SMEresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 19 instead of the peptides from TABLE3.

TABLE 19 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy positivity number Peptide (minutes) Q1 Q3 (eV)threshold 1 AIYQNWLK 18.69 518.29 426.22 25.3 2500 2 AIYQNWLK 18.69518.29 688.38 25.3 2500 3 AIYQNWLK 18.69 518.29 851.44 25.3 2500 4APLIVSIYTTR 20.21 617.36 740.39 30.9 2500 5 APLIVSIYTTR 20.21 617.36839.46 30.9 2500 6 APLIVSIYTTR 20.21 617.36 952.55 30.9 2500 7ASVPADWVVGDK 17.56 622.32 493.75 31.2 2500 8 ASVPADWVVGDK 17.56 622.32543.29 31.2 2500 9 ASVPADWVVGDK 17.56 622.32 986.49 31.2 2500 10AVANSLNK 8.75 408.73 461.27 19 2500 11 AVANSLNK 8.75 408.73 575.32 192500 12 AVANSLNK 8.75 408.73 646.35 19 2500 13 DLEYHSPITTK 14.48 435.22473.75 20.6 2500 14 DLEYHSPITTK 14.48 435.22 538.28 20.6 2500 15DLEYHSPITTK 14.48 435.22 646.38 20.6 2500 16 DLEYYSPITTK 17.4 665.33559.35 33.7 2500 17 DLEYYSPITTK 17.4 665.33 646.38 33.7 2500 18DLEYYSPITTK 17.4 665.33 809.44 33.7 2500 19 DTSTPK 1.45 324.66 345.2114.2 2500 20 DTSTPK 1.45 324.66 432.25 14.2 2500 21 DTSTPK 1.45 324.66533.29 14.2 2500 22 FLGGPEGMTK 14.94 518.76 662.32 25.3 2500 23FLGGPEGMTK 14.94 518.76 719.34 25.3 2500 24 FLGGPEGMTK 14.94 518.76776.36 25.3 2500 25 GFLAAAVLER 20.49 523.80 587.35 25.6 2500 26GFLAAAVLER 20.49 523.80 658.39 25.6 2500 27 GFLAAAVLER 20.49 523.80729.43 25.6 2500 28 GNTTGDAR 6.45 396.19 418.20 18.3 2500 29 GNTTGDAR6.45 396.19 519.25 18.3 2500 30 GNTTGDAR 6.45 396.19 620.30 18.3 2500 31IGVFAIDTGSGNTFGYR 21.45 592.30 542.27 25.4 2500 32 IGVFAIDTGSGNTFGYR21.45 887.94 1174.51 46.3 2500 33 IGVFAIDTGSGNTFGYR 21.45 887.94 958.4446.3 2500 34 LALGNVLNAK 18.56 506.81 414.75 24.6 2500 35 LALGNVLNAK18.56 506.81 715.41 24.6 2500 36 LALGNVLNAK 18.56 506.81 828.49 24.62500 37 LDINQK 10.3 365.71 389.21 16.6 2500 38 LDINQK 10.3 365.71 502.3016.6 2500 39 LDINQK 10.3 365.71 617.33 16.6 2500 40 LEEDFDGR 12.51490.72 609.26 23.7 2500 41 LEEDFDGR 12.51 490.72 738.31 23.7 2500 42LEEDFDGR 12.51 490.72 867.35 23.7 2500 43 SDAAAK 7.06 281.65 289.19 11.82500 44 SDAAAK 7.06 281.65 360.22 11.8 2500 45 SDAAAK 7.06 281.65 475.2511.8 2500 46 SIGDNEFR 12.81 469.22 565.27 22.5 2500 47 SIGDNEFR 12.81469.22 680.30 22.5 2500 48 SIGDNEFR 12.81 469.22 737.32 22.5 2500 49TGSCGAIGTANDYAVIWPK 20.29 660.99 430.25 27.6 2500 50 TGSCGAIGTANDYAVIWPK20.29 660.99 713.43 27.6 2500 51 TGSCGAIGTANDYAVIWPK 20.29 990.98 430.2552.2 2500 52 TGSCGAYGTANDYAVIWPK 19.78 1015.97 430.25 53.6 2500 53TGSCGAYGTANDYAVIWPK 19.78 677.65 642.40 28.1 2500 54 TGSCGAYGTANDYAVIWPK19.78 677.65 713.43 28.1 2500 55 TIAEASR 6.98 374.20 333.19 17.1 2500 56TIAEASR 6.98 374.20 462.23 17.1 2500 57 TIAEASR 6.98 374.20 646.35 17.12500 58 WELELNTAIPGDK 21.06 495.92 416.21 22.5 2500 59 WELELNTAIPGDK21.06 743.38 1170.64 38.1 2500 60 WELELNTAIPGDK 21.06 743.38 416.21 38.12500

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: yes    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 40.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Declustering potential (DP): 100.00 V    -   Entry potential before Q0 (EP): 10.00 V    -   Collision cell exit potential (CXP): 15.00 V

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE19, the detection of the transition is considered to be positive and islabelled “1” in TABLE 20. When a transition has an area less than thepositivity threshold described in TABLE 19, the transition is considerednon-detected and is labelled “0” in TABLE 20.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 20 Transition number Sam91 Sam92 Sam93 Sam94 Sam95 1 0 1 0 0 0 2 11 0 0 1 3 0 1 0 0 0 4 0 0 0 0 0 5 0 0 0 0 0 6 0 0 0 0 0 7 1 1 1 1 1 8 11 1 1 1 9 1 1 1 1 1 10 1 1 1 1 1 11 1 1 1 1 1 12 1 1 1 1 1 13 1 1 1 1 114 1 1 1 1 1 15 1 1 1 1 1 16 0 0 0 0 0 17 0 0 0 0 0 18 0 0 0 0 0 19 0 00 0 0 20 0 0 0 0 0 21 0 0 0 0 0 22 1 1 1 0 1 23 1 1 1 0 1 24 1 1 1 0 125 1 1 1 1 1 26 1 1 1 1 1 27 1 1 1 1 1 28 0 0 0 0 0 29 0 0 0 0 0 30 0 00 0 0 31 0 0 0 0 0 32 0 0 0 0 0 33 0 0 0 0 0 34 1 1 1 1 1 35 1 1 1 1 136 1 1 1 1 1 37 0 0 0 0 0 38 0 0 0 0 0 39 0 0 0 0 0 40 1 1 1 0 1 41 1 11 0 1 42 1 1 1 0 1 43 0 0 0 0 0 44 0 0 0 0 0 45 0 0 0 0 0 46 0 0 1 0 047 0 0 1 0 0 48 0 0 1 0 0 49 0 0 0 0 0 50 0 0 0 0 0 51 0 0 0 0 0 52 0 00 0 0 53 0 0 0 0 0 54 0 0 0 0 0 55 0 0 0 0 0 56 0 0 0 0 0 57 0 0 0 0 058 0 0 0 0 0 59 0 0 0 0 0 60 0 0 0 0 0

Samples Sam91 to Sam95 comprise at least one peptide which ischaracteristic of SMEs. The bacteria present in samples Sam91 to Sam95therefore express a beta-lactamase which confers on them a resistance topenicillins, to cephalosporins and to carbapenems.

EXAMPLE 12: IDENTIFICATION OF A RESISTANCE TO IMP BETA-LACTAMS

The samples corresponding to a species able to comprise an IMPresistance mechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 21 instead of thepeptides from TABLE 3.

TABLE 21 (m/z) (m/z) Transition Retention time filtered in filtered inCollision number Peptide (minutes) Q1 Q3 energy (eV) 1 EVNGWGVVPK 16.02542.79 742.35 29 2 EVNGWGVVPK 16.02 542.79 856.47 29 3 EVNGWGVVPK 16.02542.79 955.54 29 4 GSISSHFHSDSTGGIGWLNSR 16.97 551.26 675.36 31 5GSISSHFHSDSTGGIGWLNSR 16.97 551.26 732.38 31 6 GSISSHFHSDSTGGIGWLNSR16.97 734.68 959.51 41 7 HGLVILVNTDAYLIDTPFTAK 24.53 767.75 892.48 42 8HGLVILVNTDAYLIDTPFTAK 24.53 767.75 1005.56 42 9 HGLVILVNTDAYLIDTPFTAK24.53 767.75 1133.63 42 10 HGLVVLVNNDAYLIDTPFTNK 22.75 781.75 822.4 4311 HGLWLVNNDAYLIDTPFTNK 22.75 781.75 935.48 43 12 HGLVVLVNNDAYLIDTPFTNK22.75 781.75 1132.61 43 13 HGLVVLVNTDAYLIDTPFTAK 23.91 763.08 779.39 4214 HGLVVLVNTDAYLIDTPFTAK 23.91 763.08 892.48 42 15 HGLVVLVNTDAYLIDTPFTAK23.91 763.08 1119.62 42 16 HGLVVLVNTEAYLIDTPFTAK 24.53 767.75 779.39 4217 HGLVVLVNTEAYLIDTPFTAK 24.53 767.75 892.48 42 18 HGLVVLVNTEAYLIDTPFTAK24.53 767.75 1133.63 42 19 IEVFYPGPGHTQDNVVVWLPK 22.25 599.57 642.4 3320 IEVFYPGPGHTQDNVVVWLPK 22.25 599.57 741.47 33 21 IEVFYPGPGHTQDNVVVWLPK22.25 799.09 872.46 44 22 ILMEK 11.28 317.19 407.2 19 23 ILMEK 11.28317.19 487.26 19 24 ILMEK 11.28 317.19 520.28 19 25 ILMSK 10.48 296.18365.19 18 26 ILMSK 10.48 296.18 445.25 18 27 ILMSK 10.48 296.18 478.2718 28 LDEGVYVHTSFK 15.03 465.57 482.26 27 29 LDEGVYVHTSFK 15.03 465.57619.32 27 30 LDEGVYVHTSFK 15.03 465.57 881.45 27 31 LEEGVYVHTSYEEVK14.55 594.62 855.41 34 32 LEEGVYVHTSYEEVK 14.55 594.62 992.47 34 33LEEGVYVHTSYEEVK 14.55 891.43 992.47 44 34 LLISK 12.19 287.2 347.23 18 35LLISK 12.19 287.2 427.29 18 36 LLISK 12.19 287.2 460.31 18 37 LLMSK11.18 296.18 365.19 18 38 LLMSK 11.18 296.18 445.25 18 39 LLMSK 11.18296.18 478.27 18 40 LLVSK 10.48 280.19 333.21 17 41 LLVSK 10.48 280.19413.28 17 42 LLVSK 10.48 280.19 446.3 17 43 LPDLK 12.56 293.18 375.22 1844 LPDLK 12.56 293.18 439.26 18 45 LPDLK 12.56 293.18 472.28 18 46LVVSGHSETGDATHLK 11.41 413.47 569.34 24 47 LVVSGHSETGDATHLK 11.41 550.95719.85 32 48 LVVSGHSETGDATHLK 11.41 550.95 1058.51 32 49 NSFDGVSYVVLAK20.75 693.84 767.41 36 50 NSFDGVSYWLAK 20.75 693.84 1038.53 36 51NSFDGVSYWLAK 20.75 693.84 1185.59 36

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the threetransitions of the same peptide are greater than or equal to 2500, thedetection of the peptide is considered to be positive and is labelled“1”. When at least one transition comprises an area less than 2500, thecorresponding peptide is considered non-detected and is labelled “0”.

EXAMPLE 13: IDENTIFICATION OF A RESISTANCE TO KPC BETA-LACTAMS

The samples corresponding to a species able to comprise a KPC resistancemechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 22 instead of thepeptides from TABLE 3.

TABLE 22 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy number Peptide (minutes) Q1 Q3 (eV) 1 NALVR 8.14286.68 387.27 18 2 NALVR 8.14 286.68 398.24 18 3 NALVR 8.14 286.68458.31 18 4 TGTC[CAM]GAYGTANDYAVVWPTGR 18.76 739.67 1169.45 41 5TGTC[CAM]GAYGTANDYAVVWPTGR 18.76 1109.01 1163.58 54 6TGTC[CAM]GAYGTANDYAVVWPTGR 18.76 1109.01 1169.45 54 7 WELELNSAIPSDAR20.43 534.27 545.27 31 8 WELELNSAIPSDAR 20.43 800.9 930.46 40 9WELELNSAIPSDAR 20.43 800.9 1043.55 40 10 WELEMNSAIPGDAR 19.35 794.87900.45 40 11 WELEMNSAIPGDAR 19.35 794.87 1031.49 40 12 WELEMNSAIPGDAR19.35 794.87 1074.49 40

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the threetransitions of the same peptide are greater than or equal to 2500, thedetection of the peptide is considered to be positive and is labelled“1”. When at least one transition comprises an area less than 2500, thecorresponding peptide is considered non-detected and is labelled “0”.

EXAMPLE 14: IDENTIFICATION OF A RESISTANCE TO NDM BETA-LACTAMS

The samples corresponding to a species able to comprise an NDMresistance mechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 23 instead of thepeptides from TABLE 3.

TABLE 23 (m/z) (m/z) Transition Retention time filtered in filtered inCollision number Peptide (minutes) Q1 Q3 energy (eV) 1VLLVDTAWTDDQTAQILNWIK 27.87 815.1 914.55 45 2 VLLVDTAWTDDQTAQILNWIK27.86 815.1 985.58 45 3 VLLVDTAWTDDQTAQILNWIK 27.85 815.1 1086.63 45

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the threetransitions of the same peptide are greater than or equal to 2500, thedetection of the peptide is considered to be positive and is labelled“1”. When at least one transition comprises an area less than 2500, thecorresponding peptide is considered non-detected and is labelled “0”.

EXAMPLE 15: IDENTIFICATION OF A RESISTANCE TO VIM BETA-LACTAMS

The samples corresponding to a species able to comprise a VIM resistancemechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 24 instead of thepeptides from TABLE 3.

TABLE 24 (m/z) (m/z) Transition Retention time filtered in filtered inCollision number Peptide (minutes) Q1 Q3 energy (eV) 1LANEIPTHSLEGLSSSGDAVR 16.72 718.37 778.37 40 2 LANEIPTHSLEGLSSSGDAVR16.72 718.37 948.47 40 3 LANEIPTHSLEGLSSSGDAVR 16.72 718.37 1077.52 40

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the threetransitions of the same peptide are greater than or equal to 2500, thedetection of the peptide is considered to be positive and is labelled“1”. When at least one transition comprises an area less than 2500, thecorresponding peptide is considered non-detected and is labelled “0”.

EXAMPLE 16: IDENTIFICATION OF A RESISTANCE TO OXA BETA-LACTAMS

The samples corresponding to a species able to comprise an OXAresistance mechanism can be detected by employing the following method.

Each sample is treated according to Example 5, then analysed accordingto Example 6 by detecting the peptides from TABLE 25 instead of thepeptides from TABLE 3.

TABLE 25 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy number Peptide (minutes) Q1 Q3 (eV) 1AAAYELAENLFEAGQADGWR 24.48 728.01 1249.6 40 2 AAAYELAENLFEAGQADGWR 24.481091.51 1193.58 53 3 AAAYELAENLFEAGQADGWR 24.48 1091.51 1249.6 53 4AAEGFIPASTFK 17.74 619.82 763.43 32 5 AAEGFIPASTFK 17.74 619.82 910.5 326 AAEGFIPASTFK 17.74 619.82 967.52 32 7 ADGQVVAFALNMQMK 21.27 811.91982.48 41 8 ADGQVVAFALNMQMK 21.29 811.91 1053.52 41 9 ADGQVVAFALNMQMK21.27 811.91 1152.59 41 10 ADINEIFK 17.3 475.25 650.35 26 11 ADINEIFK17.3 475.25 763.43 26 12 ADINEIFK 17.3 475.25 878.46 26 13 ADWGK 6.9288.64 390.21 18 14 ADWGK 6.91 288.64 430.17 18 15 ADWGK 6.89 288.64505.24 18 16 AEGAIVISDER 13.52 387.2 419.19 23 17 AEGAIVISDER 13.53387.2 506.22 23 18 AEGAIVISDER 13.52 387.2 619.3 23 19 AFALNLDIDK 20.16560.31 717.38 30 20 AFALNLDIDK 20.16 560.31 830.46 30 21 AFALNLDIDK20.16 560.31 901.5 30 22 AFAPMSTFK 16.96 500.25 710.35 27 23 AFAPMSTFK16.96 500.25 781.39 27 24 AFAPMSTFK 16.96 500.25 928.46 27 25AFGYGNADVSGDPGQNNGLDR 15.12 708.65 873.42 39 26 AFGYGNADVSGDPGQNNGLDR15.12 708.65 970.47 39 27 AFGYGNADVSGDPGQNNGLDR 15.12 708.65 1154.47 3928 AFTMTK 11.32 349.68 480.25 20 29 AFTMTK 11.33 349.68 552.25 20 30AFTMTK 11.33 349.68 627.32 20 31 AGDDIALR 12.23 415.72 587.35 23 32AGDDIALR 12.23 415.72 702.38 23 33 AGDDIALR 12.23 415.72 759.4 23 34AGHVYAFALNIDMPR 20.63 558.95 631.32 32 35 AGHVYAFALNIDMPR 20.63 558.95745.37 32 36 AGHVYAFALNIDMPR 20.63 558.95 817.4 32 37 AGLWR 13.44 301.67361.2 18 38 AGLWR 13.44 301.67 474.28 18 39 AGLWR 13.44 301.67 531.3 1840 AHTEYVPASTFK 13.18 450.89 553.3 27 41 AHTEYVPASTFK 13.18 450.89602.26 27 42 AHTEYVPASTFK 13.18 450.89 650.35 27 43 AIIPWDGKPR 15.84384.89 428.23 23 44 AIIPWDGKPR 15.84 384.89 457.29 23 45 AIIPWDGKPR15.84 384.89 572.32 23 46 AISDITITR 14.8 495.28 603.38 27 47 AISDITITR14.8 495.28 718.41 27 48 AISDITITR 14.8 495.28 805.44 27 49 ALGQDR 11.25330.18 475.23 20 50 ALGQDR 11.25 330.18 485.24 20 51 ALGQDR 11.25 330.18588.31 20 52 ALQAK 1.86 265.67 346.21 17 53 ALQAK 1.87 265.67 384.22 1754 ALQAK 1.87 265.67 459.29 17 55 AMETFSPASTFK 17.06 658.81 737.38 34 56AMETFSPASTFK 17.05 658.81 985.5 34 57 AMETFSPASTFK 17.06 658.81 1114.5434 58 AMLFLQER 18.48 504.27 545.3 27 59 AMLFLQER 18.48 504.27 692.37 2760 AMLFLQER 18.48 504.27 805.46 27 61 AMLVFDPVR 19.87 524.29 732.4 28 62AMLVFDPVR 19.87 524.29 845.49 28 63 AMLVFDPVR 19.87 524.29 976.53 28 64AMTLLESGPGWELHGK 19.32 575.96 923.47 33 65 AMTLLESGPGWELHGK 19.32 575.96980.49 33 66 AMTLLESGPGWELHGK 19.32 575.96 1067.53 33 67 ANLHITLHGK12.18 368.55 403.24 22 68 ANLHITLHGK 12.18 368.55 555.32 22 69ANLHITLHGK 12.18 368.55 668.41 22 70 ANQLIVK 11.87 393.25 600.41 22 71ANQLIVK 11.86 393.25 639.38 22 72 ANQLIVK 11.86 393.25 714.45 22 73ANTEYVPASTFK 14.54 664.33 912.48 34 74 ANTEYVPASTFK 14.54 664.33 1041.5334 75 ANTEYVPASTFK 14.54 664.33 1142.57 34 76 ANVSR 9.57 273.65 361.2217 77 ANVSR 9.57 273.65 372.19 17 78 ANVSR 9.57 273.65 475.26 17 79APIGWFIGWATR 25.58 687.87 850.46 35 80 APIGWFIGWATR 25.58 687.87 1093.5635 81 APIGWFIGWATR 25.58 687.87 1206.64 35 82 APLGWFIGWATHEER 24.69590.63 742.35 34 83 APLGWFIGWATHEER 24.69 590.63 985.45 34 84APLGWFIGWATHEER 24.69 590.63 1098.53 34 85 AQDEVQSMLFIEEK 20.15 833.9996.51 42 86 AQDEVQSMLFIEEK 20.14 833.9 1124.57 42 87 AQDEVQSMLFIEEK20.15 833.9 1223.63 42 88 AQGVIVLWNENK 18.95 685.87 902.47 35 89AQGVIVLWNENK 18.95 685.87 1015.56 35 90 AQGVIVLWNENK 18.95 685.871171.65 35 91 ASAIAVYQDLAR 18.05 639.35 765.39 33 92 ASAIAVYQDLAR 18.05639.35 864.46 33 93 ASAIAVYQDLAR 18.05 639.35 935.49 33 94 ASAILVYQDLAR19.08 660.37 765.39 34 95 ASAILVYQDLAR 19.08 660.37 864.46 34 96ASAILVYQDLAR 19.08 660.37 977.54 34 97 ASAIPVYQDLAR 17.45 652.35 765.3934 98 ASAIPVYQDLAR 17.45 652.35 864.46 34 99 ASAIPVYQDLAR 17.45 652.35961.51 34 100 ASAIPVYQDLPR 17.59 665.36 791.4 34 101 ASAIPVYQDLPR 17.59665.36 890.47 34 102 ASAIPVYQDLPR 17.6 665.36 987.53 34 103 ASAIQVYQDLAR18.37 667.86 765.39 34 104 ASAIQVYQDLAR 18.37 667.86 864.46 34 105ASAIQVYQDLAR 18.37 667.86 992.52 34 106 ASAISVYQDLAR 17.93 647.34 765.3933 107 ASAISVYQDLAR 17.93 647.34 864.46 33 108 ASAISVYQDLAR 17.93 647.34951.49 33 109 ASALPVYQDLAR 17.77 652.35 864.46 34 110 ASALPVYQDLAR 17.77652.35 961.51 34 111 ASALPVYQDLAR 17.77 652.35 1074.59 34 112ASAMPVYQDLAR 16.64 661.33 765.39 34 113 ASAMPVYQDLAR 16.64 661.33 864.4634 114 ASAMPVYQDLAR 16.64 661.33 961.51 34 115 ASAVPVYQDLAR 16.29 645.35765.39 33 116 ASAVPVYQDLAR 16.29 645.35 864.46 33 117 ASAVPVYQDLAR 16.29645.35 961.51 33 118 ASIEYVPASTFK 16.7 656.84 749.42 34 119 ASIEYVPASTFK16.7 656.84 912.48 34 120 ASIEYVPASTFK 16.7 656.84 1041.53 34 121ASNVPVYQELAR 18.48 673.86 779.4 35 122 ASNVPVYQELAR 18.48 673.86 878.4735 123 ASNVPVYQELAR 18.48 673.86 975.53 35 124 ASPASTFK 10.29 404.71553.3 23 125 ASPASTFK 10.29 404.71 650.35 23 126 ASPASTFK 10.28 404.71737.38 23 127 ASTAYIPASTFK 15.69 628.83 763.43 33 128 ASTAYIPASTFK 15.69628.83 926.5 33 129 ASTAYIPASTFK 15.69 628.83 997.54 33 130 ASTEYVPASTFK14.59 650.82 749.42 34 131 ASTEYVPASTFK 14.59 650.82 912.48 34 132ASTEYVPASTFK 14.6 650.82 1041.53 34 133 ASTTEVFK 11.78 441.73 623.34 24134 ASTTEVFK 11.78 441.73 724.39 24 135 ASTTEVFK 11.78 441.73 811.42 24136 ATSTEIFK 13.15 448.74 637.36 25 137 ATSTEIFK 13.15 448.74 724.39 25138 ATSTEIFK 13.15 448.74 825.44 25 139 ATTNEIFK 13.21 462.25 650.35 25140 ATTNEIFK 13.21 462.25 751.4 25 141 ATTNEIFK 13.21 462.25 852.45 25142 ATTTAVFK 11.9 419.74 464.29 23 143 ATTTAVFK 11.9 419.74 565.33 23144 ATTTAVFK 11.9 419.74 666.38 23 145 ATTTEIFK 13.64 455.75 637.36 25146 ATTTEIFK 13.65 455.75 738.4 25 147 ATTTEIFK 13.65 455.75 839.45 25148 ATTTEVFK 11.98 448.74 623.34 25 149 ATTTEVFK 11.98 448.74 724.39 25150 ATTTEVFK 11.98 448.74 825.44 25 151 AVSDITILEQTDNYTLHGK 19.19 706.7974.49 39 152 AVSDITILEQTDNYTLHGK 19.19 706.7 1048.51 39 153AVSDITILEQTDNYTLHGK 19.18 706.7 1176.56 39 154 AVSDITILEQTYNYTLHGK 22.29722.71 995.49 40 155 AVSDITILEQTYNYTLHGK 22.29 722.71 998.5 40 156AVSDITILEQTYNYTLHGK 22.28 722.71 1224.6 40 157 AVVPHFEAGDWDVQGK 17.81585.62 743.34 33 158 AVVPHFEAGDWDVQGK 17.81 585.62 792.88 33 159AVVPHFEAGDWDVQGK 17.81 585.62 904.42 33 160 AWEHDMSLR 13.99 572.76758.36 30 161 AWEHDMSLR 13.99 572.76 887.4 30 162 AWEHDMSLR 13.99 572.761073.48 30 163 AWIGSSLQISPLEQLEFLGK 26.98 739.4 963.51 41 164AWIGSSLQISPLEQLEFLGK 26.99 739.4 1173.65 41 165 AWIGSSLQISPLEQLEFLGK26.98 1108.6 1173.65 54 166 DAFLK 12.42 297.17 407.27 18 167 DAFLK 12.43297.17 447.22 18 168 DAFLK 12.42 297.17 478.3 18 169 DDFILHGK 13.99472.75 714.43 26 170 DDFILHGK 13.99 472.75 798.38 26 171 DDFILHGK 13.99472.75 829.46 26 172 DDVLK 8.62 295.16 359.27 18 173 DDVLK 8.63 295.16443.21 18 174 DDVLK 8.62 295.16 474.29 18 175 DEFHVFR 15.39 475.23705.38 26 176 DEFHVFR 15.39 475.23 775.34 26 177 DEFHVFR 15.39 475.23834.43 26 178 DEFQIFR 19.02 477.74 520.2 26 179 DEFQIFR 19.02 477.74563.33 26 180 DEFQIFR 19.02 477.74 710.4 26 181 DEFQVFR 17.29 470.73549.31 26 182 DEFQVFR 17.28 470.73 619.27 26 183 DEFQVFR 17.29 470.73696.38 26 184 DELVR 9.33 316.17 387.27 19 185 DELVR 9.35 316.17 457.2319 186 DELVR 9.33 316.17 516.31 19 187 DFDYGNQDFSGDK 14.72 754.3 967.4138 188 DFDYGNQDFSGDK 14.72 754.3 1130.47 38 189 DFDYGNQDFSGDK 14.72754.3 1245.5 38 190 DFTLGEAMQASTVPVYQELAR 24.19 776.05 975.53 43 191DFTLGEAMQASTVPVYQELAR 24.19 776.05 1074.59 43 192 DFTLGEAMQASTVPVYQELAR24.19 1163.57 1175.64 56 193 DHDLITAMK 14.23 522.26 563.32 28 194DHDLITAMK 14.23 522.26 695.34 28 195 DHDLITAMK 14.23 522.26 791.43 28196 DIAAWNR 13.63 423.22 546.28 24 197 DIAAWNR 13.63 423.22 617.32 24198 DIAAWNR 13.62 423.22 730.4 24 199 DILYIQELAGGWK 24.49 753.4 888.4638 200 DILYIQELAGGWK 24.48 753.4 1001.54 38 201 DILYIQELAGGWK 24.49753.4 1164.6 38 202 DITILEK 15.9 416.24 603.37 23 203 DITILEK 15.91416.24 685.38 23 204 DITILEK 15.91 416.24 716.46 23 205 DLLSAK 12.45323.69 429.23 19 206 DLLSAK 12.44 323.69 500.27 19 207 DLLSAK 12.45323.69 531.35 19 208 DLMITEAGR 15.07 503.26 533.27 27 209 DLMITEAGR15.07 503.26 646.35 27 210 DLMITEAGR 15.07 503.26 777.39 27 211DLMIVEAGR 16.68 502.27 531.29 27 212 DLMIVEAGR 16.68 502.27 644.37 27213 DLMIVEAGR 16.68 502.27 775.41 27 214 DLMIVEAK 16.23 459.75 473.24 25215 DLMIVEAK 16.23 459.75 559.34 25 216 DLMIVEAK 16.23 459.75 690.39 25217 DLSGNPGK 6.69 394.2 472.25 22 218 DLSGNPGK 6.69 394.2 559.28 22 219DLSGNPGK 6.7 394.2 672.37 22 220 DLSLR 12.37 302.18 375.24 18 221 DLSLR12.35 302.18 429.23 18 222 DLSLR 12.36 302.18 488.32 18 223 DLTLR 12.48309.18 389.25 19 224 DLTLR 12.47 309.18 443.25 19 225 DLTLR 12.47 309.18502.33 19 226 DMTLGDAIK 15.97 482.24 503.28 26 227 DMTLGDAIK 15.97482.24 616.37 26 228 DMTLGDAIK 15.97 482.24 717.41 26 229DMTLGDAMALSAVPVYQELAR 25.76 751.04 975.53 42 230 DMTLGDAMALSAVPVYQELAR25.76 1126.06 1145.63 55 231 DMTLGDAMALSAVPVYQELAR 25.75 1126.06 1232.6655 232 DMTLGDAMK 14.46 491.22 634.32 27 233 DMTLGDAMK 14.46 491.22735.37 27 234 DMTLGDAMK 14.46 491.22 866.41 27 235 DMTLGEAMALSAVPVYQDLAR25.92 751.04 961.51 42 236 DMTLGEAMALSAVPVYQDLAR 25.92 1126.06 1131.6255 237 DMTLGEAMALSAVPVYQDLAR 25.92 1126.06 1218.65 55 238DMTLGEAMALSAVPVYQELAR 26.48 755.71 779.4 42 239 DMTLGEAMALSAVPVYQELAR26.48 755.71 975.53 42 240 DMTLGEAMALSAVPVYQELAR 26.47 1133.07 1232.6655 241 DMTLGEAMK 15.09 498.23 535.25 27 242 DMTLGEAMK 15.09 498.23648.34 27 243 DMTLGEAMK 15.09 498.23 749.39 27 244 DMTLGQAMQASAVPVYQELAR23.29 760.38 779.4 42 245 DMTLGQAMQASAVPVYQELAR 23.29 760.38 975.53 42246 DMTLGQAMQASAVPVYQELAR 23.29 760.38 976.42 42 247 DQDLR 2.54 323.66403.23 19 248 DQDLR 2.55 323.66 472.2 19 249 DQDLR 2.55 323.66 531.29 19250 DQQIGWFVGWASKPGK 21.64 601.98 830.45 34 251 DQQIGWFVGWASKPGK 21.64902.46 929.52 45 252 DQQIGWFVGWASKPGK 21.64 902.46 1076.59 45 253DQQVQVYGNDLNR 13.59 774.87 851.4 39 254 DQQVQVYGNDLNR 13.58 774.87950.47 39 255 DQQVQVYGNDLNR 13.59 774.87 1078.53 39 256 DQTLESAFK 15.21519.76 581.29 28 257 DQTLESAFK 15.21 519.76 694.38 28 258 DQTLESAFK15.21 519.76 795.42 28 259 DSIVWYSQELTR 19.61 748.87 896.45 38 260DSIVWYSQELTR 19.61 748.87 1082.53 38 261 DSIVWYSQELTR 19.61 748.871181.59 38 262 DSIVWYSQQLTR 19.1 748.38 895.46 38 263 DSIVWYSQQLTR 19.11748.38 1081.54 38 264 DSIVWYSQQLTR 19.1 748.38 1180.61 38 265 DSNLR 1.77302.66 402.25 18 266 DSNLR 1.77 302.66 430.19 18 267 DSNLR 1.77 302.66489.28 18 268 DSYIAWGGEAWK 19.67 691.82 833.39 35 269 DSYIAWGGEAWK 19.67691.82 904.43 35 270 DSYIAWGGEAWK 19.66 691.82 1017.52 35 271 DTLNPEWPYK17.3 631.81 819.4 33 272 DTLNPEWPYK 17.3 631.81 933.45 33 273 DTLNPEWPYK17.3 631.81 1046.53 33 274 DVDEVFYK 15.62 507.74 685.36 27 275 DVDEVFYK15.62 507.74 800.38 27 276 DVDEVFYK 15.62 507.74 899.45 27 277 DWILR17.44 351.7 415.2 20 278 DWILR 17.44 351.7 528.28 20 279 DWILR 17.44351.7 587.37 20 280 EAFLR 12.51 318.18 435.27 19 281 EAFLR 12.51 318.18461.24 19 282 EAFLR 12.51 318.18 506.31 19 283 EAIVR 7.84 294.18 387.2718 284 EAIVR 7.84 294.18 413.24 18 285 EAIVR 7.84 294.18 458.31 18 286EAIVTEATPEYIVHSK 16.43 596.31 746.42 34 287 EAIVTEATPEYIVHSK 16.43596.31 972.51 34 288 EAIVTEATPEYIVHSK 16.42 596.31 1073.56 34 289EALVTEAAPEYLVHSK 17.3 586.31 875.46 33 290 EALVTEAAPEYLVHSK 17.3 586.31972.51 33 291 EALVTEAAPEYLVHSK 17.3 586.31 1114.59 33 292EALVTEAPEYLVHSK 17.58 562.63 637.32 32 293 EALVTEAPEYLVHSK 17.58 562.63972.51 32 294 EALVTEAPEYLVHSK 17.58 562.63 1043.55 32 295 EEIVR 8.41323.18 387.27 19 296 EEIVR 8.4 323.18 471.24 19 297 EEIVR 8.4 323.18516.31 19 298 EEVLAALPAQLK 19.48 641.37 740.47 33 299 EEVLAALPAQLK 19.47641.37 811.5 33 300 EEVLAALPAQLK 19.47 641.37 924.59 33 301EFSAEAVNGVFVLC[CAM]K 21.1 835.42 936.5 42 302 EFSAEAVNGVFVLC[CAM]K 21.1835.42 1106.6 42 303 EFSAEAVNGVFVLC[CAM]K 21.1 835.42 1235.65 42 304EFSSESVHGVFVLC[CAM]K 18.26 575.62 666.36 33 305 EFSSESVHGVFVLC[CAM]K18.26 575.62 822.45 33 306 EFSSESVHGVFVLC[CAM]K 18.26 575.62 959.51 33307 EGMSGSIR 9.88 418.7 432.26 23 308 EGMSGSIR 9.88 418.7 519.29 23 309EGMSGSIR 9.88 418.7 707.35 23 310 EGMTGSIR 10.63 425.71 432.26 24 311EGMTGSIR 10.63 425.71 533.3 24 312 EGMTGSIR 10.63 425.71 664.34 24 313EIAVWNR 14.78 444.24 475.24 25 314 EIAVWNR 14.77 444.24 574.31 25 315EIAVWNR 14.77 444.24 645.35 25 316 EIAYK 8.46 312.17 381.21 19 317 EIAYK8.46 312.17 477.23 19 318 EIAYK 8.46 312.17 494.3 19 319 EIFER 11.7347.18 451.23 20 320 EIFER 11.7 347.18 519.24 20 321 EIFER 11.7 347.18564.31 20 322 EIFYHYR 13.31 514.25 785.37 28 323 EIFYHYR 13.31 514.25853.39 28 324 EIFYHYR 13.32 514.25 898.46 28 325 EIGDDK 1.99 338.66434.19 20 326 EIGDDK 1.99 338.66 530.21 20 327 EIGDDK 1.99 338.66 547.2720 328 EIGDGK 1.76 309.66 376.18 19 329 EIGDGK 1.75 309.66 472.2 19 330EIGDGK 1.75 309.66 489.27 19 331 EIGEDK 2.32 345.67 448.2 20 332 EIGEDK2.33 345.67 544.22 20 333 EIGEDK 2.33 345.67 561.29 20 334 EIGEDNAR10.05 452.21 604.27 25 335 EIGEDNAR 10.05 452.21 661.29 25 336 EIGEDNAR10.06 452.21 774.37 25 337 EIGENK 1.86 345.18 447.22 20 338 EIGENK 1.86345.18 543.24 20 339 EIGENK 1.86 345.18 560.3 20 340 EIGSEIDK 11.04445.73 591.3 25 341 EIGSEIDK 11.04 445.73 648.32 25 342 EIGSEIDK 11.04445.73 761.4 25 343 EMIYLK 15.11 398.72 536.34 23 344 EMIYLK 15.11398.72 650.32 23 345 EMIYLK 15.11 398.72 667.38 23 346 EMLYVER 14.12470.23 566.29 26 347 EMLYVER 14.12 470.23 679.38 26 348 EMLYVER 14.12470.23 810.42 26 349 ENIEK 11.07 316.67 389.24 19 350 ENIEK 11.07 316.67486.22 19 351 ENIEK 11.07 316.67 503.28 19 352 ENQLIVK 12.15 422.25472.35 24 353 ENQLIVK 12.15 422.25 600.41 24 354 ENQLIVK 12.15 422.25714.45 24 355 EQAILLFR 19.88 495.29 548.36 27 356 EQAILLFR 19.88 495.29661.44 27 357 EQAILLFR 19.88 495.29 732.48 27 358 EQIQFLLR 19.45 523.8548.36 28 359 EQIQFLLR 19.45 523.8 676.41 28 360 EQIQFLLR 19.45 523.8789.5 28 361 EQLAFDPQVQQQVK 16.43 829.43 954.54 41 362 EQLAFDPQVQQQVK16.42 829.43 1069.56 41 363 EQLAFDPQVQQQVK 16.42 829.43 1216.63 41 364EQVDFVQR 13.09 510.76 549.31 27 365 EQVDFVQR 13.09 510.76 664.34 27 366EQVDFVQR 13.09 510.76 763.41 27 367 EVGEIR 9.35 351.69 474.27 20 368EVGEIR 9.35 351.69 528.27 20 369 EVGEIR 9.35 351.69 573.34 20 370 EVGEVR6.91 344.68 460.25 20 371 EVGEVR 6.91 344.68 514.25 20 372 EVGEVR 6.91344.68 559.32 20 373 EYLPASTFK 15.41 528.27 553.3 28 374 EYLPASTFK 15.41528.27 650.35 28 375 EYLPASTFK 15.41 528.27 763.43 28 376 EYLPVSTFK17.16 542.29 581.33 29 377 EYLPVSTFK 17.16 542.29 678.38 29 378EYLPVSTFK 17.16 542.29 791.47 29 379 EYNTSGTFVFYDGK 18.2 814.37 1033.541 380 EYNTSGTFVFYDGK 18.2 814.37 1120.53 41 381 EYNTSGTFVFYDGK 18.2814.37 1221.58 41 382 EYVPASTFK 13.89 521.27 553.3 28 383 EYVPASTFK13.89 521.27 650.35 28 384 EYVPASTFK 13.89 521.27 749.42 28 385 FAPESTFK13.67 463.73 482.26 25 386 FAPESTFK 13.67 463.73 611.3 25 387 FAPESTFK13.67 463.73 708.36 25 388 FAQYAK 9.39 364.19 509.27 21 389 FAQYAK 9.39364.19 580.31 21 390 FAQYAK 9.39 364.19 581.27 21 391 FDYGNR 10.1 386.17509.25 22 392 FDYGNR 10.1 386.17 597.23 22 393 FDYGNR 10.09 386.17624.27 22 394 FEDLYK 13.52 407.7 423.26 23 395 FEDLYK 13.52 407.7 538.2923 396 FEDLYK 13.52 407.7 667.33 23 397 FEDTFHISNQK 14.33 455.89 476.2527 398 FEDTFHISNQK 14.33 455.89 589.33 27 399 FEDTFHISNQK 14.33 455.89726.39 27 400 FEDTFHTSNQQHEK 10.66 583.26 870.41 33 401 FEDTFHTSNQQHEK10.66 583.26 971.45 33 402 FEDTFHTSNQQHEK 10.66 583.26 1108.51 33 403FEYGNQDVSGDSGK 11.95 751.82 764.34 38 404 FEYGNQDVSGDSGK 11.95 751.821063.47 38 405 FEYGNQDVSGDSGK 11.95 751.82 1226.53 38 406 FFSDFQAK 16495.24 608.3 27 407 FFSDFQAK 16 495.24 695.34 27 408 FFSDFQAK 16 495.24842.4 27 409 FFSDLQAEGAIVIADER 20.44 627.65 1143.6 35 410FFSDLQAEGAIVIADER 20.43 940.97 1143.6 46 411 FFSDLQAEGAIVIADER 20.44940.97 1179.57 46 412 FFSDLR 15.38 392.7 490.26 22 413 FFSDLR 15.38392.7 610.29 22 414 FFSDLR 15.38 392.7 637.33 22 415 FFSEFQAK 16.13502.25 622.32 27 416 FFSEFQAK 16.13 502.25 709.35 27 417 FFSEFQAK 16.13502.25 856.42 27 418 FGLEGQLR 15.8 460.25 473.28 25 419 FGLEGQLR 15.8460.25 602.33 25 420 FGLEGQLR 15.8 460.25 772.43 25 421 FLESLYLNNLPASK20.75 804.94 856.49 40 422 FLESLYLNNLPASK 20.75 804.94 1019.55 40 423FLESLYLNNLPASK 20.75 804.94 1219.67 40 424 FLLEGQLR 18.06 488.28 602.3326 425 FLLEGQLR 18.06 488.28 715.41 26 426 FLLEGQLR 18.06 488.28 828.4926 427 FQQYVDR 11.19 478.24 552.28 26 428 FQQYVDR 11.19 478.24 680.34 26429 FQQYVDR 11.19 478.24 808.39 26 430 FSDYVQR 11.83 457.72 565.31 25431 FSDYVQR 11.83 457.72 680.34 25 432 FSDYVQR 11.83 457.72 767.37 25433 FSTASTFK 12.71 444.73 553.3 25 434 FSTASTFK 12.7 444.73 654.35 25435 FSTASTFK 12.7 444.73 741.38 25 436 FSWDGK 14.32 370.17 505.24 21 437FSWDGK 14.32 370.17 592.27 21 438 FSWDGK 14.32 370.17 593.24 21 439FSYGNQNISGGIDK 14.61 750.36 803.43 38 440 FSYGNQNISGGIDK 14.61 750.361045.53 38 441 FSYGNQNISGGIDK 14.61 750.36 1102.55 38 442 FSYGNQNISGGTDK12.74 744.34 791.39 38 443 FSYGNQNISGGTDK 12.74 744.34 1033.49 38 444FSYGNQNISGGTDK 12.74 744.34 1090.51 38 445 FSYGSQNISGGIDK 14.74 736.85803.43 37 446 FSYGSQNISGGIDK 14.74 736.85 1075.54 37 447 FSYGSQNISGGIDK14.75 736.85 1238.6 37 448 FTEYVK 11.81 393.71 538.29 22 449 FTEYVK11.81 393.71 639.33 22 450 FTEYVK 11.81 393.71 640.3 22 451 FVPASTYK11.76 456.74 498.26 25 452 FVPASTYK 11.76 456.74 569.29 25 453 FVPASTYK11.77 456.74 666.35 25 454 FVYDLAQGQLPFKPEVQQQVK 20.48 821.44 955.52 45455 FVYDLAQGQLPFKPEVQQQVK 20.48 821.44 1108.59 45 456FVYDLAQGQLPFKPEVQQQVK 20.49 821.44 1109.07 45 457 FWLEDQLR 20.39 553.79660.33 29 458 FWLEDQLR 20.39 553.79 773.42 29 459 FWLEDQLR 20.38 553.79959.49 29 460 FWLEGPLK 20.63 495.28 543.31 27 461 FWLEGPLK 20.63 495.28656.4 27 462 FWLEGPLK 20.63 495.28 842.48 27 463 FWLEGQLR 19.49 524.78602.33 28 464 FWLEGQLR 19.49 524.78 715.41 28 465 FWLEGQLR 19.48 524.78901.49 28 466 FYPASSFK 14.74 473.74 636.34 26 467 FYPASSFK 14.74 473.74799.4 26 468 FYPASSFK 14.74 473.74 800.36 26 469 FYPASTFK 14.98 480.74553.3 26 470 FYPASTFK 14.99 480.74 650.35 26 471 FYPASTFK 14.98 480.74813.41 26 472 GAIQVSAVPVFQQIAR 21.6 842.48 958.55 42 473GAIQVSAVPVFQQIAR 21.6 842.48 1057.62 42 474 GAIQVSAVPVFQQIAR 21.59842.48 1128.65 42 475 GAIQVSAVPVFQQITR 21.52 857.49 988.56 43 476GAIQVSAVPVFQQITR 21.51 857.49 1087.63 43 477 GAIQVSAVPVFQQITR 21.52857.49 1158.66 43 478 GELPVSEDALEMTK 18.1 759.87 936.43 38 479GELPVSEDALEMTK 18.11 759.87 1023.47 38 480 GELPVSEDALEMTK 18.11 759.871122.53 38 481 GISSSVR 8.65 353.2 448.25 21 482 GISSSVR 8.65 353.2535.28 21 483 GISSSVR 8.67 353.2 648.37 21 484 GNQTLVFAR 14.83 503.28605.38 27 485 GNQTLVFAR 14.83 503.28 706.42 27 486 GNQTLVFAR 14.83503.28 834.48 27 487 GPLEISAFEEAR 18.95 659.84 809.38 34 488GPLEISAFEEAR 18.94 659.84 922.46 34 489 GPLEISAFEEAR 18.94 659.841051.51 34 490 GPLTITPIQEVK 18.14 648.38 814.47 34 491 GPLTITPIQEVK18.15 648.38 927.55 34 492 GPLTITPIQEVK 18.14 648.38 1028.6 34 493GSLLLWDQK 19.61 530.3 576.28 28 494 GSLLLWDQK 19.61 530.3 689.36 28 495GSLLLWDQK 19.61 530.3 802.45 28 496 GTFVLYDVQR 17.93 599.32 680.34 31497 GTFVLYDVQR 17.93 599.32 793.42 31 498 GTFVLYDVQR 17.93 599.32 892.4931 499 GTIVVADER 11.82 480.26 490.23 26 500 GTIVVADER 11.82 480.26589.29 26 501 GTIVVADER 11.82 480.26 688.36 26 502 GTIVVLDAR 15.77472.28 573.34 26 503 GTIVVLDAR 15.77 472.28 672.4 26 504 GTIVVLDAR 15.77472.28 785.49 26 505 GTIVVVDER 13.6 494.28 518.26 27 506 GTIVVVDER 13.6494.28 617.33 27 507 GTIVVVDER 13.6 494.28 716.39 27 508 GTLPFSAR 14.96424.73 577.31 24 509 GTLPFSAR 14.96 424.73 690.39 24 510 GTLPFSAR 14.97424.73 791.44 24 511 HIADSK 11.91 335.68 420.21 20 512 HIADSK 11.9335.68 524.25 20 513 HIADSK 11.91 335.68 533.29 20 514 HNGTDGAWIISSLR19.36 509.6 575.35 29 515 HNGTDGAWIISSLR 19.35 509.6 653.26 29 516HNGTDGAWIISSLR 19.36 509.6 688.44 29 517 HTLSVFDQER 14.25 411.21 432.2225 518 HTLSVFDQER 14.25 411.21 547.25 25 519 HTLSVFDQER 14.25 411.21694.32 25 520 HVTFASFR 14.36 322.17 338.18 20 521 HVTFASFR 14.36 322.17409.22 20 522 HVTFASFR 14.36 322.17 485.25 20 523 IAISLMGYDAGFLR 23.93763.91 898.44 39 524 IAISLMGYDAGFLR 23.93 763.91 1029.48 39 525IAISLMGYDAGFLR 23.94 763.91 1229.6 39 526 IALSLMGFDSGILK 24.91 732.91836.45 37 527 IALSLMGFDSGILK 24.91 732.91 967.49 37 528 IALSLMGFDSGILK24.91 732.91 1167.61 37 529 IANALIGLENHK 15.95 431.58 697.36 26 530IANALIGLENHK 15.95 646.87 697.36 33 531 IANALIGLENHK 15.95 646.87 810.4533 532 IDTFWLDNSLK 21.79 676.35 689.38 35 533 IDTFWLDNSLK 21.79 676.35875.46 35 534 IDTFWLDNSLK 21.79 676.35 1123.58 35 535 IDYYNLDR 14.85536.26 680.34 29 536 IDYYNLDR 14.85 536.26 843.4 29 537 IDYYNLDR 14.85536.26 958.43 29 538 IFNALIALDSGVIK 24.74 737.44 802.47 37 539IFNALIALDSGVIK 24.74 737.44 915.55 37 540 IFNALIALDSGVIK 24.74 737.441028.64 37 541 IFNSLLALDSGALDNER 22.76 924.48 976.43 46 542IFNSLLALDSGALDNER 22.77 924.48 1089.52 46 543 IFNSLLALDSGALDNER 22.76924.48 1160.55 46 544 IFNTLIGLENGIVK 23.29 765.95 829.48 39 545IFNTLIGLENGIVK 23.3 765.95 942.56 39 546 IFNTLIGLENGIVK 23.3 765.951055.65 39 547 IGLDLMQK 17.7 459.26 634.32 25 548 IGLDLMQK 17.7 459.26747.41 25 549 IGLDLMQK 17.7 459.26 804.43 25 550 IGLEK 8.54 280.18389.24 17 551 IGLEK 8.55 280.18 413.24 17 552 IGLEK 8.54 280.18 446.2617 553 IGLELMQQEVQR 18.73 722.38 787.41 37 554 IGLELMQQEVQR 18.73 722.38918.45 37 555 IGLELMQQEVQR 18.73 722.38 1031.53 37 556 IGLELMSK 17.52445.75 478.27 25 557 IGLELMSK 17.52 445.75 720.4 25 558 IGLELMSK 17.52445.75 777.42 25 559 IGLELMSNEVK 18.73 616.83 707.34 32 560 IGLELMSNEVK18.73 616.83 820.42 32 561 IGLELMSNEVK 18.73 616.83 949.47 32 562 IGLER10.96 294.18 304.16 18 563 IGLER 10.96 294.18 417.25 18 564 IGLER 10.96294.18 474.27 18 565 IGLNK 9.59 272.68 374.24 17 566 IGLNK 9.59 272.68398.24 17 567 IGLNK 9.59 272.68 431.26 17 568 IGLNLMQK 17.1 458.77633.34 25 569 IGLNLMQK 17.09 458.77 746.42 25 570 IGLNLMQK 17.11 458.77803.44 25 571 IGPSLMQSELQR 17.02 679.86 760.39 35 572 IGPSLMQSELQR 17.02679.86 891.44 35 573 IGPSLMQSELQR 17.02 679.86 1188.6 35 574IGYGNMQIGTEVDQFWLK 24.31 700.35 935.5 39 575 IGYGNMQIGTEVDQFWLK 24.321050.02 1164.54 51 576 IGYGNMQIGTEVDQFWLK 24.3 1050.02 1222.61 51 577IINHNLPVK 11.88 349.88 456.32 21 578 IINHNLPVK 11.88 349.88 570.36 21579 IINHNLPVK 11.88 349.88 592.32 21 580 IINHNLPVR 12.04 359.22 598.3722 581 IINHNLPVR 12.04 538.32 598.37 29 582 IINHNLPVR 12.04 538.32849.47 29 583 ILFQQGTQQAC[CAM]AER 14.51 550.61 606.27 32 584ILFQQGTQQAC[CAM]AER 14.51 825.41 1020.45 41 585 ILFQQGTQQAC[CAM]AER14.51 825.41 1148.51 41 586 ILNNWFK 18.98 467.76 594.3 26 587 ILNNWFK18.98 467.76 708.35 26 588 ILNNWFK 18.97 467.76 821.43 26 589ILNTLISLEEK 19.98 636.87 718.4 33 590 ILNTLISLEEK 19.98 636.87 1046.5733 591 ILNTLISLEEK 19.98 636.87 1159.66 33 592 INIVK 11.43 293.7 359.2718 593 INIVK 11.43 293.7 440.29 18 594 INIVK 11.43 293.7 473.31 18 595INLYGNALSR 16.05 560.81 617.34 30 596 INLYGNALSR 16.05 560.81 780.4 30597 INLYGNALSR 16.05 560.81 893.48 30 598 IPFSLNLEMK 21.68 596.33 834.4431 599 IPFSLNLEMK 21.67 596.33 981.51 31 600 IPFSLNLEMK 21.67 596.331078.56 31 601 IPHTLFALDADAVR 20 513.62 531.29 30 602 IPHTLFALDADAVR 20513.62 646.32 30 603 IPHTLFALDADAVR 20 769.92 1191.64 39 604IPHTLFALDAGAAR 18.58 726.9 744.4 37 605 IPHTLFALDAGAAR 18.58 726.9891.47 37 606 IPHTLFALDAGAAR 18.58 726.9 1004.55 37 607 IPHTLFALDAGAVR19.72 494.28 588.31 29 608 IPHTLFALDAGAVR 19.71 494.28 780.44 29 609IPHTLFALDAGAVR 19.72 740.92 1133.63 38 610 IPNAIIGLETGVIK 21.75 719.44816.48 37 611 IPNAIIGLETGVIK 21.75 719.44 929.57 37 612 IPNAIIGLETGVIK21.75 719.44 1227.73 37 613 IPNALIGLETGAIK 20.96 705.42 788.45 36 614IPNALIGLETGAIK 20.96 705.42 901.54 36 615 IPNALIGLETGAIK 20.96 705.421014.62 36 616 IPNSLIAFDTGAVR 20.24 737.41 765.39 37 617 IPNSLIAFDTGAVR20.24 737.41 836.43 37 618 IPNSLIAFDTGAVR 20.24 737.41 949.51 37 619IPSAIIGLETGVIK 21.66 705.93 816.48 36 620 IPSAIIGLETGVIK 21.67 705.93929.57 36 621 IPSAIIGLETGVIK 21.66 705.93 1200.72 36 622 ISAFNQVK 13.02453.76 488.28 25 623 ISAFNQVK 13.02 453.76 706.39 25 624 ISAFNQVK 13.02453.76 793.42 25 625 ISAHEQILFLR 18.28 442.92 548.36 26 626 ISAHEQILFLR18.28 442.92 789.5 26 627 ISAHEQILFLR 18.28 663.88 918.54 34 628ISAMEQTR 9.84 468.23 664.31 26 629 ISAMEQTR 9.84 468.23 735.35 26 630ISAMEQTR 9.84 468.23 822.38 26 631 ISAMEQVK 11.65 453.24 634.32 25 632ISAMEQVK 11.65 453.24 705.36 25 633 ISAMEQVK 11.65 453.24 792.39 25 634ISATEQVAFLR 17.7 412.23 435.27 25 635 ISATEQVAFLR 17.71 412.23 506.31 25636 ISATEQVAFLR 17.7 412.23 605.38 25 637 ISATQQIAFLR 18.58 624.36747.45 32 638 ISATQQIAFLR 18.58 624.36 1047.59 32 639 ISATQQIAFLR 18.58624.36 1134.63 32 640 ISAVNQVEFLESLFLNK 28.77 976.03 988.51 48 641ISAVNQVEFLESLFLNK 28.77 976.03 1110.62 48 642 ISAVNQVEFLESLFLNK 28.77976.03 1239.66 48 643 ISAVNQVK 10.32 429.76 488.28 24 644 ISAVNQVK 10.32429.76 658.39 24 645 ISAVNQVK 10.32 429.76 745.42 24 646 ISPEEQIQFLR18.87 680.37 933.52 35 647 ISPEEQIQFLR 18.87 680.37 1062.56 35 648ISPEEQIQFLR 18.87 680.37 1159.61 35 649 ISPEEQVR 10.49 479.25 531.29 26650 ISPEEQVR 10.49 479.25 660.33 26 651 ISPEEQVR 10.49 479.25 757.38 26652 ISPEGQVR 9.86 443.24 459.27 25 653 ISPEGQVR 9.86 443.24 588.31 25654 ISPEGQVR 9.86 443.24 685.36 25 655 ISPLEQLAFLR 24.02 643.88 876.4933 656 ISPLEQLAFLR 24.01 643.88 989.58 33 657 ISPLEQLAFLR 24.02 643.881086.63 33 658 ITAFQQVDFLR 21.11 669.36 777.43 34 659 ITAFQQVDFLR 21.12669.36 905.48 34 660 ITAFQQVDFLR 21.12 669.36 1123.59 34 661ITPIQEVNFADDFANNR 21.25 655.32 736.34 37 662 ITPIQEVNFADDFANNR 21.25655.32 851.36 37 663 ITPIQEVNFADDFANNR 21.25 655.32 922.4 37 664ITPIQEVNFADDLANNR 20.95 643.99 817.38 36 665 ITPIQEVNFADDLANNR 20.95965.49 1149.53 47 666 ITPIQEVNFADDLANNR 20.96 965.49 1248.6 47 667ITPQQEAQFAYK 14.52 712.36 856.42 36 668 ITPQQEAQFAYK 14.52 712.36 984.4836 669 ITPQQEAQFAYK 14.52 712.36 1209.59 36 670 ITPQQEAQFTYK 14.33485.25 558.29 28 671 ITPQQEAQFTYK 14.33 727.37 1014.49 37 672ITPQQEAQFTYK 14.33 727.37 1239.6 37 673 ITPVQEVNFADDLAHNR 18.98 646.99840.4 36 674 ITPVQEVNFADDLAHNR 18.98 646.99 862.92 36 675ITPVQEVNFADDLAHNR 18.98 646.99 911.43 36 676 IVAFALK 17.21 381.25 478.322 677 IVAFALK 17.22 381.25 549.34 22 678 IVAFALK 17.21 381.25 648.41 22679 IVAFALNMEMR 17.95 647.84 864.41 34 680 IVAFALNMEMR 17.95 647.841011.48 34 681 IVAFALNMEMR 17.97 647.84 1082.51 34 682 IVESTTLADGTWHGK13.69 542.96 697.4 31 683 IVESTTLADGTWHGK 13.69 542.96 812.43 31 684IVESTTLADGTWHGK 13.68 542.96 883.46 31 685 IYNSLIGLNEK 17.37 632.35673.39 33 686 IYNSLIGLNEK 17.37 632.35 786.47 33 687 IYNSLIGLNEK 17.37632.35 987.55 33 688 KPDIGVVWVGWIER 24.47 547.96 660.35 31 689KPDIGVVWVGWIER 24.47 547.96 883.45 31 690 KPDIGVVWVGWIER 24.46 821.431188.59 41 691 LAC[CAM]ATNNLAR 11.22 552.28 688.37 29 692LAC[CAM]ATNNLAR 11.22 552.28 759.41 29 693 LAC[CAM]ATNNLAR 11.22 552.28919.44 29 694 LAQGELPFPAPVQSTVR 19.84 905.5 954.54 45 695LAQGELPFPAPVQSTVR 19.84 905.5 1101.61 45 696 LAQGELPFPAPVQSTVR 19.84905.5 1198.66 45 697 LAQNELPYPIEIQK 19.09 828.45 929.47 41 698LAQNELPYPIEIQK 19.09 828.45 987.55 41 699 LAQNELPYPIEIQK 19.08 828.451100.64 41 700 LAQNELQYPIEIQK 17.98 843.96 890.5 42 701 LAQNELQYPIEIQK17.98 843.96 1018.56 42 702 LAQNELQYPIEIQK 17.98 843.96 1131.64 42 703LDFGNK 11.75 347.18 465.25 20 704 LDFGNK 11.74 347.18 547.25 20 705LDFGNK 11.75 347.18 580.27 20 706 LDGSLNR 9.48 387.71 402.25 22 707LDGSLNR 9.48 387.71 546.3 22 708 LDGSLNR 9.48 387.71 661.33 22 709LEILQQALAELGLYPK 29.81 900.02 1003.58 45 710 LEILQQALAELGLYPK 29.81900.02 1074.62 45 711 LEILQQALAELGLYPK 29.81 900.02 1202.68 45 712LENQEQVK 7.6 494.26 631.34 27 713 LENQEQVK 7.59 494.26 745.38 27 714LENQEQVK 7.59 494.26 874.43 27 715 LETQEEVEK 9.88 552.77 633.31 29 716LETQEEVEK 9.88 552.77 862.42 29 717 LETQEEVEK 9.88 552.77 991.46 29 718LETQEEVK 9.5 488.25 504.27 26 719 LETQEEVK 9.49 488.25 733.37 26 720LETQEEVK 9.49 488.25 862.42 26 721 LFAAEGVK 13.53 417.74 503.28 23 722LFAAEGVK 13.53 417.74 574.32 23 723 LFAAEGVK 13.53 417.74 721.39 23 724LFESAGVK 12.99 425.74 461.27 24 725 LFESAGVK 12.99 425.74 590.31 24 726LFESAGVK 12.99 425.74 737.38 24 727 LFGAAGVK 13.94 381.73 445.28 22 728LFGAAGVK 13.94 381.73 502.3 22 729 LFGAAGVK 13.94 381.73 649.37 22 730LGVDR 8.51 280.16 290.15 17 731 LGVDR 8.51 280.16 389.21 17 732 LGVDR8.5 280.16 446.24 17 733 LLNLLSQSK 17.97 508.31 562.32 27 734 LLNLLSQSK17.97 508.31 789.45 27 735 LLNLLSQSK 17.97 508.31 902.53 27 736 LLQDER9.34 387.21 547.25 22 737 LLQDER 9.31 387.21 599.3 22 738 LLQDER 9.34387.21 660.33 22 739 LLVQDGDC[CAM]GR 11.92 566.77 679.25 30 740LLVQDGDC[CAM]GR 11.92 566.77 807.3 30 741 LLVQDGDC[CAM]GR 11.92 566.77906.37 30 742 LNEVGYGNR 10.74 511.26 566.27 27 743 LNEVGYGNR 10.74511.26 665.34 27 744 LNEVGYGNR 10.73 511.26 794.38 27 745 LNYGNADPSTK10.76 590.29 732.35 31 746 LNYGNADPSTK 10.76 590.29 789.37 31 747LNYGNADPSTK 10.76 590.29 952.44 31 748 LNYGNK 7.21 354.69 481.24 21 749LNYGNK 7.24 354.69 562.26 21 750 LNYGNK 7.22 354.69 595.28 21 751 LPASK1.93 258.16 305.18 16 752 LPASK 1.93 258.16 369.21 16 753 LPASK 1.93258.16 402.23 16 754 LPHTLFALDADAVR 19.98 769.92 977.51 39 755LPHTLFALDADAVR 19.98 769.92 1090.59 39 756 LPHTLFALDADAVR 19.98 769.921191.64 39 757 LPHTLFALDAGAVR 19.7 740.92 919.5 38 758 LPHTLFALDAGAVR19.67 740.92 1032.58 38 759 LPHTLFALDAGAVR 19.7 740.92 1133.63 38 760LPLAIMGFDSGILQSPK 25.08 893.99 944.5 44 761 LPLAIMGFDSGILQSPK 25.08893.99 1091.57 44 762 LPLAIMGFDSGILQSPK 25.08 893.99 1148.59 44 763LPLAIMGYDADILLDATTPR 27.86 720.39 773.42 40 764 LPLAIMGYDADILLDATTPR27.87 720.39 886.5 40 765 LPLAIMGYDADILLDATTPR 27.87 720.39 1160.57 40766 LPSSLIALETGAVR 20.6 713.92 816.46 36 767 LPSSLIALETGAVR 20.6 713.92929.54 36 768 LPSSLIALETGAVR 20.6 713.92 1216.69 36 769 LPVSAQTLQYTANILK21.84 880.5 950.53 44 770 LPVSAQTLQYTANILK 21.84 880.5 1063.61 44 771LPVSAQTLQYTANILK 21.85 880.5 1164.66 44 772 LPVSER 9.57 350.7 490.26 20773 LPVSER 9.57 350.7 526.29 20 774 LPVSER 9.57 350.7 587.31 20 775LPVSPTAVDMTER 16.21 708.36 1019.48 36 776 LPVSPTAVDMTER 16.21 708.361106.51 36 777 LPVSPTAVDMTER 16.21 708.36 1205.58 36 778 LSASK 10.72253.15 305.18 16 779 LSASK 10.71 253.15 359.19 16 780 LSASK 10.71 253.15392.21 16 781 LSAVPIYQEVAR 17.96 673.38 765.39 35 782 LSAVPIYQEVAR 17.96673.38 975.53 35 783 LSAVPIYQEVAR 17.95 673.38 1074.59 35 784LSAVPVYQELAR 18.45 449.25 616.34 26 785 LSAVPVYQELAR 18.44 673.38 779.435 786 LSAVPVYQELAR 18.44 673.38 975.53 35 787 LSC[CAM]TLVIDEASGDLLHR20.38 633.66 797.43 36 788 LSC[CAM]TLVIDEASGDLLHR 20.38 633.66 868.46 36789 LSC[CAM]TLVIDEASGDLLHR 20.38 633.66 1112.53 36 790 LSLQHGWFIGWIEK23.95 571.98 632.34 33 791 LSLQHGWFIGWIEK 23.95 571.98 892.49 33 792LSLQHGWFIGWIEK 23.95 571.98 969.49 33 793 LSQNSLPFSQEAMNSVK 18.64 627.311140.54 35 794 LSQNSLPFSQEAMNSVK 18.63 940.46 1140.54 46 795LSQNSLPFSQEAMNSVK 18.64 940.46 1237.59 46 796 LSVNPK 9.8 329.2 457.28 19797 LSVNPK 9.79 329.2 511.29 19 798 LSVNPK 9.8 329.2 544.31 19 799LTVGAR 9.51 308.69 402.25 19 800 LTVGAR 9.51 308.69 442.27 19 801 LTVGAR9.51 308.69 503.29 19 802 LYGFALNIDMPGGEADIGK 23.35 661 843.42 37 803LYGFALNIDMPGGEADIGK 23.35 990.99 1089.49 49 804 LYGFALNIDMPGGEADIGK23.35 990.99 1202.57 49 805 LYHNELPFR 15.29 396.88 414.21 24 806LYHNELPFR 15.29 396.88 419.24 24 807 LYHNELPFR 15.29 396.88 657.3 24 808LYHNK 8.54 337.68 414.21 20 809 LYHNK 8.53 337.68 528.26 20 810 LYHNK8.53 337.68 561.28 20 811 LYQNDLPFR 17.2 583.3 761.39 31 812 LYQNDLPFR17.2 583.3 889.45 31 813 LYQNDLPFR 17.2 583.3 1052.52 31 814 MDDLFK 15.5384.68 522.29 22 815 MDDLFK 15.5 384.68 622.25 22 816 MDDLFK 15.5 384.68637.32 22 817 MEDLHK 6.66 386.69 512.28 22 818 MEDLHK 6.65 386.69 626.2622 819 MEDLHK 6.66 386.69 641.33 22 820 MLIALIGLENHK 21.33 451.26 527.2627 821 MLIALIGLENHK 21.33 451.26 697.36 27 822 MLIALIGLENHK 21.33 451.26810.45 27 823 MLLIK 15.81 309.21 373.28 19 824 MLLIK 15.81 309.21 471.319 825 MLLIK 15.81 309.21 486.36 19 826 MLNALIGLEHHK 16.89 459.26 550.2727 827 MLNALIGLEHHK 16.89 459.26 720.38 27 828 MLNALIGLEHHK 16.89 459.26833.46 27 829 MLNALIGLENHK 18.39 451.58 697.36 27 830 MLNALIGLENHK 18.38676.87 697.36 35 831 MLNALIGLENHK 18.39 676.87 810.45 35 832MLNALIGLENQK 19.71 672.37 688.36 35 833 MLNALIGLENQK 19.71 672.37 801.4535 834 MLNALIGLENQK 19.71 672.37 914.53 35 835 MLNALIGLEYHK 19.6 701.38746.38 36 836 MLNALIGLEYHK 19.6 701.38 859.47 36 837 MLNALIGLEYHK 19.6701.38 1157.63 36 838 MLNALIGLQHGK 17.5 432.25 582.34 26 839MLNALIGLQHGK 17.5 432.25 639.36 26 840 MLNALIGLQHGK 17.5 432.25 752.4426 841 MLNALISLEHHK 17.2 352.2 359.17 21 842 MLNALISLEHHK 17.21 469.26750.39 27 843 MLNALISLEHHK 17.2 469.26 863.47 27 844 MQAYVDAFDYGNR 17.56775.34 957.41 39 845 MQAYVDAFDYGNR 17.56 775.34 1056.47 39 846MQAYVDAFDYGNR 17.56 775.34 1219.54 39 847 MQEGLNK 8.68 410.21 560.3 23848 MQEGLNK 8.66 410.21 673.3 23 849 MQEGLNK 8.68 410.21 688.36 23 850MSPASTYK 9.49 442.71 569.29 24 851 MSPASTYK 9.49 442.71 666.35 24 852MSPASTYK 9.49 442.71 753.38 24 853 NEHDPVLPYR 13.09 413.88 435.24 25 854NEHDPVLPYR 13.09 620.31 744.44 32 855 NEHDPVLPYR 13.09 620.31 859.47 32856 NEHQIFK 9.91 458.24 509.21 25 857 NEHQIFK 9.91 458.24 622.29 25 858NEHQIFK 9.91 458.24 672.38 25 859 NEHQVFK 7.74 451.23 658.37 25 860NEHQVFK 7.74 451.23 755.35 25 861 NEHQVFK 7.74 451.23 787.41 25 862NEITYK 9.35 384.2 524.31 22 863 NEITYK 9.35 384.2 621.29 22 864 NEITYK9.35 384.2 653.35 22 865 NELLMK 13.08 374.21 504.32 21 866 NELLMK 13.09374.21 601.3 21 867 NELLMK 13.09 374.21 633.36 21 868 NELPFR 14.39388.21 419.24 22 869 NELPFR 14.39 388.21 532.32 22 870 NELPFR 14.4388.21 661.37 22 871 NISSYGNNLVR 14.36 618.82 835.44 32 872 NISSYGNNLVR14.36 618.82 922.47 32 873 NISSYGNNLVR 14.36 618.82 1009.51 32 874NISTYGNNLTR 13.1 626.82 674.36 33 875 NISTYGNNLTR 13.09 626.82 837.42 33876 NISTYGNNLTR 13.1 626.82 1025.5 33 877 NLFNEVHTTGVLVIR 20.69 571.32757.49 33 878 NLFNEVHTTGVLVIR 20.7 571.32 858.54 33 879 NLFNEVHTTGVLVIR20.7 571.32 995.6 33 880 NLSTYGNALAR 14.34 590.31 764.4 31 881NLSTYGNALAR 14.35 590.31 865.45 31 882 NLSTYGNALAR 14.35 590.31 952.4831 883 NMENLELFGK 19.08 597.79 820.46 31 884 NMENLELFGK 19.08 597.79949.5 31 885 NMENLELFGK 19.08 597.79 1080.54 31 886 NMLLLEENNGYK 16.71719.36 853.37 37 887 NMLLLEENNGYK 16.69 719.36 966.45 37 888NMLLLEENNGYK 16.68 719.36 1079.54 37 889 NMLLLEESNGYK 18.12 705.85939.44 36 890 NMLLLEESNGYK 18.13 705.85 1052.53 36 891 NMLLLEESNGYK18.11 705.85 1165.61 36 892 NMLLLEK 16.99 430.75 502.32 24 893 NMLLLEK16.98 430.75 615.41 24 894 NMLLLEK 16.98 430.75 746.45 24 895 NMTLGDAMK14.42 490.73 521.24 27 896 NMTLGDAMK 14.42 490.73 634.32 27 897NMTLGDAMK 14.42 490.73 735.37 27 898 NNGLTEAWLESSLK 20.61 781.4 862.4739 899 NNGLTEAWLESSLK 20.6 781.4 933.5 39 900 NNGLTEAWLESSLK 20.62 781.41163.59 39 901 NQLPFK 13.49 373.71 391.23 21 902 NQLPFK 13.49 373.71504.32 21 903 NQLPFK 13.49 373.71 632.38 21 904 NQLPFQVEHQR 14.33 698.36796.41 36 905 NQLPFQVEHQR 14.33 698.36 1040.53 36 906 NQLPFQVEHQR 14.33698.36 1153.61 36 907 NSAIENTIDNMYLQDLENSTK 22.77 805.04 934.45 44 908NSAIENTIDNMYLQDLENSTK 22.77 805.04 1047.53 44 909 NSAIENTIDNMYLQDLENSTK22.77 805.04 1210.6 44 910 NSAIENTIENMYLQDLDNSTK 23.13 805.04 920.43 44911 NSAIENTIENMYLQDLDNSTK 23.13 805.04 1033.52 44 912NSAIENTIENMYLQDLDNSTK 23.14 805.04 1196.58 44 913 NSAIENTIENMYLQDLENSTK23.7 809.72 934.45 44 914 NSAIENTIENMYLQDLENSTK 23.7 809.72 1047.53 44915 NSAIENTIENMYLQDLENSTK 23.7 809.72 1217.55 44 916 NSAVWVYELFAK 24.66713.87 869.48 36 917 NSAVWVYELFAK 24.66 713.87 1055.56 36 918NSAVWVYELFAK 24.65 713.87 1154.62 36 919 NSQVPAYK 9.78 453.74 478.27 25920 NSQVPAYK 9.78 453.74 577.33 25 921 NSQVPAYK 9.78 453.74 705.39 25922 NSTVWIYELFAK 25.64 735.88 883.49 37 923 NSTVWIYELFAK 25.64 735.881069.57 37 924 NSTVWIYELFAK 25.64 735.88 1168.64 37 925 NSTVWVYELFAK24.42 728.88 770.41 37 926 NSTVWVYELFAK 24.43 728.88 869.48 37 927NSTVWVYELFAK 24.42 728.88 1055.56 37 928 NSTVWVYQLFAK 23.9 728.39 769.4237 929 NSTVWVYQLFAK 23.91 728.39 1054.57 37 930 NSTVWVYQLFAK 23.91728.39 1153.64 37 931 NTSGALVIQTDK 13.34 623.84 816.48 32 932NTSGALVIQTDK 13.34 623.84 944.54 32 933 NTSGALVIQTDK 13.34 623.841031.57 32 934 NTSGVLVIQTDK 14.9 637.85 816.48 33 935 NTSGVLVIQTDK 14.9637.85 972.57 33 936 NTSGVLVIQTDK 14.91 637.85 1059.6 33 937NVDEMFYYYDGSK 18.86 815.84 895.38 41 938 NVDEMFYYYDGSK 18.86 815.841042.45 41 939 NVDEMFYYYDGSK 18.85 815.84 1173.49 41 940 NWILR 16.3351.21 414.21 20 941 NWILR 16.29 351.21 527.3 20 942 NWILR 16.3 351.21587.37 20 943 NWNAAMDLR 16.54 545.76 605.31 29 944 NWNAAMDLR 16.55545.76 676.34 29 945 NWNAAMDLR 16.54 545.76 790.39 29 946NYVDAFHYGNQDISGDK 15.76 648.29 933.43 36 947 NYVDAFHYGNQDISGDK 15.77648.29 1096.49 36 948 NYVDAFHYGNQDISGDK 15.76 971.93 1233.55 48 949QADHAILVFDQAR 16.58 495.26 523.23 29 950 QADHAILVFDQAR 16.61 495.26636.31 29 951 QADHAILVFDQAR 16.58 495.26 735.38 29 952 QAEHALLVFGQER16.86 499.93 636.31 29 953 QAEHALLVFGQER 16.85 499.93 735.38 29 954QAEHALLVFGQER 16.87 499.93 763.41 29 955 QAITK 11 280.67 361.24 17 956QAITK 11 280.67 414.23 17 957 QAITK 11.01 280.67 432.28 17 958QAMLTEANSDYIIR 18.26 812.9 951.49 41 959 QAMLTEANSDYIIR 18.25 812.91080.53 41 960 QAMLTEANSDYIIR 18.26 812.9 1181.58 41 961 QEVQFVSALAR17.69 624.34 763.45 32 962 QEVQFVSALAR 17.68 624.34 891.5 32 963QEVQFVSALAR 17.68 624.34 990.57 32 964 QFASIK 11.66 347.2 434.2 20 965QFASIK 11.66 347.2 547.29 20 966 QFASIK 11.68 347.2 565.33 20 967QGMPGSIR 11.4 423.22 529.31 24 968 QGMPGSIR 11.43 423.22 660.35 24 969QGMPGSIR 11.4 423.22 717.37 24 970 QGMSGSIR 9.44 418.21 519.29 23 971QGMSGSIR 9.45 418.21 650.33 23 972 QGMSGSIR 9.44 418.21 707.35 23 973QGQTQQSYGNDLAR 11.16 783.37 895.43 39 974 QGQTQQSYGNDLAR 11.17 783.371023.49 39 975 QGQTQQSYGNDLAR 11.16 783.37 1151.54 39 976 QIDYGNADPSTIK13.41 711.35 845.44 36 977 QIDYGNADPSTIK 13.42 711.35 902.46 36 978QIDYGNADPSTIK 13.42 711.35 1065.52 36 979 QIDYGNVDPSTIK 15.08 725.36873.47 37 980 QIDYGNVDPSTIK 15.07 725.36 930.49 37 981 QIDYGNVDPSTIK15.07 725.36 1093.55 37 982 QIGQAR 2.3 336.69 431.24 20 983 QIGQAR 2.33336.69 498.27 20 984 QIGQAR 2.32 336.69 544.32 20 985 QIMLIEQTPAFTLR24.42 830.96 933.52 42 986 QIMLIEQTPAFTLR 24.42 830.96 1062.56 42 987QIMLIEQTPAFTLR 24.42 830.96 1175.64 42 988 QLGSAIDQFWLR 22.67 717.38864.44 37 989 QLGSAIDQFWLR 22.68 717.38 977.52 37 990 QLGSAIDQFWLR 22.67717.38 1192.61 37 991 QLPVK 9.57 292.69 343.23 18 992 QLPVK 9.58 292.69438.27 18 993 QLPVK 9.57 292.69 456.32 18 994 QLSLDVLDK 18.63 515.79589.32 28 995 QLSLDVLDK 18.62 515.79 789.44 28 996 QLSLDVLDK 18.63515.79 902.52 28 997 QLVYAR 11.04 375.22 508.29 22 998 QLVYAR 11.04375.22 575.32 22 999 QLVYAR 11.04 375.22 621.37 22 1000 QMMLTEASTDYIIR19.82 836.41 867.46 42 1001 QMMLTEASTDYIIR 19.82 836.41 1067.54 42 1002QMMLTEASTDYIIR 19.82 836.41 1168.58 42 1003 QMSIVEATPDYVLHGK 18.77894.45 1029.54 44 1004 QMSIVEATPDYVLHGK 18.77 894.45 1100.57 44 1005QMSIVEATPDYVLHGK 18.77 894.45 1229.62 44 1006 QTLVFAR 14.65 417.75492.29 23 1007 QTLVFAR 14.65 417.75 605.38 23 1008 QTLVFAR 14.65 417.75706.42 23 1009 QVVFAR 12.06 360.21 492.29 21 1010 QVVFAR 12.04 360.21545.31 21 1011 QVVFAR 12.06 360.21 591.36 21 1012 SADEVLPYGGKPQR 12.96506.26 642.37 29 1013 SADEVLPYGGKPQR 12.96 506.26 805.43 29 1014SADEVLPYGGKPQR 12.96 506.26 902.48 29 1015 SC[CAM]ATNDLAR 9.37 504.23689.36 27 1016 SC[CAM]ATNDLAR 9.37 504.23 760.39 27 1017 SC[CAM]ATNDLAR9.37 504.23 920.43 27 1018 SC[CAM]ATNNLAR 8.66 503.74 688.37 27 1019SC[CAM]ATNNLAR 8.66 503.74 759.41 27 1020 SC[CAM]ATNNLAR 8.67 503.74919.44 27 1021 SDIPGGSK 7.63 380.7 558.32 22 1022 SDIPGGSK 7.63 380.7614.28 22 1023 SDIPGGSK 7.63 380.7 673.35 22 1024 SDWGK 5.75 296.64390.21 18 1025 SDWGK 5.75 296.64 446.17 18 1026 SDWGK 5.75 296.64 505.2418 1027 SEDNFHISSQQHEK 10.36 422.19 541.27 24 1028 SEDNFHISSQQHEK 10.36422.19 730.28 24 1029 SEDNFHISSQQHEK 10.36 422.19 756.36 24 1030SEMPASIR 12.02 445.72 674.37 25 1031 SEMPASIR 12.02 445.72 716.33 251032 SEMPASIR 12.02 445.72 803.41 25 1033 SEMPASIR 8.2 439.71 662.33 241034 SEMPASTR 8.19 439.71 704.29 24 1035 SEMPASTR 8.19 439.71 791.37 241036 SFAAHNQDQDLR 10.35 467.89 531.29 27 1037 SFAAHNQDQDLR 10.35 467.89871.37 27 1038 SFAAHNQDQDLR 10.35 467.89 888.42 27 1039 SFAGHNK 9.4380.69 455.24 22 1040 SFAGHNK 9.4 380.69 526.27 22 1041 SFAGHNK 9.38380.69 673.34 22 1042 SFAGHNQDQDLR 10.18 694.32 888.42 36 1043SFAGHNQDQDLR 10.18 694.32 1025.48 36 1044 SFAGHNQDQDLR 10.18 694.321082.5 36 1045 SFAGHNQDQNLR 9.8 462.89 530.3 27 1046 SFAGHNQDQNLR 9.8462.89 773.39 27 1047 SFAGHNQDQNLR 9.8 462.89 887.43 27 1048 SFLESWAK18.27 484.25 491.26 26 1049 SFLESWAK 18.27 484.25 620.3 26 1050 SFLESWAK18.27 484.25 733.39 26 1051 SFTAWEK 14.44 434.71 462.23 24 1052 SFTAWEK14.44 434.71 533.27 24 1053 SFTAWEK 14.44 434.71 634.32 24 1054 SFTTWEK14.1 449.72 462.23 25 1055 SFTTWEK 14.1 449.72 563.28 25 1056 SFTTWEK14.1 449.72 664.33 25 1057 SGSGWLR 13.25 381.7 531.3 22 1058 SGSGWLR13.25 381.7 618.34 22 1059 SGSGWLR 13.25 381.7 675.36 22 1060SGWGMAVDPQVGWYVGFVEK 24.65 738.02 841.45 41 1061 SGWGMAVDPQVGWYVGFVEK24.65 738.02 1029.45 41 1062 SGWGMAVDPQVGWYVGFVEK 24.68 1106.53 1128.5154 1063 SGWGMDVSPQVGWLTGWVEK 26.32 1110.03 1144.51 54 1064SGWGMDVSPQVGWLTGWVEK 26.32 1110.03 1174.63 54 1065 SGWGMDVSPQVGWLTGWVEK26.32 1110.03 1201.53 54 1066 SGWGMDVTPQVGWLTGWVEK 26.61 745.03 832.4641 1067 SGWGMDVTPQVGWLTGWVEK 26.61 745.03 1018.54 41 1068SGWGMDVTPQVGWLTGWVEK 26.61 745.03 1075.56 41 1069 SIHPASTFK 10.74 494.27650.35 27 1070 SIHPASTFK 10.73 494.27 787.41 27 1071 SIHPASTFK 10.73494.27 900.49 27 1072 SISTK 10.41 268.16 335.19 17 1073 SISTK 10.42268.16 389.2 17 1074 SISTK 10.42 268.16 448.28 17 1075 SLGLSNNLSR 14.23530.79 690.35 28 1076 SLGLSNNLSR 14.23 530.79 803.44 28 1077 SLGLSNNLSR14.23 530.79 860.46 28 1078 SLSMSGK 9.31 355.18 509.24 21 1079 SLSMSGK9.32 355.18 563.25 21 1080 SLSMSGK 9.32 355.18 622.32 21 1081 SMLFIEEK17.82 498.76 518.28 27 1082 SMLFIEEK 17.82 498.76 665.35 27 1083SMLFIEEK 17.82 498.76 778.43 27 1084 SNGLTHSWLGSSLK 16.78 743.89 877.4838 1085 SNGLTHSWLGSSLK 16.78 743.89 1014.54 38 1086 SNGLTHSWLGSSLK 16.78743.89 1115.58 38 1087 SPTWELKPEYNPSPR 16.02 600.97 733.36 34 1088SPTWELKPEYNPSPR 16.02 600.97 808.91 34 1089 SPTWELKPEYNPSPR 16.02 600.97959.46 34 1090 SQDIVR 8.4 359.2 502.3 21 1091 SQDIVR 8.38 359.2 543.2821 1092 SQDIVR 8.4 359.2 630.36 21 1093 SQQKPTDPTIWLK 16.6 514.62 660.4130 1094 SQQKPTDPTIWLK 16.6 514.62 757.46 30 1095 SQQKPTDPTIWLK 16.6514.62 785.38 30 1096 SQVGWLTGWVEQPDGK 22.27 893.94 1015.5 44 1097SQVGWLTGWVEQPDGK 22.28 893.94 1116.53 44 1098 SQVGWLTGWVEQPDGK 22.28893.94 1229.62 44 1099 SSSNSC[CAM]TTNNAAR 16.84 685.29 907.41 35 1100SSSNSC[CAM]TTNNAAR 16.85 685.29 994.44 35 1101 SSSNSC[CAM]TTNNAAR 16.84685.29 1108.48 35 1102 SVYGELR 12.65 412.22 417.25 23 1103 SVYGELR 12.65412.22 474.27 23 1104 SVYGELR 12.65 412.22 637.33 23 1105 SWILR 16.33337.7 401.29 20 1106 SWILR 16.32 337.7 500.29 20 1107 SWILR 16.33 337.7587.37 20 1108 SYLEK 9.09 320.17 389.24 19 1109 SYLEK 9.09 320.17 493.2319 1110 SYLEK 9.1 320.17 552.3 19 1111 TAYIPASTFK 15.43 549.8 650.35 291112 TAYIPASTFK 15.43 549.8 763.43 29 1113 TAYIPASTFK 15.43 549.8 926.529 1114 TDDLFK 13.48 369.69 407.27 21 1115 TDDLFK 13.48 369.69 522.29 211116 TDDLFK 13.48 369.69 637.32 21 1117 TDINEIFK 17.44 490.26 650.35 271118 TDINEIFK 17.44 490.26 763.43 27 1119 TDINEIFK 17.44 490.26 878.4627 1120 TFIHNDPR 18.92 500.25 751.38 27 1121 TFIHNDPR 18.92 500.25825.39 27 1122 TFIHNDPR 18.92 500.25 898.45 27 1123 TGAGFTANR 9.64447.72 461.25 25 1124 TGAGFTANR 9.64 447.72 665.34 25 1125 TGAGFTANR9.64 447.72 793.4 25 1126 TGFNDGQK 7.5 433.7 561.26 24 1127 TGFNDGQK 7.5433.7 708.33 24 1128 TGFNDGQK 7.5 433.7 765.35 24 1129 TGLADSK 9.7346.18 533.29 20 1130 TGLADSK 9.67 346.18 545.26 20 1131 TGLADSK 9.7346.18 590.31 20 1132 TGLDLMQK 15.32 453.24 634.32 25 1133 TGLDLMQK15.32 453.24 747.41 25 1134 TGLDLMQK 15.32 453.24 804.43 25 1135TGLELMQK 15.03 460.25 648.34 25 1136 TGLELMQK 15.03 460.25 761.42 251137 TGLELMQK 15.03 460.25 818.44 25 1138 TGMGYPK 10.28 377.18 464.25 221139 TGMGYPK 10.28 377.18 595.29 22 1140 TGMGYPK 10.28 377.18 652.31 221141 TGNGR 0.8 252.63 330.14 16 1142 TGNGR 0.8 252.63 346.18 16 1143TGNGR 0.81 252.63 403.2 16 1144 TGTGSFIDAR 13.35 512.76 708.37 28 1145TGTGSFIDAR 13.35 512.76 765.39 28 1146 TGTGSFIDAR 13.35 512.76 866.44 281147 TGTGSLSDAK 8.32 468.74 620.32 26 1148 TGTGSLSDAK 8.32 468.74 677.3526 1149 TGTGSLSDAK 8.32 468.74 778.39 26 1150 TGVATEYQPEIGWWAGWVER 25.49779.04 903.45 43 1151 TGVATEYQPEIGWWAGWVER 25.5 779.04 1146.55 43 1152TGVATEYQPEIGWWAGWVER 25.52 1168.06 1189.57 56 1153 TGVSYPLLADGTR 17.4675.36 842.47 35 1154 TGVSYPLLADGTR 17.41 675.36 1005.54 35 1155TGVSYPLLADGTR 17.4 675.36 1092.57 35 1156 TGWAMDIK 16.71 461.23 577.3 251157 TGWAMDIK 16.71 461.23 763.38 25 1158 TGWAMDIK 16.72 461.23 820.4 251159 TGWATR 9.71 346.18 517.24 20 1160 TGWATR 9.69 346.18 533.28 20 1161TGWATR 9.69 346.18 590.3 20 1162 TGWC[CAM]FDC[CAM]TPELGWWVGWVK 28.39795.36 960.51 44 1163 TGWC[CAM]FDC[CAM]TPELGWWVGWVK 28.39 795.36 1017.5344 1164 TGWC[CAM]FDC[CAM]TPELGWWVGWVK 28.38 795.36 1028.36 44 1165TGWEGR 9.1 353.17 531.22 21 1166 TGWEGR 9.09 353.17 547.26 21 1167TGWEGR 9.09 353.17 604.28 21 1168 TGWFVDK 16.08 426.72 694.36 24 1169TGWFVDK 16.1 426.72 706.32 24 1170 TGWFVDK 16.08 426.72 751.38 24 1171TGYDTK 2.09 342.66 526.25 20 1172 TGYDTK 2.09 342.66 538.21 20 1173TGYDTK 2.08 342.66 583.27 20 1174 TGYGVR 8.09 326.67 478.23 19 1175TGYGVR 8.1 326.67 494.27 19 1176 TGYGVR 8.1 326.67 551.29 19 1177 TGYSAR2.24 327.66 480.21 19 1178 TGYSAR 2.24 327.66 496.25 19 1179 TGYSAR 2.24327.66 553.27 19 1180 TGYSTR 2.08 342.67 510.22 20 1181 TGYSTR 2.08342.67 526.26 20 1182 TGYSTR 2.08 342.67 583.28 20 1183 THESSNWGK 5.36523.24 678.32 28 1184 THESSNWGK 5.37 523.24 807.36 28 1185 THESSNWGK5.37 523.24 944.42 28 1186 TIC[CAM]TAIADAGTGK 14.35 639.82 732.39 331187 TIC[CAM]TAIADAGTGK 14.35 639.82 904.47 33 1188 TIC[CAM]TAIADAGTGK14.35 639.82 1064.5 33 1189 TIGGAPDAYWVDDSLQISAR 21.22 712.35 1004.5 401190 TIGGAPDAYWVDDSLQISAR 21.22 712.35 1103.57 40 1191TIGGAPDAYWVDDSLQISAR 21.21 1068.02 1103.57 52 1192 TLPFSASSYETLR 18.73736.37 855.42 37 1193 TLPFSASSYETLR 18.73 736.37 1013.49 37 1194TLPFSASSYETLR 18.73 736.37 1160.56 37 1195 TLPFSPK 15 395.23 478.27 221196 TLPFSPK 15 395.23 575.32 22 1197 TLPFSPK 15 395.23 688.4 22 1198TLPFSQEVQDEVQSILFIEEK 28.55 827.09 891.52 45 1199 TLPFSQEVQDEVQSILFIEEK28.56 827.09 978.55 45 1200 TLPFSQEVQDEVQSILFIEEK 28.56 827.09 1106.6145 1201 TLPFSQEVQDEVQSMLFIEEK 27.7 833.08 996.51 46 1202TLPFSQEVQDEVQSMLFIEEK 27.69 833.08 1124.57 46 1203 TLPFSQEVQDEVQSMLFIEEK27.7 833.08 1223.63 46 1204 TLQNGWFEGFIISK 24.12 820.43 940.51 41 1205TLQNGWFEGFIISK 24.11 820.43 1126.59 41 1206 TLQNGWFEGFIISK 24.11 820.431183.61 41 1207 TMQEYLNK 12.6 513.75 666.35 28 1208 TMQEYLNK 12.6 513.75794.4 28 1209 TMQEYLNK 12.6 513.75 925.44 28 1210 TQTYQAYDAAR 11.2 644.3666.32 33 1211 TQTYQAYDAAR 11.2 644.3 957.44 33 1212 TQTYQAYDAAR 11.2644.3 1058.49 33 1213 TTDPTIWEK 14.39 545.77 676.37 29 1214 TTDPTIWEK14.39 545.77 773.42 29 1215 TTDPTIWEK 14.39 545.77 888.45 29 1216TTTTEVFK 12.06 463.75 522.29 25 1217 TTTTEVFK 12.06 463.75 623.34 251218 TTTTEVFK 12.06 463.75 724.39 25 1219 TWASNDFSR 13.73 542.25 638.2929 1220 TWASNDFSR 13.73 542.25 725.32 29 1221 TWASNDFSR 13.73 542.25796.36 29 1222 TWDMVQR 14.28 468.22 648.31 26 1223 TWDMVQR 14.28 468.22761.33 26 1224 TWDMVQR 14.28 468.22 834.39 26 1225 TYWDPAR 12.15 460.75557.3 25 1226 TYWDPAR 12.14 460.75 656.37 25 1227 TYWDPAR 12.15 460.75819.44 25 1228 VAFSLNIEMK 20.65 576.31 747.41 30 1229 VAFSLNIEMK 20.65576.31 834.44 30 1230 VAFSLNIEMK 20.65 576.31 981.51 30 1231VANSLIGLSTGAVR 17.97 679.39 760.43 35 1232 VANSLIGLSTGAVR 17.97 679.39873.52 35 1233 VANSLIGLSTGAVR 17.97 679.39 986.6 35 1234 VELGK 7.74273.17 342.2 17 1235 VELGK 7.75 273.17 399.22 17 1236 VELGK 7.74 273.17446.26 17 1237 VFLDSWAK 18.2 483.26 606.29 26 1238 VFLDSWAK 18.2 483.26719.37 26 1239 VFLDSWAK 18.2 483.26 866.44 26 1240 VFLESWAK 18.11 490.27620.3 27 1241 VFLESWAK 18.11 490.27 733.39 27 1242 VFLESWAK 18.11 490.27880.46 27 1243 VFLSSWAQDMNLSSAIK 23.66 948.98 978.49 47 1244VFLSSWAQDMNLSSAIK 23.66 948.98 1106.55 47 1245 VFLSSWAQDMNLSSAIK 23.66948.98 1177.59 47 1246 VGFER 10.32 304.16 433.21 18 1247 VGFER 10.32304.16 451.23 18 1248 VGFER 10.32 304.16 508.25 18 1249 VILVFDQVR 19.69544.83 664.34 29 1250 VILVFDQVR 19.69 544.83 763.41 29 1251 VILVFDQVR19.69 544.83 876.49 29 1252 VMAAMVR 12.3 389.21 476.26 22 1253 VMAAMVR12.3 389.21 547.3 22 1254 VMAAMVR 12.3 389.21 678.34 22 1255VPLAVMGYDAGILVDAHNPR 21.61 703.37 709.34 39 1256 VPLAVMGYDAGILVDAHNPR21.61 703.37 808.41 39 1257 VPLAVMGYDAGILVDAHNPR 21.61 703.37 921.49 391258 VQDEVQSMLFIEEK 20.48 847.92 996.51 42 1259 VQDEVQSMLFIEEK 20.48847.92 1124.57 42 1260 VQDEVQSMLFIEEK 20.47 847.92 1223.63 42 1261VQDGVQSMLFIEEK 20.26 811.91 996.51 41 1262 VQDGVQSMLFIEEK 20.27 811.911124.57 41 1263 VQDGVQSMLFIEEK 20.25 811.91 1223.63 41 1264VSC[CAM]LPC[CAM]YQVVSHK 14.32 526.26 569.34 30 1265VSC[CAM]LPC[CAM]YQVVSHK 14.32 526.26 860.46 30 1266VSC[CAM]LPC[CAM]YQVVSHK 14.31 526.26 1020.49 30 1267VSC[CAM]VWC[CAM]YQALAR 18.41 756.86 881.43 38 1268VSC[CAM]VWC[CAM]YQALAR 18.41 756.86 1067.51 38 1269VSC[CAM]VWC[CAM]YQALAR 18.41 756.86 1166.58 38 1270VSDVC[CAM]SEVTAEGWQEVR 17.33 650.97 774.39 37 1271VSDVC[CAM]SEVTAEGWQEVR 17.34 975.95 1075.52 48 1272VSDVC[CAM]SEVTAEGWQEVR 17.34 975.95 1174.59 48 1273 VSEVEGWQIHGK 13.92456.9 582.34 27 1274 VSEVEGWQIHGK 13.92 456.9 768.42 27 1275VSEVEGWQIHGK 13.92 456.9 825.44 27 1276 VSFSLNIEMK 20.65 584.31 834.4431 1277 VSFSLNIEMK 20.64 584.31 981.51 31 1278 VSFSLNIEMK 20.65 584.311068.54 31 1279 VSPC[CAM]SSFK 11.04 456.22 468.25 25 1280 VSPC[CAM]SSFK11.04 456.22 628.28 25 1281 VSPC[CAM]SSFK 11.04 456.22 725.33 25 1282VSQVPAYK 10.68 446.25 478.27 25 1283 VSQVPAYK 10.68 446.25 577.33 251284 VSQVPAYK 10.68 446.25 705.39 25 1285 WFAR 11.17 296.18 393.22 181286 WFAR 11.17 296.18 417.25 18 1287 WFAR 11.17 296.18 492.29 18 1288WDGAK 4.9 288.64 302.11 18 1289 WDGAK 4.9 288.64 390.2 18 1290 WDGAK 4.9288.64 430.17 18 1291 WDGHIYDFPDWNR 20.52 574.25 590.27 33 1292WDGHIYDFPDWNR 20.52 574.25 687.32 33 1293 WDGHIYDFPDWNR 20.52 574.25887.37 33 1294 WDGIK 12.03 309.67 359.13 19 1295 WDGIK 12.03 309.67432.25 19 1296 WDGIK 12.03 309.67 472.22 19 1297 WDGKPR 6.36 379.7457.29 22 1298 WDGKPR 6.35 379.7 572.32 22 1299 WDGKPR 6.36 379.7 584.2822 1300 WDGQTR 7.41 381.68 461.25 22 1301 WDGQTR 7.41 381.68 576.27 221302 WDGQTR 7.41 381.68 588.24 22 1303 WDGVK 10.1 302.66 359.13 18 1304WDGVK 10.1 302.66 418.23 18 1305 WDGVK 10.1 302.66 458.2 18 1306 WDGVNR10.39 373.68 445.25 21 1307 WDGVNR 10.39 373.68 560.28 21 1308 WDGVNR10.42 373.68 572.25 21 1309 YAQAK 12.58 290.66 363.17 18 1310 YAQAK12.58 290.66 417.25 18 1311 YAQAK 12.58 290.66 434.2 18 1312 YFSDFNAK14.21 496.23 681.32 27 1313 YFSDFNAK 14.21 496.23 828.39 27 1314YFSDFNAK 14.21 496.23 828.39 27 1315 YGTHLDR 8.51 431.21 641.34 24 1316YGTHLDR 8.52 431.21 687.31 24 1317 YGTHLDR 8.51 431.21 698.36 24 1318YLDELVK 15.52 440.24 488.31 24 1319 YLDELVK 15.53 440.24 603.33 24 1320YLDELVK 15.52 440.24 716.42 24 1321 YLMITEAGR 15.86 527.27 533.27 281322 YLMITEAGR 15.86 527.27 646.35 28 1323 YLMITEAGR 15.86 527.27 777.3928 1324 YLNLFSYGNANIGGGIDK 22.16 639.32 773.42 36 1325YLNLFSYGNANIGGGIDK 22.16 958.48 1015.52 47 1326 YLNLFSYGNANIGGGIDK 22.16958.48 1178.58 47 1327 YPVVWYSQQVAHHLGAQR 18.11 535.53 544.32 30 1328YPVVWYSQQVAHHLGAQR 18.11 535.53 681.38 30 1329 YPVVWYSQQVAHHLGAQR 18.11535.53 889.48 30 1330 YSNVLAFK 16.44 471.26 478.3 26 1331 YSNVLAFK 16.44471.26 691.41 26 1332 YSNVLAFK 16.44 471.26 778.45 26 1333 YSPASTFK12.22 450.73 553.3 25 1334 YSPASTFK 12.22 450.73 650.35 25 1335 YSPASTFK12.22 450.73 737.38 25 1336 YSVVPVYQQLAR 18.42 711.89 778.42 36 1337YSVVPVYQQLAR 18.42 711.89 974.54 36 1338 YSVVPVYQQLAR 18.43 711.891073.61 36 1339 YSVVWYSQLTAK 19.75 722.88 810.44 37 1340 YSVVWYSQLTAK19.76 722.88 996.51 37 1341 YSVVWYSQLTAK 19.76 722.88 1095.58 37 1342YSVVWYSQQVAHHLGAQR 18.61 533.02 544.32 30 1343 YSVVWYSQQVAHHLGAQR 18.61533.02 681.38 30 1344 YSVVWYSQQVAHHLGAQR 18.61 533.02 889.48 30 1345YTPASTFK 11.95 305.49 553.3 19 1346 YTPASTFK 11.98 457.73 553.3 25 1347YTPASTFK 11.98 457.73 650.35 25 1348 YTSAFGYGNADVSGEPGK 15.03 607.28673.35 34 1349 YTSAFGYGNADVSGEPGK 15.02 607.28 788.38 34 1350YTSAFGYGNADVSGEPGK 15.02 910.41 1030.48 45 1351 YVFVSALTGNLGSNLTSSIK23.66 691.04 906.49 39 1352 YVFVSALTGNLGSNLTSSIK 23.66 1036.06 1165.6351 1353 YVFVSALTGNLGSNLTSSIK 23.67 1036.06 1190.64 51 1354YVFVSALTGSLGSNLTSSIK 24.04 682.04 906.49 38 1355 YVFVSALTGSLGSNLTSSIK24.04 1022.55 1106.61 50 1356 YVFVSALTGSLGSNLTSSIK 24.04 1022.55 1163.6350

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the threetransitions of the same peptide are greater than or equal to 2500, thedetection of the peptide is considered to be positive and is labelled“1”. When at least one transition comprises an area less than 2500, thecorresponding peptide is considered non-detected and is labelled “0”.

EXAMPLE 17: IDENTIFICATION OF A RESISTANCE TO IMP BETA-LACTAMS

Samples Sam145 to Sam154 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 26.

TABLE 26 Names Species Sam145 A. baumannii Sam146 A. baumannii Sam147 E.coli Sam148 K. pneumoniae Sam149 K. pneumoniae Sam150 P. aeruginosaSam151 P. aeruginosa Sam152 P. aeruginosa Sam153 P. aeruginosa Sam154 P.putida

Samples Sam145 to Sam154 correspond to a species able to comprise an IMPresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 27 instead of the peptides from TABLE3.

TABLE 27 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy Positivity number Peptide (minutes) Q1 Q3 (eV)threshold 1 DTENLVNWFVER 24.3 761.37 550.3 39.1 2000 2 DTENLVNWFVER 24.3761.37 850.42 39.1 2000 3 DTENLVNWFVER 24.3 761.37 949.49 39.1 2000 4GDASLMK 10.6 361.18 391.24 16.3 2000 5 GDASLMK 10.6 361.18 478.27 16.32000 6 GDASLMK 10.6 361.18 549.31 16.3 2000 7 GFNESK 2 341.16 312.6515.2 2000 8 GFNESK 2 341.16 363.19 15.2 2000 9 GFNESK 2 341.16 477.2315.2 2000 10 GLNESK 1.1 324.17 363.19 14.2 2000 11 GLNESK 1.1 324.17477.23 14.2 2000 12 GLNESK 1.1 324.17 590.31 14.2 2000 13 GLNESR 2.2338.18 309.66 15 2000 14 GLNESR 2.2 338.18 391.19 15 2000 15 GLNESR 2.1338.18 505.24 15 2000 16 GVYVHTSFEEVK 15.1 465.57 488.74 21.5 2000 17GVYVHTSFEEVK 15.1 465.57 538.28 21.5 2000 18 GVYVHTSFEEVK 15.1 465.57619.81 21.5 2000 19 GWGVVTK 14.3 373.71 345.2 17 2000 20 GWGVVTK 14.3373.71 347.23 17 2000 21 GWGVVTK 14.3 373.71 503.32 17 2000 22 GWSVVTK14.2 388.72 347.23 17.9 2000 23 GWSVVTK 14.2 388.72 446.3 17.9 2000 24GWSVVTK 14.2 388.72 533.33 17.9 2000 25 HGLVVLVK 15.4 432.79 557.4 20.42000 26 HGLVVLVK 15.5 432.79 670.49 20.4 2000 27 HGLVVLVK 15.4 432.79727.51 20.4 2000 28 HSFNGVSYSLIK 17 451.24 460.31 21.1 2000 29HSFNGVSYSLIK 17 451.24 623.38 21.1 2000 30 HSFNGVSYSLIK 17 451.24 710.4121.1 2000 31 LEEGVYVHTSFEEVK 16.9 589.29 697.85 25.4 2000 32LEEGVYVHTSFEEVK 16.9 589.29 762.37 25.4 2000 33 LEEGVYVHTSFEEVK 16.9589.29 826.89 25.4 2000 34 LFVLCVCFLCSITAAGAR 19.5 686.68 659.38 28.42000 35 LFVLCVCFLCSITAAGAR 19.6 686.68 906.45 28.4 2000 36LFVLCVCFLCSITAAGAR 19.5 1029.52 374.22 54.4 2000 37 LFVLCVCFLCSITAAGAR19.5 1029.52 659.38 54.4 2000 38 LTLEQAVK 15.2 451.27 574.32 21.5 200039 LTLEQAVK 15.2 451.27 687.4 21.5 2000 40 LTLEQAVK 15.2 451.27 788.4521.5 2000 41 LTWEQAVK 16.3 487.77 574.32 23.5 2000 42 LTWEQAVK 16.3487.77 760.4 23.5 2000 43 LTWEQAVK 16.3 487.77 861.45 23.5 2000 44LTWEQTVK 15.4 502.77 395.71 24.4 2000 45 LTWEQTVK 15.4 502.77 604.3324.4 2000 46 LTWEQTVK 15.4 502.77 790.41 24.4 2000 47 LVAWFVGR 21.3474.28 478.28 22.8 2000 48 LVAWFVGR 21.3 474.28 664.36 22.8 2000 49LVAWFVGR 21.3 474.28 735.39 22.8 2000 50 LVNWFIEHGYR 20.1 478.58 611.2921.9 2000 51 LVNWFIEHGYR 20.1 478.58 660.83 21.9 2000 52 LVNWFIEHGYR20.1 478.58 661.31 21.9 2000 53 LVNWFVER 20.9 531.79 550.3 26 2000 54LVNWFVER 20.9 531.79 736.38 26 2000 55 LVNWFVER 20.9 531.79 850.42 262000 56 LVTWFVER 20.6 525.29 550.3 25.7 2000 57 LVTWFVER 20.6 525.29736.38 25.7 2000 58 LVTWFVER 20.6 525.29 837.43 25.7 2000 59LVVPGHSEVGDASLLK 17.6 540.97 655.34 23.9 2000 60 LVVPGHSEVGDASLLK 17.6540.97 704.88 23.9 2000 61 LVVPGHSEVGDASLLK 17.6 810.95 655.34 42 200062 LVVPSHSDIGDASLLK 18 550.97 670.35 24.2 2000 63 LVVPSHSDIGDASLLK 18550.97 719.88 24.2 2000 64 LVVPSHSDIGDASLLK 18 825.96 670.35 42.8 200065 LVVPSHSDIGDSSLLK 17.7 556.31 678.34 24.3 2000 66 LVVPSHSDIGDSSLLK17.7 556.31 719.39 24.3 2000 67 LVVPSHSDIGDSSLLK 17.7 556.31 727.88 24.32000 68 LVVPSHSDVGDASLLK 17.5 546.3 663.34 24 2000 69 LVVPSHSDVGDASLLK17.5 546.3 712.87 24 2000 70 LVVPSHSDVGDASLLK 17.5 818.95 663.34 42.42000 71 LVVPSHSEAGDASLLK 16.1 541.63 656.33 23.9 2000 72LVVPSHSEAGDASLLK 16.1 541.63 705.87 23.9 2000 73 LVVPSHSEAGDASLLK 16.1541.63 755.4 23.9 2000 74 LVVPSHSEVGDASLLK 17.5 550.97 670.35 24.2 200075 LVVPSHSEVGDASLLK 17.5 550.97 719.88 24.2 2000 76 LVVPSHSEVGDASLLK17.5 825.96 670.35 42.8 2000 77 LVVSGHSEIGNASLLK 16.8 541.97 656.85 23.92000 78 LVVSGHSEIGNASLLK 16.8 541.97 706.38 23.9 2000 79LVVSGHSEIGNASLLK 16.8 541.97 755.92 23.9 2000 80 LVVSSHSDIGDVSLLK 18.9556.98 679.35 24.3 2000 81 LVVSSHSDIGDVSLLK 18.9 556.98 728.89 24.3 200082 LVVSSHSDIGDVSLLK 18.9 556.98 778.42 24.3 2000 83 LVVSSHSEIGDASLLK17.6 552.31 672.34 24.2 2000 84 LWSSHSEIGDASLLK 17.6 552.31 721.88 24.22000 85 LWSSHSEIGDASLLK 17.6 552.31 771.41 24.2 2000 86LVVSSHSEIGNASLLQR 16.8 604 416.26 25.8 2000 87 LVVSSHSEIGNASLLQR 16.8604 616.38 25.8 2000 88 LWSSHSEIGNASLLQR 16.8 604 799.42 25.8 2000 89LVVSSHSEK 8.1 329.18 387.19 17.3 2000 90 LVVSSHSEK 8.1 329.18 587.2817.3 2000 91 LVVSSHSEK 8.1 493.27 773.38 23.9 2000 92 LVVSSHSETGNASLLK14.7 547.97 665.83 24.1 2000 93 LVVSSHSETGNASLLK 14.7 547.97 715.37 24.12000 94 LVVSSHSETGNASLLK 14.7 547.97 764.9 24.1 2000 95 NDAYLIDTPITAK18.8 717.88 745.41 36.7 2000 96 NDAYLIDTPITAK 18.8 717.88 858.49 36.72000 97 NDAYLIDTPITAK 18.8 717.88 971.58 36.7 2000 98 NSFGGVNYWLVK 21.4692.36 822.45 35.2 2000 99 NSFGGVNYWLVK 21.4 692.36 1035.56 35.2 2000100 NSFGGVNYWLVK 21.4 692.36 1182.63 35.2 2000 101 NSFSGASYWLVK 20.8679.84 795.44 34.5 2000 102 NSFSGASYWLVK 20.8 679.84 923.5 34.5 2000 103NSFSGASYWLVK 20.8 679.84 1010.53 34.5 2000 104 NSFSGGSYWLVNNK 18.8786.88 375.2 40.6 2000 105 NSFSGGSYWLVNNK 18.8 786.88 474.27 40.6 2000106 NSFSGGSYWLVNNK 18.8 786.88 1224.6 40.6 2000 107 NSFSGVSYWLLK 23.6700.86 809.46 35.7 2000 108 NSFSGVSYWLLK 23.6 700.86 1052.58 35.7 2000109 NSFSGVSYWLLK 23.6 700.86 1199.65 35.7 2000 110 NSFSGVSYWLVK 22.3693.86 795.44 35.3 2000 111 NSFSGVSYWLVK 22.3 693.86 951.53 35.3 2000112 NSFSGVSYWLVK 22.3 693.86 1038.56 35.3 2000 113 SIPTYASELTNELLK 23.8560.3 717.41 24.5 2000 114 SIPTYASELTNELLK 23.8 560.3 739.89 24.5 2000115 SIPTYASELTNELLK 23.8 839.95 739.89 43.6 2000 116 TLEQAVK 10.5 394.73445.28 18.2 2000 117 TLEQAVK 10.5 394.73 574.32 18.2 2000 118 TLEQAVK10.5 394.73 687.4 18.2 2000 119 TWEQALK 15.1 438.24 459.29 20.7 2000 120TWEQALK 15.1 438.24 588.34 20.7 2000 121 TWEQALK 15.1 438.24 774.41 20.72000 122 TWEQAVK 12.8 431.23 445.28 20.3 2000 123 TWEQAVK 12.8 431.23574.32 20.3 2000 124 TWEQAVK 12.8 431.23 760.4 20.3 2000 125VQATNSFSGVNYWLVK 22.1 604.98 708.41 25.8 2000 126 VQATNSFSGVNYWLVK 22.1604.98 822.45 25.8 2000 127 VQATNSFSGVNYWLVK 22.1 906.97 1212.64 47.42000 128 VQATNSFSGVSYSLIK 19.9 567.63 710.41 24.7 2000 129VQATNSFSGVSYSLIK 19.9 567.63 953.53 24.7 2000 130 VQATNSFSGVSYSLIK 19.9850.95 710.41 44.2 2000 131 VQATNSFSGVSYWLVK 22.5 595.98 708.41 25.62000 132 VQATNSFSGVSYWLVK 22.5 595.98 795.44 25.6 2000 133VQATNSFSGVSYWLVK 22.5 893.46 1038.56 46.7 2000 134 YSFSEVSYWLVK 23.8754.38 795.44 38.7 2000 135 YSFSEVSYWLVK 23.8 754.38 894.51 38.7 2000136 YSFSEVSYWLVK 23.8 754.38 1110.58 38.7 2000 137 YSFSGVSYWLVK 23.4718.37 795.44 36.7 2000 138 YSFSGVSYWLVK 23.4 718.37 951.53 36.7 2000139 YSFSGVSYWLVK 23.4 718.37 1185.63 36.7 2000

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: yes    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 50.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Declustering potential (DP): 100.00 V    -   Entry potential before Q0 (EP): 6.00 V    -   Collision cell exit potential (CXP): 15 V    -   Total cycle time: 1 sec    -   Detection window: 120 sec

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE27, the detection of the transition is considered to be positive and islabelled “1” in TABLE 28. When a transition has an area less than thepositivity threshold described in TABLE 27, the transition is considerednon-detected and is labelled “0” in TABLE 28.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 28 Transition number Sam145 Sam146 Sam147 Sam148 Sam149 Sam150Sam151 Sam152 Sam153 Sam154 1 0 0 1 0 0 0 0 0 0 0 2 0 0 1 0 0 0 0 0 0 03 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 1 0 5 0 0 0 0 0 0 0 0 1 0 6 0 00 0 0 0 0 0 1 0 7 0 0 0 0 0 0 0 0 0 0 8 0 0 0 0 0 0 0 0 0 0 9 0 0 0 0 00 0 0 0 0 10 1 1 0 0 0 0 0 0 0 0 11 1 1 0 0 0 0 0 0 0 0 12 0 0 0 0 0 0 00 0 0 13 0 0 0 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 15 0 0 0 0 0 0 0 0 00 16 0 0 0 0 0 0 0 0 0 0 17 0 0 0 0 0 1 1 0 1 0 18 0 0 0 0 0 0 0 0 0 019 0 1 0 0 0 0 0 0 0 0 20 0 0 0 0 0 1 0 1 1 0 21 0 0 0 0 0 0 0 1 0 0 220 0 0 0 1 0 0 0 0 0 23 0 0 1 1 1 0 0 0 1 0 24 0 0 0 0 0 0 0 0 0 0 25 0 00 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0 0 27 0 0 0 0 0 0 0 0 0 0 28 0 0 0 00 0 0 0 0 0 29 0 0 0 0 0 0 0 0 0 0 30 0 0 0 0 0 0 0 0 0 0 31 0 0 0 0 0 00 0 0 0 32 0 0 0 0 0 0 0 0 0 0 33 1 0 0 0 0 0 0 0 0 0 34 0 0 0 0 0 0 0 00 0 35 0 0 0 0 0 0 0 0 0 0 36 0 0 0 0 0 0 0 0 0 0 37 0 0 0 0 0 0 0 0 0 038 0 1 1 1 0 0 0 1 0 0 39 0 1 1 1 0 0 0 1 0 0 40 0 1 1 1 0 0 0 1 0 0 410 0 1 0 0 0 0 0 0 1 42 0 0 0 0 0 0 0 0 0 1 43 0 0 0 0 0 0 0 0 0 1 44 0 00 0 0 0 0 0 0 0 45 0 0 0 0 0 0 0 0 0 0 46 0 0 0 0 0 0 0 0 0 0 47 0 0 0 00 0 0 0 0 0 48 0 0 0 0 0 0 0 0 0 1 49 0 0 0 0 0 0 0 0 0 0 50 0 0 0 0 0 00 0 0 0 51 0 0 0 0 0 0 0 0 0 0 52 0 0 0 0 0 1 0 0 0 0 53 1 0 0 0 1 1 0 01 0 54 1 0 1 0 0 1 0 0 1 0 55 1 1 1 0 1 1 0 0 1 0 56 0 1 1 1 1 0 1 1 0 057 0 1 1 1 1 0 1 1 0 0 58 0 1 1 1 1 0 1 1 0 0 59 0 0 0 0 0 1 1 0 0 0 600 0 0 0 0 1 1 0 0 0 61 0 0 0 0 0 1 1 0 0 0 62 0 0 0 1 0 0 1 1 0 0 63 0 00 1 0 0 1 1 0 0 64 0 0 0 1 0 0 1 1 0 0 65 0 0 0 0 0 1 1 1 1 0 66 0 0 0 00 0 0 0 0 0 67 0 0 0 0 0 0 0 0 0 0 68 0 0 0 0 0 0 0 0 0 0 69 0 0 0 0 0 00 0 0 0 70 0 1 0 0 0 0 0 0 0 0 71 1 1 1 0 0 0 0 0 0 0 72 0 1 1 0 0 0 0 00 0 73 0 1 1 0 0 0 0 0 0 0 74 0 0 0 1 0 0 1 1 0 0 75 0 0 0 1 0 0 1 1 0 076 0 0 0 1 0 0 1 1 0 0 77 0 0 0 0 0 0 0 0 0 1 78 0 0 0 0 0 0 0 0 0 1 790 1 1 0 0 0 0 0 0 1 80 0 0 0 0 0 0 0 0 0 0 81 0 0 0 0 0 0 0 0 0 0 82 0 10 0 0 0 0 0 0 0 83 1 0 0 0 1 1 0 0 0 1 84 1 0 0 0 1 1 0 0 1 0 85 1 0 1 11 1 1 1 1 0 86 0 0 1 0 0 0 0 0 0 0 87 0 0 1 0 0 0 0 0 0 0 88 0 0 0 0 0 00 0 0 0 89 0 0 0 0 0 0 0 0 0 0 90 0 0 0 0 0 0 0 0 1 0 91 0 0 0 0 0 0 0 01 0 92 1 0 0 0 0 0 0 0 0 0 93 0 0 0 0 0 0 0 0 0 0 94 0 0 0 0 0 0 0 0 0 095 0 1 0 0 0 0 0 0 0 0 96 0 0 0 0 0 0 0 0 0 0 97 0 0 0 0 0 0 0 0 0 0 980 1 1 0 0 0 0 0 0 0 99 0 1 1 0 0 0 0 0 0 0 100 0 1 1 1 0 0 0 0 0 0 101 00 0 0 0 0 0 0 0 0 102 0 0 0 0 0 0 0 0 0 0 103 0 0 0 0 0 0 1 1 0 0 104 00 0 1 0 0 0 0 0 0 105 0 0 0 1 1 0 0 0 0 0 106 0 0 0 0 0 0 0 0 0 0 107 00 0 0 0 0 0 0 0 0 108 0 0 0 0 0 0 0 0 0 0 109 0 0 0 0 0 0 0 0 0 0 110 11 0 0 0 0 0 0 0 0 111 1 1 0 0 0 0 0 0 1 0 112 1 0 0 0 0 0 0 0 0 0 113 00 0 1 0 0 0 0 0 0 114 0 0 0 1 0 0 0 1 0 0 115 0 0 0 1 0 0 0 0 0 0 116 01 0 1 0 0 1 0 0 0 117 0 1 1 1 0 0 1 0 0 0 118 0 1 0 1 0 0 1 0 0 0 119 00 0 0 0 0 0 0 1 0 120 0 0 0 0 0 0 0 0 1 0 121 0 0 0 0 0 0 0 0 1 0 122 10 0 0 1 1 0 0 0 0 123 1 0 0 0 1 1 0 0 0 0 124 1 0 0 0 1 1 0 0 0 0 125 00 0 0 0 0 0 0 0 0 126 0 0 0 0 0 0 0 1 0 0 127 0 0 0 1 1 0 0 0 0 0 128 00 0 0 0 0 0 0 0 1 129 0 0 0 0 0 0 0 0 0 0 130 0 0 0 0 0 0 0 0 0 0 131 00 0 0 0 0 0 0 0 0 132 0 0 0 0 0 0 0 0 0 0 133 0 0 0 0 0 0 0 0 0 0 134 00 0 0 0 0 0 0 0 0 135 0 0 0 0 0 0 1 0 0 0 136 0 0 0 0 0 0 0 0 0 0 137 10 0 0 0 0 0 0 0 0 138 0 0 0 0 0 0 0 0 0 0 139 0 0 0 0 0 0 0 0 0 0

Samples Sam145 to Sam154 comprise at least one peptide which ischaracteristic of IMPs. The bacteria present in samples Sam145 to Sam154therefore express a beta-lactamase which confers on them a resistance topenicillins, to cephalosporins and to carbapenems.

EXAMPLE 18: IDENTIFICATION OF A RESISTANCE TO OXA-48 BETA-LACTAMS

Samples Sam155 to Sam164 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 29.

TABLE 29 Names Species Sam155 K. pneumoniae Sam156 K. pneumoniae Sam157K. pneumoniae Sam158 E. cloacae Sam159 E. cloacae Sam160 K. pneumoniaeSam161 K. pneumoniae Sam162 K. pneumoniae Sam163 K. pneumoniae Sam164 K.pneumoniae

Samples Sam155 to Sam164 correspond to a species able to comprise anOXA-48 resistance mechanism. The following method is then performed todetect such a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 30 instead of the peptides from TABLE3.

TABLE 30 Charge Tran- state of Retention (m/z) (m/z) Collision sitionthe time filtered filtered energy Positivity number Peptide precursorFragment ion (minutes) in Q1 in Q3 (eV) threshold 1 ANQAFLPASTFK 2 y6monocharged 18.09 647.84 650.35 32.7 2000 2 ANQAFLPASTFK 2 y7monocharged 18.11 647.84 763.44 32.7 2000 3 ANQAFLPASTFK 2 y8monocharged 18.09 647.84 910.5 32.7 2000 4 DEHQVFK 3 y5 dicharged 9.89301.48 329.69 16.4 2000 5 DEHQVFK 2 y4 monocharged 9.89 451.72 521.3121.5 2000 6 DEHQVFK 2 y5 monocharged 9.91 451.72 658.37 21.5 2000 7DHNLITAMK 3 y3 monocharged 14.57 348.18 349.19 17.9 2000 8 DHNLITAMK 3y4 monocharged 14.57 348.18 450.24 17.9 2000 9 DHNLITAMK 2 y7monocharged 14.57 521.77 790.45 25.5 2000 10 DIATWNR 2 y3 monocharged13.79 438.22 475.24 20.7 2000 11 DIATWNR 2 y4 monocharged 13.79 438.22576.29 20.7 2000 12 DIATWNR 2 y5 monocharged 13.79 438.22 647.33 20.72000 13 IPNSLIALDLGVVK 3 y6 monocharged 23.68 484.63 630.38 22.1 2000 14IPNSLIALDLGVVK 2 y13 dicharged 23.68 726.45 669.9 37.1 2000 15IPNSLIALDLGVVK 2 y8 monocharged 23.68 726.45 814.5 37.1 2000 16ISATEQISFLR 2 y4 monocharged 19.17 632.85 522.3 31.8 2000 17 ISATEQISFLR2 y5 monocharged 19.17 632.85 635.39 31.8 2000 18 ISATEQISFLR 2 y6monocharged 19.17 632.85 763.45 31.8 2000 19 QAMLTEANGDYIIR 3 y4monocharged 18.36 532.27 564.35 23.6 2000 20 QAMLTEANGDYIIR 3 y6monocharged 18.36 532.27 736.4 23.6 2000 21 QAMLTEANGDYIIR 2 y10monocharged 18.36 797.9 1151.57 41.2 2000 22 QQGFTNNLK 2 y4 monocharged12.58 525.27 488.28 25.7 2000 23 QQGFTNNLK 2 y5 monocharged 12.58 525.27589.33 25.7 2000 24 QQGFTNNLK 2 y7 monocharged 12.58 525.27 793.42 25.72000 25 SQGVVVLWNENK 2 y5 monocharged 18.54 686.87 690.32 34.9 2000 26SQGVVVLWNENK 2 y6 monocharged 18.54 686.87 803.41 34.9 2000 27SQGVVVLWNENK 2 y7 monocharged 18.52 686.87 902.47 34.9 2000 28SWNAHFTEHK 3 y8 dicharged 12.23 419.53 492.24 20.1 2000 29 SWNAHFTEHK 3y9 dicharged 12.23 419.53 585.28 20.1 2000 30 SWNAHFTEHK 3 y5monocharged 12.23 419.53 661.33 20.1 2000 31 VLALSAVFLVASIIGMPAVAK 3 y6monocharged 34.92 690.75 616.35 28.5 2000 32 VLALSAVFLVASIIGMPAVAK 3 y7monocharged 34.94 690.75 673.37 28.5 2000 33 VLALSAVFLVASIIGMPAVAK 3 y8monocharged 34.94 690.75 786.45 28.5 2000 34 YSVVPVYQEFAR 3 y5monocharged 20.05 486.59 650.33 22.2 2000 35 YSVVPVYQEFAR 2 y8 dicharged20.07 729.38 505.26 37.3 2000 36 YSVVPVYQEFAR 2 y8 monocharged 20.07729.38 1009.51 37.3 2000

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: no    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 40.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Declustering potential (DP): 100.00 V    -   Entry potential before Q0 (EP): 6.00 V    -   Collision cell exit potential (CXP): 15 V    -   Total cycle time: 1.1 sec

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE30, the detection of the transition is considered to be positive and islabelled “1” in TABLE 31. When a transition has an area less than thepositivity threshold described in TABLE 30, the transition is considerednon-detected and is labelled “0” in TABLE 31.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 31 Transition number Sam155 Sam156 Sam157 Sam158 Sam159 Sam160Sam161 Sam162 Sam163 Sam164 1 0 1 1 0 1 1 1 1 1 0 2 0 1 1 0 1 1 1 0 1 03 0 1 0 0 0 1 1 0 0 0 4 0 0 0 0 0 0 0 0 0 0 5 0 0 0 0 0 0 0 0 0 0 6 0 00 0 0 0 0 0 0 0 7 0 1 0 0 0 1 1 0 0 0 8 0 1 1 1 0 1 1 0 1 0 9 1 1 1 1 11 1 1 1 0 10 0 0 0 0 0 0 0 0 0 0 11 0 0 0 1 1 0 0 0 0 0 12 0 0 0 0 0 0 01 0 0 13 0 1 1 1 1 1 1 1 1 0 14 0 1 1 1 1 1 1 1 1 1 15 0 1 1 1 1 1 1 1 10 16 1 1 1 1 1 1 1 1 1 1 17 1 1 1 1 1 1 1 1 1 1 18 1 1 1 1 1 1 1 1 1 119 1 1 1 1 1 1 1 1 1 1 20 1 1 1 1 1 1 1 1 1 0 21 1 1 1 1 1 1 1 1 1 1 221 1 1 1 1 1 1 1 1 0 23 1 1 1 1 1 1 1 1 1 1 24 1 1 1 1 1 1 1 1 1 0 25 0 00 0 0 0 0 0 0 0 26 0 0 0 0 0 0 0 0 0 0 27 0 0 0 0 0 0 0 0 0 0 28 1 1 1 11 1 1 1 1 1 29 1 1 1 1 1 1 1 1 1 1 30 1 1 1 1 1 1 1 1 1 0 31 1 0 0 0 1 00 0 0 0 32 1 1 1 1 1 1 1 1 1 0 33 1 1 0 1 1 1 1 1 1 0 34 0 1 1 0 1 1 1 01 0 35 0 1 1 0 1 1 1 0 1 0 36 0 1 1 0 1 1 1 0 1 0

Samples Sam155 to Sam164 comprise at least one peptide which ischaracteristic of the OXA-48 group. The bacteria present in samplesSam155 to Sam164 therefore express a beta-lactamase which confers onthem a resistance to penicillins, to first-generation andsecond-generation cephalosporins (but not to broad-spectrumcephalosporins), and to carbapenems.

EXAMPLE 19: IDENTIFICATION OF A RESISTANCE TO VIM BETA-LACTAMS

Samples Sam165 to Sam170 are identified according to one of the methodsdescribed in examples 1, 3 or 4. The identification of the species isset out in TABLE 32.

TABLE 32 Names Species Sam165 P. aeruginosa Sam166 E. coli Sam167 A.baumannii complex Sam168 A. junii Sam169 E. coli Sam170 K. pneumoniaessp pneumoniae

Samples Sam165 to Sam170 correspond to a species able to comprise a VIMresistance mechanism. The following method is then performed to detectsuch a mechanism.

Each sample is treated according to Example 5, then analysed accordingto Example 6 unless otherwise stated in the rest of the example, bydetecting the peptides from TABLE 33 instead of the peptides from TABLE3.

TABLE 33 Retention (m/z) (m/z) Collision Transition time filtered infiltered in energy Positivity number Peptide (minutes) Q1 Q3 (eV)threshold 1 AAGVATYASPSAR 12.3 611.32 588.31 30.6 2500 2 AAGVATYASPSAR12.3 611.32 852.42 30.6 2500 3 AAGVATYASPSAR 12.3 611.32 923.46 30.62500 4 AAGVATYASPSIR 14.5 632.34 630.36 31.8 2500 5 AAGVATYASPSIR 14.5632.34 894.47 31.8 2500 6 AAGVATYASPSIR 14.5 632.34 965.51 31.8 2500 7AAGVATYASPSTR 12 626.32 618.32 31.4 2500 8 AAGVATYASPSTR 12 626.32882.43 31.4 2500 9 AAGVATYASPSTR 12 626.32 953.47 31.4 2500 10AAGVATYTSPLTR 15.7 654.35 674.38 33 2500 11 AAGVATYTSPLTR 15.7 654.35938.49 33 2500 12 AAGVATYTSPLTR 15.7 654.35 1009.53 33 2500 13AGVATYASPSTR 11.8 590.8 547.28 29.4 2500 14 AGVATYASPSTR 11.8 590.8618.32 29.4 2500 15 AGVATYASPSTR 11.8 590.8 781.38 29.4 2500 16ALSSSGDVVR 11.3 495.76 632.34 24 2500 17 ALSSSGDVVR 11.3 495.76 719.3724 2500 18 ALSSSGDVVR 11.3 495.76 806.4 24 2500 19 AVSTHFHDDR 9.2 395.52413.68 19.3 2500 20 AVSTHFHDDR 9.2 395.52 507.72 19.3 2500 21 AVSTHFHDDR9.2 395.52 689.3 19.3 2500 22 DADELLLIDTAWGAK 24.3 544.28 748.36 24 250023 DADELLLIDTAWGAK 24.3 815.92 544.31 42.2 2500 24 DADELLLIDTAWGAK 24.3815.92 748.36 42.2 2500 25 DADELLLIDTAWGAK 24.3 815.92 861.45 42.2 250026 DGDELLLIDTAWGAK 24 539.61 748.36 23.8 2500 27 DGDELLLIDTAWGAK 24808.91 748.36 41.8 2500 28 DGDELLLIDTAWGAK 24 808.91 861.45 41.8 2500 29DGDELLLIDTAWGTK 24.1 549.61 778.37 24.1 2500 30 DGDELLLIDTAWGTK 24.1823.92 778.37 42.7 2500 31 DGDELLLIDTAWGTK 24.1 823.92 891.46 42.7 250032 ESAGNVADANLAEWPATIK 20.2 652.99 529.33 27.3 2500 33ESAGNVADANLAEWPATIK 20.2 652.99 715.41 27.3 2500 34 ESAGNVADANLAEWPATIK20.2 978.99 529.33 51.5 2500 35 GEYPTVSEIPVGEVR 18.4 544.61 656.37 242500 36 GEYPTVSEIPVGEVR 18.4 816.42 641.85 42.3 2500 37 GEYPTVSEIPVGEVR18.4 816.42 656.37 42.3 2500 38 HTTNVVK 1.3 399.73 345.25 18.5 2500 39HTTNVVK 1.3 399.73 560.34 18.5 2500 40 HTTNVVK 1.3 399.73 661.39 18.52500 41 IGDGVWSHIATQK 17 471.25 563.8 21.7 2500 42 IGDGVWSHIATQK 17471.25 621.32 21.7 2500 43 IGDGVWSHIATQK 17 471.25 649.83 21.7 2500 44LGDTVYSSNGLIVR 17.9 747.4 387.27 38.3 2500 45 LGDTVYSSNGLIVR 17.9 747.4845.48 38.3 2500 46 LGDTVYSSNGLIVR 17.9 747.4 1008.55 38.3 2500 47LYQIADGVWSHIATK 20.8 567.97 592.81 24.7 2500 48 LYQIADGVWSHIATK 20.8567.97 649.35 24.7 2500 49 LYQIADGVWSHIATK 20.8 567.97 713.38 24.7 250050 LYQIADGVWSHIATR 21 577.31 606.81 25 2500 51 LYQIADGVWSHIATR 21 577.31663.35 25 2500 52 LYQIADGVWSHIATR 21 577.31 727.38 25 2500 53NTAALLAEIEK 19.8 586.83 589.32 29.2 2500 54 NTAALLAEIEK 19.8 586.83702.4 29.2 2500 55 NTAALLAEIEK 19.8 586.83 886.52 29.2 2500 56NTVALLAEIEK 21.2 600.85 589.32 30 2500 57 NTVALLAEIEK 21.2 600.85 702.430 2500 58 NTVALLAEIEK 21.2 600.85 886.52 30 2500 59 QIGLPVTR 15.6442.27 472.29 20.9 2500 60 QIGLPVTR 15.6 442.27 642.39 20.9 2500 61QIGLPVTR 15.6 442.27 755.48 20.9 2500 62 QLAEAAGNEVPAHSLK 13.8 545.62597.32 24 2500 63 QLAEAAGNEVPAHSLK 13.8 545.62 652.38 24 2500 64QLAEAAGNEVPAHSLK 13.8 545.62 697.36 24 2500 65 SFDGAVYPSNGLIVR 19.2797.92 559.32 41.2 2500 66 SFDGAVYPSNGLIVR 19.2 797.92 855.51 41.2 250067 SFDGAVYPSNGLIVR 19.2 797.92 1018.57 41.2 2500 68 SISTHFHDDR 10.6405.52 413.68 19.7 2500 69 SISTHFHDDR 10.6 405.52 507.72 19.7 2500 70SISTHFHDDR 10.6 405.52 689.3 19.7 2500 71 SVSTHFHDDR 9.2 400.85 413.6819.5 2500 72 SVSTHFHDDR 9.2 400.85 507.72 19.5 2500 73 SVSTHFHDDR 9.2400.85 689.3 19.5 2500 74 TSAGNVADADLAEWPGSVER 19.2 682.32 322.67 28.22500 75 TSAGNVADADLAEWPGSVER 19.2 682.32 644.34 28.2 2500 76TSAGNVADADLAEWPGSVER 19.2 682.32 830.42 28.2 2500 77TSAGNVADADLAEWPGSVER 19.2 1022.98 644.34 54 2500 78 TSAGNVADADLAEWPTSIER20.7 701.67 351.69 28.8 2500 79 TSAGNVADADLAEWPTSIER 20.7 701.67 702.3828.8 2500 80 TSAGNVADADLAEWPTSIER 20.7 701.67 888.46 28.8 2500 81TSAGNVADADLAEWPTSIER 20.7 1052 702.38 55.7 2500 82 TSAGNVADADLAEWPTSVER19.6 697 344.69 28.7 2500 83 TSAGNVADADLAEWPTSVER 19.6 697 688.36 28.72500 84 TSAGNVADADLAEWPTSVER 19.6 697 874.44 28.7 2500 85TSAGNVADADLAEWPTSVER 19.6 1045 688.36 55.3 2500 86 VGGVDALR 12.8 393.73474.27 18.2 2500 87 VGGVDALR 12.8 393.73 630.36 18.2 2500 88 VGGVDALR12.8 393.73 687.38 18.2 2500 89 VGGVDVLR 14.8 407.74 502.3 19 2500 90VGGVDVLR 14.8 407.74 658.39 19 2500 91 VGGVDVLR 14.8 407.74 715.41 192500 92 VLFGGCAVHEASR 15.1 468.24 522.24 21.6 5100 93 VLFGGCAVHEASR 15.1468.24 595.77 21.6 5100 94 VLFGGCAVHEASR 15.1 468.24 599.29 21.6 5100 95VLYGGCAVHELSR 15.3 487.58 543.26 22.2 2500 96 VLYGGCAVHELSR 15.3 487.58624.79 22.2 2500 97 VLYGGCAVHELSR 15.3 487.58 641.34 22.2 2500

-   -   The other machine parameters used are as follows:    -   Scan type: MRM    -   MRM planned: yes    -   Polarity: Positive    -   Ionising source: Turbo V™ (Applied BioSystems)    -   Q1 setting: Filtering with unit resolution    -   Q3 setting: Filtering with unit resolution    -   Inter-scan pause: 5.00 msec    -   Scanning speed: 10 Da/s    -   Curtain gas: 50.00 psi    -   Cone voltage: 5500.00 V    -   Source temperature: 500.00° C.    -   Nebulising gas: 50.00 psi    -   Heating gas: 50.00 psi    -   Collision gas which induces dissociation: 9.00 psi    -   Dynamic filling: activated    -   Declustering potential (DP): 100.00 V    -   Entry potential before Q0 (EP): 6.00 V    -   Collision cell exit potential (CXP): 15 V    -   Total cycle time: 0.04 sec    -   Detection window: 120 sec

The areas obtained for each of the transitions and for each of themicroorganisms studied were measured. When the areas of the transitionsare greater than or equal to the positivity threshold described in TABLE33, the detection of the transition is considered to be positive and islabelled “1” in TABLE 34. When a transition has an area less than thepositivity threshold described in TABLE 33, the transition is considerednon-detected and is labelled “0” in TABLE 34.

For a given peptide, when at least 3 transitions are labelled “1”, thepeptide is considered as being detected.

TABLE 34 Transition number Sam165 Sam166 Sam167 Sam168 Sam169 Sam170 1 00 0 0 0 0 2 0 0 0 0 0 0 3 0 0 0 0 0 0 4 0 0 0 0 0 0 5 0 0 0 0 0 0 6 0 00 0 0 0 7 0 0 0 0 0 1 8 0 0 0 0 0 1 9 0 0 0 0 0 1 10 0 0 0 0 0 0 11 0 00 0 0 0 12 0 0 0 0 0 0 13 0 0 0 0 0 1 14 0 0 0 0 0 1 15 0 0 0 0 0 1 16 00 0 0 0 0 17 0 0 0 0 0 0 18 0 0 0 0 0 0 19 1 1 1 1 1 1 20 1 1 1 1 1 1 211 1 1 1 1 1 22 0 0 0 0 0 0 23 0 0 0 0 0 0 24 0 0 0 0 0 0 25 0 0 0 0 0 026 0 0 0 0 0 0 27 0 0 0 0 0 0 28 0 0 0 0 0 0 29 0 0 0 0 0 0 30 0 0 0 0 00 31 0 0 0 0 0 0 32 0 0 0 0 0 0 33 0 0 0 0 0 0 34 0 0 0 0 0 0 35 0 0 0 00 0 36 0 0 0 0 0 0 37 0 0 0 0 0 0 38 0 0 0 0 0 0 39 0 0 0 0 0 0 40 0 0 00 0 0 41 0 0 0 0 0 0 42 0 0 0 0 0 0 43 0 0 0 0 0 0 44 0 0 0 0 0 0 45 0 00 0 0 0 46 0 0 0 0 0 0 47 0 0 0 0 0 0 48 0 0 0 0 0 0 49 0 0 0 0 0 0 50 00 0 0 0 0 51 0 0 0 0 0 0 52 0 0 0 0 0 0 53 0 0 0 0 0 0 54 0 0 0 0 0 0 550 0 0 0 0 0 56 0 0 0 0 0 0 57 0 0 0 0 0 0 58 0 0 0 0 0 0 59 0 0 0 0 0 060 0 0 0 0 0 0 61 0 0 0 0 0 0 62 0 0 0 0 0 0 63 0 0 0 0 0 0 64 0 0 0 0 00 65 0 0 0 0 0 0 66 0 0 0 0 0 0 67 0 0 0 0 0 0 68 0 0 0 0 0 0 69 0 0 0 00 0 70 0 0 0 0 0 0 71 0 0 0 0 0 0 72 0 0 0 0 0 0 73 0 0 0 0 0 0 74 0 0 00 0 0 75 0 0 0 0 0 0 76 0 0 0 0 0 0 77 0 0 0 0 0 0 78 1 0 1 0 0 0 79 1 01 0 0 0 80 1 0 1 0 0 0 81 1 0 1 0 0 0 82 0 0 0 1 1 0 83 0 0 0 1 1 0 84 00 0 1 1 0 85 0 0 0 1 1 0 86 0 0 0 0 0 0 87 0 0 0 0 0 0 88 0 0 0 0 0 0 891 1 1 1 1 1 90 1 1 1 1 1 1 91 1 1 1 1 1 1 92 0 0 0 0 0 0 93 0 0 0 0 0 094 0 0 0 0 0 0 95 0 0 0 0 1 1 96 0 0 0 0 1 1 97 0 0 0 0 1 1

Samples Sam165 to Sam170 comprise at least one peptide which ischaracteristic of VIMs. The bacteria present in samples Sam165 to Sam170therefore express a beta-lactamase which confers on them a resistance topenicillins, to cephalosporins and to carbapenems.

The detection methods described in examples 6 to 11 are particularlyadvantageous because they make it possible to assay a large number ofpeptides and at the same time to detect the presence of one or moreresistance mechanisms induced by one or more carbapenemases.

Furthermore, the detection is performed in a short time, less than onehour. In fact, only the part of the gradient between 3 and 34 minutes isuseful to the analysis. Furthermore, the retention times of the assayedpeptides are all below 34 minutes.

In addition, the detection methods described in examples 6 to 11 aremore advantageous than the molecular biology methods because they detectthe product of the expression of the genes, and not the genesthemselves. The detection of a resistance may not have any clinicalmeaning if this gene is not expressed, or it if is expressed too weaklyto lead to an effective resistance. The detection of a peptidecharacterising a protein characteristic of a resistance mechanism doesnot have this disadvantage.

Surprisingly, the above examples show that it is possible to attain bymass spectrometry the sensitivity necessary for the specific detectionof the existence of a mechanism of resistance to at least oneantimicrobial of a microorganism contained in a sample, withoutemploying an amplification method as is usually the case when molecularbiology methods are used.

BIBLIOGRAPHIC REFERENCES

-   [1] J. Anhalt & C. Fenselau, 1975, Anal. Chem., 47(2):219-225.-   [2] A. Fox et al., ed., 1990, Analytical microbiology methods:    chromatography and mass spectrometry, Plenum Press, New York, N.Y.-   [3] M. Claydon et al., 1996, Nature Biotech. 14:1584-1586.-   [4] T. Krishnamurthy & P. Ross, 1996, Rapid Com. Mass Spec.,    10:1992-1996.-   [5] P. Seng et al. 2009, Clin. Infect. Dis., 49:543-551.-   [6] C. Fenselau et al., 2008, Appl. Environ. Microbial., 904-906.-   [7] S. Hofstadler et al., 2005, Int. J. Mass Spectrom., 242:23-41.-   [8] D. Ecker, 2008, Nat. Rev. Microbial., 6(7):553-558.-   [9] Bush and Jacoby, 2010, Antimicrobial Agents and Chemotherapy; 54    (3): 969-976-   [10] W.-J. Chen et al., 2008, Anal. Chem., 80: 9612-9621-   [11] D. Lopez-Ferrer et al., 2008, Anal. Chem., 80:8930-8936-   [12] D. Lopez-Ferrer et al., 2005, J. Proteome res., 4(5): 1569-1574-   [13] T. Fortin et al., 2009, Mol. Cell Proteomics, 8(5): 1006-1015.-   [14] H. Keshishian et al., 2007, Mol. Cell Proteomics, 2212-2229.-   [15] J. Stal-Zeng et al., 2007, Mol. Cell Proteomics, 1809-1817.-   [16] Gaskell, Electrospray: principles and practise, 1997, J. Mass    Spectrom., 32, 677-688).-   [17] V. Fusaro et al., 2009, Nature Biotech. 27, 190-198.-   [18] J. Mead et al., 15 Nov. 2008, Mol. Cell Proteomics, E-pub.-   [19] F. Desiere et al., 2006, Nucleic Acids Res., 34 (database    issue): D655-8).-   [20] L. Anderson & C. Hunter, 2006, Mol. Cell Proteomics, 573-588).-   [21] B. Han & R. Higgs, 2008, Brief Funct Genomic Proteomic.,    7(5):340-54).-   [22] K.-Y. Wang et al., 2008, Anal. Chem, 80(16) 6159-6167).-   [23] J. Bundy & C. Fenselau, 1999, Anal. Chem. 71: 1460-1463.-   [24] K-C Ho et al., 2004, Anal. Chem. 76: 7162-7268.-   [25] Y. S. Lin et al., 2005, Anal. Chem., 77: 1753-1760.-   [26] S. Vaidyanathan et al., 2001, Anal. Chem., 73:4134-4144.-   [27] R. Everley et al., 2009, J. Microbial. Methods, 77:152-158.-   [28] P. Seng et al., 2009, Clin. Infect. Dis., 49:543-551.-   [29] Manes N. et al., 2007, Mol. & Cell. Proteomics, 6(4): 717-727.-   [30] R. Nandakumar et al., 2009, Oral Microbiology Immunology,    24:347-352).-   [31] L. Hernychova et al., 2008, Anal. Chem., 80:7097-7104.-   [32] J.-M. Pratt et al., 2006, Nat. Protoc., 1:1029-1043.-   [33] V. Brun et al., 2007, Mol. Cell Proteomics, 2139-2149.

The invention claimed is:
 1. A method of detecting a VIM protein in asample, comprising: subjecting the sample to MS/MS spectrometry in MRMmode and detecting whether one or more VIM fragments selected from thegroup consisting of SEQ ID NOs: 314-318 and 320-346 is present, whereindetection of any of the VIM fragments by the MRM mass spectrometryindicates the presence of VIM protein in the sample.
 2. The methodaccording to claim 1, further comprising, before performing MS/MSspectrometry in MRM mode, digesting proteins to produce peptides in thesample.
 3. The method according to claim 2, wherein the digestion isperformed by an enzyme.
 4. The method according to claim 3, wherein theenzyme is trypsin.
 5. The method according to claim 1, wherein the oneor more VIM fragments is selected from the group consisting of SEQ IDNOs: 316, 318, 321, 341, 342, 344, and
 346. 6. The method according toclaim 1, further comprising performing MS/MS spectometry in MRM mode onthe sample to determine whether the sample includes NDM, GES, IMP, IND,SME, and OXA.
 7. A method of detecting an OXA protein in a sample,comprising: subjecting the sample to MS/MS spectrometry in MRM mode anddetecting whether one or more OXA fragments selected from the groupconsisting of SEQ ID NOs: 509-523, 525-572, 574-604, 606-618, 620-696,698-1077, and 1098-1109 is present, wherein detection of any of the OXAfragments by the MRM mass spectrometry indicates the presence of OXAprotein in the sample.
 8. The method according to claim 7, furthercomprising, before performing MS/MS spectrometry in MRM mode, digestingproteins to produce peptides in the sample.
 9. The method according toclaim 8, wherein the digestion is performed by an enzyme.
 10. The methodaccording to claim 9, wherein the enzyme is trypsin.
 11. The methodaccording to claim 7, wherein the one or more OXA fragments is selectedfrom the group consisting of SEQ ID NOs: 509, 510, 512, 513, 514, 515,516, 517, 518, 519, 520, 521, 522, 523, 525, 526, 528, 530, 531, 532,533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546,547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560,561, 562, 563, 564, 565, 566, 567, 571, 572, 574, 575, 576, 577, 578,580, 581, 583, 584, 586, 587, 588, 589, 590, 591, 593, 594, 595, 596,597, 598, 599, 600, 601, 602, 604, 606, 607, 609, 611, 612, 613, 614,615, 616, 618, 620, 622, 623, 624, 625, 626, 627, 632, 633, 635, 636,637, 638, 639, 640, 641, 642, 643, 645, 648, 649, 651, 652, 653, 654,655, 656, 659, 660, 664, 665, 666, 667, 669, 670, 672, 673, 674, 675,676, 677, 678, 679, 680, 681, 685, 686, 687, 688, 689, 690, 691, 692,693, 694, 696, 698, 699, 700, 701, 702, 703, 706, 707, 710, 714, 717,719, 720, 722, 725, 726, 727, 728, 729, 732, 735, 736, 737, 738, 740,741, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755,756, 757, 759, 760, 762, 763, 766, 767, 768, 769, 770, 771, 773, 774,775, 776, 777, 778, 779, 780, 781, 782, 783, 785, 786, 787, 788, 789,790, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 803, 804, 805,806, 807, 809, 810, 811, 812, 813, 814, 815, 818, 821, 822, 824, 825,826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 840,841, 842, 844, 845, 846, 847, 848, 849, 850, 851, 853, 854, 855, 856,857, 858, 859, 860, 861, 862, 865, 866, 867, 868, 869, 871, 874, 875,876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889,890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903,904, 905, 906, 907, 908, 909, 910, 912, 913, 914, 918, 920, 921, 922,923, 928, 930, 932, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944,945, 946, 947, 948, 949, 950, 951, 953, 954, 955, 956, 958, 961, 962,963, 964, 967, 968, 970, 972, 973, 974, 975, 976, 977, 978, 979, 980,981, 982, 983, 984, 985, 986, 988, 990, 992, 993, 994, 995, 996, 997,998, 1000, 1001, 1003, 1004, 1005, 1008, 1009, 1011, 1012, 1013, 1014,1015, 1018, 1019, 1020, 1022, 1024, 1025, 1026, 1027, 1028, 1030, 1031,1034, 1036, 1041, 1042, 1044, 1045, 1046, 1048, 1049, 1050, 1052, 1053,1054, 1058, 1059, 1060, 1062, 1063, 1064, 1067, 1068, 1069, 1070, 1071,1072, 1073, 1074, 1075, 1076, 1098, 1099, 1100, 1101, 1102, 1103, 1104,1105, 1106, 1107, 1108, and
 1109. 12. The method according to claim 7,wherein the one or more OXA fragments is selected from the groupconsisting of SEQ ID NOs: 510, 512, 513, 514, 520, 521, 522, 523, 525,530, 532, 537, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551,552, 556, 557, 558, 559, 560, 561, 562, 574, 581, 582, 583, 584, 596,597, 598, 599, 600, 601, 602, 607, 609, 632, 633, 635, 636, 649, 655,656, 667, 674, 675, 689, 690, 698, 714, 719, 720, 722, 727, 729, 741,746, 748, 750, 751, 752, 755, 756, 757, 763, 767, 768, 772, 775, 781,782, 790, 792, 793, 794, 795, 796, 797, 798, 801, 809, 811, 812, 813,814, 824, 832, 834, 837, 838, 847, 851, 853, 854, 855, 856, 857, 858,859, 860, 862, 868, 869, 870, 874, 875, 876, 877, 879, 880, 881, 882,894, 895, 898, 902, 903, 904, 906, 907, 908, 912, 913, 914, 920, 922,923, 937, 938, 939, 945, 946, 948, 949, 950, 951, 954, 956, 962, 964,967, 969, 971, 972, 974, 975, 979, 980, 985, 988, 990, 993, 994, 995,996, 997, 1000, 1001, 1003, 1004, 1005, 1011, 1013, 1015, 1018, 1019,1027, 1030, 1034, 1035, 1036, 1042, 1048, 1052, 1058, 1060, 1070, 1098,1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106, 1107, 1108, and 1109.13. The method according to claim 7, wherein the one or more OXAfragments is selected from the group consisting of SEQ ID NOs: 1098,1100, 1102, 1103, 1104, 1105, 1107, 1108, and
 1109. 14. The methodaccording to claim 7, further comprising performing MS/MS spectometry inMRM mode on the sample to determine whether the sample includes NDM,GES, IMP, IND, SME, and VIM.